---
document_datetime: 2023-09-21 21:40:39
document_pages: 188
document_pathfilename: www.ema.europa.eu/en/documents/variation-report/enhertu-h-c-005124-ii-0012-epar-assessment-report-variation_en.pdf
document_name: enhertu-h-c-005124-ii-0012-epar-assessment-report-variation_en.pdf
version: success
processing_time: 385.7667606
conversion_datetime: 2026-01-01 21:48:50.294004
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.66.0
  docling-core: 2.57.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.2-arm64-arm-64bit-Mach-O
---
<!-- image -->

10 November 2022 EMA/CHMP/931431/2022 Committee for Medicinal Products for Human Use (CHMP)

## Assessment report

## Enhertu

International non-proprietary name: trastuzumab deruxtecan

Procedure No. EMEA/H/C/005124/II/0012

## Note

Variation assessment report as adopted by the CHMP with all information of a commercially confidential nature deleted.

<!-- image -->

<div style=\"page-break-after: always\"></div>

## Table of contents

| 1. Background information on the procedure                                                                                  | ..............................................7                                                      |
|-----------------------------------------------------------------------------------------------------------------------------|------------------------------------------------------------------------------------------------------|
| Steps taken for the assessment of the product ...............................................................7              |                                                                                                      |
| 2. Scientific discussion                                                                                                    | ................................................................................8                    |
| 2.1. Introduction.........................................................................................................8 |                                                                                                      |
| 2.1.1. Problem statement                                                                                                    | ............................................................................................8        |
| 2.1.2. About the product............................................................................................12      |                                                                                                      |
| 2.1.3. The development programme/compliance with CHMP guidance/scientific                                                   | advice ......12                                                                                      |
| 2.1.4. General comments on compliance with                                                                                  | GCP........................................................12                                        |
| 2.2. Non-clinical aspects                                                                                                   | ............................................................................................12       |
| 2.2.1. Introduction....................................................................................................12   |                                                                                                      |
| 2.2.2. Ecotoxicity/environmental risk assessment                                                                            | .........................................................13                                          |
| 2.2.1. Discussion on non-clinical aspects......................................................................18           |                                                                                                      |
| 2.2.2. Conclusion on the non-clinical aspects................................................................18             |                                                                                                      |
| 2.3. Clinical aspects                                                                                                       | ..................................................................................................18 |
| 2.3.1. Introduction....................................................................................................18   |                                                                                                      |
| 2.3.2. Pharmacokinetics.............................................................................................20      |                                                                                                      |
| 2.3.3. Pharmacodynamics..........................................................................................43         |                                                                                                      |
| 2.3.4. Discussion on clinical pharmacology...................................................................61             |                                                                                                      |
| 2.3.5. Conclusions on clinical pharmacology.................................................................62              |                                                                                                      |
| 2.4. Clinical efficacy                                                                                                      | ..................................................................................................62 |
| 2.4.1. Dose response studies......................................................................................62        |                                                                                                      |
| 2.4.2. Main study......................................................................................................64   |                                                                                                      |
| 2.4.3. Discussion on clinical efficacy..........................................................................            | 107                                                                                                  |
| 2.4.4. Conclusions on the clinical efficacy...................................................................              | 110                                                                                                  |
| 2.5. Clinical safety ..................................................................................................     | 111                                                                                                  |
| 2.5.2. Patient exposure                                                                                                     | ........................................................................................... 117      |
| 2.5.3. Adverse events                                                                                                       | ............................................................................................. 119    |
| 2.5.4. Serious adverse event/deaths/other significant events .......................................                        | 130                                                                                                  |
| 2.5.5. Laboratory findings........................................................................................          | 145                                                                                                  |
| 2.5.6. Safety in special populations...........................................................................             | 158                                                                                                  |
| 2.5.7. Safety related to drug-drug interactions and other interactions                                                      | ........................... 169                                                                      |
| 2.5.8. Discontinuation due to adverse events                                                                                | ............................................................. 170                                    |
| 2.5.9. Post marketing experience..............................................................................              | 173                                                                                                  |
| 2.5.10. Discussion on clinical safety ..........................................................................            | 173                                                                                                  |
| 2.5.11. Conclusions on clinical safety                                                                                      | ........................................................................ 175                         |
| 2.5.12. PSUR cycle..................................................................................................        | 176                                                                                                  |
| 2.6. Risk management plan......................................................................................             | 176                                                                                                  |
| 2.7. Overall conclusion on the RMP ...........................................................................              | 180                                                                                                  |
| 2.8. Changes to the Product Information                                                                                     | ................................................................... 180                              |
| 2.8.1. User consultation...........................................................................................         | 180                                                                                                  |
| 3. Benefit-Risk Balance............................................................................180                      |                                                                                                      |
| 3.1. Therapeutic Context .........................................................................................          | 180                                                                                                  |

<div style=\"page-break-after: always\"></div>

3.1.2. Available therapies and unmet medical need  ..................................................... 181

3.1.3. Main clinical studies .......................................................................................  181

3.2. Favourable effects ............................................................................................  182

3.3. Uncertainties and limitations about favourable effects  ........................................... 182

3.4. Unfavourable effects  .........................................................................................  182

3.5. Uncertainties and limitations about unfavourable effects ....................................... 183

3.6. Effects Table  ....................................................................................................  184

3.7. Benefit-risk assessment and discussion  ............................................................... 185

3.7.1. Importance of favourable and unfavourable effects  ............................................ 185

3.7.2. Balance of benefits and risks  ...........................................................................  186

3.7.3. Additional considerations on the benefit-risk balance ......................................... 186

3.8. Conclusions .....................................................................................................  187

4. Recommendations ...............................................................................  187

5. EPAR changes  ......................................................................................  188

<div style=\"page-break-after: always\"></div>

## List of abbreviations

## Abbreviation

Definition

AC

Adjudication Committee

ADA

antidrug antibody

ADC

antibody-drug conjugate

ADR

adverse drug reaction

AE

adverse event

AESI

adverse event of special interest

AR

Applied Radioactivity

ASCO-CAP

American Society of Clinical Oncology-College of American Pathologists

AST

aspartate aminotransferase

AUC

area under the serum concentration-time curve

AUClast

area under the serum concentration-time curve up to last quantifiable time

AUCss

area under the serum concentration-time curve at steady state breast cancer

BC

BOR

best overall response

BSV

between subject variability

BSC

best supportive care

Cavg

average concentration

CHMP

Committee for Medicinal Products for Human Use

CI

confidence interval

CLcr

creatinine clearance

CLDXd

clearance of DXd

CLT-DXd

clearance of intact T-DXd

Cmax

maximum serum concentration

Cmax,ss

maximum serum concentration at steady state

CMH

Cochran-Mantel-Haenszel

Cmin

minimum serum concentration

Cmin,ss

minimum serum concentration at steady state

CPS

combined positive score

CSR

clinical study report

CT

computed tomography

CTCAE

Common Terminology Criteria for Adverse Events

CYP

cytochrome P450

DAR

drug-to-antibody ratio

DCO

data cut-off

DCR

disease control rate

Deruxtecan

drug-linker in T-DXd composed of cleavable tetrapeptide linker and

released drug

DoR

duration of response

DXd

the released drug in T-DXd; topoisomerase I inhibitor derivative of exatecan

EC50

Concentration of the test substance dissolved in test medium that

results in a 50% reduction in the measured endpoint

ECHA

European Chemicals Agency

ECOG PS

Eastern Cooperative Oncology Group performance status

EMA

European Medicines Agency

EQ-5D-5L

EuroQol 5-dimension 5-level (of severity) assessment

E-R

exposure-response

ERA

Environmental Risk Assessment

EU

European Union

FACT-Ga

Functional Assessment of Cancer Therapy-Gastric

FAS

Full Analysis Set

FDA

Food and Drug Administration

FIH

first-in-human

FL-DP1

frozen liquid drug product 1

Foc

Fraction of Organic Carbon

Fpen

Market penetration factor

GC

gastric cancer

GEJ

gastroesophageal junction

GI

gastrointestinal

HER2

human epidermal growth factor receptor 2

HR

hazard ratio

ICI

immune checkpoint inhibitor

ICR

independent central review

IHC

immunohistochemistry

ILD

interstitial lung disease

IQR

interquartile range

IRR

infusion-related reaction

ISH

in situ hybridization

ITT

Intent-to-Treat

IV

intravenous

Kd

Adsorption distribution coefficient

KM

Kaplan-Meier

Koc

Organic carbon normalized adsorption coefficient

LOEC

Lowest Observed Effect Concentration

LV

left ventricular

LVEF

left ventricular ejection fraction

Lyo-DP

lyophilized powder drug product

MAA

Marketing Authorisation Application

mAb (of T-DXd)

monoclonal antibody (anti-HER2 component of T-DXd)

MedDRA

Medical Dictionary for Regulatory Activities

mRNA

messenger ribonucleic acid

MRI

magnetic resonance imaging

MSI

microsatellite instability

Nab

neutralizing antibody

NCCN

National Comprehensive Cancer Network

NE

not estimable

NOEC

No Observed Effect Concentration

NSCLC

non-small cell lung cancer

OECD

Organisation for Economic Co-operation and Development

ORR

objective response rate

OS

overall survival

PBT

Persistent, Bioaccumulative and Toxic

PD-1

programmed cell death receptor 1

PD-L1

programmed cell death ligand 1

PEC

Predicted Environmental Concentration

PFS

progression-free survival

PK

pharmacokinetic(s)

PMDA

Japan Pharmaceutical and Medical Devices Agency

PNEC

Predicted No Effect Concentration

PopPK

population pharmacokinetics

pp

percentage points

PRO

patient reported outcome

PT

preferred term

PTX

paclitaxel

Q3W

every 3 weeks

QoL

quality of life

QTc

QT interval corrected for heart rate

<div style=\"page-break-after: always\"></div>

<div style=\"page-break-after: always\"></div>

| QTcF        | QT interval corrected for heart rate using Fridericia's formula   |
|-------------|-------------------------------------------------------------------|
| Ram         | ramucirumab                                                       |
| RDI         | relative dose intensity                                           |
| RECIST v1.1 | Response Evaluation Criteria in Solid Tumors Version 1.1          |
| RES         | Response Evaluable Set                                            |
| SAE         | serious adverse event                                             |
| SAP         | Statistical Analysis Plan                                         |
| SCS         | Summary of Clinical Safety                                        |
| SmPC        | Summary of Product Characteristics                                |
| SMQ         | Standardised MedDRA Queries                                       |
| SoC         | standard of care                                                  |
| SOC         | system organ class                                                |
| SoD         | sum of diameters                                                  |
| t1/2        | terminal elimination half-lifeT-DM1 trastuzumab emtansine         |
| T-DXd       | trastuzumab deruxtecan                                            |
| TEAE        | treatment-emergent adverse event                                  |
| Tmax        | time to reach maximum serum concentration                         |
| ToGA        | traztuzumab for gastic cancer                                     |
| TPC         | treatment of physician's choice (irinotecan or paclitaxel)        |
| TTR         | time to response                                                  |
| US          | United States                                                     |
| V1, T-DXd   | intact T-DXd central volume of distribution                       |
| V2,T-DXd    | intact T-DXd peripheral volume of distribution                    |
| VDXd        | DXd volume of distribution                                        |
| vs.         | versus                                                            |

Not all abbreviations have been used

<div style=\"page-break-after: always\"></div>

## 1. Background information on the procedure

Pursuant to Article 16 of Commission Regulation (EC) No 1234/2008, Daiichi Sankyo Europe GmbH submitted to the European Medicines Agency on 12 October 2021 an application for a variation.

The following changes were proposed:

| Variation requested   | Variation requested                                                                                                            | Type    | Annexes affected   |
|-----------------------|--------------------------------------------------------------------------------------------------------------------------------|---------|--------------------|
| C.I.6.a               | C.I.6.a - Change(s) to therapeutic indication(s) - Addition of a new therapeutic indication or modification of an approved one | Type II | I and IIIB         |

Extension of indication to include monotherapy treatment of adult patients with locally advanced or metastatic HER2-positive gastric or gastroesophageal junction (GEJ) adenocarcinoma who have received a prior anti-HER2-based regimen for Enhertu based on final results from studies DS8201-AU205 (DESTINY Gastric02) and DS8201-A-J202 (DESTINY Gastric01); as a consequence, sections 4.1, 4.2, 4.4, 4.8, 5.1, and 5.2 of the SmPC are updated. The Package Leaflet is updated in accordance. In addition, changes regarding the dosing recommendation for corticosteroid treatment and the protection of the infusion bag from light have been introduced. Version 1.1 of the RMP has also been submitted.

The requested variation proposed amendments to the Summary of Product Characteristics and Package Leaflet and to the Risk Management Plan (RMP).

## Information on paediatric requirements

Pursuant to Article 8 of Regulation (EC) No 1901/2006, the application included an EMA Decision(s) CW/0001/2015 on the granting of a class waiver.

## Information relating to orphan market exclusivity

## Similarity

Pursuant to Article 8 of Regulation (EC) No. 141/2000 and Article 3 of Commission Regulation (EC) No 847/2000, the MAH did not submit a critical report addressing the possible similarity with authorised orphan medicinal products because there is no authorised orphan medicinal product for a condition related to the proposed indication.

## Scientific advice

The MAH did not seek Scientific advice at the CHMP.

## Steps taken for the assessment of the product

The Rapporteur and Co-Rapporteur appointed by the CHMP were:

Rapporteur:

Aaron Sosa Mejia

Co-Rapporteur:

Paula Boudewina van Hennik

<div style=\"page-break-after: always\"></div>

| Timetable                                                   | Actual dates     |
|-------------------------------------------------------------|------------------|
| Submission date                                             | 12 October 2021  |
| Start of procedure:                                         | 30 October 2021  |
| CHMP Rapporteur Assessment Report                           | 17 December 2021 |
| PRAC Rapporteur Assessment Report                           | 3 January 2022   |
| CHMP Co-Rapporteur Critique                                 | 5 January 2022   |
| PRAC members comments                                       | 5 January 2022   |
| PRAC Outcome                                                | 13 January 2022  |
| CHMP members comments                                       | 17 January 2022  |
| Updated CHMP Rapporteur(s) (Joint) Assessment Report        | 21 January 2022  |
| Request for supplementary information (RSI)                 | 27 January 2022  |
| CHMP Rapporteur Assessment Report                           | 7 June 2022      |
| PRAC Rapporteur Assessment Report                           | 30 May 2022      |
| PRAC members comments                                       | 1 June 2022      |
| Updated PRAC Rapporteur Assessment Report                   | 7 June 2022      |
| PRAC Outcome                                                | 10 June 2022     |
| CHMP members comments                                       | 13 June 2022     |
| Updated CHMP Rapporteur Assessment Report                   | 17 June 2022     |
| Request for supplementary information (RSI)                 | 23 June 2022     |
| CHMP Rapporteur Assessment Report                           | 17 October 2022  |
| CHMP members comments                                       | 28 October 2022  |
| Updated CHMP Rapporteur Assessment Report                   | 4 November 2022  |
| SAG experts meeting to address questions raised by the CHMP | 3 November 2022  |
| Opinion                                                     | 10 November 2022 |

## 2. Scientific discussion

## 2.1. Introduction

## 2.1.1. Problem statement

## Disease

In most cases stomach (gastric) cancer (GC) starts in the lining of the stomach, growing slowly over the course of several years and causing few if any symptoms. Most patients (up to 95 percent) develop adenocarcinoma and are typically classified based on anatomic location (cardia/proximal, arising in the region adjoining the GEJ, or non-cardia/distal, arising in the lower portion of the stomach) and histologic type (diffuse, with undifferentiated tumour cells, or intestinal, with well-differentiated tumour cells).

<div style=\"page-break-after: always\"></div>

1 Overexpression  or  amplification  of  the  HER2  gene  or  protein  is  reported  in  approximately  20%  of patients with gastric adenocarcinoma, with higher rates of HER2 positivity seen in patients with intestinal histology than those with diffuse histology.

## State the claimed therapeutic indication

The wording of the proposed indication is:

ENHERTU as monotherapy is indicated for the treatment of adult patients with advanced HER2-positive gastric or gastroesophageal junction (GEJ) adenocarcinoma who have received a prior trastuzumabbased regimen.

The proposed dose of ENHERTU is 6.4 mg/kg every 3 weeks (Q3W) administered as an intravenous (IV) infusion over 90 minutes.  2 , 3  Patients who tolerate the first 90 -minute infusion can receive subsequent infusions  over  30  minutes.  Treatment  may  be  continued  until  symptomatic  disease  progression  or unacceptable toxicity.

## Epidemiology, risk factors, screening tools/prevention

GC is the fourth most commonly diagnosed cancer  4,5 (5.6% of all newly diagnosed cancers) and the third  most  common  cause  of  cancer-related  deaths  worldwide.  In  Western,  Southern  and  Northern Europe in 2020, there were an estimated 70,522 new cases of GC and 46,979 patients died of GC. The rates of GC are 2-fold higher in men than in women. The incidence of GC varies significantly among geographic regions, with the highest rates reported in Eastern Asia (including Japan and South Korea where it is amongst the most commonly diagnosed cancers in men), Central and Eastern Europe, and South America, while rates in Western Europe, Northern Europe, and North America are lower. Most patients present with inoperable advanced or metastatic disease requiring palliative treatment, although early detection is more common in Asia than in other regions. 5-year survival for advanced or metastatic gastric cancer is around 5-20%, with median overall survival being less than 1 year.

The major risk factors for developing gastric cancer include male gender, H. pylori infection, increasing age, smoking, and alcohol consumption. Other risk factors include salt in diet, positive family history, and pernicious anaemia. The risk of gastric cancer is nearly six times higher for H. Pylori-infected than for uninfected individuals; however, whilst around 60% of the world's population are infected with H. Pylori, less than 0.5% will develop gastric adenocarcinoma. 6

It is recognized that GC is difficult to treat at an advanced stage when it is no longer curable and survival outcomes are poor. Compared with the Asian countries that have national screening programs which starts at approximately 40 years of age allowing early detection of the disease, patients in Western countries  with  a  low  incidence  are  more  often  diagnosed  at  the  advanced  stage  and  have  a  worse prognosis.

1  National Comprehensive Cancer Network. NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®). Gastric cancer. Version 4.2021. 03 Aug 2021.

2  ENHERTU (fam-trastuzumab deruxtecan-nxki). Full Prescribing Information, Revised:12/2019 (United States). [Cited 24 Aug 2021]. Available at: www.accessdata.fda.gov/drugsatfda\\_docs/label/2019/761139s000lbl.pdf.

3  ENHERTU (fam-trastuzumab deruxtecan-nxki). Full Prescribing Information, Revised: 01/2021 (United States). [Cited 24 Aug 2021]. Available at: https://daiichisankyo.us/prescribing-informationportlet/ getPIContent?productName=Enhertu&amp;inline=true

4  World Health Organization. International Agency for Research on Cancer. GLOBOCAN 2020. Stomach Cancer.

[Cited 24 Aug 2021]. Available at: https://gco.iarc.fr/today/data/factsheets/cancers/7-Stomach-fact-sheet.pdf. 5   Sung H, Ferlay J, Siegel RL, et al. Global Cancer Statistics 2020: GLOBOCAN Estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021; 71(3):209-49.

6  Rawla P, Barsouk A. Epidemiology of gastric cancer: global trends, risk factors and prevention. Gastroenterology Rev. 2019; 14(1):26-38.

<div style=\"page-break-after: always\"></div>

## Aetiology and pathogenesis

There are three types of adenocarcinoma 7 :

Non-cardia (Distal) Stomach Cancer: This type of stomach cancer may be related to long periods of inflammation and irritation in the lower part of the stomach. It is often associated with chronic infection of bacteria called Helicobacter pylori and is more common in developing countries than in other parts of the world.

Proximal Stomach Cancer: This type of stomach cancer starts in the first (proximal) part of the stomach and may extend into the gastroesophageal junction (where the oesophagus joins the stomach). This cancer is more common in the western part than in other parts of the world, and tends to start in people who are obese or have gastro-oesophageal reflux disease.

Diffuse Stomach Cancer: This aggressive cancer grows rapidly in the cells of the stomach wall. It does not form a mass or a tumour, so it can be challenging to diagnose. It tends to start in younger people with a family history of the disease where a mutation in the adhesion molecule E Cadherin can be the cause (also associated with breast cancer) or a related genetic syndrome.

## Clinical presentation, diagnosis and stage/prognosis

The symptoms of gastric cancer are frequently vague and non-specific, with patients often unfortunately presenting at an advanced stage. The common presenting symptoms include dyspepsia (particularly if new onset or not responsive to simple PPI treatment), dysphagia, early satiety, vomiting, or melena. Non-specific cancer symptoms (anorexia, weight loss, or anaemia) are markers of late stage disease. On examination, clinical signs are usually absent, especially in the early stages, however an epigastric mass may be felt in late stage disease. Troisier sign is the presence of a palpable left supraclavicular node (Virchow node) and is considered a sign of metastatic abdominal malignancy (typically gastric). Other signs of metastatic disease include hepatomegaly, ascites, jaundice, or acanthosis nigricans.

The primary investigation of any suspected gastric cancer is an urgent upper GI endoscopy (OGD), allowing for the direct visualisation of any malignancy present and subsequent biopsies taken as needed.

Biopsies  8 from suspected gastric malignancies should be sent for:

- Histology - for classification and grading of any neoplasia present.
- CLO test - for the presence of H. Pylori.
- HER2/neu protein expression - this will allow for targeted therapies if present.

For staging and in order to plan treatment, all patients need a CT Chest-Abdomen-Pelvis and a staging laparoscopy (to look for peritoneal metastases), the most commonly used staging system for gastric cancers is TNM staging.

7  Rawla P, Barsouk A. Epidemiology of gastric cancer: global trends, risk factors and prevention. Gastroenterology Rev. 2019; 14(1):26-38.

8  Bartley AN, Washington MK, Colasacco C, et al. HER2 testing and clinical decision making in gastroesophageal adenocarcinoma: Guideline from the College of American Pathologists, American Society for Clinical Pathology, and the American Society of Clinical Oncology. J Clin Oncol. 2017; 35(4):446-64.

<div style=\"page-break-after: always\"></div>

## 5-year relative survival rates for GC

These numbers are based on people diagnosed with cancers of the stomach between 2010 and 2016. 9

<!-- image -->

| SEER stage            | 5-yearrelative survivalrate   |
|-----------------------|-------------------------------|
| Localized             | 70%                           |
| Regional              | 32%                           |
| Distant               | 6%                            |
| AllSEERstagescombined | 32%                           |

## Management

The current standard of care (SoC) for metastatic GC in the first-line setting based on guidelines in the EU,  US,  and  Japan  is  a  combination  of  chemotherapy  with  a  fluoropyrimidine  agent  (fluorouracil, capecitabine,  or  S-1  [EU  and  Japan])  and  a  platinum  agent  (oxaliplatin  or  cisplatin).  The  oral fluoropyrimidine regimen S-1 (tegafur [a prodrug of 5-fluorouracil]/gimeracil/oteracil) is approved in the EU and Japan in this indication, but not in the US.

Based on the ToGA study 10 , for patients with HER2-positive disease, the SoC in the EU, US and Japan is the fluoropyrimidine + platinum combination with the addition of the anti-HER2 monoclonal antibody (mAb) trastuzumab.

Second line treatment: Based on the REGARD and RAINBOW trials, the SoC in the EU is ramucirumab (a mAb targeting vascular endothelial growth factor receptor 2) in combination with paclitaxel. These trials included patients regardless of HER2 expression. Other treatment options in the second-line or subsequent therapy setting include single-agents docetaxel, paclitaxel, irinotecan and FOLFIRI (folinic acid,  fluorouracil,  and  irinotecan).  Regimens  recommended  in  third-line  or  beyond  are  irinotecan, taxanes, pembrolizumab if PD-L1 expression by CPS ≥ 1, and the trifluridine/tipiracil regimen.

Locally advanced or metastatic HER2-positive gastric adenocarcinoma remains an incurable disease. Once patients have progressed after a first-line regimen that includes an anti-HER2 therapy, the disease outcomes  are  poor.  Currently,  there  is  no  approved  targeted  anti-HER2  therapy  in  the  EU  for  the treatment of metastatic HER2-positive gastric adenocarcinoma in the second-line setting and beyond, which constitutes an unmet medical need.

9  John S, Broggio J. Office for National Statistics. Cancer survival in England: adult, stage at diagnosis and childhood - patients followed up to 2018. [Cited 24 Aug 2021]. Available at:ttps://www.ons.gov.uk/peoplepopulationandcommunity/healthandsocialcare/conditionsa nddiseases/bulletins/cancersurvivalinengland/stageatdiagnosisandchildhoodpatientsfollowedupto2018

10  Bang YJ, Van Cutsem E, Feyereislova A, et al. Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a Phase 3, open-label, randomised controlled trial. Lancet. 2010; 376(9742):687-97.

<div style=\"page-break-after: always\"></div>

## 2.1.2. About the product

The active substance in ENHERTU, trastuzumab deruxtecan, is made up of two active components which are linked together:

- Trastuzumab, a monoclonal antibody that has been designed to attach to HER2, which is found in large quantities on some cancer cells. By attaching to HER2, trastuzumab activates cells of the immune system, which then kill the cancer cells. Trastuzumab also stops HER2 from stimulating the growth of cancer cells.
- Deruxtecan, a toxic substance that kills cells when they attempt to divide and grow. It becomes active once the trastuzumab component has attached to HER2 and enters the cancer cell. Deruxtecan blocks an enzyme called topoisomerase I, which is involved in copying cell DNA and is needed to make new cells. By blocking the enzyme, cancer cells are prevented from multiplying and they eventually die.

Trastuzumab deruxtecan is currently approved as monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive breast cancer who have received one or more prior anti-HER2 based regimens.  The recommended dose for HER2-positive BC is 5.4 mg/kg once every 3 weeks (Q3W).

## 2.1.3. The development programme/compliance with CHMP guidance/scientific advice

Scientific advice from the CHMP was not sought concerning the clinical development of Enhertu in the GC/GEJC setting.

A pre-submission meeting with the Rapporteurs was held on 30 August 2021.

## 2.1.4. General comments on compliance with GCP

The MAH claims that the studies are conducted in accordance with the ethical principles that have their origin  in  the  Declaration  of  Helsinki  and  that  are  consistent  with  the  International  Council  for Harmonisation (ICH) guidelines for Good Clinical Practice (GCP) and applicable regulatory requirements.

## 2.2. Non-clinical aspects

New non-clinical data have been submitted in this application, which is considered acceptable.

Results from 11 nonclinical studies with human biomaterials were previously submitted and are not described further. An additional nonclinical study (Study TCRM-DMPK-2020-19) was conducted after the initial BC application. This additional study using cryopreserved hepatocytes supported that the released drug (DXd), at concentrations of up to 30 nmol/L, did not show any induction potential or effect on the metabolic activity of cytochrome P450 (CYP)3A4, CYP1A2, or CYP2B6.

However,  a  new  environmental  risk  assessment  report  was  submitted  to  reflect  the  new  intended indication.

## 2.2.1. Introduction

Trastuzumab  deruxtecan  (herein  referred  to  as  T-DXd)  has  been  approved  in  the  EU  for  use  as  a monotherapy  indicated  for  the  treatment  of  adult  patients  with  unresectable  or  metastatic  human epidermal growth factor receptor 2 (HER2)-positive breast cancer who have received 2- or more prior anti-HER2-based  regimens  (EMEA/H/C/005124).  Daiichi  Sankyo  Europe  is  submitting  this  type  II

<div style=\"page-break-after: always\"></div>

variation to register T-DXd, as a monotherapy indicated for the treatment of adult patients with locally advanced or metastatic HER2-positive gastric or gastroesophageal junction (GEJ) adenocarcinoma who have received a prior anti-HER2-based regimen. An Environmental Risk Assessment (ERA) has been undertaken for T-DXd in accordance with the EMA Guidance (CHMP 2006: EMEA/CPMP/SWP/4447/00 and CHMP 2016: EMA/CHMP/SWP/44609/2010).

## 2.2.2. Ecotoxicity/environmental risk assessment

Tabulated summary:

<!-- image -->

| Substance (INN/Invented Name): DXd (as MAAA-1l8ld; released drug of T-DXd)   | Substance (INN/Invented Name): DXd (as MAAA-1l8ld; released drug of T-DXd)   | Substance (INN/Invented Name): DXd (as MAAA-1l8ld; released drug of T-DXd)   | Substance (INN/Invented Name): DXd (as MAAA-1l8ld; released drug of T-DXd)           |
|------------------------------------------------------------------------------|------------------------------------------------------------------------------|------------------------------------------------------------------------------|--------------------------------------------------------------------------------------|
| CAS-number (if available): N/A                                               | CAS-number (if available): N/A                                               | CAS-number (if available): N/A                                               | CAS-number (if available): N/A                                                       |
| PBT screening                                                                |                                                                              | Result                                                                       | Conclusion                                                                           |
| Bioaccumulationpotential-log Kow                                             | OECD107 (1075.00204)                                                         | pH 5 = 1.92 pH 7 = 1.80 pH 9 = 1.28                                          | <4.5: not B < 4.5: not PBT                                                           |
| Phase I                                                                      | Phase I                                                                      | Phase I                                                                      | Phase I                                                                              |
| Calculation                                                                  | Value                                                                        | Unit                                                                         | Conclusion                                                                           |
| PEC sufacewater , default                                                    | If Fpen=0.01 0.0565 (default)                                                | μg/L                                                                         | Refined PEC <0.01 μg/L No Phase II                                                   |
| Breast cancerrefined PECsufacewater                                          | If Fpen=0.000288 1.40 x10-3 (refined)                                        | μg/L                                                                         | assessmentrequired                                                                   |
| Gastric cancer refined PECsufacewater                                        | If Fpen=0.000190 1.07 x10-3 (refined)                                        | μg/L                                                                         | Refined PEC <0.01 μg/L No Phase II                                                   |
| Combinedl (total) PECsurfacewater                                            | 0.00247                                                                      | μg/L                                                                         | Refined PEC <0.01 μg/L No Phase II                                                   |
| Other concems (e.g. chemical class)                                          |                                                                              |                                                                              | None                                                                                 |
| PhaseII Physical-chemicalproperties andfate                                  | PhaseII Physical-chemicalproperties andfate                                  | PhaseII Physical-chemicalproperties andfate                                  | PhaseII Physical-chemicalproperties andfate                                          |
| Study type                                                                   | Test protocol                                                                | Results                                                                      | Remarks                                                                              |
| Water Solubility                                                             | OECD 105 (1075.00203)                                                        | 7.52 mg/L                                                                    |                                                                                      |
| Dissociation Constant (pKa)                                                  | OECD 112 (1075.00201)                                                        | N/A                                                                          | Study not possible due to low watersolubility and other physical chemical properties |

## Summary

T-DXd is an Antibody Drug Conjugate (ADC) composed of an anti-HER2 mAb covalently conjugated to a drug-linker, deruxtecan. The drug-linker is composed of a cleavable maleimide tetrapeptide and the released drug, DXd. DXd is a potent topoisomerase I inhibitor. The three components of T-DXd, mAb, tetrapeptide linker, and drug (DXd), will be examined individually within this assessment. The three components are designed to dissociate from one another once bound to the HER2 positive target cell in patients and therefore they will be excreted separately and can be treated as separate molecules within the environmental risk assessment.

Both the mAb and the tetrapeptide linker are considered to be naturally occurring molecules (i.e., they are polypeptides or proteins), which are not expected to remain either stable or biologically active in the environment for any significant period of time because of their high susceptibility to rapid chemical (e.g., oxidation,  deamidation,  proteolysis,  beta  elimination  and  disulfide  scrambling)  and  physical  (e.g., denaturation (protein unfolding), aggregation, precipitation, and surface adsorption) degradation, as well  as  biodegradation  by  a  wide  range  of  microflora,  and  various  physical  removal  mechanisms.

<div style=\"page-break-after: always\"></div>

Degradation may be easily triggered from exposure to uncontrolled ambient environmental conditions (e.g., due to desiccation, suboptimal pH or temperature, and light exposure).

The mAb and the tetrapeptide linker  molecules  are  considered  to  be  non-hazardous,  biodegradable products. As such, the environmental risk in terms of use and disposal is considered to be negligible and in accordance with the guideline (CHMP 2006: EMEA/CHMP/SWP/4447/00), ERA studies are not required.

The active pharmaceutical ingredient DXd is a topoisomerase I inhibitor and is released from the mAb and linker portion of T-DXd upon binding to the target cell. Therefore, the environmental risk assessment considers this molecule in isolation.

The calculated refined PECsurfacewater is below the Phase I action li mit (0.01 μg/L); therefore, the risk assessment for T-DXd ceases at Phase I. No Phase II environmental risk assessment is required, see below for details.

## Screening for Persistence, Bioaccumulation and Toxicity

The monohydrate form of DXd (named MAAA-1181d) was used for all experimental testing but is referred to as DXd throughout this assessment. This is not considered to impact the risk assessment to any significant extent. No molar conversion of the monohydrate form is considered necessary within this risk assessment.

The octanol-water distribution coefficient, Log Dow, of DXd was determined across an environmentally relevant pH-range. The log Dow values were in the range 1.28 to 1.92, and since they are &lt;4.5, no further screening for persistence, bioaccumulation and toxicity is necessary.

## Calculation of Predicted Environmental Concentration (PEC)

## Approved indications

T-DXd is approved as a monotherapy indicated for the treatment of adult patients with unresectable or metastatic human epidermal growth factor receptor 2 (HER2)-positive breast cancer who have received 2 or more prior anti-HER2-based regimens.

## Extensions and New indications

Daiichi Sankyo Europe is submitting this type II variation (extension of indication) to register T-DXd, as a monotherapy indicated for the treatment of adult patients with locally advanced or metastatic HER2positive gastric or gastroesophageal junction (GEJ) adenocarcinoma who have received a prior antiHER2-based regimen. The maximum recommended dose of T-DXd is 6.4 mg/kg, given as an intravenous infusion once every 3 weeks (21-day cycle) until disease progression or unacceptable toxicity.

## Default PEC Calculation

On average, the target number of drug-linker (deruxtecan) to 1 antibody molecule is 8. The molecular weight of deruxtecan is 1034.05 and the molecular weight of the mAb is approximately 150,000 Da. Therefore, the total molecular weight of T-DXd is approximately 158,000 Da. On average 8 molecules of the active drug (DXd at 493.484 Da) are present on each molecule (8 × 493.484 = 3947.872 Da), thus DXd represents approximately 2.5% of the total dose of T-DXd (3947.872 ÷ 158 000 = 2.5%).

The maximum recommended dose of T-DXd taken in one day is 6.4 mg/kg; which is given once every 3 weeks for gastric cancer indications. Breast cancer indications require a lower dose and therefore are sufficiently covered assuming a worst-case daily dose of 6.4 mg/kg. Average body weight in Europe has been estimated to be approximately 70.8 kg (Walpole et al 2012).

The maximum daily dose is calculated based on the maximum recommended dose which can be taken in one day (6.4 mg/kg) and the average weight of a European adult (6.4 mg/kg × 70.8 kg). A reduction

<div style=\"page-break-after: always\"></div>

is then applied to this maximum daily dose based on the percentage of total dose representing the active drug (2.5%); equivalent to 11.3 mg per day.

In line with the conservative nature of the assessment, no consideration is given to the posology of the dose only being given once every 3 weeks. The calculation conservatively assumes the maximum daily dose is taken every day by all patients; this equates to an approximate 21-fold over estimate in the PEC. For example, the average daily dose taken by a patient receiving one dose per week would be equivalent to: 11.3 mg (maximum daily dose) ÷ 21 days (3 weeks) = 0.53 mg / day

<!-- image -->

where;

DOSEai = maximum daily dose consumed per inhabitant = 11.3 mg x inh-1 x d-

Fpen = market penetration factor (default) 0.01

x  x T o = A    o e =

DILUTION = dilution factor = 10

<!-- formula-not-decoded -->

<!-- formula-not-decoded -->

<!-- formula-not-decoded -->

The default PECsurfacewater is above the PEC action limit for triggering a full ERA. As mentioned previously the PEC based on maximum daily dose is approximately 21-fold higher than if based on the actual dose regime recommended (once every 3 weeks). A PEC accounting for the actual dosing regimen would clearly be below the trigger ( ≤ 0.01 μ g/L); however, the PEC has subsequently been refined utilising prevalence data on the stated indication(s).

<div style=\"page-break-after: always\"></div>

## Refined PEC Calculation

The disease prevalence has been used to estimate the refined PECsurfacewater for each individual indication. The total PECsurfacewater is then calculated as the sum of all the PECsurfacewaters for each indication.

## Breast Cancer

The Globocan database estimates Belgium to be the European Member State with the highest prevalence of breast cancer; 1-year prevalence is 191.8 per 100 000 females (Globocan 2018; Appendix 2). The prevalence data is available on a 'per female' only; the prevalence rate therefore was adjusted to that of the total population assuming a 1:1 male: female ratio. As such, the single year prevalence for breast cancer in Belgium is estimated to be 191.8 per 200 000 to account for the equivalent numbers of males in the total population; equivalent to 95.9 per 100 000 total population. In addition, HER2-positive breast cancers have been demonstrated to account for approximately 20% and not more than 30% of all breast cancer sub-types (Wolff et al., 2013; Slamon et al., 1987; Hudis 2007).

The worst-case Fpen used for dose calculation is therefore proposed to be refined to (30% × 0.000959) 0.000288. The maximum daily dose is calculated based on the maximum recommended dose which can be taken in one day (5.4 mg/kg) and the average weight of a European adult (5.4 mg/kg × 70.8 kg). A reduction is then applied to this maximum daily dose based on the percentage of total dose representing the active drug (2.5%); equivalent to 9.56 mg per day.

In line with the conservative nature of the assessment, no consideration is given to the posology of the dose only being given once every 3 weeks. The calculation conservatively assumes the maximum daily dose is taken every day by all patients; this equates to an approximate 21-fold over estimate in the PEC. For example, the average daily dose taken by a patient receiving one dose per week would be equivalent to: 9.56 mg (maximum daily dose) ÷ 21 days (3 weeks) = 0.45 mg / day

<!-- image -->

## where,

DOSEai = maximum daily dose consumed per inhabitant = 9.56 mg × inhr1 x d-l

Fpen = 0.000288 (highest EU prevalence of HER2-positive breast cancer)

1 x  x o =  d    go  =

<!-- formula-not-decoded -->

<!-- formula-not-decoded -->

<!-- formula-not-decoded -->

<div style=\"page-break-after: always\"></div>

## Gastric Cancer

The  Globocan  database  estimates  Lithuania  to  be  the  European  Member  State  with  the  highest prevalence of gastric cancer; 1-year prevalence is 19.0 per 100 000 (Globocan 2018; Appendix 3). The worst-case Fpen used for dose calculation is therefore proposed to be 0.000190.

The maximum daily dose is calculated based on the maximum recommended dose which can be taken in one day (6.4 mg/kg) and the average weight of a European adult (6.4 mg/kg × 70.8 kg). A reduction is then applied to this maximum daily dose based on the percentage of total dose representing the active drug (2.5%); equivalent to 11.3 mg per day.

In line with the conservative nature of the assessment, no consideration is given to the posology of the dose only being given once every 3 weeks. The calculation conservatively assumes the maximum daily dose is taken every day by all patients; this equates to an approximate 21-fold over estimate in the PEC. For example, the average daily dose taken by a patient receiving one dose per week would be equivalent to: 11.3 mg (maximum daily dose) ÷ 21 days (3 weeks) = 0.53 mg / day

<!-- image -->

where;

DOSEai = maximum daily dose consumed per inhabitant = 11.3 mg x inh-1 x d-1

Fpen = 0.000190 (highest EU prevalence of gastric cancer)

<!-- formula-not-decoded -->

DILUTION = dilution factor = 10

<!-- formula-not-decoded -->

<!-- formula-not-decoded -->

or

<!-- image -->

<!-- formula-not-decoded -->

## Combined PECsurfacewater

The total or combined PECsurfacewater is calculated as the sum of all the refined PECsurfacewater values for each indication as detailed below.

<div style=\"page-break-after: always\"></div>

<!-- formula-not-decoded -->

The refined PECsur facewater is below the PEC action limit of 0.01 μg/L for triggering a full Phase II ERA. No Phase II ERA is therefore required or presented.

## 2.2.1. Discussion on non-clinical aspects

The active pharmaceutical ingredient DXd is a topoisomerase I inhibitor and is released from the mAb and linker portion of T-DXd upon binding to the target cell. Therefore, the environmental risk assessment considers this molecule in isolation. This is accepted, since the rest of the molecule can be considered of protein nature, which is susceptible to rapid degradation in the environment.

The disease prevalence was used to estimate the refined PECsurfacewater for each individual indication. The total PECsurfacewater is then calculated as the sum of all the PECsurfacewater for each indication.

Hence, without considering the posology of administration once every 3 weeks, the sum of the two PECsurfacewaters is

<!-- formula-not-decoded -->

Which is below the action limit of 0.01 µg/L and no further environmental risk assessment should be required.

## 2.2.2. Conclusion on the non-clinical aspects

Considering the above data, Trastuzumab deruxtecan is not expected to pose a risk to the environment.

## 2.3. Clinical aspects

## 2.3.1. Introduction

## GCP

The Clinical trials were performed in accordance with GCP as claimed by the MAH.

The MAH has provided a statement to the effect that clinical trials conducted outside the community were carried out in accordance with the ethical standards of Directive 2001/20/EC.

- Tabular overview of clinical studies

<div style=\"page-break-after: always\"></div>

Table 1.2: Clinical StudiesIncluded in the Application

| Study Number, Phase,and Status                | DCO                                                           | Study Title Total Number of Subjects (Location in Module 5)                                                                                                                                                                                             | Test Products and Dosage Regimen                                                                                                                                                                                                                                                                                                                                                 |
|-----------------------------------------------|---------------------------------------------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| DS8201-A- J202 (Study J202) Phase 2 Completed | Primary efficacy analysis: 08 Nov 2019 UpdateDCO: 03 Jun 2020 | A Phase 2,multicenter, open-label study of DS-8201a in subjects with HER2-positive advanced gastric or GEJ adenocarcinoma (DESTINY-Gastric01) N= 233 subjects (see Module 5.3.5.1 DS8201-A-J202 CSR) (see Module 5.3.5.1 DS8201-A-J202 Abbreviated CSR) | T-DXd,IV infusion Q3W,6.4mg/kg Primary Cohort (HER2-positive[IHC 3+ or IHC 2+ /ISH-positive] and pretreated): 188 subjects randomized 2:1 to T-DXd (n=126)orTPC（n=62;55irinotecan, 7 PTX) Exploratory Cohorts (treatment-naivefor anti-HER2 therapy; nonrandomized): Exploratory Cohort 1 (HER2 IHC 2+/ISH-negative): 21 subjects Exploratory Cohort 2 (HER2 IHC 1+) 24 subjects |

| Study Number, Phase, and Status                | DCO                                    | Study Title Total Number of Subjects （Location in Module 5）                                                                                                                                                                                                                              | Test Products and Dosage Regimen                      |
|------------------------------------------------|----------------------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------------------------------------------------|
| DS8201-A- U205 (Study U205) Phase 2 Completeda | Primary efficacy analysis: 09 Apr 2021 | A Phase 2, open-label, single-arm study of T-DXd (DS-8201a)inHER2- positive,unresectable or metastatic gastric or GEJ adenocarcinoma subjects who have progressed on or after a trastuzumab- containingregimen (DESTINY-Gastric02) N= 79 subjects (see Module 5.3.5.2 DS8201-A-U205 CSR) | T-DXd, IV infusion Q3W, 6.4 mg/kg 79 subjects treated |

<div style=\"page-break-after: always\"></div>

| DS8201-A- J101 (Study J101) Phase 1 Completeda   | Primary efficacy analysis: 01 Feb 2019 UpdateDCO: 01 Aug 2019 (outputs only no report)   | Phase 1, 2-part, multicenter, nonrandomized,open- label, multiple dose first- in-human study of DS-8201a in subjects with advanced solid malignant tumors N=292 subjects, including 44 subjects with metastatic HER2-positive gastric or GEJ adenocarcinoma in Part 1 and Part 2b ofthe study: 19 assigned to 5.4 mg/kg and 25 assigned to 6.4 mg/kg (see Module 5.3.3.2 DS8201-A-J101 CSR)   | T-DXd,IV infusion Q3W Part 1,DoseEscalation: (27 subjects treated) 0.8 mg/kg, 1.6 mg/kg, 3.2 mg/kg 5.4 mg/kg, 6.4 mg/kg, 8.0 mg/kg Included3subjectswithHER2-positive gastric or GEJ cancer treated either at 5.4 mg/kg (n =2) or 6.4 mg/kg (n = 1) Part 2,DoseExpansion: (262 subjects treated) Part 2a (HER2-positive breast cancer): 103 subjects Part 2b (HER2-positive gastrie or GEJ cancer): 41 subjects,ofwhich 17were treated at 5.4 mg/kg and 24 at 6.4 mg/kg Part 2c (HER2-low breast cancer): 40 subjects Part 2d: HER2-positive solid tumors other than breast and gastric: 60 subjects Part 2e: HER2-positive breast cancer: 21 subjects   |
|--------------------------------------------------|------------------------------------------------------------------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

## 2.3.2. Pharmacokinetics

## Introduction

Trastuzumab  deruxtecan  (T-DXd)  is  a  human  epidermal  growth  factor  receptor  2  (HER2)-targeted antibody  and  topoisomerase  I  inhibitor  conjugate  (ADC  molecule)  approved  for  the  treatment  of unresectable or metastatic HER2-positive breast cancer (T-DXd dose 5.4 mg/kg) who have received two or more prior anti-HER2-based regimens.

The present application concerns approval of T-DXd as 2L monotherapy (T-DXd dose 6.4 mg/kg) for treatment of patients with locally advanced or metastatic HER2-positive gastric or GEJ adenocarcinoma who have received a prior anti-HER2-based regimen.

A  summary of the studies  and  analyses  conducted  as  part  of  the  clinical  pharmacology  program  is provided in this section. The clinical pharmacology package for the initial BC application included five studies (Studies J101, J102, A103, A104, and U201). The package included in the current application includes  data  from  two  additional  Phase  2  studies  in  subjects  with  HER2-positive  advanced  GC  or gastroesophageal junction (GEJ) adenocarcinoma (Studies J202 and U205). A list and brief descriptions of the seven studies that were conducted to evaluate the clinical pharmacological properties of T-DXd are shown in Table 1.1 . In each study, serum concentrations of three analytes (intact antibody-drug conjugate T-DXd, total anti-HER2 antibody, and the topoisomerase I inhibitor DXd) were measured to characterize the PK of T-DXd. A randomised, 2-arm, open-label Phase 3 Study U306 is currently enrolling subjects with HER2-positive GC who have received a prior trastuzumab containing regimen (2L setting). This study started enrolment in 2021, therefore there are no data to present from this study.

<div style=\"page-break-after: always\"></div>

Table 1.1: List of Clinical Pharmacology Studies

| Document No. Location Data Cut-Off Date   | Short Study Title   | Study Title                                                                                                                                               | Subjects                                                                                                                                                                                                                                                                                                                                                                                                                                                                      | Region              | Dose Regimen                                                                                                                                                                                                                                                                                                                                                                                                             |
|-------------------------------------------|---------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|---------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| J101 Module 5.3.3.2 01 Feb 2019           | J101                | Phase 1, two- part, multicenter, non-randomized, open-label, multiple-dose first-in-human study ofT-DXd, in subjects with advanced solid malignant tumors | Part 1: Subjects with advanced BC and gastric or GEJ adenocarcinoma Part 2a: Subjects with HER2-positive BC previously treated with T-DM1 Part 2b: Subjects with HER2-positive gastric or GEJ adenocarcinoma previously treated with trastuzumab Part 2c: Subjects with BCwith low HER2 expression Part 2d: Subjects with HER2-expressing solid cancers, except BC and gastric or GEJ adenocarcinoma or subjects with HER2 mutation Part 2e: Subjects with HER2-expressing BC | North America ,Asia | T-DXd, IV infusion Q3W Part 1, Dose Escalation: 0.8 mg/kg, 1.6 mg/kg. 3.2 mg/kg, 5.4 mg/kg. 6.4 mg/kg. 8.0 mg/kg Part 2. Dose Expansion: Part 2a: HER2- overexpressin g BC (5.4 mg/kg and 6.4 mg/kg) Part 2b: HER2- overexpressin g gastric or GEJ cancer (5.4 mg/kg and 6.4 mg/kg) Part 2c: HER2-low BC (5.4 mg/kg and 6.4 mg/kg) Part 2d: HER2- expressing solid tumors other than breast and gastric (6.4 mg/kg only) |

<div style=\"page-break-after: always\"></div>

|                                 |      |                                                                                                                                                                                                                                             |                                                                                                                    |      | Part 2e: HER2- expressing BC (6.4 mg/kg only)                                                |
|---------------------------------|------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------------------------------------------------------------------------------------------------------------|------|----------------------------------------------------------------------------------------------|
| J102 Module 5.3.4.2 05 Dec 2018 | J102 | Phase 1, multicenter, open-label, multiple-dose study of T-DXd to assess the effect on the QT interval and pharmacokinetics in subjects with HER2- expressing. metastatic and/or unresectable BC                                            | Subjects with metastatic or unresectable HER2- expressing BC                                                       | Asia | T-DXd, 6.4 mg/kg IV infusion Q3W                                                             |
| A103 Module 5.3.3.2 14 Sep 2018 | A103 | Phase l, multicenter, open-label study of T-DXd to assess safety and pharmacokinetics in subjects with HER2-positive advanced and/or refractory gastric, GEI adenocarcinoma, or BC                                                          | Taiwanese subjects with HER2-positive advanced and/or refractory gastric adenocarcinoma, GEJ adenocarcinoma, or BC | Asia | T-DXd, 6.4 mg/kg IV infusion Q3W                                                             |
| A104 Module 5.3.3.4 26 Sep 2018 | A104 | Phase 1, multicenter, open-label, single sequence crossover study to evaluate drug- drug interaction potential of OATP1B/CYP3 A inhibitor on the pharmacokinetics of T-DXd in subjects with HER2-expressing advanced solid malignant tumors | Subjects with unresectable or metastatic HER2- expressing advanced solid cancers                                   | Asia | T-DXd, 5.4 mg/kg IV infusion Q3W Cohort 1: Ritonavir + T- DXd Cohort 2: Itraconazole +T- DXd |

<div style=\"page-break-after: always\"></div>

| U201 (DESTINY- Breast01) Module 5.3.5.2 21 Mar 2019   | U201   | Phase 2, multicenter, open-label study ofT-DXd, an anti-HER2 ADC for HER2- positive, unresectable and/or metastatic BC subjects previously treated with T-DM1   | Subjects with unresectable or metastatic HER2- positive BC previously treated with T-DM1                                                                                                                                                                                                                                                                 | North America ,Asia, Europe   | T-DXd, IV infusion Q3W Part 1, PK stage: Randomized 1:1:1 5.4 mg/kg 6.4 mg/kg 7.4 mg/kg Part 1, Dose- finding stage: Randomized 1:1 5.4 mg/kg 6.4 mg/kg Part 2a and b: All subjects received T-DXd at RP2D determined to be 5.4 mg/kg   |
|-------------------------------------------------------|--------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| J202 (DESTINY- Gastric01) Module 5.3.5.1 03 Jun 2020  | J202   | Phase 2, multicenter, open-label study ofT-DXd in subjects with HER2-expressing advanced gastric or GEI adenocarcinoma                                          | Subjects with locally advanced or metastatic HER2-expressing gastric or GEJ adenocarcinoma Primary Cohort: HER2- overexpressing Progression on a trastuzumab Randomized 2:1 T-DXd group Physician's choice group Exploratory Cohort 1: HER2 IHC 2+/ISH- negative Treatment naive with T-DXd Exploratory Cohort 2: HER2 IHC 1+ Treatment naive with T-DXd | Asia                          | T-DXd, 6.4 mg/kg IV infusion Q3W                                                                                                                                                                                                        |

<div style=\"page-break-after: always\"></div>

| U205 (DESTINY- Gastric02) Module 5.3.5.2 09 Apr 2021   | U205   | Phase 2, open- label, single-arm study of T-DXd in HER2- positive, unresectable or metastatic gastric or GEI adenocarcinoma subjects who have progressed on or after a trastuzumab- containing regimen   | Subjects with unresectable or metastatic gastric or GEJ adenocarcinoma thathas progressed on or after a trastuzumab-containing regimen   | North America ,Europe   | T-DXd, 6.4 mg/kg IV infusion Q3W   |
|--------------------------------------------------------|--------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------------------------------------------------------------------------------------------------------------------------------------|-------------------------|------------------------------------|

ADC = antibody-drug conjugate; BC = breast cancer; GC = gastric cancer; GEJ = gastroesophageal junction; HER2 = human epidermal growth factor receptor 2.; IHC = immunohistochemistry; ISH = in situ hybridization; IV = wecks;RP2D=recommended Phase 2 dose; T-DM1 =trastuzumab emtansine;T-DXd=trashuzumab deruxtecan.

## Methods

In addition to the studies listed above, population pharmacokinetic (PopPK) and exposure-response (ER) analyses were used to further characterize the clinical pharmacology profile of T-DXd. The PopPK analysis developed for the initial BC application with data from five studies was updated with data from Study J202, and was further updated with inclusion of data from Study U205 ( Table 1.1 - List of Clinical Pharmacology Studies ).

Results from the updated analysis including Study U205 are presented in this document.

## Bioanalysis

The same bioanalytical methods used to quantify the three moieties from T-DXd and to detect and confirm anti-T-DXd, or ADA in human serum, in the initial breast cancer application, were also used for bioanalysis conducted in studies J202 and U205. ADA positive samples were further analysed using a new validated cell-based assay for detection of NAb against T-DXd.

The NAb method performance is summarised below:

<div style=\"page-break-after: always\"></div>

Table 1.3: Method Summary for the Detection of Neutralizing Antibodies Against T-DXd inHumanSerum (. Project RIRM2 -Method VSDCBA 82)

| Analyte                         | Neutralizing antibodies against trastuzumab deruxtecan                                                                        | Neutralizing antibodies against trastuzumab deruxtecan                                                                        | Neutralizing antibodies against trastuzumab deruxtecan                                                                        |
|---------------------------------|-------------------------------------------------------------------------------------------------------------------------------|-------------------------------------------------------------------------------------------------------------------------------|-------------------------------------------------------------------------------------------------------------------------------|
| Precision a                     |                                                                                                                               | HPC                                                                                                                           | LPC                                                                                                                           |
| Precision a                     | Concentration                                                                                                                 | 4.00 μg/mL                                                                                                                    | 2.00 μg/mL                                                                                                                    |
| Precision a                     | Inter-assay (%CV)                                                                                                             | 37.0                                                                                                                          | 6.59                                                                                                                          |
| Precision a                     | Intra-assay (%CV)                                                                                                             | 0.842                                                                                                                         | 7.34                                                                                                                          |
| Screening assay cut point(s)    | ≥ 1.15 (NHS); ≥ 1.10 (BCS) (upper bound 99% limit of prediction interval)                                                     | ≥ 1.15 (NHS); ≥ 1.10 (BCS) (upper bound 99% limit of prediction interval)                                                     | ≥ 1.15 (NHS); ≥ 1.10 (BCS) (upper bound 99% limit of prediction interval)                                                     |
| Specificity/Matrix Interference | Unspiked: Ten out of ten individuals were negative (NHS and BCS) LPC: Ten out of ten individuals were reactive (NHS and BCS)  | Unspiked: Ten out of ten individuals were negative (NHS and BCS) LPC: Ten out of ten individuals were reactive (NHS and BCS)  | Unspiked: Ten out of ten individuals were negative (NHS and BCS) LPC: Ten out of ten individuals were reactive (NHS and BCS)  |
| Sensitivity                     | 1.41 μg/mL                                                                                                                    | 1.41 μg/mL                                                                                                                    | 1.41 μg/mL                                                                                                                    |
| Cell Passage Limit              | Passages 4 to 27                                                                                                              | Passages 4 to 27                                                                                                              | Passages 4 to 27                                                                                                              |
| Drug Tolerance b                | LPC: up to 50.0 μg/mL excess trastuzumab deruxtecan HPC: up to 100 μg/mL excess trastuzumab deruxtecan                        | LPC: up to 50.0 μg/mL excess trastuzumab deruxtecan HPC: up to 100 μg/mL excess trastuzumab deruxtecan                        | LPC: up to 50.0 μg/mL excess trastuzumab deruxtecan HPC: up to 100 μg/mL excess trastuzumab deruxtecan                        |
| LipemiaInterference             | Five out of six unspiked, and six out of six samples spiked at the LPC and HPC levels met acceptance criteria.                | Five out of six unspiked, and six out of six samples spiked at the LPC and HPC levels met acceptance criteria.                | Five out of six unspiked, and six out of six samples spiked at the LPC and HPC levels met acceptance criteria.                |
| Hemolysis Interference          | 1%,5%and 10%hemolysis levels tested.For each level, six out of six unspiked, spiked at LPC, and spiked at HPC met acceptance. | 1%,5%and 10%hemolysis levels tested.For each level, six out of six unspiked, spiked at LPC, and spiked at HPC met acceptance. | 1%,5%and 10%hemolysis levels tested.For each level, six out of six unspiked, spiked at LPC, and spiked at HPC met acceptance. |
| StabilityFreeze/Thaw            | Eight cycles thawed at room temperature                                                                                       | Eight cycles thawed at room temperature                                                                                       | Eight cycles thawed at room temperature                                                                                       |
| Thawed Matrix Stability         | 12 hours at room temperature and 24 hours at 2 to 8 °C                                                                        | 12 hours at room temperature and 24 hours at 2 to 8 °C                                                                        | 12 hours at room temperature and 24 hours at 2 to 8 °C                                                                        |
| Clinical Studies sd             | DS8201-A-J101,DS8201-A-J102,DS8201-A-A103,DS8201-A-A104,DS8201- A-U201,DS8201-A-J202,and DS8201-A-U205.                       | DS8201-A-J101,DS8201-A-J102,DS8201-A-A103,DS8201-A-A104,DS8201- A-U201,DS8201-A-J202,and DS8201-A-U205.                       | DS8201-A-J101,DS8201-A-J102,DS8201-A-A103,DS8201-A-A104,DS8201- A-U201,DS8201-A-J202,and DS8201-A-U205.                       |

- b Drug tolerance demonstrated in validation is higher than mean Ctrough concentrations, which are 5.5, 9.2, 8.8, and 11.8 μg/mL for 5.4, 6.4, 7.4 and 8.0 mg/kg dose levels, respectively. Data source - Table 3.1 of initial breast cancer application CTD 2.7.2.

For clinical studiesDS8201-A-J101,DS8201-A-J102,DS8201-A-A103,DS8201-A-A104,andDS8201-A-U201, breast cancer specific cut point was applied for sample analysis.For clincial studies DS8201-A-J202, DS8201-A204, and DS8201-A-205, normal human serum cut point was applied for sample analysis.

d NAb sample analysis reports for DS8201-A-J101, DS8201-A-J102, DS8201-A-A103, DS8201-A-A104, DS8201A-U201 studies (which were not included in the original CSRs) can be found in the Combined NAb Assay Sample Analysis Report for DS-8201a Studies.For all other studies(DS8201-A-J202 and DS8201-A-U205) NAb sample analysis reports can be found in respective CSRs.

Source:Method ValidationReport RIRM2 and RIRM2Amendment 1,Combined NAbAssaySampleAnalysis ReportforDS-8201aStudies.

## Population PK analysis

NONMEM (version 7.4.3) for nonlinear mixed-effects analysis (ICON, Hanover, MD, US) with FOCEI was used  for  PopPK  modelling.  Xpose  4  (version  4.6.1)  and  PsN  (version  4.8.1)  was  used  for  model diagnostics  and  covariate  testing.  R  (version  4.0.2  or  higher)  was  used  for  data  exploration  and simulations.

A previous PopPK analysis for trastuzumab deruxtecan (T-DXd, intact ADC) was based on data from Studies J101, J102, A103, A104, U201 and J202 served as the starting point for model development. In this model the time-course of intact T-DXd concentrations, adjusted for the drug-antibody ratio of 8 and molar mass, was the input to the released drug model (Fig 3-1).

<div style=\"page-break-after: always\"></div>

Figure 3-1 Structural model schematic

<!-- image -->

Abbreviations: CLr-Dxd = elimination clearance of T-DXd; CLDxd = elimination clearance of DXd; IV = intravenous; Krel = release rate constant; Q = distributional clearance; V1, T-Dxd = T-DXd central volume of distribution; V2, T-Dxd = T-DXd peripheral volume of distribution; VDxd = DXd volume of distribution.

An updated dataset with additional dose and PK observations from subjects with gastric cancer from studies J101 and J202 and new data from Study U205 (conducted in US/European patients) was used to re-estimate model parameters including covariate effects. Study U205 contributed a total of 779 TDXd and 778 DXd (only the topoisomerase I inhibitor) PK-evaluable samples from 76 subjects enrolled at study sites in USA and Europe. A total of 6 outlier concentrations in Study U205 were identified using a |CWRES|&gt;5 criterion and excluded from covariate testing. No further data exclusions were conducted. The final combined T-DXd PopPK model were estimated using 14852 T-DXd and 14933 DXd PK samples collected from 884 subjects. Figure 4-5 shows the distribution of weights in the data set.

Figure 4-5 Distribution of weight among cancer type and regions

<!-- image -->

Abbreviations: BC = breast cancer; GC = gastric cancer.

Note: Dashed lines present the means of the subpopulations. Solid lines represent the density distributions for each subpopulation.

Source: weight\\_region\\_poptype\\_distributions.pdf, 2021-06-17-ds8201a-205-intact.r

<div style=\"page-break-after: always\"></div>

The prior model was fit to the updated dataset with re-estimation of parameters for T-DXd and covariate effects using the T-DXd PK data only. Then, using both the T-DXd and DXd data, DXd parameters and corresponding covariate effects were re-estimated with fixed estimates for T-DXd, including the fixed and random-effects terms. The final model for T-DXd was the same as the base model and comprised a two-compartment model with linear elimination. Numerous covariates appeared correlated (e.g., sex, cancer type, and body weight; age, body weight and creatinine clearance). Cancer type on CLT-DXd was retained in the base model (run331) while sex was not tested as a covariate. The PK of DXd was described by a one-compartment model with a two-component, time-varying release rate from T-DXd. The release rate (Krel) was modelled to decrease over time based on a term for constant reduction after Cycle 1 (FPC1) and a term for gradual decline per cycle (FPC2). Covariate effects included in the final model are shown in Table 4-7 and 4-9 for intact T-DXd and DXd, respectively.

Table 4-7 Overview of covariate analysis for the T-DXd model

| Steps                                                                 | Covariate Effects                                                                                                                       |
|-----------------------------------------------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------|
| Initial covariates from PopPK analysis included in gastric cancer BLA | CLr-Dxd: baseline tumor size, albumin, body weight, race-country, cancer type V1,T-Dxd: body weight, cancer type V2,1-Dxd: race-country |
| Exploratory covariate analysis                                        | CLT-Dxd: sex V1,T-DXd: seX                                                                                                              |
| Final covariate model                                                 | CLr-Dxd: baseline tumor size, albumin, body weight, race-country, cancer type V1,T-Dxd: body weight, cancer type V2,1-Dxd: race-country |

Abbreviations: BLA = biologics license application; CLr-Dxd = T-DXd clearance; PopPK = population pharmacokinetics; V1,T-Dxd = T-DXd central volume of distribution; V2,T-Dxd = T-DXd peripheral volume of distribution.

Source: 2021-21-05-ds8201-205-gof.R, Intact\\_key models\\_withrerun.csv

<div style=\"page-break-after: always\"></div>

Table 4-9 Overview of covariate analysis for the DXd model

| Steps                                               | Covariate Effects                                                                                                                                                                                                                                                                                                                                                                                    |
|-----------------------------------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Initial covariates from previous BLA PopPK analysis | CLDxd: body weight, total bilirubin, AST, itraconazole co-administration, ritonavir co-administration effect, cancer type (gastric cancer, other cancer types compared to breast cancer) Vpxa: formulation, age, BSA, cancer type (other cancer types compared to gastric cancer and breast cancer)                                                                                                  |
| Full covariate model                                | CLDxa: body weight, total bilirubin, AST, itraconazole co-administration, ritonavir co-administration effect and cancer type (gastric cancer, other cancer types compared to breast cancer), race-country (Asian vs non-Asian) and line of therapy Vpxd: formulation, age, BSA, cancer type (other cancer types compared to gastric cancer and breast cancer) and race-country (Asian vs non- Asian) |
| Backward elimination                                | CLpxd: race-country (Asian vs non-Asian) and line of therapy removed                                                                                                                                                                                                                                                                                                                                 |
| Final covariate model                               | CLDxd: body weight, total bilirubin, AST, itraconazole co-administration, ritonavir co-administration effect and cancer type (gastric cancer, other cancer types compared to breast cancer) Vpxa: formulation, age, BSA, cancer type (other cancer types compared to gastric cancer and breast cancer) and race-country (Asian vs non- Asian)                                                        |

Abbreviations: BLA = biologics license application; CLDxd = DXd clearance; PopPK = population pharmacokinetics; Vpxd = DXd volume of distribution. Source: key\\_models\\_RD.csv

Model parameters were estimated with good precision (RSE &lt;30%) except for the effect of 'Other cancer' on CL,T-DXd, CL,DXd and V1,T-DXd. Shrinkage ranged up to 35%. BSV terms were included on CLDXd, VDXd, Krel, and FPC1. RUV was modelled with a proportional error structure. The RUV was estimated to be 30% with 6.6% shrinkage. Final model parameters for T-DXd and DXd are shown in Tables 4-6 and 4-10 . A sensitivity analysis of the final T-DXd PopPK model (run542) including CWRES outliers (run542s) was performed and found no large shifts in model parameters.

<div style=\"page-break-after: always\"></div>

Table 4-6 Parameters of the T-DXd base model (run331)

| Parameter                                        | T-DXd Base Model (run33l)   | T-DXd Base Model (run33l)   | T-DXd Base Model (run33l)   | T-DXd Base Model (run33l)   | T-DXd Base Model (run33l)   | Typical Value Estimate Previous Analysis without Study U205 (RSE %)   |
|--------------------------------------------------|-----------------------------|-----------------------------|-----------------------------|-----------------------------|-----------------------------|-----------------------------------------------------------------------|
| Parameter                                        | Estimate                    | Estimate                    | Between-subjectVariability  | Between-subjectVariability  | Between-subjectVariability  | Typical Value Estimate Previous Analysis without Study U205 (RSE %)   |
| Parameter                                        | Typical Value               | RSE (%)                     | Magnitud e (%CV)            | RSE (%)                     | Shrinkage (%)               | Typical Value Estimate Previous Analysis without Study U205 (RSE %)   |
| Clearance (CLT-Dxad, L/d)                        | 0.422                       | 1.39                        | 24.51                       | 2.70                        | 6.23                        | 0.420 (1.43)                                                          |
| Central volume of distribution (V1,T-Dxa, L)     | 2.78                        | 0.791                       | 15.7                        | 2.79                        | 5.58                        | 2.78 (0.780)                                                          |
| Distribution clearance (Qr-Dxd, L/d)             | 0.201                       | 1.55                        | 30.6                        | 4.58                        | 28.4                        | 0.198 (1.58))                                                         |
| Peripheral volume of distribution (V2,T-Dxa L)   | 5.05                        | 4.38                        | 71.7                        | 4.60                        | 24.3                        | 4.98 (4.68)                                                           |
| Albumin (g/L) on CLT-Dxd                         | -0.566                      | 10.9                        |                             |                             |                             | -0.601 (11.0)                                                         |
| Asian fom Japan on CLT. pXa                      | -0.106                      | 14.8                        |                             |                             |                             | -0.0952 (18.2)                                                        |
| Tumor size (mm) on CLT- PXa                      | 0.0642                      | 17.9                        |                             |                             |                             | 0.0638 (19.0)                                                         |
| Body weight (kg) on CLT. PXC                     | 0.436                       | 9.92                        |                             |                             |                             | 0.460 (10.2)                                                          |
| Gastric cancer on CLT-DXd                        | 0.158                       | 15.4                        |                             |                             |                             | 0.154 (19.0)                                                          |
| Other cancer (not breast or gastric) on CLT-DXd  | 0.06361                     | 54.5                        |                             |                             |                             | 0.0566 (61.7)                                                         |
| Body weight (kg) on V1,T- PXa                    | 0.533                       | 5.09                        |                             |                             |                             | 0.552 (5.36)                                                          |
| Gastric cancer on V1,T-Dxd                       | 0.153                       | 9.09                        |                             |                             |                             | 0.178 (8.75)                                                          |
| Other cancer (not breast of gastric) on V1,T-Dxd | 0.0468                      | 44.6                        |                             |                             |                             | 0.0456 (45.4)                                                         |
| Asian from Japan on V2,T- PXC                    | -0.168                      | 28.9                        |                             |                             |                             | -0.156 (32.6)                                                         |
| Residual unexplained variability                 |                             |                             |                             |                             |                             |                                                                       |
| Proportional residual error SD                   | 0.151                       | 0.380                       |                             |                             |                             | 0.151 (0.39)                                                          |
| Additive residual error SD (ng/mL)               | 1223                        | 2.24                        |                             |                             |                             | 1220 (2.41)                                                           |
| Covariance of CLT-Dxd and V1,T-DXd               | 0.0205                      | 4.08                        |                             |                             |                             | 0.0204 (8.50)                                                         |

Abbreviations:CV=coefficient of variation;RSE=relative standard error;SD=standard deviation;SE=standard error; sqrt = square root.

Notes:RSE ofparameter estimate are calculated as 100x(SE/typical value); RSE of between-subject variability magnitudearecalculatedas100x(SE/varianceestimate)/2.CV%forthebetween-subjectvariabilityestimates

<div style=\"page-break-after: always\"></div>

Table 4-10 Parameters of the DXd final model (run542)

| Parameter                                     | Final DXd Model (run542)   | Final DXd Model (run542)   | Final DXd Model (run542)    | Final DXd Model (run542)    | Final DXd Model (run542)    |
|-----------------------------------------------|----------------------------|----------------------------|-----------------------------|-----------------------------|-----------------------------|
| Parameter                                     | Estimate                   | Estimate                   | Betveen-subject Variability | Betveen-subject Variability | Betveen-subject Variability |
| Parameter                                     | Typical Value              | RSE (%)                    | Magnitude (%CV)             | RSE (%)                     | Shrinkage (%)               |
| DXd clearance (CLDxd, L/h)                    | 18.5                       | 3.78                       | 27.2                        | 5.18                        | 35.2                        |
| DXd volume of distribution (Vpxa, L)          | Fixed 17*BSA               |                            | 41.2                        | 4.18                        | 23.0                        |
| Release rate (Kre, 1/h)                       | 0.0150                     | 3.40                       | 36.4                        | 4.01                        | 18.5                        |
| Fraction of Kral at Cycle>1 (FPC1)            | 0.799                      | 1.43                       | 24.6                        | 3.37                        | 18.5                        |
| Exponent of cycle effect on Krel (FPC2)       | -0.143                     | 4.51                       |                             |                             |                             |
| Ritonavir on CLDxd                            | -0.116                     | 14.9                       |                             |                             |                             |
| Itraconazole on CLDxd                         | -0.105                     | 21.1                       |                             |                             |                             |
| AST (U/L) on CLDxd                            | -0.230                     | 11.1                       |                             |                             |                             |
| Total bilirubin (μmol/L) on CLDxd             | -0.174                     | 16.7                       |                             |                             |                             |
| Body weight (kg) on CLDxd                     | 0.465                      | 14.4                       |                             |                             |                             |
| Gastric cancer on CLpxd                       | -0.157                     | 18.0                       |                             |                             |                             |
| Other cancer (not breast or gastric) on CLDxd | -0.133                     | 38.1                       |                             |                             |                             |
| Age (y) on Vdxd                               | 0.503                      | 15.9                       |                             |                             |                             |
| FL-DP2formulation on VDxd                     | 0.309                      | 19.9                       |                             |                             |                             |
| FL-DP1 formulation on VDxd                    | -0.171                     | 21.5                       |                             |                             |                             |
| Other cancer (notbreast of gastric) on VDxd   | -0.245                     | 24.4                       |                             |                             |                             |
| Non-Asian on VDxd                             | -0.177                     | 17.4                       |                             |                             |                             |
| Residual unexplained variability              |                            |                            |                             |                             |                             |
| Proportional residual error SD                | 0.302                      | 0.435                      |                             |                             |                             |

Abbreviations: AST = aspartate aminotransferase; BSA = body surface area; CV = coefficient of variation; FL-DP1 = frozen liquid drug product 1; FL-DP2 = frozen liquid drug product 2; RSE =relative standard error; SD = standard deviation; SE=standard error; sqrt = square root.

Notes:RSE ofparameter estimate are calculated as100x(SE/typical value);RSE ofbetween-subject variability magnitude are calculated as 10ox(SE/variance estimate)/2. CV% for the between-subject variability estimates are based on the estimated variances. Shrinkage (%) is calculated as 100x(1-SD(ETA)/sqrt(variance). Overall residual unexplained variability shrinkage was estimated tobe 6.61%.

Source: payload-DXd-update-final-542-nmtable.csv, 2021-07-ds8201a-205-payload.r

<div style=\"page-break-after: always\"></div>

Figure 4-8 Goodness-of-fit diagnostics of theT-DXd basemodel (run331)

<!-- image -->

Abbreviations:CWRES=conditionalweightedresidual.

Note: The dots represent observations, the black dashed lines represent identity lines, and gray curves represent loess smoothers.

Source:g0f-INonly-final-331-all.pdf,2021-21-05-ds8201-205-gof.R

Figure 4-13( Goodness-of-fitdiagnosticsoftheDXdfinalmodel(run542)

<!-- image -->

Abbreviations:CWRES=conditionalweightedresiduals.

DXd Individual predictions(ng/mL)

Note: The circles represent observations, the black dashed lines represent identity lines, and gray curves represent loess smoothers.

Source: gof-PAY-FINAL-combined-542-all.pdf, 2021-21-05-ds8201-205-gofR

T-DXdDS-8201aIndividual predictions(ng/mL)

<div style=\"page-break-after: always\"></div>

Figure 4-15 Prediction-corrected VPC for the T-DXd and DXd PopPK model (run542), all data

All data by time since first dose for T-DXd and DXd

<!-- image -->

All data by Time after last dose for T-DXd and DXd

<!-- image -->

Abbreviations: PopPK = population pharmacokinetics; pred-corr = prediction-corrected; VPC = visual predictive check.

Note: Blue dots are prediction-corrected observed concentrations; blue lines are 50th (solid), 5th (dashed), and 95th (dashed) percentiles of observed concentrations; and black lines are 50th (solid), 5th (dashed), and 95th (dashed) percentiles of simulations. Gray bands are 95% prediction interval for corresponding black lines based on500simulations.Shortyellowlinesindicatebinintervals.

Source:VPC-TIME-both-all-data542.pdf, VPC-TAD-both-all-data-542.pdf, 2021-21-05-ds8201-205-gofR

<div style=\"page-break-after: always\"></div>

Figure l: Prediction-correctedVPCfortheT-DXdandDXdPopPKmodel,byRacein subjectswith GC T-DXd-all data

<!-- image -->

Abbreviations: GC=gastric cancer;PopPK=population pharmacokinetics;pred-corrected =prediction-corrected;VPC=visual predictive check. Note:Blue dots are prediction-corrected observed concentrations; blue lines are 50th (solid),5th (dashed), and 95th (dashed) percentiles of observed concentrations; and black lines are 50th (solid), 5th (dashed), and 95th (dashed) percentiles of simulations. Gray bands are 95% prediction interval for corresponding black lines based on 500 simulations.Short yellow lines indicate bin intervals.

Source:VPC-TAD-RD-GC-RACE542.pdf,VPC-TAD-RACE-GC-C3-542.pdf,2022-01-10-ds8201-205-EUresponse.R

## Covariate effects on exposure estimates

In the previous model all covariates had effects contained within the 0.8 to 1.25 exposure ratios with the exceptions of high values of albumin for T-DXd which increased Cmin by 33% and gastric vs. breast

<div style=\"page-break-after: always\"></div>

cancer for T-DXd at 6.4 mg/kg Q3W. For DXd, high values of baseline AST increased AUC and Cmin by 27%. In the updated model, post hoc DXd exposure estimates of subjects dosed at 6.4 mg/kg Q3W TDXd showed differences based on cancer type but not by sex, region and race-country. Presence of ADA was tested for T-DXd and line of therapy was tested for both T-DXd and DXd. None had significant effect.

Subpopulation analyses of DXd exposures performed under proposed regimens based on T-DXd exposure differences, 5.4 mg/kg Q3W T-DXd for breast cancer and 6.4 mg/kg Q3W T-DXd for gastric cancer, showed greater DXd exposure in the 6.4 mg/kg Q3W T-DXd gastric cancer group at Cycle 1 (up to 41% higher), but comparable exposures between the two groups at steady state (geometric mean ratio 1.12 to 1.22).

## Exposure-response analyses

The initial exposure-safety analysis used data from four Phase 1 studies (Studies J101, J102, A103, and A104) and two Phase 2 studies (Studies U201 and J202). Models were updated with data from U205 (Table 3-3).

Table 3-3: StudyU205SDTM/ADaM datasets

| Category                   | Description (Label)                | Selected Inforimation                                       |
|----------------------------|------------------------------------|-------------------------------------------------------------|
| General Datasets           | Subject-level data (ADSL)          | Demographics, populations, endpoints                        |
| General Datasets           | Concomitant medications (ADSL, CM) | Prior therapy                                               |
| General Datasets           | Demographics (ADSL, DM)            | Age, sex, race, country                                     |
| General Datasets           | Disposition (AE)                   | Discontinuations due to AEs                                 |
| General Datasets           | Medical history (MH)               | Cancer type                                                 |
| General Datasets           | Tumor type (TU)                    | Cancer type                                                 |
| General Datasets           | Questionnaires (QS)                | ECOG PS                                                     |
| General Datasets           | Vital signs (VS)                   | Weight                                                      |
| General Datasets           | Supplemental demographics (SUPPDM) | Identifiers for study populations                           |
| General Datasets           | Chemistry labs (LB)                | Hepatic and renal function parameters, HER2ECD, HER2 status |
| Exposure-Efficacy Analysis | Tumor response (ADRS2)             | Confinmed ORR                                               |
| Exposure-Efficacy Analysis | Survival (ADTTE)                   | PFS, DoR                                                    |
| Exposure-Safety Analysis   | Adverse events (ADAE, AE)          | AE listings                                                 |
| Exposure-Safety Analysis   | Adverse events(SUPPAE)             | Special AEs of interest (ILD, LVEF decrease)                |
| Exposure-Safety Analysis   | Cardiovascular (CV)                | LVEF change (ECHO)                                          |
| Exposure-Safety Analysis   | Chemistry labs (LB)                | Neutropenia, thrombocytopenia, anemia                       |

Abbreviations: ADaM = analysis data model; AE = adverse event; DoR = duration of response; ECHO = echocardiogram;ECOGPS=EasteinCooperativeOncologyGroupPerformanceStatus;HER2=human epidermal growth factor receptor 2; HER2ECD = human epidermal growth factor receptor 2 extracellular domain; ILD = interstitial lung disease; LVEF = left ventricular ejection fraction; ORR = objective response rate; PFS = progression-free survival; PK = pharmacokinetic; SDTM = standard data tabulation model.

R (version 4.0.5) was used for the exposure-efficacy/safety modeling, as well as for data explorations prior to and/or after modeling and simulations. Exploratory plots were used to assess whether to perform detailed modeling of each efficacy or safety endpoint. Covariates that were not significant (p&gt;0.05 using z-test) were removed followed by a forward inclusion at p&lt;0.05 and a backward elimination at p&lt;0.01 using the likelihood ratio test. The covariates were tested on the intercept and the slope of logistic ER relationships or on the slope of Cox regression models.

<div style=\"page-break-after: always\"></div>

No statistically significant relationships between increasing T-DXd or DXd exposures and either PFS or DoR was detected over the range of exposures for the 6.4 mg/kg Q3W dose in Study U205. No covariate relationships were explored.

Table 5-55: Grade&gt;2LVEF decrease (ECHO) final modelparameters

| Exposure-Response Model              | Exposure-Response Model      | Parameter              | Estimate   | Standard Error   | RSE (%6)   |
|--------------------------------------|------------------------------|------------------------|------------|------------------|------------|
| Exposure Metric                      | Safety Endpoint              | Parameter              | Estimate   | Standard Error   | RSE (%6)   |
| T-DXd peak conc steady state (μg/mL) | Grade>2 LVEF decrease (ECHO) | Intercept              | -3.37      | 0.514            | 15         |
| T-DXd peak conc steady state (μg/mL) | Grade>2 LVEF decrease (ECHO) | Slope                  | 0.0104     | 0.00306          | 29         |
| T-DXd peak conc steady state (μg/mL) | Grade>2 LVEF decrease (ECHO) | Tumor location GEJ     | -1.91      | 0.757            | 40         |
| T-DXd peak conc steady state (μg/mL) | Grade>2 LVEF decrease (ECHO) | Tumor location missing | 0.376      | 0.247            | 66         |
| T-DXd peak conc steady state (μg/mL) | Grade>2 LVEF decrease (ECHO) | Asian from Japan       | 0.200      | 0.211            | 106        |
| T-DXd peak conc steady state (μg/mL) | Grade>2 LVEF decrease (ECHO) | Asian not from Japan   | -0.800     | 0.387            | 48         |

Abbreviations: ECHO = echocardiogram-based; GEJ = gastroesophageal junction; LVEF = left ventricular ejection fraction; RSE = relative standard error.

Note: Asian race covariate had a relatively high RSE but was included in the base model as part of the race-country covariate.

Source: es.analysis.f

Table 5-61: Any Grade ILD final model parameters

| Exposure-Response Model            | Exposure-Response Model   |                               |          |                |         |
|------------------------------------|---------------------------|-------------------------------|----------|----------------|---------|
| Exposure Metric                    | Safety Endpoint           | Parameter                     | Estimate | Standard Error | RSE (%) |
| T-DXd AUC steady state (μg/mLxday) | Any Grade ILD             | Slope                         | 0.00181  | 0.000332       | 18      |
| T-DXd AUC steady state (μg/mLxday) | Any Grade ILD             | Creatinine clearance (mL/min) | -0.00842 | 0.00318        | 38      |
| T-DXd AUC steady state (μg/mLxday) | Any Grade ILD             | Asian from Japan              | 0.375    | 0.191          | 51      |
| T-DXd AUC steady state (μg/mLxday) | Any Grade ILD             | Asian not from Japan          | -0.752   | 0.439          | 58      |

Abbreviations: AUC = area under the concentration-time curve; ILD = interstitial lung disease; RSE =relative standard error.

Source: es.analysis.f

Table 5-62: Grade &gt;3 ILD final model parameter's

| Exposure-Response Model      | Exposure-Response Model   | Parameter     | Estimate   |         | RSE   |
|------------------------------|---------------------------|---------------|------------|---------|-------|
| Exposure Metric              | Safety Endpoint           |               |            | Error   | (%)   |
| T-DXd peak conc steady state |                           | Slope         | 0.0257     | 0.00585 | 23    |
| (μg/mL)                      | Grade ≥3 ILD              | Albumin (g/L) | -0.140     | 0.0428  | 31    |

Abbreviations: ILD = interstitial lung disease; RSE = relative standard error.

Source: es.analysis.r

Interpretation of model covariates, both presence in the model and in direction of effect, may be complex because of the correlation between covariates, multiplicity of testing, sample size of subgroups, and unknown covariate status for some of the patients.

Stratifying modelled event rates in gastric cancer by region (Asia, USA, Europe) showed more than 15% higher rates in Asia for Grade ≥3 AE, Grade ≥3 anaemia and Grade ≥3 neutropenia. Model -predicted safety event rates also showed this difference between Asians and Non-Asians and may be related to clinical practice. However, USA and European subjects had comparable AE rates across all endpoints, although the numbers of subjects in this comparison is small.

## Bridging analysis

<div style=\"page-break-after: always\"></div>

A virtual second-line or later HER2-positive gastric cancer Western population was created from realworld (RW) data. Individual longitudinal information in HER2+ gastric cancer patients in the US was extracted from electronic health records of healthcare provider sites by a third-party vendor. Patients receiving one or more line of therapy were included in the RW dataset. For patients receiving more lines of therapy, baseline time was defined as the start time of the last received therapy. Covariates were taken from the visit corresponding to the baseline time, or nearest available visit, or indicated as missing. Per real-world patient, 50 virtual patients were simulated using the population PK model to obtain PK exposures  for  intact  antibody  and  released  drug.  Each  virtual  patient  utilized  the  corresponding covariates of the real-world patient, except for imputed covariates. Missing covariates were sampled from other patients in the RW dataset, or from the bridging population (Table 1.1 - Summary of Subject Populations  used  for  Bridging).  The  real-world  population  included  49  HER2-positive  gastric  cancer patients, of which 25 patients were identified as second-line or later and included in the Western RW dataset. The inclusion criteria were: patients diagnosed with gastric cancer, HER2-positive and received trastuzumab. Therefore, the virtual PK population included 1250 subjects.

The PK model parameters were used to compute the exposure metrics Cmin, Cmax and AUC at Cycle 1 and at steady-state (Cycle 9). Exposure metrics obtained in Japan and the virtual Western population were compared. For time-to-event exposure metrics, dose regimens and endpoint times were randomly sampled from the bridging population in Table 1.1 - Summary of Subject Populations used for Bridging. These regimens incorporated dose interruptions, dose reductions and treatment discontinuations. For each efficacy or safety endpoint, 1000 trial simulations were conducted. Each trial simulation used the RW dataset sample size, by sampling the virtual population with replacement. Each trial simulation also incorporated uncertainty in the exposure-response models by sampling parameters from the variancecovariance matrix of the parameter estimates of the exposure-response models. Trial simulations were also conducted in the Japan gastric cancer bridging population as outlined in Table 1.1 for comparison. Each trial simulation provided an event probability. Across the 1000 trial simulations, 1000 probabilities were obtained to derive the 90% confidence intervals. Sensitivity analyses were conducted to elucidate the covariates accounting for differences between Japan and Western populations and illustrated using forest plots.

Table 1.1: Summary of Subject Populations used for Bridging

| Previous Analysis   | Original population          |   N in original analysis [2] | Exclusions                                                                                                                            | Bridging population                                                |   N in bridging population |
|---------------------|------------------------------|------------------------------|---------------------------------------------------------------------------------------------------------------------------------------|--------------------------------------------------------------------|----------------------------|
| Exposure- efficacy  | HER2-positive gastric cancer |                          160 | Dose other than 6.4 mg/kg (N=19) Dose of 6.4 mg/kg but not in Japan (N=24)                                                            | Japan, HER2-positive gastric cancer subjects received 6.4 mg/kg    |                        117 |
| Exposure- safety    | HER2-expressing solid tumors |                          808 | Dose other than 6.4 mg/kg (N=348) Dose of 6.4 mg/kg but not in Japan (N=136) Dose of 6.4 mg/kg, Japan, but not gastric cancer (N=166) | Japan, HER2- expressing gastric cancer subjects received 6.4 mg/kg |                        158 |

Abbreviations: N = number of subjects, HER2 = human epidermal growth factor receptor 2.

Notes: HER2-expressing includes HER2-positive, HER2-low or HER2 status unknown. Exclusions from the exposure-efficacy and the exposure-safety bridging population include 5 gastric-cancer subjects from Western countries who received a dose of 5.4 mg/kg.

Source: DS-8201a E-R report in gastric cancer and other solid tumors ([2]).

The PK simulations results from the virtual bridging analysis indicated that in HER2-positive second-lineor-later subjects with GC receiving 6.4 mg/kg T-DXd Q3W, PK exposures of intact T-DXd and DXd are generally comparable between Western and Japanese subjects with GC. Based on the exposure-efficacy simulations, there was a similar incidence of ucORR in Western subjects relative to Japanese subjects;

<div style=\"page-break-after: always\"></div>

however, the incidence of cORR in Western subjects was lower relative to that in Japanese subjects. The results  from  exposure-safety  simulations  suggested  that  any  grade  ILD  was  lower  in  the  Japan population, and ILD3 rates in Japan and Western populations were comparable. The incidence of other TEAEs was comparable, with the exception of Grade ≥ 3 neutropenia, which was lower in Western subjects relative to Japanese subjects.

The bridging analysis enabled projections of efficacy/safety rates for the 6.4 mg/kg Q3W T-DXd regimen in Western subjects, prior to the availability of results from Study U205. In general, the efficacy and safety data from Study U205 agreed with the results of the virtual bridging analysis, thereby confirming the extrapolation of the results from the Asian patients with GC to Western patients with GC.

## ADME

The absorption, distribution, metabolism, and excretion characteristics of T-DXd (and each individual component) are well characterized based on a series of nonclinical studies using human biomaterials as described in the initial BC application, and based on data from clinical studies J101, J102, A103, A104, and U201.

PopPK modelling, based on a dataset updated with GC data, suggested that T-DXd clearance increased with body weight, baseline tumor size, and having GC or other cancers (relative to BC).

Following intravenous administration of trastuzumab deruxtecan in patients with metastatic HER2-positive breast cancer, the clearance of trastuzumab deruxtecan in population pharmacokinetic analysis was calculated to be 0.42 L/day. In patients with locally advanced or metastatic gastric or GEJ adenocarcinoma, trastuzumab deruxtecan clearance was 16% higher than in patients with metastatic HER2-positive breast cancer. The clearance of DXd based on population pharmacokinetic analysis was estimated to be 446 L/day and 401 L/day for patients with metastatic HER2-positive breast cancer and locally advanced or metastatic gastric or GEJ adenocarcinoma, respectively.

As for DXd, the model identified body weight, total bilirubin, AST, coadministration of itraconazole or ritonavir, and having GC or other cancers as significant covariates on the clearance of DXd.

## Exposure data in GC or GEJ patients compared with BC data

## Serum T-DXd

The cycle 1 PK data (calculated using noncompartmental methods) for T-DXd in subjects with GC and BC were integrated across six studies (J101, J102, A103, U201, J202, and U205) and PK parameters are presented by dose for subjects with HER2-positive GC and BC in Table 3.1 . The PK exposure parameters for T-DXd in cycle 1 at 6.4 mg/kg for subjects with GC were similar to those at 5.4 mg/kg for subjects with BC.

<div style=\"page-break-after: always\"></div>

Table 3.1: Summary of T-DXd PharmacokineticParameters:Integrated Analysis of Cycle 1 Pharmacokinetic Data in Subjects with Gastric or Breast Cancer

| Dose                     | PK Parameter (unit)   | PK Parameter (unit)   | PK Parameter (unit)   | PK Parameter (unit)   | PK Parameter (unit)   |
|--------------------------|-----------------------|-----------------------|-----------------------|-----------------------|-----------------------|
|                          | Cmax (μg/mL)          | Tmax (h)a             | AUClast (μg · d/mL)   | AUC21d (μg · d/mL)    | Ctrough (μg/mL)       |
| 5.4 mg/kgGC              | 5.4 mg/kgGC           | 5.4 mg/kgGC           | 5.4 mg/kgGC           | 5.4 mg/kgGC           | 5.4 mg/kgGC           |
| N Mean (Std Dev) Min/Max | 19 113 (28.5)         | 19 2.03 1.58/4.08     | 19 524 (165)          | 19 522 (164) 211 631  | 19 5.34 (2.60)        |
| 6.4 mg/kg GC             | 6.4 mg/kg GC          |                       |                       |                       |                       |
| N Mean (Std Dev)         | 226 133 (36.4)        | 226 3.17              | 226 629 (188)         | (181)                 | 5.52                  |
| Min/Max                  | Min/Max               | Min/Max               |                       |                       | 218                   |
| N                        |                       | 0.00/572.16           |                       |                       | (3.11)                |
| 5.4 mg/kg BC             | 5.4 mg/kg BC          | 5.4 mg/kg BC          | 5.4 mg/kg BC          | 5.4 mg/kg BC          | 5.4 mg/kg BC          |
| Mean (Std Dev) Min / Max | 232 124.15 (32.61)    | 232 2.167 0.02/166.7  | 232 544.68 (163.42)   | 190 572.6 (167.1)     | 215 5.5 (5.13)        |
| 6.4 mg/kg BC             | 6.4 mg/kg BC          | 6.4 mg/kg BC          | 6.4 mg/kg BC          | 6.4 mg/kg BC          | 6.4 mg/kg BC          |
| N Mean                   | 122 165.23            | 122 2.07              | 122 740.9             | 115 756.5             | 116                   |
| Min / Max                | (50.96)               | 0.02/ 7.05            |                       |                       | 9.246                 |
|                          |                       |                       |                       | (205.1)               |                       |
| (Std Dev)                |                       |                       | (212.27)              |                       | (20.02)               |

AUC21d = area under the serum concentration-time curve from time zero to Day 21; AUClast = area under the serum concentration-time curve from time zero to the time of the last quantifiable serum concentration; BC = breast cancer; Cmax = maximum serum concentration; Ctrough = trough serum concentration; GC = gastric cancer; HER2 = human epidermal growth factor receptor 2; PK = pharmacokinetic; Std Dev = standard deviation; T-DXd =

trastuzumab deruxtecan; Tmax =time to reach peak serum concentration.

a Values are presented as N / mean (Std Dev) except for Tmax, which shows N / median (range). Source:Module5.3.5.3SCPTFLsTable1.1.1;initialGastricCancerBLATable3.1.

## Serum total anti-HER2 antibody

The Cycle 1 PK data for total anti-HER2 antibody in subjects with HER2-positive cancer were integrated across  six  studies  (J101,  J102,  A103,  U201,  J202,  and  U205)  and  PK  parameters  (calculated  using noncompartmental  methods)  are  presented  by  dose  for  subjects  with  HER2-positive  GC  and  BC Table 3.2 .

<div style=\"page-break-after: always\"></div>

Table 3.2: Summaryof TotalAnti-HER2AntibodyPharmacokineticParameters: Integrated Analysis of Cycle 1 Pharmacokinetic Data in Subjects with Gastric or Breast Cancer

| Dose                       | PKParameter (unit)   | PKParameter (unit)    | PKParameter (unit)   | PKParameter (unit)                   | PKParameter (unit)   |
|----------------------------|----------------------|-----------------------|----------------------|--------------------------------------|----------------------|
|                            | Cmax (μg/mL)         | Tmax (h)a             | AUClast (μg · d/mL)  | AUC21d (μg · d/mL)                   | Ctrough (μg/mL)      |
| 5.4 mg/kg GC               | 5.4 mg/kg GC         | 5.4 mg/kg GC          | 5.4 mg/kg GC         | 5.4 mg/kg GC                         | 5.4 mg/kg GC         |
| N Mean (Std Dev) Min / Max | 19 105 (36.4)        | 19 2.02 1.55/6.82     | 19 683 (533)         | 19 681 (533)                         | 19 11.8 (20.1)       |
| 6.4 mg/kg GC               | 6.4 mg/kg GC         | 6.4 mg/kg GC          | 6.4 mg/kg GC         | 6.4 mg/kg GC                         | 6.4 mg/kg GC         |
| N Mean (Std Dev) Min / Max | 226 125 (37.7)       | 226 2.32 0.00/572.16  | 226 726 (319)        | 209 716 (299)                        | 217 9.77 (10.0)      |
| 5.4 mg/kg BC               | 5.4 mg/kg BC         | 5.4 mg/kg BC          | 5.4 mg/kg BC         | 5.4 mg/kg BC                         | 5.4 mg/kg BC         |
| N Mean (Std Dev) Min / Max | 232 125.34 (35.07)   | 232 2.00 0.02 /310.66 | 232 712.96 (320.58)  | 196 772.1 (370.98) 118 937.4 (359.8) | 211 13.2 (13.26)     |
| 6.4 mg/kg BC               | 6.4 mg/kg BC         | 6.4 mg/kg BC          | 6.4 mg/kg BC         | 6.4 mg/kg BC                         | 6.4 mg/kg BC         |
| N Mean (Std Dev) Min / Max | 122 160.98 (60.68)   | 122 2.00 0.02/22.15   | 122 910.5 (357.46)   |                                      | 116 15.80 (20.959)   |

AUC21d = area under the serum concentration-time curve from time zero to Day 21; AUClast = area under the serum concentration-time curve from time zero to the time of the last quantifiable serum concentration; BC = breast cancer;Cmax=maximum serum concentration; Ctrough =trough serum concentration; GC =gastric cancer;HER2 = human epidermal growth factor receptor 2; PK = pharmacokinetic; Std Dev = standard deviation; Tmax = time to reach peak serum concentration.

a Values are presented as N / mean (Std Dev) except for Tmax, which shows N / median (range). Source:Module5.3.5.3SCPTFLs Table1.1.2;initialGastricCancer BLA Table3.2.

## Serum DXd

The cycle 1 PK data for DXd in subjects with HER2-positive cancer were integrated across six studies (J101, J102, A103, U201, J202, and U205) and PK parameters are presented by dose for subjects with HER2-positive GC and BC in Table 3.3 .

<div style=\"page-break-after: always\"></div>

Table 3.3: Summary of DXd Pharmacokinetic Parameters: Integrated Analysis in Subjects with Gastric Cancer or Breast Cancer

| Dose                       | PKParameter (unit)   | PKParameter (unit)        | PKParameter (unit)                     | PKParameter (unit)                     | PKParameter (unit)                  |
|----------------------------|----------------------|---------------------------|----------------------------------------|----------------------------------------|-------------------------------------|
|                            | Cmax (ng/mL)         | Tmax (h)a                 | AUClast (ng·d/mL)                      | AUC21d (ng · d/mL)                     | Ctrough (ng/mL)                     |
| 5.4 mg/kg GC               | 5.4 mg/kg GC         | 5.4 mg/kg GC              | 5.4 mg/kg GC                           | 5.4 mg/kg GC                           | 5.4 mg/kg GC                        |
| N Mean (Std Dev) Min / Max | 19 9.30 (6.86)       | 19 6.92 3.78/24.07        | 19 43.3 (42.5)                         | 18 43.3 (43.2)                         | 19 0.404 (0.400)                    |
| 6.4 mg/kgGC                | 6.4 mg/kgGC          | 6.4 mg/kgGC               | 6.4 mg/kgGC                            | 6.4 mg/kgGC                            | 6.4 mg/kgGC                         |
| N Mean (Std Dev) Min / Max | 226 12.3 (5.59)      | 226 6.77 1.61/ 572.16     | 226 48.7 (23.4)                        | 186 47.2 (19.2)                        | 217 0.306 (0.269)                   |
| 5.4 mg/kg BC               | 5.4 mg/kg BC         | 5.4 mg/kg BC              | 5.4 mg/kg BC                           | 5.4 mg/kg BC                           | 5.4 mg/kg BC                        |
| N Mean (Std Dev) Min / Max | 232 8.187 (5.722)    | 232 6.792 0.24/166.51 122 | 232 31.729 (17.658) 122 43.69 (32.364) | 109 33.334 (16.551) 103 43.61 (31.395) | 226 0.263 (0.250) 115 0.351 (0.244) |
| 6.4 mg/kg BC               | 6.4 mg/kg BC         | 6.4 mg/kg BC              | 6.4 mg/kg BC                           | 6.4 mg/kg BC                           | 6.4 mg/kg BC                        |
| N Mean (Std Dev) Min / Max | 122 10.453 (9.343)   | 6.840 0.34/191.47         |                                        |                                        |                                     |

AUC21d = area under the serum concentration-time curve from time zero toDay 21; AUClast = area under the serum concentration-time curve from time zero to the time of the last quantifiable serum concentration; BC =breast cancer; Cmax = maximum serum concentration; Ctrough = trough serum concentration; DXd = released drug; GC = gastric cancer; HER2 = human epidermal growth factor receptor 2; PK = pharmacokinetic; Std Dev = standard deviation; Tmax =time to reach peak serum concentration.

a Values are presented as N / mean (Std Dev) except for Tmax, which shows N / median (range). Source:Module5.3.5.3SCPTFLsTable1.1.3; initialGastric Cancer BLA Table 3.3.

## Dose proportionality and time dependencies

Not addressed in the present application.

## Special populations

A popPK analysis performed with an analysis dataset pooled from five studies (J101, J102, A103, A104, and U201) for the initial BC application was updated with inclusion of data from study J202 and U205. This analysis explored the exposures among subpopulations of interest, including tumor type, sex, racecountry, region, hepatic function, and renal function.

## Covariate Effect on DXd Pharmacokinetics

The  effect  of  each  significant  covariate  included  in  the  final  model  on  the  AUCss  of  DXd  after administration of T-DXd at 6.4 mg/kg Q3W was evaluated by forest plots ( Figure 3.8 ). A typical subject who was administered T-DXd lyophilized drug product was a 65-year-old Asian subject with GC, body weight 59 kg, total bilirubin 8.6 μmol/L, and AST 26 U/L. The magnitude of all covariate effects on DXd exposure (Cmax,ss, Cmin,ss, and AUCss) was contained within a 0.8 to 1.25 ratio interval except for effects of extreme values of AST and body weight.

<div style=\"page-break-after: always\"></div>

| Covariate                | Percentile   | Value         | Ratio [95% CI]       |
|--------------------------|--------------|---------------|----------------------|
| Body weight (kg)         | 5%           | 42            | 0.836 [0.808, 0.868] |
|                          | 25%          |               | 0.908 [0.893, 0.924] |
|                          | 50%          | 58            | 1 [0.998, 1.01]      |
|                          | %9           | 68            | 1.05 [1.03, 1.06]    |
|                          | 95%          | 88            | 1.18 [1.13, 1.23]    |
| AST (U/L)                | 5%           | 18            | 0.874 [0.856, 0.89]  |
|                          | 25%          | 21            | 0.93 [0.922, 0.938]  |
|                          | 50%          | 29            | 1 [0.998, 1.01]      |
|                          | 75%          | 41            | 1.08 [1.07, 1.11]    |
|                          | 95%          | 82            | 1.27 [1.22, 1.34]    |
| Total bilirubin (umol/L) | 5%           | 4             | 0.857 [0.821, 0.885] |
|                          | 25%          | 6             | 0.92 [0.902, 0.934]  |
|                          | 50%          | 8             | 1 [0.998, 1.01]      |
|                          | 75%          | 11            | 1.02 [1.01, 1.03]    |
|                          | 95%          | 18            | 1.11 [1.08, 1.16]    |
| Race-country             |              | Non-Asian     | 0.976 [0.976, 0.977] |
| Cancer type              |              | Breast cancer | 0.887 [0.835, 0.926] |

<!-- image -->

| Covariate               | Percentile   | Value         | Ratio [95%CI]        |
|-------------------------|--------------|---------------|----------------------|
| Body weight (kg)        | 5%           | 42            | 0.81 [0.784, 0.839]  |
|                         | 25%          | 50            | 0.896 [0.883, 0.911] |
|                         | 50%          | 58            | 1 [0.999, 1.01]      |
|                         | 75%          | 68            | 1.06 [1.05, 1.08]    |
|                         | 95%          | 88            | 1.22 [1.17, 1.27]    |
| AST (U/L)               | 5%           | 16            | 0.88 [0.863, 0.896]  |
|                         | 25%          | 21            | 0.934 [0.926, 0.941] |
|                         | %0S          | 29            | 1 [0.999, 1.01]      |
|                         | 75%          | 41            | 1.08 [1.06, 1.1]     |
|                         | 95%          | 82            | 1.26 [1.21, 1.32]    |
| Totalbilirubin (umol/L) | 5%           | 4             | 0.864 [0.829, 0.891] |
|                         | 25%          | 6             | 0.924 [0.907, 0.937] |
|                         | 50%          | 8             | 1 [0.999, 1.01]      |
|                         | 75%          | 11            | 1.02 [1.01, 1.03]    |
|                         | 95%          | 18            | 1.11 [1.07, 1.15]    |
| Race-country            |              | Non-Asian     | 0.987 [0.985, 0.989] |
| Cancer type             |              | Breast cancer | 0.837 [0.789, 0.872] |

Figure 3.8: Forest Plot of Covariate Effect on theExposure of DXd at SteadyState

<!-- image -->

<!-- image -->

<div style=\"page-break-after: always\"></div>

AST = aspartate aminotransferase; AUC = area under the concentration-time curve; Cmax =maximum concentration; Cmin = minimum concentration; GC = gastric cancer; Lyo-DP = lyophilized drug product. Note: First and second dashed vertical lines correspond to ratios of 0.8 and 1.25, respectively. The solid vertical line corresponds to a ratio of 1 and represents the typical subject. Points and whiskers represent the estimate and 90% confidence interval, respectively. A typical subject is defined as a 65-year-old Asian subject with GC, baseline weight of 59 kg, AST of 26 U/L, total bilirubin of 8.6 μmol/L. For DXd race-country categories Asian fromJapan and Asian not from Japan were grouped together and are displayed here against the non-Asian group. Source:Module 5.3.3.5Population PK Report (PMx x008)Figure 4-14

<!-- image -->

## Pharmacokinetic interaction studies

## Clinical data

No new drug drug interaction studies have been conducted.

## Immunogenicity

Anti-drug antibodies (ADAs) against T-DXd were evaluated in subjects from Studies J202 and U205, and these data were combined with the data from the studies included in the initial BC application to provide an integrated immunogenicity assessment across the seven clinical studies (J101, J102, A103, A104, U201, J202, and U205). Immunogenicity data are summarized across all studies in Table 4.2 .

Immunogenicity data are summarized at baseline and post-treatment, which includes the incidence of treatment-emergent ADA-positive results. Across the clinical studies, 892 subjects were tested for ADAs against T-DXd, and the median duration of immunogenicity assessment was 25 weeks (range of median values across studies: 15.1 weeks to 39.0 weeks). In general, the rate of baseline and post-baseline ADA-positive  immunogenicity  was  low  with  4.5%  and  2.4%  prevalence,  respectively.  The  rate  of treatment-emergent ADAs (defined as subjects who were ADA-negative at baseline and became ADApositive post-treatment; or subjects who were ADA-positive at baseline and post-treatment, but had an increase in ADA titer from baseline to posttreatment; or subjects who had missing ADA data at baseline and  were  ADA-positive  posttreatment)  continued  to  be  low,  with  1.8%  subjects  (16/892)  having treatment-emergent ADAs. No apparent difference was noted in the incidence of treatment-emergent ADAs  across  different  tumor  types.  None  of  the  treatment-emergent  ADA-positive  subjects  had neutralizing antibody (NAb)-positive samples. No obvious effect of immunogenicity on PK, efficacy, or

<div style=\"page-break-after: always\"></div>

safety was observed. No apparent impact of ADA positivity on systemic concentrations of T-DXd was noted. The population PK analysis confirmed lack of an impact of ADA status on the CLT-DXd.

Table 4.2: Summary of Clinical ImmunogenicityData for T-DXd

|                                              |                          | Clinical Study           | Clinical Study           | Clinical Study           | Clinical Study           | Clinical Study           | Clinical Study           | Clinical Study           | Overall                  |
|----------------------------------------------|--------------------------|--------------------------|--------------------------|--------------------------|--------------------------|--------------------------|--------------------------|--------------------------|--------------------------|
| Statistic                                    | Statistic                | J101                     | J102                     | A103                     | A104                     | U201                     | J202                     | U205                     |                          |
| Baseline assessment                          | Baseline assessment      | Baseline assessment      | Baseline assessment      | Baseline assessment      | Baseline assessment      | Baseline assessment      | Baseline assessment      | Baseline assessment      | Baseline assessment      |
| Total number of subjects assessed            |                          | 289                      | 51                       | 12                       | 40                       | 253                      | 169                      | 78                       | 892                      |
| ADA-positive at baselinea                    | n (%)                    | 5 (1.7)                  | 3 (5.9)                  | 0                        | 1 (2.5)                  | 13 (5.2)                 | 13 (7.7)                 | 5 (6.7)                  | 40 (4.5)                 |
| NAb-positive at baselinea                    | n (%)                    | 0                        | 0                        | 0                        | 0                        | 1 (0.4)                  | 0                        | 0                        | 1 (0.1)                  |
| Post-baseline assessment                     | Post-baseline assessment | Post-baseline assessment | Post-baseline assessment | Post-baseline assessment | Post-baseline assessment | Post-baseline assessment | Post-baseline assessment | Post-baseline assessment | Post-baseline assessment |
| Total number of subjects assessed            |                          | 289                      | 51                       | 12                       | 40                       | 253                      | 169                      | 78                       | 892                      |
| ADA-positive post- baselineb                 | n (%)                    | 1 (0.3)                  | 1 (2.0)                  | 0                        | 0                        | 5 (2.0)                  | 12 (7.2)                 | 2 (2.6)                  | 21 (2.4)                 |
| NAb-positive post- baselineb                 | n (%)                    | 0                        | 0                        | 0                        | 0                        | 0                        | 0                        | 0                        | 0                        |
| ADA-positive at baseline and post-baselinec  | n(%)                     | 1 (0.3)                  | 1 (2.0)                  | 0                        | 0                        | 3 (1.2)                  | 1 (0.6)                  | 0                        | 6 (0.7)                  |
| NAb-positive at baseline and post- baselinec | n (%)                    | 0                        | 0                        | 0                        | 0                        | 0                        | 0                        | 0                        | 0                        |
| Treatment-emergent ADA-positiveb             | n (%)                    | 0                        | 0                        | 0                        | 0                        | 3 (1.2)                  | 11 (6.6)                 | 2 (2.6)                  | 16 (1.8)                 |
| Treatment-induced ADA-positiveb              | n (%)                    | 0                        | 0                        | 0                        | 0                        | 2 (0.8)                  | 11 (6.6)                 | 2 (2.6)                  | 15 (1.7)                 |
| Treatment-boosted ADA-positiveb              | n(%)                     | 0                        | 0                        | 0                        | 0                        | 1 (0.4)                  | 0                        | 0                        | 1 (0.1)                  |
| Treatment-emergent Nab-positiveb             | n (%)                    | 0                        | 0                        | 0                        | 0                        | 0                        | 0                        | 0                        | 0                        |

Source:Module5.3.5.3SCPTFLsTable 2.1.1.

## 2.3.3. Pharmacodynamics

## Mechanism of action

Trastuzumab  deruxtecan  (T-DXd)  is  a  human  epidermal  growth  factor  receptor  2  (HER2)-targeted antibody linked to topoisomerase I inhibitor molecules (ADC molecule). DXd acts as a cytotoxic payload.

## Primary and secondary pharmacology

## Exposure-response analyses

## Exposure-efficacy analysis

For the E-R analysis for efficacy, data from subjects with HER2-positive GC were analysed separately using  an  integrated  dataset  from  Studies  J101  and  J202  and  a  dataset  from  Study  U205.  For  the

<div style=\"page-break-after: always\"></div>

integrated analysis of Studies J101 and J202, 160 subjects were included, with the median age being 66 years and male subjects accounting for 74%; the study subjects were from Japan (82%), non-Japan Asia  (South  Korea)  (15%),  and  non-Asia  (3%).  For  the  analysis  of  Study  U205,  76  subjects  were included, with the median age being 61.5 years and male subjects accounting for 72.4%.

The exposure indicators investigated were the AUC, Cmax, and Cmin of T-DXd and DXd in Cycle 1 and at steady state, and Cavg during the period up to the development of the efficacy event under analysis. The efficacy endpoints were cORR, DoR, and PFS in subjects with HER2-positive GC.

None of the T-DXd or DXd exposure metrics had a statistically significant relationship with the primary efficacy endpoint of ucORR.

In the integrated analysis of Studies J101 and J202, the analysis of cORR by logistic regression showed that cORR was statistically significantly higher in subjects with higher Cmin,ss of T-DXd (P = 0.023; Figure 3.13 ).

In  the  analysis  of  Study  U205,  cORR  by  logistic  regression  showed  that  cORR  was  not  statistically significantly higher in subjects with higher Cmin,ss of T-DXd (P = 0.591; Figure 3.14 ).

Figure 3.13: RelationshipBetweenExposure and Confirmed ObjectiveResponseRate: StudyJ101 andStudyJ202

<!-- image -->

CI = confidence interval; Cmin = minimum concentration; cORR = confirmed objective response rate; Intact = intact T-DXd; N = number of subjects; ORR = objective response rate.

Note: Yes and No refer to if subjects experienced or did not experience objective response. Subjects are stratified into exposure quartiles. Red points are mean exposure and cORR per quartile. Vertical red bars are 90% CIs of the plot shows data for all dose groups. Horizontal boxplots below the plot show the exposure distribution for the 6.4 mg/kg dose group. The P value is for the slope of the logistic regression fit. Source: Module 5.3.3.5 Exposure-Response Analysis Report PMx006 Figure 4-4.

<div style=\"page-break-after: always\"></div>

Figure 3.14: Relationship Between Exposure and Confirmed Objective Response Rate: StudyU205

<!-- image -->

CI = confidence interval; conc = concentration; N = number of subjects; ORR = objective response rate. Note: Yes and No refer to if subjects experienced or did not experience an objective response. Subjects are stratified into exposure quartiles. Red points are ORR per exposure quartile plotted at the mean exposure per quartile. Vertical red bars are 90% CIs of the ORR. Gray band represents the 5th to 95th percentile CI ofa linear logistic regression fit. The P value is the significance level for the slope ofthe logistic fit using a z-test. Horizontal boxplots below the plot show the exposure distribution for the 6.4 mg/kg dose group; the box shows the interquartile range and whiskers show points within 1.5 times the interquartile range.

Source: Module 5.3.3.5 Exposure-Response Analysis Report PMx009 Figure 5-2.

A  Forest  plot  of  the  covariate  effect  on  cORR  as  predicted  from  the  E-R  relationships  is  shown  in Figure 3.15.

<div style=\"page-break-after: always\"></div>

Figure 3.15: Forest Plot of Confirmed Objective Response Rate: Study J101 and Study J202

## ConfirmedcentralORR

<!-- image -->

Probability

Cmin,ss = steady-state minimum concentration; HER2ECD = extracellular domain ofHER2; HER2 = human epidermal growth factor receptor 2; IHC = immunohistochemistry; Intact = intact T-DXd; ISH = in situ hybridization; ORR = objective response rate.

Note: Dot and horizontal line corresponds to the probability estimate and 90% confidence interval, respectively, for 1000 simulated models incorporating parameter uncertainty. Vertical line corresponds to the model-predicted probability for a GC subject with HER2 IHC 3+, HER2ECD ≥16.2 ng/mL, intestinal histology, no prior checkpoint inhibitor use, and the indicated median exposure.

Source: Module 5.3.3.5 Exposure-Response Analysis Report PMx006 Figure 4-5

There were no statistical trends for PFS (P = 0.725; Figure 3.17 ) or DoR (P = 0.164; Figure 3.19 ) with increasing T-DXd exposures over the range of exposures for the 6.4 mg/kg Q3W dose. In the integrated analysis of Studies J101 and J202, PFS was longer in subjects with higher T-DXd Cmin,ss, but there was no statistically significant E-R relationship (P = 0.228; Figure 3.16 ).

<div style=\"page-break-after: always\"></div>

<!-- image -->

Cmin = minimum concentration; Intact = intact T-DXd; PFS = progression-free survival; Q = quartile. Source:Module 5.3.3.5 Exposure-Response Analysis Report PMx006Figure 4-7

In the analysis of Study U205, there were no statistically significant relationships between the probability of PFS and increasing T-DXd Cmin,ss (P = 0.725; Figure 3.17 ).

<div style=\"page-break-after: always\"></div>

Figure 3.17:Kaplan-Meier Curve for Progression-FreeSurvival Stratified by Interquartile Ranges of Exposure: Study U205

<!-- image -->

conc = concentration; N= number of subjects; PFS = progression-free survival; Q = quartile.

Note: P value is significance level oflog-rank test of the survival distributions by quartile.

Source: Module 5.3.3.5 Exposure-Response Analysis Report PMx009 Figure 5-4.

In the integrated analysis of Studies J101 and J202, there was no E-R relationship with any exposure indicator  and  DoR.  In  the  analysis  of  Study  U205,  there  was  no  statistically  significant  relationship between DoR and increasing exposures of T-DXd (P = 0.164). Figure 3.18 and Figure 3.19 show an exploratory Kaplan-Meier curve for DoR stratified by the interquartile ranges of Cavg of T-DXd for the integrated analysis of Studies J101 and J202 and the analysis of Study U205, respectively.

<div style=\"page-break-after: always\"></div>

Figure 3.18: Kaplan-Meier Curve for Duration of Response Stratified byInterquartile Ranges of Exposure: Study J101 and Study J202

<!-- image -->

Cavg = average serum concentration; DoR = duration ofresponse; Intact = intact T-DXd; Q = quartile; T-DXd = trastuzumab deruxtecan.

Note: No P value is noted because there was no exposure-DoR relationship.

Source: Module 5.3.3.5 Exposure-Response Analysis Report PMx006 Figure 4-6.

Figure 3.19:Kaplan-Meier Curve for Duration of ResponseStratified byInterquartile Ranges of Exposure: Study U205

<!-- image -->

Cavg = average serum concentration; DoR = duration of response; N = number of subjects; Q = quartile.

Note: Pvalue is significance level oflog-rank test of the survival distributions by quartile.

Source: Module 5.3.3.5 Exposure-Response Analysis Report PMx009 Figure 5-3.

<div style=\"page-break-after: always\"></div>

## DXd exposure metrics

In the exposure-response analysis report, the following figure is presented, showing the distribution of cORR (yes/no) in relation to different DXd exposure metrics ( Figure 10-2 ).

Figure 10-2 : Exploratory exposure boxplots stratified by ORR

<!-- image -->

Abbreviations: AUC = area under the concentration-time curve; Cavg = average concentration; ORR = confirmed objective response by independent central review.

Note: Thick horizontal line represents the median, box ends show the upper and lower quartiles of the data, whiskers show the range of points within 1.5 times the interquartile range, and points are data that lie outside the whiskers (circles). The p-value is for a Kruskal-Wallis test of difference between distributions.

Source: ee.analysis.r

## Exposure-safety analysis

An integrated dataset across five clinical studies (J101, J102, A103, A104, and U201) for the initial BC application was updated with inclusion of data from Study J202 and then further updated with inclusion of data from Study U205. The most recently updated report included 884 subjects with GC, BC, and other  tumors  for  the  E-R  analysis  for  key  safety  endpoints.  The  safety  endpoints  and  the  exposure metrics evaluated in the current analysis are consistent with those evaluated in the analysis updated with data from Study J202 and the analysis included in the initial BC application. The analysis set was the same as in the PopPK analysis.

<div style=\"page-break-after: always\"></div>

The exposure indicators investigated were Cavg in addition to the AUC, Cmax, and Cmin of T-DXd and DXd for Cycle 1 and at steady state.

Figure 3.20: :Relationship Between Exposure and Adverse Events Associated with Discontinuation of Study Drug

<!-- image -->

AE = adverse event; CI = confidence interval; N = number of subjects. Note: Plot shows probability of AE vs. exposure. Yes and No refer to if subjects experienced or did not experience study drug discontinuation associated with AEs. Subjects are stratified into exposure quartiles. Red points are AE rates per exposure quartile plotted at the median exposure of the quartile. Vertical red bars are 90% CIs of the AE rate. Blue line is the linear logistic regression fit. Gray band represents the 5th to 95th percentile CI of the fit. The p-value is the significance level of the slope of the logistic regression fit using a z-test. The plot shows data for all dose groups. Horizontal boxplot below the graph shows the exposure distribution for the 6.4 mg/kg dose group; the box shows the interquartile range and whiskers show points within 1.5 times the interquartile range. The p-value is for the slope of the logistic regression fit.

Source:Module 5.3.3.5 Exposure-Response Analysis Report PMx009 Figure 5-6.

<div style=\"page-break-after: always\"></div>

## Grade ≥ 3 Adverse Events

Figure 3.24: Relationship Between Exposure and Grade ≥3 Adverse Events

<!-- image -->

AE = adverse event; Cavg = average serum concentration; CI = confidence interval; N = number of subjects. Note: Plot shows probability of AE vs. exposure. Yes and No refer to if subjects experienced or did not experience Grade ≥3 AEs. Subjects are stratified into exposure quartiles. Red points are AE rates per exposure quartile plotted at the mean exposure of the quartile. Vertical red bars are 90% CIs of the AE rate. Blue line is the linear logistic below shows the exposure distribution for the 6.4 mg/kg dose group the box shows the interquartile range and whiskers show points within 1.5 times the interquartile range.

Source: Module 5.3.3.5 Exposure-Response Analysis Report PMx009 Figure 5-17.

<div style=\"page-break-after: always\"></div>

## Serious Adverse Events

Figure 3.26:Relationship Between Exposure and Serious Adverse Events

<!-- image -->

AE = adverse event; Cavg = average serum concentration; CI = confidence interval; N = number of subjects. Note: Plot shows probability of AE vs. exposure. Yes and No refer to if subjects experienced or did not experience serious AEs. Subjects are stratified into exposure quartiles. Red points are mean AE rates per exposure quartile level of the slope of the logistic regression fit using a z-test. The plot shows data for all dose groups. Horizontal boxplot below shows the exposure distribution for the 6.4 mg/kg dose group; the box shows the interquartile range and whiskers show points within 1.5 times the interquartile range.

Source:Module5.3.3.5Exposure-Response AnalysisReportPMx009Figure5-22.

<div style=\"page-break-after: always\"></div>

## Anemia

Figure 3.28: Relationship Between Exposure and Anemia (Grade ≥3)

<!-- image -->

AE = adverse event; Cavg = average serum concentration; CI = confidence interval; N = number of subjects. Note: Plot shows probability of AE vs. exposure. Yes and No refer to if subjects experienced or did not experience anemia (laboratory-based). Subjects are stratified into exposure quartiles. Red points are mean AE rates per exposure quartile plotted at the mean exposure of the quartile. Vertical red bars are 90% CIs of the AE rate. Blue the significance level of the slope of the logistic regression fit using a z-test. The plot shows data for all dose groups. Horizontal boxplot below the graph shows the exposure distribution for the 6.4 mg/kg dose group; the box shows the interquartile range and whiskers show points within 1.5 times the interquartile range. Source: Module 5.3.3.5 Exposure-Response Analysis Report PMx009 Figure 5-27.

<div style=\"page-break-after: always\"></div>

## Neutropenia

Figure3.30: Relationship Between Exposure and Neutrophil Count Decreased (Any Grade)

<!-- image -->

AE = adverse event; Cavg = average serum concentration; CI = confidence interval; N = number of subjects. Note: Plot shows probability of AE vs. exposure. Yes and No refer to if subjects experienced or did not experience neutropenia (laboratory-based). Subjects are stratified into exposure quartiles. Red points are AE rates per exposure quartile plotted at the median exposure ofthe quartile. Vertical red bars are 90% CIs of the AE rate. Blue line is the linear logistic regression fit. Gray band represents the 5th to 95th percentile CI of the fit. The p-value is the Horizontal boxplot below the graph shows the exposure distribution for the 6.4 mg/kg dose group; the box shows the interquartile range and whiskers show points within 1.5 times the interquartile range. Source: Module 5.3.3.5 Exposure-Response Analysis Report PMx009 Figure 5-32.

<div style=\"page-break-after: always\"></div>

## Thrombocytopenia

Figure 3.33: Relationship Between Exposure and Platelet Count Decreased (Grade ≥3)

<!-- image -->

AE = adverse event; Cavg = average serum concentration; CI = confidence interval; N = number of subjects. Note: Plot shows probability of AE vs. exposure. Yes and No refer to if subjects experienced or did not experience thrombocytopenia (laboratory-based). Subjects are stratified into exposure quartiles. Red points are AE rates per exposure quartile plotted at the median exposure of the quartile. Vertical red bars are 90% CIs of the AE rate. Blue the significance level of the slope of the logistic regression fit using a z-test. The plot shows data for all dose groups. Horizontal boxplot below shows the exposure distribution for the 6.4 mg/kg dose group; the box shows the interquartile range and whiskers show points within 1.5 times the interquartile range. Source:Module 5.3.3.5Exposure-ResponseAnalysis Report PMx009 Figure 5-37.

Figure 3.33 in the CTD is shown below (Figure 6). The risk for thrombocytopenia at 3 ng/mL in the Asian-Non-Japan group is approximately 25% (center panel). However, in the Japan-Asian group (left panel), the risk for Grade ≥3 thrombocytopenia at 3 ng/mL is approximately 50% (left panel), which is in line with the results as shown in the forest plot. Across all groups, the overall risk for Grade ≥3 thrombocytopenia is approximately 20%.

<div style=\"page-break-after: always\"></div>

Figure 6: Probability of thrombocytopenia (Figure 3.33 in original report)

<!-- image -->

Abbreviations: Cavg = average concentration N = number of subjects.

Note: The solid line is the model-predicted curve per population.

Source: DS8201-PMx009 Figure 5-381

## Interstitial lung disease

Figure  3.37 shows  Kaplan-Meier  curves  of  the  time  to  ILD  (any  grade  and  Grade  &gt;3)  for  each interquartile  range  based  on  an  exposure  metrics  (AUC,ss  and  Cmax,ss  of  T-DXd).  There  was  a statistically significant relationship between the exposure to T-DXd (AUCss) and the incidence rate of ILD (any grade and Grade &gt;3) (P &lt; 0.001); the incidence rate of ILD (any grade) tended to be higher in subjects with higher exposure.

Note:P-value in the topplot is for log-rank test.

<div style=\"page-break-after: always\"></div>

<!-- image -->

On the basis of the result of Cox regression, race-country and baseline creatinine clearance were selected as  statistically  significant  covariates  for  ILD  (any  grade).  The  effect  of  the  exposure  indicators  and covariates  based  on  the  final  model  on  the  incidence  rate  was  evaluated  by  forest  plots  at  Day  90 ( Figure 3.38 ).

<div style=\"page-break-after: always\"></div>

Figure 3.38: Forest Plot of Interstitial Lung Disease (Any Grade) at Day 90

InterstitialLungDisease,anyGradeatDAY9o

<!-- image -->

Probability

AUC = area under the concentration-time curve; ILD = interstitial lung disease.

Note: Dot and horizontal line corresponds to the probability estimate and 90% confidence interval, respectively, for 1000 simulated models incorporating parameter uncertainty. Vertical line corresponds to the model-predicted probability for a typical subject (Asian from Japan and median creatinine clearance of 85 mL/min) and the indicated median T-DXd exposure for 6.4 mg/kg T-DXd in the overall population including all tumor types. Creatinine clearance values correspond to boundaries for normal (90 mL/min), mild (60 mL/min), and moderate (30 mL/min) renal impairment.

Source: Module 5.3.3.5 Exposure-Response Analysis Report PMx009 Figure 5-54.

The model-predicted E-R relationships for safety events were used to estimate the probability of each safety variable for 5.4 mg/kg doses in subjects with BC and 6.4 mg/kg doses in subjects with GC ( Table 3.7 ). The incidence of these safety endpoints at the 6.4 mg/kg dose in subjects with GC was estimated to be generally comparable to the 5.4 mg/kg dose in subjects with BC with the exception of Grade ≥3 TEAE, SAEs, anemia Grade ≥3, and neutropenia Grade ≥3, which were predicted to be &gt;10% higher at the 6.4 mg/kg dose in subjects with GC.

<div style=\"page-break-after: always\"></div>

Table 3.7: Model-Predicted Exposure-Response Relationships for SafetyParameters

| Endpoint                                        | Model-predictedRate(%)Estimate(90%Cl)   | Model-predictedRate(%)Estimate(90%Cl)   |
|-------------------------------------------------|-----------------------------------------|-----------------------------------------|
|                                                 | BC 5.4 mg/kg Q3W                        | GC 6.4 mg/kg Q3W                        |
| Study drug discontinuation associated with TEAE | 18.7 [13.7, 25]                         | 14 [9.7, 19.4]                          |
| Dosereduction associatedwithTEAE                | 23.2 [18.9, 28.4]                       | 30.0 [22.8, 38.5]                       |
| Grade≥3TEAE                                     | 58.9 [54.3, 63.7]                       | 69.4 [63.3, 74.7]                       |
| SAE                                             | 23.3 [18.5, 28.9]                       | 35.2 [28.5,41.9]                        |
| Anemia (laboratory-based), Grade ≥3             | 12.5 [8.9, 17.0]                        | 27.5 [21.5, 34.4]                       |
| Neutropenia (laboratory-based), any grade       | 67.2 [60.8, 73.0]                       | 64 [56.4, 70.9]                         |
| Neutropenia (laboratory-based), Grade ≥3        | 20.6 [16.2, 25.7]                       | 31.7 [26.2, 38.2]                       |
| Thrombocytopenia (laboratory-based), any grade  | 60.4 [54.7, 65.3]                       | 67.5 [62.1, 72.8]                       |
| Thrombocytopenia (laboratory-based), Grade ≥3   | 6.3 [4.3, 9.2]                          | 10.5 [6.9, 14.8]                        |
| LVEF decreased (ECG-based),Grade ≥2             | 16.3 [12.7, 20.7]                       | 9.7 [6.5, 14.3]                         |

Note: Modeled safety rates include all subjects with BC and GC. Exposures are dose-normalized to 5.4 mg/kg in BC and to 6.4 mg/kg in GC. The number of subjects with BC is 512. The number of subjects with GC is 293. Source:Module5.3.3.5Exposure-Response Analysis Report PMx009 Table 5-71.

Table 7 shows AEs for subjects in Study U205 who received 6.4 mg/kg, stratified by the 25 th , 25 th  to 75 th ,  and  75 th percentile  body  weight  (&lt;65.5,  65.5  to  &lt;85.5,  ≥85.5,  respectively). For  all  safety endpoints, except thrombocytopenia, the event rates are comparable across the categories of  body weight.

Table 7: Adverse events for subjects in Study U205 receiving 6.4 mg/kg, stratified by body weight

| AE a                                 | <65.5 kg (25 th percentile)   | 65.5 kg to <85.5 kg (25 th to 75 th percentile)   | ≥ 85.5 kg (75 th percentile)   |
|--------------------------------------|-------------------------------|---------------------------------------------------|--------------------------------|
| Any AE, Grade ≥ 3                    | 10/19 (52.6%)                 | 17/38 (44.7%)                                     | 10/19 (52.6%)                  |
| Any serious AE                       | 9/19 (47.4%)                  | 11/38 (28.9%)                                     | 7/19 (36.8%)                   |
| Discontinuation associated with AE   | 2/19 (10.5%)                  | 7/38 (18.4%)                                      | 3/19 (15.8%)                   |
| Dose reduction associated with AE    | 4/19 (21.1%)                  | 9/38 (23.7%)                                      | 5/19 (26.3%)                   |
| Dose interruption associated with AE | 3/19 (15.8%)                  | 8/38 (21.1%)                                      | 5/19 (26.3%)                   |
| Lab-Based Anemia, any grade          | 17/19 (89.5%)                 | 37/38 (97.4%)                                     | 17/19 (89.5%)                  |
| Lab-Based Anemia, Grade ≥ 3          | 3/19 (15.8%)                  | 2/38 (5.3%)                                       | 2/19 (10.5%)                   |
| Lab-Based Neutropenia, any grade     | 8/19 (42.1%)                  | 20/38 (52.6%)                                     | 11/19 (57.9%)                  |
| Lab-Based Neutropenia, Grade ≥ 3     | 2/19 (10.5%)                  | 5/38 (13.2%)                                      | 1/19 (5.3%)                    |

<div style=\"page-break-after: always\"></div>

| AE a                                  | <65.5 kg (25 th percentile)   | 65.5 kg to <85.5 kg (25 th to 75 th percentile)   | ≥ 85.5 kg (75 th percentile)   |
|---------------------------------------|-------------------------------|---------------------------------------------------|--------------------------------|
| Lab-Based Thrombocytopenia, any grade | 8/19 (42.1%)                  | 16/38 (42.1%)                                     | 15/19 (78.9%)                  |
| Lab-Based Thrombocytopenia, Grade ≥ 3 | 0/19 (0.0%)                   | 0/38 (0.0%)                                       | 1/19 (5.3%)                    |
| LVEF decrease, any grade              | 0/19 (0.0%)                   | 0/38 (0.0%)                                       | 0/19 (0.0%)                    |
| LVEF decrease (ECHO), Grade ≥ 2       | 2/19 (10.5%)                  | 0/38 (0.0%)                                       | 1/19 (5.3%)                    |
| Interstitial Lung Disease, any grade  | 0/19 (0.0%)                   | 6/38 (15.8%)                                      | 1/19 (5.3%)                    |
| Interstitial Lung Disease, Grade ≥ 3  | 0/19 (0.0%)                   | 1/38 (2.6%)                                       | 0/19 (0.0%)                    |

Abbreviations: AE = adverse event; ECHO = echocardiogram; LVEF = left ventricular ejection fraction.

Note: Anemia, neutropenia, and thrombocytopenia AEs are based on laboratory measurements.

a   The dataset of AEs listed comes from the DSI ER Report (DS8201-PMx009) .

Source: responses-v3.r

## 2.3.4. Discussion on clinical pharmacology

The pharmacology package included in the current application includes data from two additional Phase 2 studies in subjects with HER2-positive advanced GC or gastroesophageal junction (GEJ) adenocarcinoma (Studies J202 and U205).

No new bioanalytical methods were applied for detection of the three moieties from T-DXd or ADA in Study J202 and U205. A new NAb assay was developed. No NAbs were detected in any samples.

The  PK  for  T-DXd  was  described  by  a  two-compartment  model  with  IV  infusion  input  and  linear elimination which also served as the input to the released drug model DXd. The DXd formation was described by a one-compartment model with a two-component time-varying release rate (Krel) from TDXd. Krel was modelled to decrease as a constant reduction after Cycle 1 (FPC1) and as gradual decline per cycle (FPC2). The PK data for Western GC patients is considered rather limited and the Pop PK model could not adequately describe this population.

A bridging analysis between Asian and Western population was conducted using a virtual second-line or later  HER2-positive gastric cancer Western population by use of real-world data from gastric cancer patients in the US treated with trastuzumab deruxtecan. The PK/efficacy and safety predictions were largely comparable to the data achieved in Study U205 (US/European patients with HER2 gastric cancer, n=79).  The  virtual  RWD  analysis  in  Western  subjects  is  not  considered  sufficiently  reliable  nor representative of an entire population to bridge to the Asian population.

The ADME characteristics were described in the original BC marketing application. Based on the efficacy and safety results observed when comparing the 5.4 and 6.4 mg/kg doses, the selected dose of 6.4 mg/kg Q3W in GC patients is considered acceptable. In section 5.2 of the SmPC, the value of DXd clearance has been changed from 19.2 L/h to 18.5 L/h due to new data included in the model (see SmPC for new issue). 'The clearance of DXd based on population pharmacokinetic analysis was estimated to be 18.6 L/h and 16.7 L/h for patients with metastatic HER2-positive breast cancer and locally advanced or metastatic gastric or GEJ adenocarcinoma, respectively.'

18.6 L/h x 24 = 446.4 L/day

16.7 L/h x 24 = 400.8 L/day

The exposure parameters in cycle 1 for DXd, the cytotoxic payload of T-DXd, is slightly higher in GC subjects receiving either 5.4 or 6.4 mg/kg compared with BC subjects receiving the same doses.

PopPK analyses show that the covariates of interest, except from an impact of extreme weight (5 th  and 95 th  percentile) and high AST, do not affect the PK of DXd compared with the reference subject. None of the estimated values are considered to have a clinically meaningful impact on DXd PK.

<div style=\"page-break-after: always\"></div>

No new clinical DDI studies have been conducted since the BC application.

Across all studies, the rate of treatment-emergent ADAs was low (1.8% of the subjects (16/892)). No treatment-emergent Nab-positive samples were found.

Exposure-response  analyses  were  performed  using  data  from  Study  U205.    The  exposure-response models were linear logistic regression models, except for interstitial lung disease endpoints, DoR and PFS,  which  were  linear  Cox  regression  models.  No  relation  to  exposure  was  found  for  the  efficacy endpoints. No covariates were tested on the intercept and slope terms for ORR or on the slope term for PFS and DoR. In general, race-country had impact on the slope term for most safety endpoints.

Exposure of trastuzumab deruxtecan and DXd in the first cycle were 16% and 9% higher in subjects with GC in study U205 compared to subjects in study J202. This is likely related to the higher bodyweight of subjects in study U205 vs J202, 75 kg vs 57 kg, respectively, and consequently higher doses. Based on the currently available data, capping the dose for subjects with higher body weight is not necessary. For subjects in study U205, there was no clear correlation between body-weight and AEs except for thrombocytopenia  and  to  lesser  extent  for  neutropenia  any  grade,  but  this  did  not  result  in  more discontinuations due to AEs in subjects in the 75 th  percentile body-weight compared to subjects with a lower body-weight.

The flat exposure-efficacy relationship while exposure-safety relationships were generally steeper with higher exposures of trastuzumab deruxtecan and/or DXd were for the breast cancer indication reason to select the 5.4 mg/kg Q3W over the 6.4 mg/kg Q3W. It could be argued that the lower dose of 5.4 mg/kg Q3W might also be preferred for the treatment of GC because of the steep exposure-safety relationship and the lower AEs incidence observed for 5.4 mg/kg vs 6.4 mg/kg in breast cancer. However, there is insufficient data for trastuzumab deruxtecan treatment of GC other than with 6.4 mg/kg Q3W. Hence, the benefit-risk assessment for trastuzumab deruxtecan for treatment of HER2-positive advanced GC should be based on 6.4 mg/kg dose (see also B/R). It is, however, unknown if the optimal dose has been selected.

## 2.3.5. Conclusions on clinical pharmacology

The pharmacology package included in the current application includes data from two additional Phase 2 studies in the intended patient population and is considered adequate to support the extension of indication as 2L monotherapy (T-DXd dose 6.4 mg/kg) for treatment of patients with locally advanced or metastatic HER2-positive gastric or GEJ adenocarcinoma.

## 2.4. Clinical efficacy

The sought new therapeutic indication of Enhertu for advanced HER2+ GC/GEJC  in the 2L+ setting (after a prior trastuzumab-based regimen) is based on efficacy data from the pivotal single-arm phase II trial DS8201-A-U205 (DESTINY-Gastric02) , which took place in Europe and the USA.

Results from phase II study DS8201-A-J202 (DESTINY-Gastric01) , a randomised controlled trial in the third line setting in patients from Japan and South Korea, are considered supportive.

## 2.4.1. Dose response studies

Study J101:

<div style=\"page-break-after: always\"></div>

A completed phase 1, multicenter, 2-part (dose escalation followed by dose expansion), open-label, nonrandomized, multiple-dose first-in-human (FIH) study conducted in the US and Japan in several types of advanced solid malignant tumours that contributed 44 subjects with pre-treated metastatic HER2positive gastric or GEJ adenocarcinoma who had received prior trastuzumab and were treated at 1 of 2 doses in the study: the 6.4 mg/kg target dose (N = 25) or a 5.4 mg/kg dose (N = 19).

Figure 4.3: Study J101 Design

<!-- image -->

## Study D967LC00001 (DESTINY-Gastric03):

An on-going Phase 1b/2 open-label 2-part dose escalation (Part 1) and dose expansion (Part 2) study, to evaluate the safety, tolerability, pharmacokinetics (PK), immunogenicity, and antitumor activity of TDXd 6.4 mg/kg monotherapy and combinations in adult subjects with HER2-positive GC. As of 01 Aug 2021, 100 subjects have been enrolled and treated.

The  MAH  has  provided  a  finished  phase  1  dose  escalation  study  followed  by  dose  expansion  in  44 subjects. This has been followed by a larger on-going Phase 1b/2 open-label 2-part dose escalation (Part 1)  and  dose  expansion  (Part  2)  study,  to  evaluate  the  safety,  tolerability,  pharmacokinetics  (PK), immunogenicity, and antitumor activity of T-DXd 6.4 mg/kg monotherapy and combinations in adult subjects with HER2-positive GC. The Applicant did not submit dose response studies to justify the higher proposed posology in gastric cancer. The Applicant considers the ICH E4 requirements on dose-response evaluation were addressed by the analyses described above and the dose-response relationship in the BC population. However, it is not agreed with the Applicant that ICH E4 requirements are addressed.

Trastuzumab deruxtecan is considered to be a molecularly targeted agent (MTA). In particular in the case of dose-finding for MTAs, the dose-finding strategy should not only focus on safety endpoints, but also on determining an optimal biologically active dose (alternatively termed 'optimal biological dose' or 'optimum biologic dose') (EMA/CHMP/205/95 Rev.6). This refers to a dose at which optimal biological response  according  to  a  predefined  effect  marker  is  achieved  (e.g.  as  determined  in  tumour  tissue response) and giving a higher dose does not further improve outcomes  (i.e. a dose somewhere at the beginning of the plateau of the dose-response curve). Identification of the beginning of the plateau on the dose response curve is not possible with two studied doses (6.4 mg/kg target dose (N = 25) or a

<div style=\"page-break-after: always\"></div>

5.4 mg/kg dose (N = 19). At least three doses in a sufficient number of patients are required to identify the plateau on the dose response curve.

Approval decisions are based on a consideration of the totality of information on a drug. Although doseresponse information should be available, depending on the kind and degree of effectiveness shown, imperfections in the database may be acceptable with the expectation that further studies will be carried out after approval (CPMP/ICH/378/95).

## 2.4.2. Main study

## Study U205 (DESTINY-Gastric02)

Study U205 was a Phase 2, multicenter, single-arm, open-label study to evaluate the efficacy and safety of T-DXd (6.4 mg/kg as IV infusion Q3W) in subjects with unresectable or metastatic HER2-positive gastric or GEJ adenocarcinoma who had progressed during or after a trastuzumab-containing regimen (2L). The study was conducted in a Western population at 24 sites in the US and Europe. The primary efficacy analysis of confirmed ORR by ICR has been completed.

Figure 1.2: StudyU205Design

<!-- image -->

ECOG=Eastem Cooperative Oncology Group:GEJ=gastroesophageal junction;HER2=human cpidermal growth factor receptor 2;ORR=objective response rate;Q3W=every3 weeks;T-DXd=trastuzumab deruxtecan,DS 8201a

## Methods

## Study participants

## Inclusion Criteria

Subjects had to satisfy all of the following criteria to be included in the study:

1. Must have been able to comprehend, sign, and date a main informed consent form (ICF) approved by the IRB or Ethics Committee (EC) before any study-specific procedures or tests were performed.
2. Men or women ≥ 18 years of age. (Followed local regulatory requirements if the legal age of consent for study participation was &gt;18 years of age.)
3. Had pathologically documented gastric or GEJ cancer that was:

<div style=\"page-break-after: always\"></div>

-  Unresectable or metastatic, and

-  Centrally confirmed HER2-positive disease (IHC 3+ or IHC 2+ and evidence of HER2 amplification by ISH) as determined according to American Society of Clinical Oncology - College of American Pathologists guidelines based on a new tumor biopsy obtained after progression on or after a first-line trastuzumabcontaining regimen. If a tumor biopsy was already collected after discontinuation of first-line treatment with a trastuzumab-containing regimen, it was acceptable to consider that biopsy to have been a new biopsy for the purpose of this study, provided that there was sufficient tissue for exploratory biomarker studies.

4. Experienced disease progression (based on RECIST v1.1 criteria) during or after first-line therapy with a  trastuzumab-containing  regimen.  Note:  Prior  first-line  treatment  with  trastuzumab  brand  name (Herceptin®) or approved biosimilar was acceptable.

- Note: Prior adjuvant therapy with a trastuzumab-containing regimen could have been counted as a line of therapy if the subject progressed on or within 6 months of completing adjuvant therapy.

5. Had at least 1 measurable lesion per RECIST v1.1 as confirmed by the investigator review.

6. Eastern Cooperative Oncology Group performance status (ECOG PS) of 0 or 1.

7. Left ventricular ejection fraction (LVEF) ≥ 50% within 28 days before first dose per echocardiogram (ECHO)/multigated acquisition (MUGA) scan.

8. Had adequate organ function within 14 days before first dose.

9. Had adequate treatment washout period before first dose, defined as:

| Treatment                                                              | Washout Period                                                               |
|------------------------------------------------------------------------|------------------------------------------------------------------------------|
| Major surgery                                                          | ≥4 weeks                                                                     |
| Radiation therapy including palliative stereotactic radiation to chest | ≥4 weeks (palliative stereotactic radiation therapy to other areas ≥2 weeks) |

| Treatment                                                                    | Washout Period                                                                                                                                                                                                                                                                                                                                                                                                                 |
|------------------------------------------------------------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Chemotherapy (Immunotherapy [non- antibody-based therapy]), retinoid therapy | ≥3 weeks (≥2 weeks or 5 half-lives , whichever was longer, for small-molecule targeted agents such as 5-fluorouracil-based agents, folinate agents, weekly paclitaxel; ≥6 weeks for nitrosureas or mitomycin C), ≥1 week for tyrosine kinase inhibitors (TKIs) approved for the treatment of non-small cell lung cancer (NSCLC) - baseline computed tomography (CT) scan must have been completed after discontinuation of TKI |
| Antibody-based anticancer therapy                                            | ≥4 weeks                                                                                                                                                                                                                                                                                                                                                                                                                       |
| Chloroquine /Hydroxychloroquine                                              | >14 days                                                                                                                                                                                                                                                                                                                                                                                                                       |

10. Male and female subjects of reproductive/childbearing potential were required to agree to use a highly effective form of contraception or avoid intercourse during and upon completion of the study and for at least 7 months for females and 4 months for males after the last dose of study drug.

<div style=\"page-break-after: always\"></div>

11. If the subject was a female of childbearing potential, she was to have a negative serum pregnancy test at screening and/or 72 hours before the first dose of study drug, during the treatment period, and for 7 months, following the last dose of study drug.

12. Male subjects were not allowed to freeze or donate sperm starting at screening and throughout the study period, and at least 4 months after the final study drug administration.

13. Female subjects were not allowed to donate, or retrieve for their own use, ova from the time of screening and throughout the study treatment period, and for at least 7 months  after the final study drug administration.

## Exclusion Criteria

Subjects who met any of the following criteria were disqualified from entering the study:

1. Use of anticancer therapy after first-line treatment with a trastuzumab-containing regimen.

2. Uncontrolled or significant cardiovascular disease, including any of the following:

- History of myocardial infarction (MI) within 6 months of first dose
- History of symptomatic congestive heart failure (New York Heart Association Class II to IV)

- Troponin levels consistent with MI as defined according to the manufacturer within 28 days prior to first dose

- QT interval corrected for heart rate (QTc) prolongation to &gt;470 milliseconds (ms) (female) or &gt;450 ms (male) based on Screening triplicate 12-lead electrocardiogram (ECG).

3. History of non-infectious ILD/pneumonitis that required corticosteroid therapy, current ILD/pneumonitis, or suspected ILD/pneumonitis that could not be ruled out by imaging at screening.

4. Clinically severe pulmonary compromise resulting from intercurrent pulmonary illnesses including, but not limited to, any underlying pulmonary disorder (ie, pulmonary emboli within 3 months of the first dose, severe asthma, severe chronic obstructive pulmonary disease (COPD), restrictive lung disease, pleural  effusion,  etc.),  and  any  autoimmune,  connective  tissue,  or  inflammatory  disorders  with pulmonary involvement (ie, rheumatoid arthritis, Sjogren's, sarcoidosis, etc.), or prior pneumonectomy.

5. Pleural effusion, ascites, or pericardial effusion that required drainage, peritoneal shunt, or Cell-free and Concentrated Ascites Reinfusion Therapy (CART). (Drainage and CART were not allowed within 2 weeks prior to screening.)

6. Spinal cord compression or clinically active central nervous system metastases, defined as untreated and  symptomatic  or  requiring  therapy  with  corticosteroids  or  anticonvulsants  to  control  associated symptoms. Baseline brain CT/magnetic resonance imaging (MRI) scan was mandatory.

- Subjects with clinically inactive brain metastases could be included in the study.

-  Subjects  with  treated  brain  metastases  that  were  no  longer  symptomatic  and  who  required  no treatment with corticosteroids or anticonvulsants could be included in the study if they had recovered from the acute toxic effect of radiotherapy. A minimum of 2 weeks must have elapsed between the end of whole brain radiotherapy and signing of main ICF (1 week for stereotactic radiotherapy).

7. History of other malignancy(ies), except adequately treated non-melanoma skin cancer, curatively treated in-situ disease, or other solid tumors curatively treated, with no evidence of disease for ≥ 3 years.

<div style=\"page-break-after: always\"></div>

8. History of severe hypersensitivity reactions to either the drug substance or inactive ingredients in the drug product.

9. History of severe hypersensitivity reactions to other monoclonal antibodies.

10. Current uncontrolled infection requiring IV antibiotics, antivirals, or antifungals.

11. Substance abuse or any other medical conditions such as clinically significant cardiac or pulmonary diseases or psychological conditions, that could, in the opinion of the investigator, interfere with the subject's participation in the clinical study or evaluation of the clinical study results.

12. Social, familial, or geographical factors that could interfere with study participation or follow-up. 13. Known human immunodeficiency virus (HIV) infection, or active hepatitis B or C infection. Subjects were tested for HIV prior to enrollment if required by local regulations or IRB/EC. Subjects positive for hepatitis C virus (HCV) antibody were eligible only if polymerase chain reaction was negative for HCV ribonucleic acid (RNA).

14. Unresolved toxicities from previous anticancer therapy, defined as toxicities (other than alopecia) not yet resolved to Grade ≤ 1 or baseline. Subjects with chronic Grade 2 toxicities could be eligible at the discretion of the investigator after consultation with the Sponsor Global Clinical Lead or designee (eg, Grade 2 chemotherapy-induced neuropathy).

15. Prior treatment with an antibody-drug conjugate consisting of an exatecan derivative that was a topoisomerase I inhibitor.

16. Therapeutic radiation therapy (including palliative stereotactic radiation to chest) or major surgery within 4 weeks before study drug treatment or palliative stereotactic radiation therapy within 2 weeks before study drug treatment (refer to exclusion criterion 6 for whole brain radiotherapy and stereotactic radiotherapy for central nervous system metastases).

17. Systemic treatment with anticancer chemotherapy therapy (immunotherapy [non-antibody-based therapy], retinoid therapy) within 3 weeks ( ≥ 2 weeks or 5 half-lives, whichever was longer, for smallmolecule targeted agents such as 5-fluorouracil-based agents, folinate agents, weekly paclitaxel; ≥ 6 weeks for nitrosureas or mitomycin C).

18. Antibody-based anticancer therapy within 4 weeks of Cycle 1 Day 1.

19. Participation in a therapeutic clinical study within 3 weeks before study treatment (for small-molecule targeted agents, this non-participation period was 2 weeks or 5 half-lives, whichever was longer); or current participation in other investigational procedures.

20. Pregnant or breastfeeding subjects or subjects planning to become pregnant.

21. Subject was an immediate family member of study site personnel or of Sponsor personnel.

## Treatments

Treatment cycles were 21 days (±2 days) in length. T-DXd at a body weight-based dose of 6.4 mg/kg was administered as an IV infusion on Day 1 (±2 days) of every 21-day cycle (Q3W).

<div style=\"page-break-after: always\"></div>

The first infusion of T-DXd occurred over at least 90 minutes. If there was no infusion related reaction (IRR), the subsequent infusions of T-DXd were over at least 30 minutes. In case of IRR of any severity grade  at  any  time  during  the  first  administration  of  T-DXd,  all  subsequent  infusions  occurred  over approximately 90 minutes.

T-DXd was continued according to the dosing criteria until the occurrence of any of the events defined as reasons for discontinuation of study drug:

- -Progressive disease per criteria set forth in RECIST v1.1
- -Clinical  progression  (definitive  clinical  signs  of  progressive  disease  [PD])  but  a  recent radiographic assessment did not meet the criteria for PD according to RECIST v1.1
- -Adverse event (AE)
- -Withdrawal by subject
- -Physician decision
- -Death
- -Pregnancy
- -Protocol deviation
- -Study termination by the Sponsor
- -Loss to follow-up
- -Sponsor decision

If the study drug was delayed more than 28 days from the planned date of administration, the subject was withdrawn from the study drug.

All subjects who were withdrawn from study drug completed protocol-specified withdrawal procedures and follow-up procedures.

## Objectives

## Primary Objectives

The primary objective of this study was to investigate the efficacy of T-DXd based on confirmed ORR, as assessed by an independent central imaging facility review (ICR) using Response Evaluation Criteria in Solid Tumors (RECIST) v1.1, in subjects with HER2-positive unresectable or metastatic gastric or GEJ adenocarcinoma that had progressed on or after a trastuzumab containing regimen.

## Secondary Objectives

The key secondary objective was to evaluate the efficacy of T-DXd on progression-free survival (PFS), based on ICR using RECIST v1.1.

Other secondary objectives were as follows:

- OS
- PFS, based on investigator assessment using RECIST v1.1
- ORR, based on investigator assessment using RECIST v1.1
- Duration of response (DoR), based on ICR and investigator assessment using RECIST v1.1

<div style=\"page-break-after: always\"></div>

- To determine the pharmacokinetics (PK) of T-DXd in serum

- To further evaluate the safety of T-DXd based on treatment-emergent adverse events (TEAEs) and anti-drug antibodies (ADAs)

- To evaluate Health Economics and Outcomes Research (HEOR) endpoints based on patient-reported outcomes (PROs)

## Exploratory Objectives

- Disease control rate (DCR), based on ICR and investigator assessment
- Time to response, based on both ICR and investigator assessment
- Best percentage change in the sum of diameters of measurable tumors
- Predictive, prognostic, and pharmacodynamic exploratory biomarkers in tissue samples and blood, and their association with disease status and/or response to treatment

## Outcomes/endpoints

## Primary Efficacy Endpoint

The primary efficacy endpoint was confirmed ORR, defined as the proportion of subjects who achieved a best overall response (BOR) of confirmed complete response (CR) or confirmed partial response (PR), as determined by ICR using RECIST v1.1.

## Secondary Efficacy Endpoints

The key secondary efficacy endpoint was PFS, based on ICR, defined as the time from the date of the first dose of study drug to the date of radiographic disease progression per RECIST v1.1 or death due to any  cause.  Subjects  who  were  alive  with  no  objective  documentation  of  (radiographic)  disease progression by the data cut-off (DCO) date for PFS analysis were censored at the date of their last evaluable tumor assessment.

Other secondary efficacy endpoints included the following:

- OS, defined as the time from the date of first dose of study drug to the date of death due to any cause

- PFS, defined as the time from the date of first dose of study drug to the date of disease progression or death due to any cause based on investigator assessment

- ORR, based on investigator assessment

- DoR, defined as the time from the date of first documentation of objective response to the date of the first documentation of disease progression, based on ICR and investigator assessment, or to death due to any cause, using RECIST v1.1

## Exploratory Efficacy Endpoints

Exploratory efficacy endpoints included the following:

-  DCR,  based  on  both  ICR  and  investigator  assessment,  defined  as  the  proportion  of  subjects  who achieved a BOR of CR or PR or stable disease (SD)
- Time to response, based on both ICR and investigator assessment
- Best percentage change in the sum of diameters of measurable tumors

<div style=\"page-break-after: always\"></div>

## Sample size

The target sample size of this study was 79 subjects.

On  the  basis  of  historical  data  of  current  SoC,  Western  subjects  with  second-line  gastric  or  GEJ adenocarcinoma have reported an ORR of approximately 27%. Seventy-two subjects provided a 90% power to achieve a lower limit of 95% CI for the ORR that exceeded 27% (threshold) under the expected ORR of 45%. Taking into consideration potential dropouts, a sample size of approximately 80 subjects was recruited. The sample size computation was performed by using EAST v6.4.

## Randomisation

U205 study was a single-arm study, randomisation did not take place.

## Blinding (masking)

U205 study was an open-label study, and no blinding was performed.

## Statistical methods

## Analysis Sets

## All Screened Analysis Set

The All Screened Analysis Set included all subjects who signed an ICF.

## Full Analysis Set

The FAS included all subjects who received at least 1 dose of the study drug.

## Response Evaluable Set

The RES included all subjects who received at least 1 dose of study drug and had measurable disease at baseline per ICR.

Table 7.1 Data Sets Analyzed

| Analysis Sets                     | Number (%) of Subjects T-DXd   |
|-----------------------------------|--------------------------------|
| All Screened Analysis Set a       | 89                             |
| Full Analysis Set (FAS)           | 79 (100.0)                     |
| Response Evaluable Set (RES)      | 78 (98.7)                      |
| Safety Analysis Set               | 79 (100.0)                     |
| Pharmacokinetic (PK) Analysis Set | 78 (98.7)                      |

Percentages are calculated based on the number of subjects in the Full Analysis Set as the denominator.

a All Screened Analysis Set presents the number of subjects with no percentage since it includes all subjects who signed a main informed consent form.

Data cut-off=09Apr 2021

Source: Table 14.1.1.1

<div style=\"page-break-after: always\"></div>

## Primary endpoint ORR

The estimate of ORR was calculated, along with the corresponding 95% exact CI using the ClopperPearson method. The primary efficacy analysis was performed based on the FAS and repeated on the RES.

## Key secondary endpoint PFS

Subjects  who  were  alive  with  no  objective  documentation  of  radiographic  disease  progression  as assessed by ICR were censored at the date of their last adequate tumor assessment with additional censoring rules specified in the SAP (Appendix 16.1.4). Kaplan-Meier estimate and survival curve were presented. The median event time and the corresponding 95% CI were provided using the Brookmeyer and Crowley method. PFS rates at fixed time points along with the 95% CIs were estimated. The PFS analysis was performed on the FAS.

## Other Secondary Efficacy Analyses

All  analyses  of  secondary  efficacy  endpoints  were  performed  based  on  the  FAS,  unless  otherwise specified.

Additional secondary efficacy endpoints were analyzed as follows:

-  PFS by investigator assessment was analyzed in the same way as that used for PFS based on ICR. PFS based on ICR and investigator assessment were compared to assess the concordance.

- OS: If a subject was alive at the time of data analysis, OS was censored at the last contact date at which the subject was known to be alive. The Kaplan-Meier estimate and survival curve were presented. The median event time and the corresponding 95% CI were provided using Brookmeyer and Crowley method. The proportion of subjects alive at fixed time points was also estimated.

-  ORR  based  on  investigator  assessment,  measured  for  responding  subjects  (PR  or  CR)  only,  was analyzed in a similar manner as used for the primary endpoint.

- DoR was measured for responding subjects (PR or CR) only. Subjects who were alive and progressionfree at the time of the analyses were censored at the date of the last evaluable tumor assessment. DoR based on ICR and investigator assessment was summarized separately with median event times and its 95% CIs using the Brookmeyer and Crowley method. A swimmer's plot for response over time was provided.

## Exploratory Efficacy Analyses

DCR was defined as the proportion of subjects with BOR of CR, PR or SD according to RECIST v1.1. DCR was calculated, along with the corresponding 95% exact CI using Clopper-Pearson method.

Time to response was defined as the time from the date of start of treatment to the date of the first documentation of objective response (CR or PR). Time to response was measured for subjects with confirmed response (confirmed BOR of CR or PR) only. Time to response based on ICR and investigator assessment was summarized separately with median event times and their 95% CIs for the median by using Brookmeyer and Crowley method.

Best percent change from baseline in the sum of diameters of measurable tumours was calculated based on RECIST v1.1 criteria. Best percent change was the percent change in the smallest sum of diameters from all post-baseline tumor assessments, taking as reference the baseline sum of diameters. The closest tumor measurement prior to the date of start of treatment was used as the baseline tumor measurement. Best percentage change in tumor size was graphed by using a waterfall plot and spider plot.

<div style=\"page-break-after: always\"></div>

The following subgroups were examined for the primary endpoint of confirmed ORR based on ICR, PFS based on ICR, and DoR based on ICR to assess homogeneity of estimate of treatment effect: region, age, sex, ECOG PS, HER2 status, primary tumor location, histological subtype, number of metastatic sites, previous total gastrectomy, prior adjuvant/neoadjuvant therapy, prior nivolumab or pembrolizumab treatment, prior treatment with immuno-checkpoint inhibitor or other immuno-oncology therapy, presence of liver metastasis at baseline, renal impairment at baseline, and hepatic impairment at baseline. In each subgroup, the analysis was carried out using the same type of methodology as described  for  the  corresponding  endpoint.  Results  of  the  subgroup  analyses  were  presented  using descriptive  summaries.  Some  subcategories  may  have  been  combined  if  the  sample  size  within categories was too small (eg, &lt;10 subjects). A forest plot was used to depict the estimated treatment effects for the corresponding endpoints.

## Changes in the Planned Analyses

The SAP (Version 1.0, 18 Nov 2020) was amended (Version 2.0 08 April 2021) primarily driven by the updated  safety  information  to  be  include  in  the  selected  adverse  events  and  addition  of  analysis subgroups. Other minor changes are administrative and/or editorial.

| Section Number   | Description of Changes                                                                                                                                  |
|------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------|
| 1                | Change the protocol version to the most current version (V3.0)                                                                                          |
| 7.2.2.2          | Add further analysis details for clarification                                                                                                          |
| 7.2.4 and 7.3.4  | Subgroup Age (<75/>=75) is added for both efficacy and safety analyses per team request                                                                 |
| 7.3.2.2          | List of selected AEs have been updated to include the most current program level list                                                                   |
| 7.3.3.1          | Definition of major bleeding is updated by safety group                                                                                                 |
| 7.3.5            | Remove the descriptive summary by visit for coagulation and troponin as the data are collected at limited visit. Listing will be sufficient to present. |
| 7.5              | Remove the analyses as the analysis plan and reported will be prepared by Translational Sciences Bioinformatics group                                   |
| 8.2.1            | Visit window definition is revised per updated standard                                                                                                 |
| 8.2.3.3          | Added imputation rule for calculating time since diagnosis in case of partial date of diagnosis.                                                        |
| 8.2.3.4          | Added imputation rule for partial date of death per updated program level standard                                                                      |
| 11.1 and 11.2    | The grouped terms and list of PTs in AESI have been updated to include the most current program level list                                              |

<div style=\"page-break-after: always\"></div>

## Results

## Patient flow

Table 7.2: Subject Disposition (All Screened Analysis Set)

| Parameter                                              | Number (%) of Subjects T-DXd (N = 89)   |
|--------------------------------------------------------|-----------------------------------------|
| Screened (signed main informed consent form)a          | 89                                      |
| Failed screening b                                     | 10 (11.2)                               |
| Treated subjects c                                     | 79 (88.8)                               |
| Discontinued from study drug                           | 56 (70.9)                               |
| Primary reason for discontinuationfrom study treatment |                                         |
| Progressive diseased                                   | 39 (49.4)                               |
| Adverse event                                          | 9 (11.4)                                |
| Clinical progression                                   | 2 (2.5)                                 |
| Death                                                  | 2 (2.5)                                 |
| Withdrawal by subject                                  | 2 (2.5)                                 |
| Physician decision                                     | 1 (1.3)                                 |
| Otherf                                                 | 1 (1.3)                                 |
| Duration of Follow-up (months) g                       |                                         |
| Mean                                                   | 6.8                                     |
| Standard deviation                                     | 3.55                                    |
| Median                                                 | 5.7                                     |
| Minimum, maximum                                       | 0.7,15.2                                |

T-DXd =trastuzumab deruxtecan

a The All Screened Analysis Set includes all subjects who signed a main informed consent form.

c Percentage is based on the number of subjects in the Full Analysis Set (N = 79).

b Percentage is based on the number of subjects in the All Screened Analysis Set.

d Discontinued based on objective evidence of disease progression.

f A drug hold for a treatment-emergent adverse event (preferred term of COVID-19 pneumonia) that exceeded the protocol allowed time limit of 49 days from the last infusion date (Listing 16.2.7.3).

e Discontinued based on clinical manifestations as judged by the investigator.

Duration of follow-up (months) was defined as (last visit date - first dosing date +1)/365.25*12.

Data cut-off=09 Apr 2021

Source: Table 14.1.1.1

<div style=\"page-break-after: always\"></div>

Figure 7.1: Subject Disposition

<!-- image -->

DCO = data cut-off; DXd = released drug; HER2 = human epidermal growth factor receptor 2;

PK = pharmacokinetics; T-DXd = trastuzumab deruxtecan

Data cut-off=09 Apr 2021

Source: Table 14.1.1.1

## Recruitment

Date First Subject Enrolled:   Date First Informed Consent Signed: 26 Nov 2019

Date First Subject Dosed: 24 Dec 2019

Data Cut-off Date: 09 Apr 2021/ Updated DCO 08 Nov 2021

A total of 79 subjects were enrolled and treated at 24 study sites in the following countries: US (11 study sites), Spain (4), Italy (3), the United Kingdom (4), and Belgium (2).

## Conduct of the study

After the initial release (v1.0, 23 Apr 2019), the study protocol was amended 2 times.

Key changes in the amendments were as follows:

Amendment 1 (v2.0) - 28 Jul 2020, During the Course of the Study Version 2.0 was an interim version that was not sent to the study sites as it was found to contain typographical errors. All changes from v2.0 were included in v3.0.

<div style=\"page-break-after: always\"></div>

Amendment 2 (v3.0) - 17 Sep 2020, During the Course of the Study The primary changes made by Amendment 2 were as follows:

-  Because of the potential impact of COVID-19 on subject safety, the Sponsor added a dose modification and management plan for subjects with confirmed or suspected COVID-19 while being treated with TDXd.

- To evaluate the impact of the global pandemic caused by COVID-19, added an analysis to identify subjects affected by COVID-19, and updated the analysis plan to identify the impact of COVID-19 on safety, efficacy, and study conduct.

-  Updated  the  inclusion  criteria  related  to  male  and  female  subjects  of  reproductive/childbearing potential.

- Removed exclusion criteria related to significant corneal disease and to current treatment with strong cytochrome P450 3A4 and organic anion transporting polypeptide inhibitors.

- Added exclusion criteria related to clinically severe pulmonary compromise within 3 months of first dose and to antibody-based therapy within 4 weeks of Cycle 1 Day 1.

- The description of determining dose based on body weight was updated.

- Updated safety information to align with the latest safety information.

- Included cell-free RNA for biomarker analysis.

-  'Health  care  resource  utilization  (hospitalization-related  records)'  was  deleted  from  list  of  HEOR endpoints.

Updated the EOT Visit to provide the conditions under which EOT assessments were to be performed.

## Protocol deviations

A  major  protocol  deviation  was  defined  as  a  deviation  that  had  an  impact  on  subject  safety,  could substantially alter risks to subjects, could have an effect on the integrity of study data, could influence the conduct of the study, or could affect the subject's willingness to participate in the study.

<div style=\"page-break-after: always\"></div>

Table 7.6: Major Protocol Deviations (Full Analysis Set)

| Parameter                                  | Number (%) of Subjects PXI-L (N= 79)   |
|--------------------------------------------|----------------------------------------|
| Subjects with any major protocol deviation | 39 (49.4)                              |
| Visit/procedure required                   | 17 (21.5)                              |
| Dosing                                     | 12 (15.2)                              |
| Enrollment criteria                        | 8 (10.1)                               |
| Informed consent                           | 6 (7.6)                                |
| Laboratory                                 | 3 (3.8)                                |
| Safety reporting                           | 3 (3.8)                                |
| Non-compliance                             | 1 (1.3)                                |
| Visit schedule                             | 1 (1.3)                                |
| Other                                      | 1 (1.3)                                |

T-DXd=trastuzumabderuxtecan

Percentages are calculated using the number of subjects in the Full Analysis Set.

Subjects may have had protocol deviations in multiple categories.

There were no major protocol deviations reported as COVID-19 related. Data cut-off=09 Apr 2021 Source: Table 14.1.1.2 and Listing 16.2.2.3

## Baseline data

<div style=\"page-break-after: always\"></div>

Table 7.3: Key Demographic Characteristics (Full Analysis Set)

| Parameter                                 | T-DXd (N =79)   |
|-------------------------------------------|-----------------|
| Age (years)a                              |                 |
| Median                                    | 60.7            |
| Minimum,maximum                           | 20.3,77.8       |
| Age group (years) (n, %)                  |                 |
| <65                                       | 46 (58.2)       |
| ≥65                                       | 33 (41.8)       |
| <75                                       | 75 (94.9)       |
| ≥75                                       | 4 (5.1)         |
| Sex (n, %)                                |                 |
| Male                                      | 57 (72.2)       |
| Female                                    | 22 (27.8)       |
| Race (n, %)                               |                 |
| White                                     | 69 (87.3)       |
| Asian                                     | 4 (5.1)         |
| Black or African American                 | 1 (1.3)         |
| Native Hawaiian or Other Pacific Islander | 1 (1.3)         |
| Missing                                   | 1 (1.3)         |
| Other                                     | 3 (3.8)         |
| Weight (kg)                               |                 |
| Median                                    | 75.8            |
| Minimum,maximum                           | 41.9, 120.7     |
| Body mass index (kg/m2) b                 |                 |
| Median                                    | 25.2            |
| Minimum,maximum                           | 16.5, 35.4      |
| Region/Country of Enrollment (n, %)       |                 |
| North America                             | 34 (43.0)       |
| US                                        | 34 (43.0)       |
| Europe                                    | 45 (57.0)       |
| Italy                                     | 20 (25.3)       |
| Great Britain                             | 17 (21.5)       |
| Belgium                                   | 4 (5.1)         |
| Spain                                     | 4 (5.1)         |

Percentages are calculated using the number of subjects in the column heading as the denominator.

a Age in years is calculated using the informed consent date and the birth date.

b Body mass index = weight (kg)/height (m2).

Data cut-off = 09 Apr 2021

Source: Table 14.1.2.1

<div style=\"page-break-after: always\"></div>

Table 7.4: BaselineDiseaseCharacteristics (FullAnalysisSet)

| Parameter                                                                          | T-DXd (N =79)   |
|------------------------------------------------------------------------------------|-----------------|
| Timefrominitialhistological diagnosis (months)                                     |                 |
| Median                                                                             | 14.2            |
| Minimum,maximum                                                                    | 3.6, 88.5       |
| Cancer type (n, %)                                                                 |                 |
| Gastric                                                                            | 27 (34.2)       |
| Gastro-esophagealjunction                                                          | 52 (65.8)       |
| HER2status(centrallaboratory)(n,%)                                                 |                 |
| IHC 3+                                                                             | 68 (86.1)       |
| IHC 2+                                                                             | 10 (12.7)       |
| ISH positive                                                                       | 10 (12.7)       |
| Not evaluable a                                                                    | 1 (1.3)         |
| Histological subtype (n, %)                                                        |                 |
| Adenocarcinoma                                                                     |                 |
| Unknown                                                                            | 57 (72.2)       |
| Intestinal                                                                         | 19 (24.1)       |
| Diffuse                                                                            | 1 (1.3)         |
| Mixed                                                                              | 1 (1.3)         |
| Other                                                                              | 1 (1.3)         |
| Number of metastatic sites (n, %)                                                  |                 |
| V2                                                                                 | 74 (93.7)       |
| 2                                                                                  | 5 (6.3)         |
| Previous total gastrectomy (n, %)                                                  |                 |
| No                                                                                 | 79 (100.0)      |
| Prior adjuvant/neoadjuvant therapy (n, %)                                          |                 |
| No                                                                                 | 70 (88.6)       |
| Yes                                                                                | 9 (11.4)        |
| Presence ofliver metastasis at baseline (n, %)                                     |                 |
| No                                                                                 | 29 (36.7)       |
| Yes                                                                                | 50 (63.3)       |
| Renal impairment at baseline (n, %)                                                |                 |
| Normal                                                                             | 32 (40.5)       |
| Mild                                                                               | 25 (31.6)       |
| Moderate                                                                           | 8 (10.1)        |
| Otherb                                                                             | 14 (17.7)       |
| Hepatic impairment at baseline (n, %)                                              |                 |
| Normal                                                                             | 65 (82.3)       |
| Mild                                                                               | 13 (16.5)       |
| Missing                                                                            | 1 (1.3)         |
| Baseline ECOG performance status (n, %)                                            |                 |
| 0                                                                                  | 29 (36.7)       |
| 1                                                                                  | 50 (63.3)       |
| Lines of prior systemic therapy intended for locally advanced or metastatic (n, %) |                 |
| Oc                                                                                 | 6 (7.6)         |
| 1                                                                                  | 73 (92.4)       |

<div style=\"page-break-after: always\"></div>

Table 35:

## SummaryofHistologicalSubtypesatBaselineofStudyU205

| Variable         | StudyU205HER2-positiveGC (DC0 = 09 Apr 2021) T-DXd 6.4 mg/kg N = 79   |
|------------------|-----------------------------------------------------------------------|
| Histology, n (%) |                                                                       |
| Adenocarcinoma   | 78 (98.7)                                                             |
| Diffuse          | 1 (1.3)                                                               |
| Intestinal       | 19 (24.1)                                                             |
| Mixed            | 1 (1.3)                                                               |
| Unknown          | 57 (72.2)                                                             |
| Other            | 1 (1.3)                                                               |

DCO = data cut-off GC = gastric cancer, HER2 = human epidemmal growth factor receptor 2; T-DXd = trastuzumab deouxtecan Source: Module 5.3.5.2 DS8201-A-U205 Table 14.1.3.1

Table 36: Confirmed Overall Response Rate by Histologica/ Subtype In Study U205

| Variable              | StudyU205HER2-positiveGC (DC0 = 08 Nov 2021) T-DXd 6.4 mg/kg   | StudyU205HER2-positiveGC (DC0 = 08 Nov 2021) T-DXd 6.4 mg/kg   |
|-----------------------|----------------------------------------------------------------|----------------------------------------------------------------|
| Histological subgroup | Confirmed ORR                                                  | 95% CI                                                         |
| Diffuse (N = 1)       | 100                                                            | 2.5, 100.0                                                     |
| Intestinal (N = 19)   | 31.6                                                           | 12.6, 56.6                                                     |
| Others (N = 59)       | 39.0                                                           | 26.5, 52.6                                                     |

## Numbers analysed

Table 3.2: Analysis Sets in Study U205

| Analysis Sets                        | Study U205 HER2-positive GC (DC0 =09 Apr 2021) T-DXd 6.4 mg/kg   |
|--------------------------------------|------------------------------------------------------------------|
| All Screened Analysis Set            | 89                                                               |
| FAS                                  | 79 (100.0)                                                       |
| RES                                  | 78 (98.7)                                                        |
| Excluded from RES                    | 1 (1.3)                                                          |
| No baseline mcasurable tumor per ICR | 1 (1.3)                                                          |

Sourcc: Module 5.3.5.2 DS8201-A-U205 CSR Table 14.1.1.1

<div style=\"page-break-after: always\"></div>

## Outcomes and estimation

Note: Since this is a single arm trial with overall response rate as primary endpoint, results from the most recent data cut-off (08-NOV-2021) have been prioritised in this section.

Primary endpoint - Confirmed ORR by Independent Central Review (ICR), FAS, DCO 08-NOV-2021

Table 43: Updated Confirmed Overall Response Rate in Study U205 (DCO 08 Nov 2021) (Full Analysis Set)

CI = confidence interval; CR = complete response; DCO = data cut-off; GC = gastric cancer; HER2 = human epidermal growth factor receptor 2; ICR = independent central review; ORR = overall response rate; PR = partial response; T-DXd = trastuzumab deruxtecan

| Parameter                                                           | StudyU205HER2-positive GC (DCO=08Nov2021) T-DXd 6.4 mg/kg   |
|---------------------------------------------------------------------|-------------------------------------------------------------|
| Full Analysis Set, N                                                | 79                                                          |
| Best overall response by ICR (with confirmation of CR or PR), n (%) |                                                             |
| Complete response                                                   | 4 (5.1)                                                     |
| Partial response                                                    | 29 (36.7)                                                   |
| Stable disease                                                      | 31 (39.2)                                                   |
| Progressive disease                                                 | 13 (16.5)                                                   |
| Not evaluable                                                       | 2 (2.5)                                                     |
| Confirmed ORR by ICR                                                |                                                             |
| ORR n (%)                                                           | 33 (41.8)                                                   |
| 95% CI                                                              | 30.8, 53.4                                                  |

Percentages were based on the number of subjects in the Full Analysis Set.

Source: Module 5.3.5.2 U205 Ad Hoc Table 2 DCO 08 Nov 2021

Secondary endpoint - Duration of Response (DOR) by ICR in responders, DCO 08-NOV-2021

Table 44: UpdatedDuration ofConfirmed Response inStudy U205（DcO 08 Nov 2021)（Full Analysis Set)

| Parameter                        | StudyU205HER2-positiveGC (DCO=08Nov2021) T-Dxd 6.4 mg/kg   |
|----------------------------------|------------------------------------------------------------|
| Full Analysis Set, N             | 79                                                         |
| Subjects with confirmed CR or PR | 33                                                         |
| Subjects with PD (%)             | 13 (39.4)                                                  |
| Subjects with death (%)          | 2 (6.1)                                                    |
| Subjects censored (%)            | 18 (54.5)                                                  |
| Median DoR (months)              | 8.1                                                        |
| 95% CI                           | 5.9, NE                                                    |

<div style=\"page-break-after: always\"></div>

Figure7: Kaplan-MelerPlotofDuration of Confirmed Response Based onIndependentCentral ReviewinStudyU205（DCO08Nov2021)

<!-- image -->

Secondary endpoint - overall survival (OS), FAS, DCO 08-NOV-2021

<div style=\"page-break-after: always\"></div>

Table 41: UpdatedOverallSurvivalinStudyU205（DcO08Nov2021)（FullAnalysisSet)

| Parameter                    | StudyU205HER2-positiveGC (DCO =08 Nov 2021) T-Dxd 6.4 mg/kg   |
|------------------------------|---------------------------------------------------------------|
| Duration offollow-up(months) |                                                               |
| N                            | 79                                                            |
| Median                       | 10.2                                                          |
| Min, max                     | 0.7, 22.1                                                     |
| Overall survival             |                                                               |
| OS events, n (%)             | 46 (58.2)                                                     |
| Censored, n (%)              | 33 (41.8)                                                     |
| 25t percentile (months)      | 6.5                                                           |
| 95% CI                       | 4.6, 9.2                                                      |
| Median OS (months)           | 12.1                                                          |
| 95% CI                       | 9.4, 15.4                                                     |
| OS rate at 6 months (%)      | 77.8                                                          |
| 95% CI                       | 66.8, 85.6                                                    |
| OS rate at 12 months (%)     | 50.6                                                          |
| 95% CI                       | 38.4, 61.5                                                    |
| OS rate at 18 months (%)     | 35.1                                                          |
| 95% CI                       | 22.1, 48.4                                                    |

Figure6: Kaplan-MelerPlotofOverallSurvivalinStudyU205(UpdateDcO08Nov2021)

<!-- image -->

<div style=\"page-break-after: always\"></div>

## Secondary endpoint - PFS by IRC, FAS, DCO 08-NOV-2021

Table 42: Updated Progression-free Survival in Study U205(DcO 08 Nov2021)(Full Analysis Set)

| Parameter                                | Study U205HER2-positive GC (DC0 = 08 Nov 2021) T-DXd. 6.4 mg/kg   |
|------------------------------------------|-------------------------------------------------------------------|
| Duration of follow-up (months)           |                                                                   |
| N                                        | 79                                                                |
| Median                                   | 10.2                                                              |
| Min, max                                 | 0.7, 22.1                                                         |
| PFS                                      |                                                                   |
| PFS events, n (%)                        | 51 (64.6)                                                         |
| Censored, n (%)                          | 28 (35.4)                                                         |
| New anticancer therapy                   | 15 (19.0)                                                         |
| Missed 2 consecutive tumor assessments   | 2 (2.5)                                                           |
| Ongoing without progression              | 7 (8.9)                                                           |
| Adequate assessment no longer availablea | 4 (5.1)                                                           |
| 25t percentile (months)                  | 2.8                                                               |
| 95% CI                                   | 1.4, 4.1                                                          |
| Median PFS (months)                      | 5.6                                                               |
| 95% CI                                   | 4.2, 8.3                                                          |
| PFS rate at 6 months (%)                 | 48.9                                                              |
| IO %56                                   | 36.6, 60.2                                                        |
| PFS rate at 12 months (%)                | 20.0                                                              |
| 95% CI                                   | 9.4, 33.3                                                         |

## Ancillary analyses

Subgroup analyses

Note: These analyses correspond to the initial DCO on 09-APR-2021.

<div style=\"page-break-after: always\"></div>

Figure 8.1: Forest Plot of Confirmed Objective Response Rate by Independent Central Review by Subgroup (Full Analysis Set)

<!-- image -->

| Subgoup       | #Subjects   | #CR/PR      | ORR(95% CI)         |             |
|---------------|-------------|-------------|---------------------|-------------|
| Over al       | 79          | 30          | 38.0 [27.3, 49.6]   |             |
| Region        | Region      | Region      | Region              | Region      |
| North America | 34          | 10          | 29.4 [15.1, 47.5)   |             |
| Europe        | 45          | 20          | 44.4 [29.6, 60.0)   |             |
| Age           | Age         | Age         | Age                 | Age         |
| <65Yers       | 46          | 16          | 34.8 (21.4, 50.2)   |             |
| >=65Years     | 33          | 14          | 42.4 [25.5, 60.8)   |             |
| <75Years      | 75          | 26          | 34.7 (24.0, 46.5)   |             |
| >=75Years     | 4           | 4           | 100.0 (39.8, 100.0) |             |
| Sex           | Sex         | Sex         | Sex                 | Sex         |
| Femae         | 22          | 11          | 50.0 [28.2, 71.8)   |             |
| Mae           | 57          | 19          | 33.3 (21.4, 47.1)   |             |
| ECOG PS       | ECOG PS     | ECOG PS     | ECOG PS             | ECOG PS     |
| 0             | 29          | 7           | 24.1 (10.3, 43.5]   |             |
| 1             | 50          | 23          | 46.0 (31.8, 60.7)   |             |
| HER2 status   | HER2 status | HER2 status | HER2 status         | HER2 status |
| IHC 3+        | 68          | 29          | 42.6 [30.7,55.2]    |             |
| IHC 2+ASH +   | 10          | 1           | 10.0 [0.3, 44.5]    |             |

T-DXd 6.4mg/kg (N=79)

<!-- image -->

| dhofqrs                       | #Sutjects   | #CR/PR   | ORR(95% CI)        | ORR [95% CI)   |
|-------------------------------|-------------|----------|--------------------|----------------|
| Primary tumor location        |             |          |                    |                |
| Gastric                       | 27          | 14       | 51.9 [31.9, 71.3)  |                |
| GEJ                           | 52          | 16       | 30.8 [18.7, 45.1)  |                |
| Histological subtype          |             |          |                    |                |
| Diffuse                       |             | 1        | 100.0 (2.5, 100.0) |                |
| Intestina                     | 19          | 6        | 31.6 [12.6, 56.6]  |                |
| Others                        | 59          | 23       | 39.0 [26.5, 52.6]  |                |
| Numberofmetastaticsites       |             |          |                    |                |
| <2                            | 5           | 2        | 40.0 (5.3, 85.3)   |                |
| >=2                           | 74          | 28       | 37.8 [26.8, 49.9]  |                |
| Prioraduvantheoaduvanttherapy |             |          |                    |                |
| Yes                           | 9           | 2        | 22.2 [2.8, 60.0)   |                |
| No                            | 70          | 28       | 40.0 [28.5, 52.4]  |                |

<div style=\"page-break-after: always\"></div>

T-DXd 6.4 mg/kg (N=79)

<!-- image -->

| Subgaup                                       | ##   |    | ORR(95%CI)        | ORR (95% CI)   |
|-----------------------------------------------|------|----|-------------------|----------------|
| Prior nivolumab or pembr olizumab treat ment  |      |    |                   |                |
| Yes                                           | 6    | 2  | 33.3 [4.3, 77.7]  |                |
| No                                            | 73   | 28 | 38.4 [27.2, 50.5) |                |
| Pr. immune- chkpnt inhibitor /bth immuno-onco |      |    |                   |                |
| Yes                                           | 7    | 2  | 28.6 [3.7, 71.0)  |                |
| No                                            | 72   | 28 | 38.9 [27.6, 51.1) |                |
| Presence of liver met ast asis at baseline    |      |    |                   |                |
| Yes                                           | 50   | 18 | 36.0 (22.9, 50.8) |                |
| No                                            | 29   | 12 | 41.4 (23.5, 61.1) |                |
| Renal impairment at baseline                  |      |    |                   |                |
| Norma                                         | 32   | 8  | 25.0 (11.5, 43.4) |                |
| Mild                                          | 25   | 12 | 48.0 (27.8, 68.7) |                |
| Moder ate                                     | 8    | 5  | 62.5 [24.5, 91.5] |                |
| Hepaticimpairment at baseline                 |      |    |                   |                |
| Norma                                         | 65   | 24 | 36.9 [25.3, 49.8) |                |
| Mild                                          | 13   | 6  | 46.2 (19.2, 74.9) |                |

## Immunogenicity

None of the subjects had NAb-positive samples (Table 14.4.7.4).

<!-- image -->

Table 1.  Summary of Efficacy for trial DS8201-A-U205 (DESTINY-Gastric02)

| Title: A Phase 2, Open-label, Single-arm Trial of Trastuzumab Deruxtecan in HER2-positive, Unresectable or Metastatic Gastric or Gastro-esophageal Junction (GEJ) Adenocarcinoma Subjects Who Have Progressed On or After a Trastuzumab-containing Regimen   | Title: A Phase 2, Open-label, Single-arm Trial of Trastuzumab Deruxtecan in HER2-positive, Unresectable or Metastatic Gastric or Gastro-esophageal Junction (GEJ) Adenocarcinoma Subjects Who Have Progressed On or After a Trastuzumab-containing Regimen   |
|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Study identifier                                                                                                                                                                                                                                             | DS-8201-A-U205                                                                                                                                                                                                                                               |
| Design                                                                                                                                                                                                                                                       | Pivotal phase 2, single-arm trial of T-DXd in a Western population (EU/US) with advanced HER-2+ GC/GEJ adenocarcinoma who have progressed on or after 1L trastuzumab containing treatment, i.e. in the 2L setting.                                           |

<div style=\"page-break-after: always\"></div>

|                                                 | Duration of main phase: Duration of Run-in phase:                                                                                                                                                                                                                                                         | Duration of main phase: Duration of Run-in phase:                                                                                                                                                                                                                                                         | 18-24 months not applicable                                                                                                                                                                                                                                                                               | 18-24 months not applicable                                                                                                                                                                                                                                                                               | 18-24 months not applicable                                                                                                                                                                                                                                                                               |
|-------------------------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Hypothesis                                      | Duration of Extension phase: not applicable Exploratory: to evaluate the efficacy and safety of T-DXd (6.4 mg/kg as IV infusion Q3W) in subjects with unresectable or metastatic HER2-positive gastric or GEJ adenocarcinoma who had progressed during on or after a trastuzumab-containing regimen (2L). | Duration of Extension phase: not applicable Exploratory: to evaluate the efficacy and safety of T-DXd (6.4 mg/kg as IV infusion Q3W) in subjects with unresectable or metastatic HER2-positive gastric or GEJ adenocarcinoma who had progressed during on or after a trastuzumab-containing regimen (2L). | Duration of Extension phase: not applicable Exploratory: to evaluate the efficacy and safety of T-DXd (6.4 mg/kg as IV infusion Q3W) in subjects with unresectable or metastatic HER2-positive gastric or GEJ adenocarcinoma who had progressed during on or after a trastuzumab-containing regimen (2L). | Duration of Extension phase: not applicable Exploratory: to evaluate the efficacy and safety of T-DXd (6.4 mg/kg as IV infusion Q3W) in subjects with unresectable or metastatic HER2-positive gastric or GEJ adenocarcinoma who had progressed during on or after a trastuzumab-containing regimen (2L). | Duration of Extension phase: not applicable Exploratory: to evaluate the efficacy and safety of T-DXd (6.4 mg/kg as IV infusion Q3W) in subjects with unresectable or metastatic HER2-positive gastric or GEJ adenocarcinoma who had progressed during on or after a trastuzumab-containing regimen (2L). |
| Treatment groups                                | Primary Cohort                                                                                                                                                                                                                                                                                            | Primary Cohort                                                                                                                                                                                                                                                                                            | T-DXd 6.4 mg/kg IV Q3W until a discontinuation criterion was met, 79 objects                                                                                                                                                                                                                              | T-DXd 6.4 mg/kg IV Q3W until a discontinuation criterion was met, 79 objects                                                                                                                                                                                                                              | T-DXd 6.4 mg/kg IV Q3W until a discontinuation criterion was met, 79 objects                                                                                                                                                                                                                              |
| Endpoints and definitions                       | Primary endpoint                                                                                                                                                                                                                                                                                          | IRC- assessed ORR                                                                                                                                                                                                                                                                                         | Objective response rate (ORR) based on a centrally reviewed evaluation in the primary cohort. ORR was defined as the proportion of patients with best overall response of complete or partial response by group (confirmed).                                                                              | Objective response rate (ORR) based on a centrally reviewed evaluation in the primary cohort. ORR was defined as the proportion of patients with best overall response of complete or partial response by group (confirmed).                                                                              | Objective response rate (ORR) based on a centrally reviewed evaluation in the primary cohort. ORR was defined as the proportion of patients with best overall response of complete or partial response by group (confirmed).                                                                              |
| Endpoints and definitions                       | Secondary endpoint                                                                                                                                                                                                                                                                                        | DOR                                                                                                                                                                                                                                                                                                       | Duration Of Response in responders                                                                                                                                                                                                                                                                        | Duration Of Response in responders                                                                                                                                                                                                                                                                        | Duration Of Response in responders                                                                                                                                                                                                                                                                        |
| Endpoints and definitions                       | Secondary endpoint                                                                                                                                                                                                                                                                                        | PFS                                                                                                                                                                                                                                                                                                       | Progression Free Survival                                                                                                                                                                                                                                                                                 | Progression Free Survival                                                                                                                                                                                                                                                                                 | Progression Free Survival                                                                                                                                                                                                                                                                                 |
| Endpoints and definitions                       | Secondary endpoint                                                                                                                                                                                                                                                                                        | OS                                                                                                                                                                                                                                                                                                        | Overall Survival                                                                                                                                                                                                                                                                                          | Overall Survival                                                                                                                                                                                                                                                                                          | Overall Survival                                                                                                                                                                                                                                                                                          |
| Database lock                                   | Updated DCO 08 Nov 2021                                                                                                                                                                                                                                                                                   | Updated DCO 08 Nov 2021                                                                                                                                                                                                                                                                                   | Updated DCO 08 Nov 2021                                                                                                                                                                                                                                                                                   | Updated DCO 08 Nov 2021                                                                                                                                                                                                                                                                                   | Updated DCO 08 Nov 2021                                                                                                                                                                                                                                                                                   |
| Results and Analysis                            | Results and Analysis                                                                                                                                                                                                                                                                                      | Results and Analysis                                                                                                                                                                                                                                                                                      | Results and Analysis                                                                                                                                                                                                                                                                                      | Results and Analysis                                                                                                                                                                                                                                                                                      | Results and Analysis                                                                                                                                                                                                                                                                                      |
| Analysis description                            | Primary Analysis (pre-planned).                                                                                                                                                                                                                                                                           | Primary Analysis (pre-planned).                                                                                                                                                                                                                                                                           | Primary Analysis (pre-planned).                                                                                                                                                                                                                                                                           | Primary Analysis (pre-planned).                                                                                                                                                                                                                                                                           | Primary Analysis (pre-planned).                                                                                                                                                                                                                                                                           |
| Analysis population and time point description  | The ITT set included all subjects randomized in the Primary Cohort of Study U205 (subjects with HER2-positive gastric cancer with a rebiopsy post- trastzumab). Data are presented for the CSR DCO (09 Apr 2021)/Updated DCO 08 Nov 2021.                                                                 | The ITT set included all subjects randomized in the Primary Cohort of Study U205 (subjects with HER2-positive gastric cancer with a rebiopsy post- trastzumab). Data are presented for the CSR DCO (09 Apr 2021)/Updated DCO 08 Nov 2021.                                                                 | The ITT set included all subjects randomized in the Primary Cohort of Study U205 (subjects with HER2-positive gastric cancer with a rebiopsy post- trastzumab). Data are presented for the CSR DCO (09 Apr 2021)/Updated DCO 08 Nov 2021.                                                                 | The ITT set included all subjects randomized in the Primary Cohort of Study U205 (subjects with HER2-positive gastric cancer with a rebiopsy post- trastzumab). Data are presented for the CSR DCO (09 Apr 2021)/Updated DCO 08 Nov 2021.                                                                 | The ITT set included all subjects randomized in the Primary Cohort of Study U205 (subjects with HER2-positive gastric cancer with a rebiopsy post- trastzumab). Data are presented for the CSR DCO (09 Apr 2021)/Updated DCO 08 Nov 2021.                                                                 |
| Descriptive statistics and estimate variability | Treatment group                                                                                                                                                                                                                                                                                           | Treatment group                                                                                                                                                                                                                                                                                           | T-DXd                                                                                                                                                                                                                                                                                                     |                                                                                                                                                                                                                                                                                                           |                                                                                                                                                                                                                                                                                                           |
| Descriptive statistics and estimate variability | Number of subjects (ITT)                                                                                                                                                                                                                                                                                  | Number of subjects (ITT)                                                                                                                                                                                                                                                                                  | 79                                                                                                                                                                                                                                                                                                        |                                                                                                                                                                                                                                                                                                           |                                                                                                                                                                                                                                                                                                           |
| Descriptive statistics and estimate variability | ORR (confirmed), number of                                                                                                                                                                                                                                                                                | ORR (confirmed), number of                                                                                                                                                                                                                                                                                | 33 (41.8%)                                                                                                                                                                                                                                                                                                |                                                                                                                                                                                                                                                                                                           |                                                                                                                                                                                                                                                                                                           |
| Descriptive statistics and estimate variability | 95% CI                                                                                                                                                                                                                                                                                                    | 95% CI                                                                                                                                                                                                                                                                                                    | 30.8, 53.4                                                                                                                                                                                                                                                                                                |                                                                                                                                                                                                                                                                                                           |                                                                                                                                                                                                                                                                                                           |
| Descriptive statistics and estimate variability | Median DOR in responders,                                                                                                                                                                                                                                                                                 | Median DOR in responders,                                                                                                                                                                                                                                                                                 | 8.1                                                                                                                                                                                                                                                                                                       |                                                                                                                                                                                                                                                                                                           |                                                                                                                                                                                                                                                                                                           |
| Descriptive statistics and estimate variability | 95% CI                                                                                                                                                                                                                                                                                                    | 95% CI                                                                                                                                                                                                                                                                                                    | 5.9, NE                                                                                                                                                                                                                                                                                                   |                                                                                                                                                                                                                                                                                                           |                                                                                                                                                                                                                                                                                                           |
| Descriptive statistics and estimate variability | Median PFS, months                                                                                                                                                                                                                                                                                        | Median PFS, months                                                                                                                                                                                                                                                                                        | 5.6                                                                                                                                                                                                                                                                                                       |                                                                                                                                                                                                                                                                                                           |                                                                                                                                                                                                                                                                                                           |
| Descriptive statistics and estimate variability | 95% CI                                                                                                                                                                                                                                                                                                    | 95% CI                                                                                                                                                                                                                                                                                                    | 4.2, 8.3                                                                                                                                                                                                                                                                                                  |                                                                                                                                                                                                                                                                                                           |                                                                                                                                                                                                                                                                                                           |
| Descriptive statistics and estimate variability | Median OS,                                                                                                                                                                                                                                                                                                | Median OS,                                                                                                                                                                                                                                                                                                | 12.1                                                                                                                                                                                                                                                                                                      |                                                                                                                                                                                                                                                                                                           |                                                                                                                                                                                                                                                                                                           |

## Analysis performed across trials (pooled analyses and meta-analysis)

Not applicable.

## Clinical studies in special populations

No studies in special populations were provided.

<div style=\"page-break-after: always\"></div>

Table 34: Age Groups of Subjects with Gastric Cancer Treated with T-Dxd 6.4mg/kg in Studies J202,U205,andJ101

|                                       | Age 65-74 (older subject number/total number)   | Age 75-84(older subject number/totalnumber)   | Age S5+ (older subject number/total number)   |
|---------------------------------------|-------------------------------------------------|-----------------------------------------------|-----------------------------------------------|
| Controlled trials (J202)              | 54/126                                          | 17/126                                        | 0/126                                         |
| Noncontrolled trials (U205 and J101*) | 43/104                                          | 7/104                                         | 0/104                                         |

Source: Module 5.3.5.1 DS8201-A-J202 CSR Table 14.1.2.1 1; Module 5.3.5.2 DS8201-A-U205 CSR Table 14.1.2.1;

Module5.3.5.3SCEJ101Table14.1.3.4.2.3

## Supportive studies

## Study DS8201-A-J202 (DESTINY-Gastric01)

This was a Phase 2, multicentre, open-label, randomized study in subjects with advanced HER2-positive gastric or GEJ adenocarcinoma who had progressed on 2 or more prior regimens that had to include a fluoropyrimidine agent (fluorouracil, capecitabine, or S-1) and a platinum agent (oxaliplatin or cisplatin) (3L). The study was conducted at sites in Japan and South Korea. Subjects were divided into 3 cohorts based on HER2 status and prior therapy with trastuzumab. The target population that is the focus of this application is the cohort of subjects with HER2-positive (i.e., IHC 3+ or IHC 2+/in situ hybridization [ISH]-positive)  tumours  (HER2  status  could  be  determined  either  pre-  or  post-trastuzumab)  in  the Primary Cohort (N=188), in which subjects were randomized to receive either T-DXd monotherapy at the proposed dose (6.4 mg/kg Q3W) or treatment of physician's choice (TPC), (N=45), (limited to 1 of 2 choices of standard regimens: irinotecan or paclitaxel in a 2:1 ratio. Subjects in the Primary Cohort had to have progressed on prior trastuzumab or a trastuzumab biosimilar in addition to a fluoropyrimidine agent and a platinum agent (i.e., 2 or more prior therapies). Subjects with a HER2 status of IHC 2+/ISHnegative  or  IHC  1+  and  treatment-naïve  for  trastuzumab  were  enrolled  in  the  nonrandomized Exploratory Cohort 1 and Exploratory Cohort 2, respectively, and are not the focus of this application.

Figure 4.1: Study J202 Design

<!-- image -->

<div style=\"page-break-after: always\"></div>

## Study participants

In Study J202, demographic and baseline disease characteristics of the ITT population were generally balanced between treatment arms (see Module 2.7.3 Table 3.7 and Module 5.3.5.3 J202 SCE Table 14.1.2.1\\_1):

- All subjects were Asian and were mostly from Japan (T-DXd: 79.4%; TPC: 80.6%).
- A majority of subjects were male (T-DXd: 76.2%; TPC: 75.8%) and the median age at informed consent was 65.5 years for the T-DXd arm and 66.0 years for the TPC arm.
- There was a similar proportion of subjects with an ECOG PS of 0 (T-DXd: 49.2% ; TPC 48.4%) or 1 (T-DXd: 50.0% ; TPC 51.6%) in both treatment arms.
- A majority of subjects had GC (T-DXd: 86.5%; TPC: 88.7%) as opposed to GEJ (T-DXd: 13.5%; TPC: 11.3%), with most having Stage IV cancer at study entry (T-DXd: 96.0%; TPC: 100.0%).
- The cancer was classified as 'inoperable advanced' in 61.1% of subjects on T-DXd and 74.2% of those on TPC, and as 'postoperative advanced' in 38.9% and 25.8% of subjects, respectively.
- A majority of subjects had the intestinal histologic subtype (T-DXd: 70.6%; TPC: 61.3%).
- All subjects had tumors with an HER2 status of IHC 3+ or IHC 2+/ISH-positive based on central laboratory testing of most recent archived tumor tissue sample. If archived sample was not available, a new sample was required as per protocol.
- Prior treatment included cancer surgery for 44.1% of subjects (T-DXd: 47.6%; TPC: 37.1%): 16.5% of subjects had prior total gastrectomy (T-DXd: 17.5%; TPC: 14.5%); 21.8% had prior partial gastrectomy (T-DXd: 23.8%; TPC: 17.7%); and 11.7% had 'other' cancer surgery (TDXd: 11.1%; TPC: 12.9%).
- 12.8% of subjects had prior radiation therapy (T-DXd: 11.1%; TPC: 16.1%).
- 21.3%  of  subjects  had  received  prior  adjuvant/neoadjuvant  therapy  (T-DXd:  23.8%;  TPC: 16.1%).
- The median number of prior anticancer regimens in the locally advanced or metastatic setting excluding radiation and surgery was 2.0 (range: 2 to 9) in the T-DXd arm and 2.0 (range: 2 to 5) in the TPC arm (Note: this included therapies intended for locally advanced or metastatic disease or for neoadjuvant or adjuvant therapy if there was progressive disease within 6 months since the end of therapy). A higher proportion of subjects had received 4 or more prior regimens in the T-DXd arm than in the TPC arm (20.6% vs. 9.7%, respectively).
- The most common prior anticancer agents were trastuzumab or a biosimilar (100.0% of subjects in  both  arms as per protocol), capecitabine (T-DXd: 74.6%; TPC: 66.1%), cisplatin (T-DXd: 63.5%; TPC: 59.7%), PTX (T-DXd: 68.3%; TPC: 74.2%), Ram (T-DXd: 74.6%; TPC: 66.1%), oxaliplatin (T-DXd: 49.2%; TPC: 43.5%), and S-1 (T-DXd: 49.2%; TPC: 46.8%). In addition, 27.0% of subjects in the T-DXd arm and 24.2% of subjects in the TPC arm had received prior nivolumab. Both S-1 and nivolumab are approved for use in Japan in this setting.

## Treatment s

Subjects were randomized to receive either T-DXd monotherapy at the proposed dose (6.4 mg/kg Q3W) or treatment of physician's choice (TPC).

<div style=\"page-break-after: always\"></div>

Therapeutic options in the TPC arm were limited to 1 of 2 choices: irinotecan (N = 55) or paclitaxel (N = 7) and the investigator had to preselect TPC therapy before the subject was randomized.

Randomization was stratified by region (Japan or South Korea), ECOG PS (0 or 1), and HER2 status (IHC 3+ or IHC 2+/ISH-positive) (HER2 status was confirmed from the most recent archival tumour sample or determined on a new tissue sample, i.e., either   pre- or post-trastuzumab).

Tumour assessments were performed at screening and every 6 weeks (± 7 days) thereafter from Cycle 1 Day 1 until progressive disease, start of a new anticancer treatment, death, or withdrawal of consent by the subject. Assessments were conducted using computed tomography (CT) or magnetic resonance imaging (MRI). Copies of CT or MRI images were provided to a blinded ICR.

Prior therapies required for randomization in the Primary Cohort (i.e., a fluoropyrimidine agent, a platinum agent, and trastuzumab) and the choice of irinotecan or PTX as active controls for the comparator arm in the third-line setting or later reflected the Japanese Gastric Cancer Treatment Guidelines 2018 (5th edition) at the time of study planning and were aligned with the 2018 Korean12 Practice Guideline.

## Outcomes/endpoints

## Primary Efficacy Endpoint

The primary efficacy endpoint was ORR (the sum of CR rate and PR rate), without confirmation of CR/PR, assessed by the ICR based on RECIST Version 1.1 (for the Primary Cohort only).

## Secondary Efficacy Endpoints

The  secondary  efficacy  endpoints  included  the  following,  which  were  assessed  by  the  ICR  unless otherwise indicated.

· OS, defined as the time from the date of randomization (the date of the registration for the Exploratory Cohorts) to the date of death due to any cause.

· PFS, defined as the time from the date of randomization (the date of the registration for the Exploratory Cohorts) to the earliest date of the first objective documentation of PD or death due to any cause. The PD was determined based on RECIST Version 1.1 criteria.

· Duration of response (DoR), defined as the time from the date of the first documentation of objective response (CR or PR) to the date of the first objective documentation of PD or death due to any cause. DoR was measured for responding subjects (PR or CR) only.

• Disease control rate (DCR), defined as the sum of CR rate, PR rate, and stable disease (SD) rate.

· Time to treatment failure (TTF), defined as the time from the date of randomization (the date of the registration for Exploratory Cohorts) to the earliest date of the first objective documentation of PD, death due to any cause, or treatment discontinuation.

· ORR assessed by the investigator based on RECIST Version 1.1, defined as the sum of CR rate and PR rate, assessed by the investigator.

## Sample size

The target sample size of this study was approximately 220 subjects (Primary Cohort, N=approximately 180; Exploratory Cohort 1, N=approximately 20; and Exploratory Cohort 2, N=approximately 20).

## Primary Cohort

A combined analysis of ORR data taken from published Phase 2 and 3 studies (a total of 13 studies) of second- or subsequent-line chemotherapy in patients with gastric cancer was conducted. As a result, the

<div style=\"page-break-after: always\"></div>

combined ORR was 9.4% (95% CI: 1.1% to 17.7%). The ORR for the physician's choice group was conservatively assumed to be 15%, which exceeded the above-mentioned combined mean estimate of ORR. The ORR for the DS-8201a group was also assumed to be 40%. The sample size of 180 subjects (120 subjects in the DS-8201a group and 60 subjects in the physician's choice group) could provide a 92.9%  power  to  detect  this  magnitude  of  difference  according  to  Fisher's  exact  test  with  2-sided significance alpha=0.05.

Approximately 133 OS events would be needed to detect an HR of 0.61 for OS (a 64% improvement in median OS from 5.5 months in the physician's choice group to 9.0 months in the DS-8201a group) with 2-sided significance alpha=0.05 and 80% power. The sample size of 180 subjects could provide an 80.8% power to detect this magnitude of OS difference, assuming a 10-month enrolment period and a 12-month follow-up period after the last subject randomization.

The sample size was calculated assuming that the ORR for the control arm would be approximately 15% and that the ORR for DS-8201a would be 40%. The MAH estimated that 120 and 60 subjects would be required to observe the mentioned difference with 93% power using a Fisher's exact test. Of note, the CMH test was implemented in the primary analysis, and therefore the expected power for the primary analysis was not reported.

The MAH expected to observe a HR of 0.61 or lower for OS with approximately 80% power if 133 OS are included in the analysis.

## Exploratory Cohorts

The exploratory cohorts are not the scope of this assessment.

## Randomisation

Subjects in Primary Cohort were randomized by IXRS into the two treatment groups in a 2:1 ratio (120 DS-8201a group and 60 physician's choice group) and the randomization will be stratified by region, ECOG PS, and HER2 status:

- Region (Japan or Korea)
- ECOG PS (0 or 1)
- HER2 status (IHC 3+ or IHC 2+/ISH +)

## Blinding (masking)

This was an open-label study, and no blinding was performed. It was not feasible to blind treatment allocations  for  individual  subjects  because  of  different  treatment  schedules  and  different  AE  profiles between DS-8201a and the physician's choice treatment.

To reduce potential bias, ICR reviewers were blinded to the treatment assignment when assessing the primary endpoint of ORR. Additionally, the sponsor was not allowed to have access to aggregate efficacy data except when data from both the DS-8201a and the physician's choice groups were combined in the Primary Cohort.

## Statistical methods

## Analysis Sets

The efficacy analyses were conducted on the following analysis sets:

<div style=\"page-break-after: always\"></div>

- The Enrolled Analysis Set included all subjects who signed the ICF and were enrolled in the study.
- The Intent-to-Treat (ITT) Analysis Set, which included all randomized subjects.
- The FAS, which included all randomized subjects who received at least 1 dose of study drug.
- The Response Evaluable Set (RES), defined as randomized subjects who received at least 1 dose of study drug and had measurable disease per ICR at baseline.

Analyses of ORR and DCR will be performed on the Response Evaluable Set. The other efficacy analyses will be performed on the full analysis set (FAS).

Several analysis sets were used for the primary analysis. The intent-to-treat analysis set (ITT) includes as randomized subjects while the Full analysis set (FAS) includes all randomized subjects who received at least one dose of study drug. The Response evaluable set (RES) includes all randomized subjects who received at least one dose of study drug and had measurable disease at baseline according to the ICR.

For the primary endpoint ORR, the response evaluable set was the RES and for OS was the FAS. The use of RES and FAS as primary analysis set is not endorsed. From a regulatory point of view, the results obtained with the ITT set are the most relevant ones since they follow the intention to treat principle. According to Table 7.1 in the CSR (page 80 /202), there was one participant randomized to study arm DS-8201a who was excluded from the FAS and several participants were excluded from the RES (7 and 4 for the DS-8201a and control arm, respectively).

## Primary endpoint ORR

Objective response rate was compared between treatment arms using the Cochran-Mantel-Haenszel (CMH) test, with region (Japan or South Korea) as a stratification factor, for statistical significance at 2sided alpha=0.05.

If  there  is  no  on-treatment  tumour  assessment,  the  best  overall  response  will  be  assigned  as 'Inevaluable'. In the case of a best overall response of SD, tumour measurements and assessments must have met the SD criteria at least once after study entry at a minimum time interval from the date of first dose of study drug, 6 weeks (± 7 days). If this minimum requirement is not met, the best overall response  will  be  determined  starting  with  the  next  tumour  assessment.  If  there  is  no  next  tumour assessment, the best overall response will be assigned as 'Inevaluable'. If a subject has no on-treatment tumour assessment, the best overall response of the subject will be assigned as 'Inevaluable'.

Subjects without on-treatment tumour assessment will be included in the denominators of best overall response and ORR (as best overall response of 'Inevaluable').

## Secondary endpoint OS

OS will  be  compared between the treatment groups using stratified log-rank tests with region as a stratification factor in Primary Cohort.

The HRs and their 95% CI will be estimated using stratified Cox proportional hazards regression models with region as a stratification factor. Kaplan-Meier estimates and survival curves will be presented for each cohort/treatment group. The HRs over time will be also plotted. The unstratified results will also be provided as a sensitivity analysis.

## Censoring rules for OS

If there is no death reported for a subject before the data cut-off for OS analysis, OS will be censored at the last contact date at which the subject is known to be alive.

<div style=\"page-break-after: always\"></div>

## Secondary endpoint PFS

PFS will be analysed as described for OS.

## Censoring rules for PFS

Subjects who are alive and progression-free at the data cut-off date will be censored at the date of the last evaluable tumour assessment.

Subjects who discontinue from the study prior to the first post-baseline evaluable tumour assessment for a reason other than disease progression or death will be censored at the date of randomization (the date of the registration for Exploratory Cohorts).

Subjects who discontinue from the study without disease progression and death will be censored at the date of the last evaluable tumour evaluation.

Subjects who start other anti-cancer therapy prior to disease progression or death will be censored at the date of the last tumour evaluable assessment prior to starting new anti-cancer therapy.

Subjects  who  progress  or  die  after  missing ≥ 2  consecutive  scheduled  tumour  assessments  will  be censored at the date of the last evaluable tumour evaluation prior to progression or death.

Subjects without baseline evaluable tumour assessment will be censored at the date of randomization or registration (the date of the registration for Exploratory Cohorts), except death within the first 2 scheduled tumour assessments (i.e., 14 weeks) will be considered as a PFS event.Interim analysis

One formal interim OS analysis will be conducted when all subjects have completed tumour assessment approximately at 24 weeks (or discontinued the study) in Primary Cohort if the OS events observed thus far do not reach the target number of OS events (i.e., 133 OS events in Primary Cohort). The interim OS will be tested only if ORR show the statistical significance at 2-sided alpha = 0.05. The overall onesided alpha is to be controlled at 0.025 for the interim OS analysis and final OS analysis using the LanDe Mets alpha-spending function with an O'Brien-Fleming boundary. The boundary used at the interim and final OS analysis depends on the actual number of observed deaths at the interim analysis.

## Multiple Comparisons/Multiplicity

The  primary  and  specified  secondary  endpoints  will  be  analysed  using  a  hierarchically  ordered gatekeeping testing procedure to control overall type I error at a significance level of a 2-sided alpha of 0.05  and  allow  the  secondary  analysis  results  to  be  claimed  in  the  label,  the  sequence  of  test  for secondary efficacy endpoint OS will be employed. They will proceed only after the result of the primary efficacy analysis of ORR (based on ICR) is statistically significant. The tests will be performed in the following order: ORR (based on ICR) and OS. The sequence of tests will continue until the test does not meet the significance level of 2-sided alpha 0.05.

## Changes in the Planned Analyses

The SAP (Version 1.0, 11 Sep 2019) was finalized prior to database lock (25 Dec 2019). There were no changes to the planned analyses. Since some duplicates and one missing protocol deviation record were found, the database was unlocked and relocked on 15 Jan 2020 to update only the protocol deviation dataset, with no impact on other than the protocol deviation dataset. Since the ADA result of the sample collected on 26 Apr 2019 was not reported correctly due to the process error for data selection by the vendor, the database was unlocked and relocked on 27 Feb 2020 to update only the ADA dataset, with no impact on other than the ADA dataset.

## Results

<div style=\"page-break-after: always\"></div>

## Participant flow

## Primary Cohort

<!-- image -->

## Recruitment

Date First Subject Enrolled:         02 Nov 2017 (First Informed Consent Signed)

14 Nov 2017 (First Subject Dosed)

Data Cut-off Date:                      08 Nov 2019/ Updated DCO as of 03 Jun 2020

Subjects in the pivotal study were enrolled and treated at study centres in Japan (48) and Korea (18).

## Baseline data

<div style=\"page-break-after: always\"></div>

Table 3.7: Demographic and Baseline Disease Characteristics in Study J202 (Intent-to-Treat Analysis Set)

<!-- image -->

|                                 | StudyJ202PrimaryCohort (DC0 = 08 Nov 2019)   | StudyJ202PrimaryCohort (DC0 = 08 Nov 2019)   | StudyJ202PrimaryCohort (DC0 = 08 Nov 2019)   | StudyJ202PrimaryCohort (DC0 = 08 Nov 2019)   |
|---------------------------------|----------------------------------------------|----------------------------------------------|----------------------------------------------|----------------------------------------------|
|                                 | T-DXd                                        | Physician's Choice                           | Physician's Choice                           | Physician's Choice                           |
|                                 | 6.4 mg/kg (N = 126)                          | Irinotecan (N = 55)                          | Paclitaxel (N=7)                             | Total (N = 62)                               |
| Age at informed consent (years) |                                              |                                              |                                              |                                              |
| Median                          | 65.5                                         | 66.0                                         | 65.0                                         | 66.0                                         |
| Min-Max                         | 34-82                                        | 28-82                                        | 51-74                                        | 28-82                                        |
| Age group (years), n (%)        |                                              |                                              |                                              |                                              |
| <65                             | 55 (43.7)                                    | 24 (43.6)                                    | 3 (42.9)                                     | 27 (43.5)                                    |
| ≥65                             | 71 (56.3)                                    | 31 (56.4)                                    | 4 (57.1)                                     | 35 (56.5)                                    |
| <75                             | 109 (86.5)                                   | 46 (83.6)                                    | 7 (100.0)                                    | 53 (85.5)                                    |
| ≥75                             | 17 (13.5)                                    | 9 (16.4)                                     | 0 (0.0)                                      | 9 (14.5)                                     |
| Sex, n (%)                      |                                              |                                              |                                              |                                              |
| Male                            | 96 (76.2)                                    | 42 (76.4)                                    | 5 (71.4)                                     | 47 (75.8)                                    |
| Female                          | 30 (23.8)                                    | 13 (23.6)                                    | 2 (28.6)                                     | 15 (24.2)                                    |
| Race, n (%)                     |                                              |                                              |                                              |                                              |
| Asian                           | 126 (100.0)                                  | 55 (100.0)                                   | 7 (100.0)                                    | 62 (100.0)                                   |
| Country of enrollment, n (%)    |                                              |                                              |                                              |                                              |
| Japan                           | 100 (79.4)                                   | 44 (80.0)                                    | 6 (85.7)                                     | 50 (80.6)                                    |
| South Korea                     | 26 (20.6)                                    | 11 (20.0)                                    | 1 (14.3)                                     | 12 (19.4)                                    |
| ECOG performance status, n (%)  |                                              |                                              |                                              |                                              |
| 0                               | 62 (49.2)                                    | 28 (50.9)                                    | 2 (28.6)                                     | 30 (48.4)                                    |
| 1                               | 63 (50.0)                                    | 27 (49.1)                                    | 5 (71.4)                                     | 32 (51.6)                                    |
| Type of cancer, n (%)           |                                              |                                              |                                              |                                              |
| Gastric                         | 109 (86.5)                                   | 50 (90.9)                                    | 5 (71.4)                                     | 55 (88.7)                                    |
| GEJ                             | 17 (13.5)                                    | 5 (9.1)                                      | 2 (28.6)                                     | 7 (11.3)                                     |

<div style=\"page-break-after: always\"></div>

<!-- image -->

|                                                                                   | StudyJ202PrimaryCohort (DC0 = 08 Nov 2019)                                        | StudyJ202PrimaryCohort (DC0 = 08 Nov 2019)                                        | StudyJ202PrimaryCohort (DC0 = 08 Nov 2019)                                        | StudyJ202PrimaryCohort (DC0 = 08 Nov 2019)                                        |
|-----------------------------------------------------------------------------------|-----------------------------------------------------------------------------------|-----------------------------------------------------------------------------------|-----------------------------------------------------------------------------------|-----------------------------------------------------------------------------------|
|                                                                                   | T-DXd                                                                             | Physician's Choice                                                                | Physician's Choice                                                                | Physician's Choice                                                                |
|                                                                                   | 6.4 mg/kg (N = 126)                                                               | Irinotecan (N = 55)                                                               | Paclitaxel (N=7)                                                                  | Total (N =62)                                                                     |
| Inoperable advanced (yes)                                                         | 77 (61.1)                                                                         | 40 (72.7)                                                                         | 6 (85.7)                                                                          | 46 (74.2)                                                                         |
| Postoperative advanced (yes)                                                      | 49 (38.9)                                                                         | 15 (27.3)                                                                         | 1 (14.3)                                                                          | 16 (25.8)                                                                         |
| Histological subtype, n (%)                                                       |                                                                                   |                                                                                   |                                                                                   |                                                                                   |
| Intestinal                                                                        | 89 (70.6)                                                                         | 34 (61.8)                                                                         | 4 (57.1)                                                                          | 38 (61.3)                                                                         |
| Diffuse                                                                           | 29 (23.0)                                                                         | 15 (27.3)                                                                         | 3 (42.9)                                                                          | 18 (29.0)                                                                         |
| Other                                                                             | 8 (6.3)                                                                           | 6 (10.9)                                                                          | 0 (0.0)                                                                           | 6 (9.7)                                                                           |
| Time from initial diagnosis (months)                                              | Time from initial diagnosis (months)                                              |                                                                                   |                                                                                   |                                                                                   |
| Median                                                                            | 22.9                                                                              | 20.7                                                                              | 13.9                                                                              | 20.3                                                                              |
| Min-Max                                                                           | 4.6-156.3                                                                         | 4.5-233.4                                                                         | 10.3-52.4                                                                         | 4.5-233.4                                                                         |
| Prior treatment type, n (%)                                                       |                                                                                   |                                                                                   |                                                                                   |                                                                                   |
| Prior cancer therapy excluding radiation and surgery (yes)                        | 126 (100.0)                                                                       | 55 (100.0)                                                                        | 7 (100.0)                                                                         | 62 (100.0)                                                                        |
| Prior adjuvant/neoadjuvant therapy                                                | 30 (23.8)                                                                         | 9 (16.4)                                                                          | 1 (14.3)                                                                          | 10 (16.1)                                                                         |
| Prior radiation therapy (yes)                                                     | 14 (11.1)                                                                         | 9 (16.4)                                                                          | 1 (14.3)                                                                          | 10 (16.1)                                                                         |
| Prior cancer surgery (yes)                                                        | 60 (47.6)                                                                         | 22 (40.0)                                                                         | 1 (14.3)                                                                          | 23 (37.1)                                                                         |
| Total gastrectomy (yes)                                                           | 22 (17.5)                                                                         | 9 (16.4)                                                                          | 0 (0.0)                                                                           | 9 (14.5)                                                                          |
| Partial gastrectomy (yes)                                                         | 30 (23.8)                                                                         | 10 (18.2)                                                                         | 1 (14.3)                                                                          | 11 (17.7)                                                                         |
| Other                                                                             | 14 (11.1)                                                                         | 7 (12.7)                                                                          | 1 (14.3)                                                                          | 8 (12.9)                                                                          |
| HER2 expression (IHC) per central laboratory (archived and fresh samples)*, n (%) | HER2 expression (IHC) per central laboratory (archived and fresh samples)*, n (%) | HER2 expression (IHC) per central laboratory (archived and fresh samples)*, n (%) | HER2 expression (IHC) per central laboratory (archived and fresh samples)*, n (%) | HER2 expression (IHC) per central laboratory (archived and fresh samples)*, n (%) |
| 2+                                                                                | 29 (23.0)                                                                         | 13 (23.6)                                                                         | 2 (28.6)                                                                          | 15 (24.2)                                                                         |
| ISH-positive                                                                      | 29 (23.0)                                                                         | 13 (23.6)                                                                         | 2 (28.6)                                                                          | 15 (24.2)                                                                         |
| 3+                                                                                | 96 (76.2)                                                                         | 42 (76.4)                                                                         | 5 (71.4)                                                                          | 47 (75.8)                                                                         |
| IHC missing                                                                       | 1 (0.8)                                                                           | 0 (0.0)                                                                           | 0 (0.0)                                                                           | 0 (0.0)                                                                           |
| Tumor stage at study entry, n (%)                                                 | Tumor stage at study entry, n (%)                                                 | Tumor stage at study entry, n (%)                                                 | Tumor stage at study entry, n (%)                                                 | Tumor stage at study entry, n (%)                                                 |
| Stage O to III                                                                    | 0 (0.0)                                                                           | 0 (0.0)                                                                           | 0 (0.0)                                                                           | 0 (0.0)                                                                           |
| Stage IV                                                                          | 121 (96.0)                                                                        | 55 (100.0)                                                                        | 7 (100.0)                                                                         | 62 (100.0)                                                                        |
| Other                                                                             | 5 (4.0)                                                                           | 0 (0.0)                                                                           | 0 (0.0)                                                                           | 0 (0.0)                                                                           |
| Lung metastases at baseline, n (%)                                                | Lung metastases at baseline, n (%)                                                | Lung metastases at baseline, n (%)                                                | Lung metastases at baseline, n (%)                                                | Lung metastases at baseline, n (%)                                                |
| Yes                                                                               | 39 (31.0)                                                                         | 12 (21.8)                                                                         | 3 (42.9)                                                                          | 15 (24.2)                                                                         |
| No                                                                                | 87 (69.0)                                                                         | 43 (78.2)                                                                         | 4 (57.1)                                                                          | 47 (75.8)                                                                         |

<div style=\"page-break-after: always\"></div>

<!-- image -->

|                                                                                                         | StudyJ202PrimaryCohort (DCO =08 Nov 2019)                                                               | StudyJ202PrimaryCohort (DCO =08 Nov 2019)                                                               | StudyJ202PrimaryCohort (DCO =08 Nov 2019)                                                               | StudyJ202PrimaryCohort (DCO =08 Nov 2019)                                                               |
|---------------------------------------------------------------------------------------------------------|---------------------------------------------------------------------------------------------------------|---------------------------------------------------------------------------------------------------------|---------------------------------------------------------------------------------------------------------|---------------------------------------------------------------------------------------------------------|
|                                                                                                         | T-DXd                                                                                                   | Physician's Choice                                                                                      | Physician's Choice                                                                                      | Physician's Choice                                                                                      |
|                                                                                                         | 6.4 mg/kg (N = 126)                                                                                     | Irinotecan (N = 55)                                                                                     | Paclitaxel (N=7)                                                                                        | Total (N=62)                                                                                            |
| Liver metastases at baseline, n (%)                                                                     | Liver metastases at baseline, n (%)                                                                     | Liver metastases at baseline, n (%)                                                                     | Liver metastases at baseline, n (%)                                                                     | Liver metastases at baseline, n (%)                                                                     |
| Yes                                                                                                     | 68 (54.0)                                                                                               | 29 (52.7)                                                                                               | 5 (71.4)                                                                                                | 34 (54.8)                                                                                               |
| No                                                                                                      | 58 (46.0)                                                                                               | 26 (47.3)                                                                                               | 2 (28.6)                                                                                                | 28 (45.2)                                                                                               |
| Sum of diameters of target lesions based on ICR at baseline, n (%)                                      | Sum of diameters of target lesions based on ICR at baseline, n (%)                                      | Sum of diameters of target lesions based on ICR at baseline, n (%)                                      | Sum of diameters of target lesions based on ICR at baseline, n (%)                                      | Sum of diameters of target lesions based on ICR at baseline, n (%)                                      |
| n                                                                                                       | 120                                                                                                     | 51                                                                                                      | 5                                                                                                       | 56                                                                                                      |
| Median (cm)                                                                                             | 4.8                                                                                                     | 5.0                                                                                                     | 7.9                                                                                                     | 5.3                                                                                                     |
| <5 cm                                                                                                   | 63 (50.0)                                                                                               | 25 (45.5)                                                                                               | 1 (14.3)                                                                                                | 26 (41.9)                                                                                               |
| ≥5,<10 cm                                                                                               | 34 (27.0                                                                                                | 19 (34.5)                                                                                               | 3 (42.9)                                                                                                | 22 (35.5)                                                                                               |
| ≥10 cm                                                                                                  | 23 (18.3)                                                                                               | 7 (12.7)                                                                                                | 1 (14.3)                                                                                                | 8 (12.9)                                                                                                |
| Missing                                                                                                 | 6 (4.8)                                                                                                 | 4 (7.3)                                                                                                 | 2 (28.6)                                                                                                | 6 (9.7)                                                                                                 |
| Prior cancer regimens in the locally advanced or metastatic setting (excluding radiation and surgery) b | Prior cancer regimens in the locally advanced or metastatic setting (excluding radiation and surgery) b | Prior cancer regimens in the locally advanced or metastatic setting (excluding radiation and surgery) b | Prior cancer regimens in the locally advanced or metastatic setting (excluding radiation and surgery) b | Prior cancer regimens in the locally advanced or metastatic setting (excluding radiation and surgery) b |
| Median                                                                                                  | 2.0                                                                                                     | 2.0                                                                                                     | 2.0                                                                                                     | 2.0                                                                                                     |
| Min-Max                                                                                                 | 2-9                                                                                                     | 2-5                                                                                                     | 2-5                                                                                                     | 2-5                                                                                                     |
| Number of prior cancer regimens in the locally advanced or metastatic setting,* n (%)                   | Number of prior cancer regimens in the locally advanced or metastatic setting,* n (%)                   | Number of prior cancer regimens in the locally advanced or metastatic setting,* n (%)                   | Number of prior cancer regimens in the locally advanced or metastatic setting,* n (%)                   | Number of prior cancer regimens in the locally advanced or metastatic setting,* n (%)                   |
| 1                                                                                                       | 0 (0.0)                                                                                                 | 0 (0.0)                                                                                                 | 0 (0.0)                                                                                                 | 0 (0.0)                                                                                                 |
| 2                                                                                                       | 66 (52.4)                                                                                               | 33 (60.0)                                                                                               | 5 (71.4)                                                                                                | 38 (61.3)                                                                                               |
| 3                                                                                                       | 34 (27.0)                                                                                               | 18 (32.7)                                                                                               | 0 (0.0)                                                                                                 | 18 (29.0)                                                                                               |
| 4                                                                                                       | 18 (14.3)                                                                                               | 3 (5.5)                                                                                                 | 1 (14.3)                                                                                                | 4 (6.5)                                                                                                 |
| 5                                                                                                       | 5 (4.0)                                                                                                 | 1 (1.8)                                                                                                 | 1 (14.3)                                                                                                | 2 (3.2)                                                                                                 |
| >5                                                                                                      | 3 (2.4)                                                                                                 | 0 (0.0)                                                                                                 | 0 (0.0)                                                                                                 | 0 (0.0)                                                                                                 |
| Prior anticancer agents,n (%)                                                                           | Prior anticancer agents,n (%)                                                                           | Prior anticancer agents,n (%)                                                                           | Prior anticancer agents,n (%)                                                                           | Prior anticancer agents,n (%)                                                                           |
| Tegafur/gimeracil/oteracil (S-1)                                                                        | 62 (49.2)                                                                                               | 25 (45.5)                                                                                               | 4 (57.1)                                                                                                | 29 (46.8)                                                                                               |
| Fluorouracil                                                                                            | 8 (6.3)                                                                                                 | 6 (10.9)                                                                                                | 0 (0.0)                                                                                                 | 6 (9.7)                                                                                                 |
| Capecitabine                                                                                            | 94 (74.6)                                                                                               | 36 (65.5)                                                                                               | 5 (71.4)                                                                                                | 41 (66.1)                                                                                               |
| Cisplatin                                                                                               | 80 (63.5)                                                                                               | 33 (60.0)                                                                                               | 4 (57.1)                                                                                                | 37 (59.7)                                                                                               |
| Oxaliplatin                                                                                             | 62 (49.2)                                                                                               | 24 (43.6)                                                                                               | 3 (42.9)                                                                                                | 27 (43.5)                                                                                               |
| Paclitaxel                                                                                              | 86 (68.3)                                                                                               | 44 (80.0)                                                                                               | 2 (28.6)                                                                                                | 46 (74.2)                                                                                               |
| Docetaxel                                                                                               | 9 (7.1)                                                                                                 | 1 (1.8)                                                                                                 | 0 (0.0)                                                                                                 | 1 (1.6)                                                                                                 |
| Irinotecan or irinotecan monohydrochloride trihydrate                                                   | 9 (7.1)                                                                                                 | 0 (0.0)                                                                                                 | 5 (71.4)                                                                                                | 5 (8.1)                                                                                                 |
| Trastuzumab                                                                                             | 125 (99.2)                                                                                              | 54 (98.2)                                                                                               | 7 (100.0)                                                                                               | 61 (98.4)                                                                                               |
| Trastuzumabbiosimilar                                                                                   | 1 (0.8)                                                                                                 | 2 (3.6)                                                                                                 | 0 (0.0)                                                                                                 | 2 (3.2)                                                                                                 |

<div style=\"page-break-after: always\"></div>

|                                     | StudyJ202PrimaryCohort (DC0 =08 Nov 2019)   | StudyJ202PrimaryCohort (DC0 =08 Nov 2019)   | StudyJ202PrimaryCohort (DC0 =08 Nov 2019)   | StudyJ202PrimaryCohort (DC0 =08 Nov 2019)   |
|-------------------------------------|---------------------------------------------|---------------------------------------------|---------------------------------------------|---------------------------------------------|
|                                     | T-DXd                                       | Physician's Choice                          | Physician's Choice                          | Physician's Choice                          |
|                                     | 6.4 mg/kg (N = 126)                         | Irinotecan (N = 55)                         | Paclitaxel (N=7)                            | (N =62)                                     |
| Ramucirumab                         | 94 (74.6)                                   | 39 (70.9)                                   | 2 (28.6)                                    | 41 (66.1)                                   |
| Nivolumab                           | 34 (27.0)                                   | 13 (23.6)                                   | 2 (28.6)                                    | 15 (24.2)                                   |
| Pembrolizumab                       | 10 (7.9)                                    | 1 (1.8)                                     | 1 (14.3)                                    | 2 (3.2)                                     |
| Margetuximab                        | 7 (5.6)                                     | 0 (0.0)                                     | 1 (14.3)                                    | 1 (1.6)                                     |
| Other                               | 35 (27.8)                                   | 13 (23.6)                                   | 1 (14.3)                                    | 14 (22.6)                                   |
| Renal function atbaseline,n (%)     | Renal function atbaseline,n (%)             | Renal function atbaseline,n (%)             | Renal function atbaseline,n (%)             | Renal function atbaseline,n (%)             |
| Normal                              | 33 (26.2)                                   | 11 (20.0)                                   | 2 (28.6)                                    | 13 (21.0)                                   |
| Mild impairment                     | 53 (42.1)                                   | 24 (43.6)                                   | 4 (57.1)                                    | 28 (45.2)                                   |
| Moderate impairment                 | 39 (31.0)                                   | 19 (34.5)                                   | 1 (14.3)                                    | 20 (32.3)                                   |
| Severeimpairment                    | 0 (0.0)                                     | 1 (1.8)                                     | 0 (0.0)                                     | 1 (1.6)                                     |
| Missing                             | 1 (0.8)                                     | 0 (0.0)                                     | 0 (0.0)                                     | 0 (0.0)                                     |
| Hepatic function at baseline, n (%) | Hepatic function at baseline, n (%)         | Hepatic function at baseline, n (%)         | Hepatic function at baseline, n (%)         | Hepatic function at baseline, n (%)         |
| Normal                              | 88 (69.8)                                   | 42 (76.4)                                   | 5 (71.4)                                    | 47 (75.8)                                   |
| Mild impairment                     | 36 (28.6)                                   | 13 (23.6)                                   | 2 (28.6)                                    | 15 (24.2)                                   |
| Moderate impairment                 | 1 (0.8)                                     | 0 (0.0)                                     | 0 (0.0)                                     | 0 (0.0)                                     |
| Missing                             | 1 (0.8)                                     | 0 (0.0)                                     | 0 (0.0)                                     | 0 (0.0)                                     |

DCO = data cut-off; ECG =electrocardiogram; ECOG =Eastern Cooperativc Oncology Group; GEJ = gastroesophagcal junction; HER2 = human epidermal growth factor receptor 2; ICR = independent central review; IHC = immunohistochemistry; ISH=in situ hybridization; Max =maximum; Min =minimum; QTcF =QT interval corected for heart rate by Fridericia's formula;SAP=Statistical Analysis Plan;SCE=Summary ofClinical Efficacy;T-DXd=trastuzumab deruxtecan

Subject whowas randomized tothe T-DXd armof J202 became ineligible beforefirst dose ashis ECGresults at Cycle 1 Day 1 predose mct exclusion criterion 2 (ie,QTcF prolongation to &gt;470 ms [females] or &gt;450 ms [males] based on average of the screening triplicate 12-lead ECG).Since the HER2 status by central laboratory was derived as the last valuc before the date of first dose (as per baseline definition in the SAP) and the subject did not have a first dose date, his central laboratory HER2 status was entered as \"IHC missing\" in demographic tables. However, the subject had a central HER2 status ofIHC 2+/ISH-positive before randomization date.

cCoded with World Health Organization Drug Dictionary March 1, 2015 version.

b Therapies intended for locally advanced/metastatic or intended for neoadjuvant or adjuvant if progressive disease was within 6 months since the end of therapy

Sourcc: Module 5.3.5.3 SCE J202Tables 14.1.2.1\\_1,14.1.3.1\\_1,and 14.1.3.3

## Numbers analysed

<div style=\"page-break-after: always\"></div>

Table 3.1: Analysis Sets in Study J202

<!-- image -->

| Analysis Sets                              | StudyJ202PrimaryCohort (DC0 =08 Nov 2019)   | StudyJ202PrimaryCohort (DC0 =08 Nov 2019)   | StudyJ202PrimaryCohort (DC0 =08 Nov 2019)   | StudyJ202PrimaryCohort (DC0 =08 Nov 2019)   |
|--------------------------------------------|---------------------------------------------|---------------------------------------------|---------------------------------------------|---------------------------------------------|
|                                            | T-DXd                                       | Physician's Choice                          | Physician's Choice                          | Physician's Choice                          |
|                                            | 6.4 mg/kg                                   | Irinotecan                                  | Paclitaxel                                  | Total                                       |
| ITT Analysis Seta                          | 126                                         | 55                                          | 7                                           | 62                                          |
| FASb                                       | 125                                         | 55                                          | 7                                           | 62                                          |
| Excluded from FAS                          | 1c                                          | 0                                           | 0                                           | 0                                           |
| No study drug administration               | 1c                                          | 0                                           | 0                                           | 0                                           |
| RESd                                       | 119                                         | 51                                          | 5                                           | 56                                          |
| Excluded from RES                          | 7                                           | 4                                           | 2                                           | 6                                           |
| No study drug administration               | 1                                           | 0                                           | 0                                           | 0                                           |
| No baseline measurable tumor burden perICR | 6                                           | 4                                           | 2                                           | 6                                           |

CSR = clinical study report; DCO = data cut-off; ECG = clectrocardiogram; FAS =Full Analysis Set; ICR = independent central review; ITT = Intent-to-Treat; QTcF =QT interval corrected for heart rate by Fridericia's formula; RES =Response Evaluable Set;SAP=StatisticalAnalysisPlan;T-DXd=trastuzumabderuxtecan

- a The ITT Analysis Set included all subjects who signed an informed consent form and were randomized in the Primary Cohort of Study J202.
- c One subject randomized to the T-DXd arm (Subject ) became ineligible prior to dosing (predose ECG at Cycle 1 Day 1 mct exclusion critcrion 2 [QTcF prolongation &gt;470ms for females or &gt;450 ms for males based on averagc ofthe screening triplicate 12-lead ECG]) and was not dosed. The subject was excluded from the FAS.
- b The FAS included all subjects who received at least 1 dose of study drug.
- d The RES included all subjects randomized in the Primary Cohort of Study J202 who received at least 1 dose of study drug and had measurable tumors assessed by ICR at Baseline.

Source: Module 5.3.5.1 DS8201-A-J202 CSR Appendix 16.1.9 SAP and Table 14.1.1.2

The ITT Analysis Set, which is the relevant set to focus on, included all subjects who signed an informed consent form and were randomized in the Primary Cohort of Study J202. The MAH has confirmed the results of Study J202 giving in the SmPC to stem from the ITT population.

## Outcomes and estimation

Primary endpoint - ORR- by Independent Central Review per RECIST v1.1 (Unconfirmed)- DCO 03 Jun 2020

<div style=\"page-break-after: always\"></div>

Table 8.2: Objective ResponseRate and Best Overall Responsefor the Primary Cohort (Based on ICR) as of 03 Jun 2020 Data Cut-off (Intent-to-Treat Analysis Set and ResponseEvaluable Set)

|                                                   | Primary Cohort (DC0 = 03 Jum 2020)                | Primary Cohort (DC0 = 03 Jum 2020)                | Primary Cohort (DC0 = 03 Jum 2020)                | Primary Cohort (DC0 = 03 Jum 2020)                |
|---------------------------------------------------|---------------------------------------------------|---------------------------------------------------|---------------------------------------------------|---------------------------------------------------|
|                                                   | T-DXd                                             | Physician's choice                                | Physician's choice                                | Physician's choice                                |
|                                                   | 6.4 mg/kg                                         | Irinotecan                                        | Paclitaxel                                        | Total                                             |
| Intent-to-Treat Analysis Seta                     |                                                   |                                                   |                                                   |                                                   |
| N                                                 | 126                                               | 55                                                | 7                                                 | 62                                                |
| Best Overall Response (Unconfirmed) by ICR, n (%) | Best Overall Response (Unconfirmed) by ICR, n (%) | Best Overall Response (Unconfirmed) by ICR, n (%) | Best Overall Response (Unconfirmed) by ICR, n (%) | Best Overall Response (Unconfirmed) by ICR, n (%) |
| Complete Response                                 | 11 (8.7)                                          | 0 (0.0)                                           | 0 (0.0)                                           | 0 (0.0)                                           |
| Partial Response                                  | 50 (39.7)                                         | 7 (12.7)                                          | 1 (14.3)                                          | 8 (12.9)                                          |
| Stable Disease                                    | 47 (37.3)                                         | 27 (49.1)                                         | 3 (42.9)                                          | 30 (48.4)                                         |
| Progressive Disease                               | 15 (11.9)                                         | 18 (32.7)                                         | 0 (0.0)                                           | 18 (29.0)                                         |
| Not Evaluable                                     | 3 (2.4)                                           | 3 (5.5)                                           | 3 (42.9)                                          | 6 (9.7)                                           |
| Unconfirmed ORR by ICRb                           | Unconfirmed ORR by ICRb                           | Unconfirmed ORR by ICRb                           | Unconfirmed ORR by ICRb                           | Unconfirmed ORR by ICRb                           |
| n (%)                                             | 61 (48.4)                                         | 7 (12.7)                                          | 1 (14.3)                                          | 8 (12.9)                                          |
| 95% CIc                                           | 39.4, 57.5                                        | 5.3, 24.5                                         | 0.4, 57.9                                         | 5.7, 23.9                                         |
| Best Overall Response (Confirmedl) by ICR, n (%)  | Best Overall Response (Confirmedl) by ICR, n (%)  | Best Overall Response (Confirmedl) by ICR, n (%)  | Best Overall Response (Confirmedl) by ICR, n (%)  | Best Overall Response (Confirmedl) by ICR, n (%)  |
| Complete Response                                 | 10 (7.9)                                          | 0 (0.0)                                           | 0 (0.0)                                           | 0 (0.0)                                           |
| Partial Response                                  | 40 (31.7)                                         | 6 (10.9)                                          | 1 (14.3)                                          | 7 (11.3)                                          |
| Stable Disease                                    | 57 (45.2)                                         | 28 (50.9)                                         | 3 (42.9)                                          | 31 (50.0)                                         |
| Progressive Disease                               | 15 (11.9)                                         | 18 (32.7)                                         | 0 (0.0)                                           | 18 (29.0)                                         |
| Not Evaluable                                     | 4 (3.2)                                           | 3 (5.5)                                           | 3 (42.9)                                          | 6 (9.7)                                           |
| Confirmed ORR by ICRb                             | Confirmed ORR by ICRb                             | Confirmed ORR by ICRb                             | Confirmed ORR by ICRb                             | Confirmed ORR by ICRb                             |
| n (%)                                             | 50 (39.7)                                         | 6 (10.9)                                          | 1 (14.3)                                          | 7 (11.3)                                          |
| 95% CIc                                           | 31.1, 48.8                                        | 4.1, 22.2                                         | 0.4, 57.9                                         | 4.7,21.9                                          |

<div style=\"page-break-after: always\"></div>

Table14.2.1.8SubgroupAnalysesforObjectiveResponseRate(ORR) (Response EvaluableSet) (Based on ICR)

|                                                                   |                         |                   | Primary Cohort HER2-Positive   |                     |              | Exp Cohort 1 HER2IHC 2+/ISH-   | ExpCohort 2 HER2IHC 1+   |
|-------------------------------------------------------------------|-------------------------|-------------------|--------------------------------|---------------------|--------------|--------------------------------|--------------------------|
|                                                                   | DS-8201a                | Phys.Choice       | Phys.Choice Paclitaxel         | Phys.Choice Overall | Overall      | DS-8201a                       | DS-8201a                 |
|                                                                   | (N=119)                 | Irinotecan (N=51) | (N=5)                          | (N=56)              | (N=175)      | (N=19)                         | (N=21)                   |
| Subgroup:Sex=male                                                 | n=89                    | n=40              | n=4                            | n=44                | n=133        | n=15                           | n=14                     |
| Objective Response Rate (CR+PR)(n,%)                              | 47 ( 52.8)              | 5 ( 12.5)         | 1(25.0)                        | 6 (13.6)            | 53 (39.8)    | 5 (33.3)                       | 4 (28.6)                 |
| 95%C                                                              | (41.9, 63.5)            | (4.2, 26.8)       | (0.6, 80.6)                    | (5.2, 27.4)         | (31.5, 48.7) | (11.8, 61.6)                   | (8.4, 58.1)              |
| Fisher'sexacttestbetweenthetreatmentsgroups                       | p<0.0001                |                   |                                |                     |              |                                |                          |
| Subgroup:ECOGPS=0                                                 | n=59                    | n=27              | n=2                            | n=29                | n=88         | n=10                           | n=10                     |
| Objective Response Rate (CR+PR)(n,%)                              | 31(52.5)                | 2( 7.4)           | 1(50.0)                        | 3 (10.3)            | 34 ( 38.6)   | 3 (30.0)                       | 3(30.0)                  |
| 95%C                                                              | (39.1, 65.7)            | (0.9, 24.3)       | (1.3, 98.7)                    | (2.2, 27.4)         | (28.4, 49.6) | (6.7, 65.2)                    | (6.7, 65.2)              |
| Fisher'sexacttestbetweenthetreatmentsgroups                       | p=0.0001                |                   |                                |                     |              |                                |                          |
| Subgroup:ECOGPS=1                                                 | n=60                    | n=24              | n=3                            | n=27                | n=87         | n=9                            | n=11                     |
| Objective Response Rate (CR+PR)(n,%)                              | 30 (50.0)               | 5 (20.8)          | 0(0.0)                         | 5 ( 18.5)           | 35 (40.2)    | 4 (44.4)                       | 1( 9.1)                  |
| 95%CI                                                             | (36.8, 63.2)            | (7.1, 42.2)       | (0.0, 70.8)                    | (6.3, 38.1)         | (29.9, 51.3) | (13.7,78.8)                    | (0.2, 41.3)              |
| Fisher'sexacttestbetweenthetreatmentsgroups                       | p=0.0087                |                   |                                |                     |              |                                |                          |
| Subgroup:HER2statusincentrallaboratory=Primary Cohort:IHC 3+      | n=91                    | n=40              | n=4                            | n=44                | n=135        | n=0                            | n=0                      |
| Objective Response Rate (CR+PR)(n,%)                              | 53 (58.2)               | 4 (10.0)          | 1(25.0)                        | 5 (11.4)            | 58 (43.0)    | ()                             | (-)                      |
| 95%C                                                              | (47.4, 68.5)            | (2.8, 23.7)       | (0.6, 80.6)                    | (3.8, 24.6)         | (34.5, 51.8) | (--)                           | (-.-)                    |
| Fisher's exact test betweenthe treatments groups                  | p<0.0001                |                   |                                |                     |              |                                |                          |
| Subgroup:HER2statusincentrallaboratory=Primary Cohort:IHC 2+/ISH+ | n=28                    | n=11              | n=1                            | n=12                | n=40         | n=0                            | n=0                      |
| Objective Response Rate(CR +PR)(n, %)                             | 8(28.6)                 | 3 ( 27.3)         | 0(0.0)                         | 3 (25.0)            | 11 ( 27.5)   |                                |                          |
| 95%C                                                              | (13.2, 48.7)            | (6.0, 61.0)       | (0.0, 97.5)                    | (5.5, 57.2)         | (14.6, 43.9) | (-,-)                          | (-.-)                    |
| Fisher'sexacttestbetweenthetreatmentsgroups                       | p=1.0000                |                   |                                |                     |              |                                |                          |
| Subgroup:Primarytumorlocation=Gastric                             | n=104                   | n=46              | n=3                            | n=49                | n=153        | n=15                           | n=19                     |
| Objective Response Rate(CR+PR)(n,%)                               | 52 (50.0)               | 6 (13.0)          | 1(33.3)                        | 7 (14.3)            | 59(38.6)     | 7 (46.7)                       | 3(15.8)                  |
| 95%C                                                              | (40.0, 60.0)            | (4.9, 26.3)       | (0.8, 90.6)                    | (5.9, 27.2)         | (30.8, 46.8) | (21.3, 73.4)                   | (3.4, 39.6)              |
| Fisher'sexacttestbetweenthetreatmentsgroups                       | p<0.0001                |                   |                                |                     |              |                                |                          |
| Subgroup:Primary tumorlocation=GEJ                                | n=15                    | n=5               | n=2                            | n=7                 | n=22         | n=4                            | n=2                      |
| Objective Response Rate (CR+PR)(n,%)                              | 9 (60.0)                | 1 (20.0)          | 0(0.0)                         | 1 (14.3)            | 10 (45.5)    | (00)0                          | 1( 50.0) (1.3, 98.7)     |
| 95%C                                                              | (32.3, 83.7)            | (0.5, 71.6)       | (0.0. 84.2)                    | (0.4, 57.9)         | (24.4, 67.8) | (0.0, 60.2)                    |                          |
| Subgroup: Histological subtype = Intestinal                       |                         | n=34              | n=3                            | n=37                | n=123        | n=12                           | n=6                      |
|                                                                   | n=86                    | 7 (20.6)          | 1(33.3)                        | 8 (21.6)            | 49 (39.8)    | 3(25.0)                        | 3(50.0)                  |
| Objective Response Rate(CR+PR)(n,%) 95%C                          | 41 ( 47.7) (36.8, 58.7) | (8.7, 37.9)       | (0.8, 90.6)                    | (9.8, 38.2)         | (31.1, 49.1) | (5.5, 57.2)                    | (11.8, 88.2)             |

Percentageiscalculatedusingthenumberofsubjectsinthecolumnheadingasthedenominator. [1]95%exactbinomial confidenceinterval.FishersexacttestwasperformedtocompareORRbetweenDS-8201aandPhys.ChoiceOverallinPrimaryCohorts. Two subjects areexcludedfromExploratoryCohort 2duetonoHER2statusincentrallaboratory.

## Secondary efficacy endpoint - OS

The primary efficacy analysis was conducted at a DCO date of 08 Nov 2019 (DCO for the primary CSR). A formal IA of OS was conducted at the time of the primary analysis and this IA is considered to be the final OS analysis. A supportive efficacy analysis was conducted as of a DCO of 03 Jun 2020 and is presented for descriptive purposes only.

<div style=\"page-break-after: always\"></div>

Table3.13: OverallSurvivalinStudyJ202(FullAnalysisSetandIntent-to-Treat Analysis Set)

|                                      | StudyJ202PrimaryCohort               | StudyJ202PrimaryCohort               | StudyJ202PrimaryCohort               | StudyJ202PrimaryCohort               |
|--------------------------------------|--------------------------------------|--------------------------------------|--------------------------------------|--------------------------------------|
|                                      | T-DXd                                | Physician's Choice                   | Physician's Choice                   | Physician's Choice                   |
|                                      | 6.4 mg/kg                            | Irinotecan                           | Paclitaxel                           | Total                                |
| Full AnalysisSeta                    | CSRDCO08N0V2019                      | CSRDCO08N0V2019                      | CSRDCO08N0V2019                      | CSRDCO08N0V2019                      |
| Durationofsurvivalfollow-up(months)b | Durationofsurvivalfollow-up(months)b | Durationofsurvivalfollow-up(months)b | Durationofsurvivalfollow-up(months)b | Durationofsurvivalfollow-up(months)b |
| N                                    | 125                                  | 55                                   | 7                                    | 62                                   |
| Median                               | 8.1                                  | 7.1                                  | 5.5                                  | 7.0                                  |
| Min-Max                              | 1.0-23.1                             | 0.3-20.3                             | 2.0-14.3                             | 0.3-20.3                             |
| OS (months)                          |                                      |                                      |                                      |                                      |
| OS events, n (%)                     | 62 (49.6)                            | 35 (63.6)                            | 4 (57.1)                             | 39 (62.9)                            |
| Censored,n (%)                       | 63 (50.4)                            | 20 (36.4)                            | 3 (42.9)                             | 23 (37.1)                            |
| MedianOSc                            | 12.5                                 | 8.4                                  | 14.3                                 | 8.4                                  |
| 95%CI                                | 9.6,14.3                             | 6.9, 10.4                            | 2.0,14.3                             | 6.9, 10.7                            |
| Stratified log-rank testd.e          | P-value=0.0097                       | P-value=0.0097                       | P-value=0.0097                       | P-value=0.0097                       |
| StratifiedHR(95%CI)                  | 0.59 (0.39,0.88)                     | 0.59 (0.39,0.88)                     | 0.59 (0.39,0.88)                     | 0.59 (0.39,0.88)                     |
| Intent-to-TreatAnalysisSetf          | CSRDCO08Noy2019                      | CSRDCO08Noy2019                      | CSRDCO08Noy2019                      | CSRDCO08Noy2019                      |
| Durationofsurvivalfollow-up(months)  | Durationofsurvivalfollow-up(months)  | Durationofsurvivalfollow-up(months)  | Durationofsurvivalfollow-up(months)  | Durationofsurvivalfollow-up(months)  |
| N                                    | 126                                  | 55                                   | 7                                    | 62                                   |
| Median(months)a                      | 8.0                                  | 7.1                                  | 5.5                                  | 7.0                                  |
| Min-Max                              | 0.4-23.1                             | 0.3-20.3                             | 2.0-14.3                             | 0.3-20.3                             |
| OS events,n(%)                       | 62 (49.2)                            | 35 (63.6)                            | 4 (57.1)                             | 39 (62.9)                            |
| Censored, n (%)                      | 64 (50.8)                            | 20 (36.4)                            | 3 (42.9)                             | 23 (37.1)                            |
| OS (months)                          | OS (months)                          | OS (months)                          | OS (months)                          | OS (months)                          |
| MedianOSc                            | 12.5                                 | 8.4                                  | 14.3                                 | 8.4                                  |
| 95%CI                                | 9.6,14.3                             | 6.9,10.4                             | 2.0,14.3                             | 6.9,10.7                             |
| Stratified log-rank testd,e          | P-value=0.0097                       | P-value=0.0097                       | P-value=0.0097                       | P-value=0.0097                       |
| Stratified HR(95%C1)                 | 0.59 (0.39,0.88)                     | 0.59 (0.39,0.88)                     | 0.59 (0.39,0.88)                     | 0.59 (0.39,0.88)                     |
| FullAnalysisSet                      | UpdateDCO03Jun2020                   | UpdateDCO03Jun2020                   | UpdateDCO03Jun2020                   | UpdateDCO03Jun2020                   |
| Durationofsurvivalfollow-up(months)  | Durationofsurvivalfollow-up(months)  | Durationofsurvivalfollow-up(months)  | Durationofsurvivalfollow-up(months)  | Durationofsurvivalfollow-up(months)  |
| N                                    | 125                                  | 55                                   | 7                                    | 62                                   |
| Median                               | 12.0                                 | 8.4                                  | 12.2                                 | 8.5                                  |
| Min-Max                              | 1.0-29.7                             | 0.3-26.5                             | 2.0-16.2                             | 0.3-26.5                             |

| OS (months)                             |                                         |                                         |                                         |                                         |
|-----------------------------------------|-----------------------------------------|-----------------------------------------|-----------------------------------------|-----------------------------------------|
| OS events,n (%)                         | 84 (67.2)                               | 45 (81.8)                               | 4 (57.1)                                | 49 (79.0)                               |
| Censored, n (%)                         | 41 (32.8)                               | 10 (18.2)                               | 3 (42.9)                                | 13 (21.0)                               |
| MedianOSc                               | 12.5                                    | 8.6                                     | 14.3                                    | 8.9                                     |
| 95%CI                                   | 10.3,15.2                               | 6.4, 10.4                               | 2.0, NE                                 | 6.4, 10.4                               |
| Stratified log-rank teste               | P-value=0.0051                          | P-value=0.0051                          | P-value=0.0051                          | P-value=0.0051                          |
| StratifiedHR(95%C1)                     | 0.60 (0.42,0.86)                        | 0.60 (0.42,0.86)                        | 0.60 (0.42,0.86)                        | 0.60 (0.42,0.86)                        |
| Intent-to-Treat Analysis Set            | UpdateDCO03Jun2020                      | UpdateDCO03Jun2020                      | UpdateDCO03Jun2020                      | UpdateDCO03Jun2020                      |
| Duration of survival follow-up (months) | Duration of survival follow-up (months) | Duration of survival follow-up (months) | Duration of survival follow-up (months) | Duration of survival follow-up (months) |
| N                                       | 126                                     | 55                                      | 7                                       | 62                                      |
| Median (months)                         | 11.9                                    | 8.4                                     | 12.2                                    | 8.5                                     |
| Min-Max                                 | 0.4-29.7                                | 0.3-26.5                                | 2.0-16.2                                | 0.3-26.5                                |
| OS events,n (%)                         | 84 (66.7)                               | 45 (81.8)                               | 4 (57.1)                                | 49 (79.0)                               |
| Censored, n (%)                         | 42 (33.3)                               | 10 (18.2)                               | 3 (42.9)                                | 13 (21.0)                               |
| Median OSc                              | 12.5                                    | 8.6                                     | 14.3                                    | 8.9                                     |
| 95%CI                                   | 10.3,15.2                               | 6.4, 10.4                               | 2.0, NE                                 | 6.4, 10.4                               |
| Stratifiedlog-ranktest                  | P-value=0.0051                          | P-value=0.0051                          | P-value=0.0051                          | P-value=0.0051                          |
| StratifiedHR°(95%CI)                    | 0.60 (0.42,0.86)                        | 0.60 (0.42,0.86)                        | 0.60 (0.42,0.86)                        | 0.60 (0.42,0.86)                        |

- Durationofsurvivalfollow-up(months)=(lastcontactdate-dateofrandomization/registration+1).
- TheFASinStudyJ202includedallrandomizedsubjectswhoreccivedatleast1doseofstudydrug.

MedianwasfromKaplan-Mciercstimate.CIformedianwascomputedusingtheBrookmeyer-Crowleymethod.

- The comparison was between the T-Dxd arm and the TPC arm,with region(Japan or SouthKorea) as a stratificationfactor.

ThehypothcsistcstingwasconductedonlyifthcprimaryendpointofORRwasproventobestatisticallysignificant.

TheITTanalysissetincludedallsubjcctswhosignedaninformedconsentformandwererandomizedinthePrimaryCohortof StudyJ202.

<div style=\"page-break-after: always\"></div>

Table14.2.3.2OverallSurvival(OS) (Intent-to-treat Analysis Set)

|                                         | DS-8201a (N=126)   | Phys. Choice Irinotecan (N=55)   | Primary Cohort HER2-Positive Phys. Choice Paclitaxel (N=7)   | Phys.Choice Overall (N=62)   | Overall (N=188)   | ExpCohort 1 HER2IHC 2+/ISH- DS-8201a (N=21)   | Exp Cohort2 HER2IHC1+ DS-8201a (N=22)   |
|-----------------------------------------|--------------------|----------------------------------|--------------------------------------------------------------|------------------------------|-------------------|-----------------------------------------------|-----------------------------------------|
| Duration of Survival Follow-Up (months) |                    |                                  |                                                              |                              |                   |                                               |                                         |
| n                                       | 126                | 55                               | 7                                                            | 62                           | 188               | 21                                            | 22                                      |
| Mean                                    | 11.6               | 8.9                              | 9.3                                                          | 8.9                          | 10.7              | 10.5                                          | 9.2                                     |
| Standard Deviation                      | 6.26               | 5.58                             | 5.88                                                         | 5.57                         | 6.15              | 7.29                                          | 5.38                                    |
| Median                                  | 11.9               | 8.4                              | 12.2                                                         | 8.5                          | 10.4              | 7.3                                           | 8.5                                     |
| Q1,Q3                                   | 6.5, 15.7          | 4.2, 11.7                        | 3.4,14.3                                                     | 4.1, 12.2                    | 5.8,14.3          | 4.7, 16.5                                     | 4.3, 13.9                               |
| Min, Max                                | 0.4, 29.7          | 0.3,26.5                         | 2.0, 16.2                                                    | 0.3, 26.5                    | 0.3, 29.7         | 0.2, 25.6                                     | 1.8, 19.6                               |
| Subjects with Events (n, %)             | 84 ( 66.7)         | 45 (81.8)                        | 4 ( 57.1)                                                    | 49 (79.0)                    | 133 ( 70.7)       | 14 ( 66.7)                                    | 18 (81.8)                               |
| Subjects Censored (n, %)                | 42(33.3)           | 10 (18.2)                        | 3 (42.9)                                                     | 13 (21.0)                    | 55 (29.3)         | 7(33.3)                                       | 4(18.2)                                 |
| Overall Survival (Months)\"              |                    |                                  |                                                              |                              |                   |                                               |                                         |
| Median                                  | 12.5               | 8.6                              | 14.3                                                         | 8.9                          | 10.7 (9.1, 12.6)  | 7.8 (4.7, 16.5)                               | 8.5 (4.3, 12.6)                         |
| 95%Clfor Median                         | (10.3, 15.2)       | (6.4, 10.4)                      | (2.0, -)                                                     | (6.4, 10.4)                  |                   |                                               |                                         |
| Min, Max                                | 0.4+, 29.7+        | 0.3+,26.5+                       | 2.0, 16.2+                                                   | 0.3+,26.5+                   | 0.3+,29.7+        | 0.2+, 25.6+                                   | 1.8, 19.6+                              |
| Stratifed Log-rank Test RIBI            | p=0.0051           | p=0.003150                       | p =0.7677                                                    |                              |                   |                                               |                                         |

[6] ComparisonwasbetweenDS-8201a andPhys.ChoicePaclitaxelinPrimary Cohorts.

[5] ComparisonwasbetweenDS-8201a andPhys.ChoiceIrinotecaninPnmary Cohorts.

[7]P-valueisoutputtedasareferenceandthecomparisonisnotintendedforthedemonstrationofsuperiority.

Two subjects ( areexcludedfromExploratoryCohort 2duetonoHER2status incentrallaboratory.

Figure 3.5: Kaplan-MeierPlotofOverallSurvivalinSubjectswithMetastatic HER2-positiveGastric orGastroesophageal JunctionCancer inPrimary CohortofStudyJ202atUpdateDataCut-off03Jun2020(Intent-to-Treat Analysis Set)

<!-- image -->

CSR=clinical studyreport;DS-820la=T-DXd(rastuzumab deruxtecan);HER2=humanepidermal growthfactorreceptor 2; No.=number,phys.=physician Source:Module5.3.5.1DS8201-A-J202AbbreviatedCSRFigure14.2.3.1\\_5

Secondary endpoint - PFS

<div style=\"page-break-after: always\"></div>

Table14.2.4.2Progression-FreeSurvival(PFS) (Intent-to-treatAnalysisSet) (BasedonICR)

|                                                 | DS-8201a (N=126)   | Phys.Choice Irinotecan (N=55)   | PrimaryCohort HER2-Positive Phys.Choice Paclitaxel (N=7)   | Phys.Choice Overall (N=62)   | Overall (N=188)   | ExpCohort1 HER2IHC 2+/ISH- DS-8201a (N=21)   | ExpCohort2 HER2IHC1+ DS-8201a (N=22)   |
|-------------------------------------------------|--------------------|---------------------------------|------------------------------------------------------------|------------------------------|-------------------|----------------------------------------------|----------------------------------------|
| Subjects with Events (n, %)                     | 82 ( 65.1)         | 33 (60.0)                       | 3 (42.9)                                                   | 36 (58.1)                    | 118 (62.8)        | 14 ( 66.7)                                   | 16 ( 72.7)                             |
| Earliest Contributing Event: ProgressiveDisease | 71 (56.3)          | 32 (58.2)                       | 2(28.6)                                                    | 34 (54.8)                    | 105 (55.9)        | 13 (61.9)                                    | 16 ( 72.7)                             |
| Death                                           | 11( 8.7)           | 1( 1.8)                         | 1 ( 14.3)                                                  | 2(3.2)                       | 13( 6.9)          | 1( 4.8)                                      | 0(0.0)                                 |
| Subjects Censored (n, %)                        | 44 (34.9)          | 22 (40.0)                       | 4 ( 57.1)                                                  | 26 (41.9)                    | 70 (37.2)         | 7(33.3)                                      | 6 (27.3)                               |
| Nobaselinetumorassessments                      | 0(0.0)             | 1( 1.8)                         | 1(14.3)                                                    | 2(3.2)                       | 2( 1.1)           | 0(0.0)                                       | (00)0                                  |
| Nopost-baselinetumorassessments                 | 2( 1.6)            | 2( 3.6)                         | 1(14.3)                                                    | 3( 4.8)                      | 5 (2.7)           | 1( 4.8)                                      | 0(0.0)                                 |
| New anti-cancer therapy                         | 14 ( 11.1)         | 13 (23.6)                       | 1 (14.3)                                                   | 14 ( 22.6)                   | 28 (14.9)         | 4 (19.0)                                     | 6 (27.3)                               |
| Missed2consecutivetumor assessments             | 5( 4.0)            | 1( 1.8)                         | (0°0)0                                                     | 1(1.6)                       | 6( 3.2)           | 0(0.0)                                       | (00)0                                  |
| No PD or death                                  | 23 (18.3)          | 5( 9.1)                         | 1(14.3)                                                    | 6(9.7)                       | 29 (15.4)         | 2( 9.5)                                      | (00)0                                  |
| Progression-FreeSurvival(Months)i1              |                    |                                 |                                                            |                              |                   |                                              |                                        |
| Median                                          | 5.6                | 2.8                             | 4.9                                                        | 3.5                          | 4.6               | 4.4                                          | 2.8                                    |
| 95%CIforMedian                                  | (4.3, 6.9)         | (2.0, 4.3)                      | (2.0, -)                                                   | (2.0, 4.3)                   | (4.1, 5.6)        | (2.7, 7.1)                                   | (1.5, 4.3)                             |
| Min, Max                                        | 0.0+,29.5+         | 0.0+,7.0+                       | 0.0+,6.8+                                                  | 0.0+,7.0+                    | 0.0+,29.5+        | 0.0+,13.8+                                   | 0.5+,13.9                              |
| StratifiedLog-rankTest                          | p=0.0003           | p=0.0002                        | p=0.6273                                                   |                              |                   |                                              |                                        |
| Log-rankTest                                    | p=0.0003同的         | p=0.0002街                       | p=0.61625                                                  |                              |                   |                                              |                                        |
| Adjusted Hazard Ratiopl                         | 0.4701             | 0.45                            | 0.75(5)                                                    |                              |                   |                                              |                                        |
| 95%CI                                           | (0.31, 0.71)       | (0.29, 0.69)                    | (0.24, 2.40)                                               |                              |                   |                                              |                                        |
| Hazard Ratio                                    | 0.4701             | 0.454                           | 0.755]                                                     |                              |                   |                                              |                                        |
| 95%CI                                           | (0.31, 0.71)       | (0.29,0.69)                     | (0.23,2.38)                                                |                              |                   |                                              |                                        |
| Kaplan-Meierestimatesand95%Clon                 |                    |                                 |                                                            |                              |                   |                                              |                                        |
| eachtime point 3Months                          | 71.9 (63.0, 79.1)  | 47.9 (32.6, 61.8)               | 75.0 (12.8, 96.1)                                          | 50.3 (35.5,63.5)             | 65.6 (57.9, 72.2) | 71.5 (44.3, 87.1)                            | 41.6 (18.1, 63.7)                      |
| 6 Months                                        | 43.0 (33.6, 52.0)  | 20.7 (8.2,36.9)                 | 25.0 (0.9, 66.5)                                           | 20.6 (8.9, 35.6)             | 37.3 (29.5, 45.0) | 33.5 (12.7, 56.1)                            | 13.9 (2.3, 35.4)                       |
| 9 Months                                        | 33.3 (24.4, 42.4)  | (--)                            | (-. -)                                                     | (-.-)                        | 27.8 (20.5, 35.5) | 25.1 (7.1, 48.6)                             | 13.9 (2.3, 35.4)                       |
| 12 Months                                       | 30.4               |                                 |                                                            |                              | 25.3              | 8.4                                          | 6.9                                    |
|                                                 | (21.5, 39.7)       | (-.-)                           | (--)                                                       | (-)                          | (18.0,33.2)       | (0.6, 30.6)                                  | (0.4, 26.7)                            |

[1]MedianisfromKaplan-MeierEstimate.CIformedianiscomputedusing theBrookmeyer-Crowley method.Minimum andmaximum includethecensoredobservationswhereusing+aftervalue indicates censoning.

[3]ComparisonwasbetweenDS-8201aandPhys.ChoiceOverallinPrimaryCohorts.

[2]Regionas a stratiicationfactor.

[4jComparisonwasbetweenDS-8201a andPhys.ChoiceIrinotecaninPrimaryCohorts.

[6jP-valueisoutputtedasareferenceandthecomparisonisnotintendedforthedemonstrationofsuperiority.

[5]ComparisonwasbetweenDS-8201aandPhys.ChoicePaclitaxelinPrimaryCohorts.

Twosubjects( )areexcludedfromExploratoryCohort 2duetonoHER2statusincentral laboratory.

Figure 8.6: Kaplan-MeierPlotofProgression-freeSurvivalBasedonIndependent CentralReviewasof03June2020(Intent-to-TreatAnalysisSet)

<!-- image -->

<div style=\"page-break-after: always\"></div>

Table 3.16: Progression-freeSurvival inStudyJ202 (Full Analysis Set and Intent-to-Treat Analysis Set)

<!-- image -->

CI =confidence interval; CSR = clinical study report;DCO=data cut-off; FAS =Full Analysis Set;HR =hazard ratio

ICR = independent central review; ITT = Intent-to-Treat; NE = not cstimablc; PFS = progression-frcc survival;

T-Dxd=trastuzumab deruxtecan; TPC = treatment of physician's choice

Percentagc was calculated using the number of subjects in the column heading as denominator.

- a The FAS inStudyJ202included all randomized subjects who reccived at least 1 dose ofstudy drug.
- c The comparison was between the T-DXd arm and the TPC arm, with region (Japan or South Korea) as a stratification factor.
- b Median was from Kaplan-Meier estimate. CI for median was computed using the Brookmeyer-Crowley method.

d The ITT analysis set included all subjects who signed an informed consent fom and were randomized in the Primary Cohort of Study J202.

Sourcc:Module5.3.5.1DS8201-A-J202CSRTables14.2.4.1and14.2.4.2;Module5.3.5.1DS8201-A-J202AbbreviatedCSR Tables14.2.4.1and14.2.4.2

<div style=\"page-break-after: always\"></div>

Figure 3.6: Kaplan-MeierPlotofProgression-freeSurvivalBasedonIndependent CentralReviewinSubjectswithMetastaticHER2-positiveGastricor GastroesophagealJunctionCancerinPrimaryCohortofStudyJ202 (Intent-to-TreatAnalysisSet)

<!-- image -->

DS-8201a=trastuzumabderuxtecan,T-DXd;HER2=humanepidermalgrowthfactorreceptor2;No.=number;

Phys.=physician;T-DXd=trastuzumab deruxtecan

Source:Module5.3.5.3SCEJ202Figure14.2.3.3\\_5

## Secondary endpoint - DoR

Figure 8.5: Kaplan-MeierPlotofDurationofConfirmedResponseBasedon IndependentCentralReviewasof03June2020DataCut-off(Intent-toTreat Analysis Set\")

<!-- image -->

Source:DS8201-A-J202updatedCSRFigure14.2.3.6

*：Results ofDoRwere identical between theITTAnalysisSetand theFAS because theFASincluded187subjects,excluding only1subjectfromITTAnalysisSetwhodidnotreceivethestudydrug.

<div style=\"page-break-after: always\"></div>

Table 26: ConfirmedBestOverallResponsebyIndependentCentralReviewinStudyJ202at UpdateDCO(ie,03Jun2020)(Intent-to-TreatAnalysisSet)

|                                                                     | Study J202Primary Cohort (DC0 = 03 Jun 2020)                        | Study J202Primary Cohort (DC0 = 03 Jun 2020)                        | Study J202Primary Cohort (DC0 = 03 Jun 2020)                        | Study J202Primary Cohort (DC0 = 03 Jun 2020)                        |
|---------------------------------------------------------------------|---------------------------------------------------------------------|---------------------------------------------------------------------|---------------------------------------------------------------------|---------------------------------------------------------------------|
|                                                                     | T-Dxd                                                               | TPC                                                                 | TPC                                                                 | TPC                                                                 |
|                                                                     | 6.4 mg/kg                                                           | Irinotecan                                                          | Paclitaxel                                                          | Total                                                               |
| ITT Analysis Seta                                                   |                                                                     |                                                                     |                                                                     |                                                                     |
| N                                                                   | 126                                                                 | 55                                                                  | 7                                                                   | 62                                                                  |
| Best overall response by ICR (with confirmation of CR or PR), n (%) | Best overall response by ICR (with confirmation of CR or PR), n (%) | Best overall response by ICR (with confirmation of CR or PR), n (%) | Best overall response by ICR (with confirmation of CR or PR), n (%) | Best overall response by ICR (with confirmation of CR or PR), n (%) |
| Complete response                                                   | 10 (7.9)                                                            | 0 (0.0)                                                             | 0 (0.0)                                                             | 0 (0.0)                                                             |
| Partial response                                                    | 40 (31.7)                                                           | 6 (10.9)                                                            | 1 (14.3)                                                            | 7 (11.3)                                                            |
| Stable disease                                                      | 57 (45.2)                                                           | 28 (50.9)                                                           | 3 (42.9)                                                            | 31 (50.0)                                                           |
| Progressive disease                                                 | 15 (11.9)                                                           | 18 (32.7)                                                           | 0 (0.0)                                                             | 18 (29.0)                                                           |
| Not evaluable                                                       | 4 (3.2)                                                             | 3 (5.5)                                                             | 3 (42.9)                                                            | 6 (9.7)                                                             |
| Confirmed ORR by ICR                                                |                                                                     |                                                                     |                                                                     |                                                                     |
| QRRbn (%)                                                           | 50 (39.7)                                                           | 6 (10.9)                                                            | 1 (14.3)                                                            | 7 (11.3)                                                            |
| 95% CIc                                                             | 31.1, 48.8                                                          | 4.1, 22.2                                                           | 0.4, 57.9                                                           | 4.7, 21.9                                                           |
| CMH testa                                                           | P-value <0.0001                                                     | P-value <0.0001                                                     | P-value <0.0001                                                     | P-value <0.0001                                                     |

Table 28: ConfirmedMedianDurationofResponsebyIndependentCentralReviewinStudyJ202 atUpdateDCO(ie,03Jun2020)(Intent-to-TreatAnalysisSet)

|                             | Study J202 Primary Cohort (DC0 = 03 Jun 2020)   | Study J202 Primary Cohort (DC0 = 03 Jun 2020)   | Study J202 Primary Cohort (DC0 = 03 Jun 2020)   | Study J202 Primary Cohort (DC0 = 03 Jun 2020)   |
|-----------------------------|-------------------------------------------------|-------------------------------------------------|-------------------------------------------------|-------------------------------------------------|
|                             | T-DXd 6.4 mg/kg                                 | TPC                                             | TPC                                             | TPC                                             |
|                             |                                                 | Irinotecan                                      | Paclitaxel                                      | Total                                           |
| ITT Analysis Seta           |                                                 |                                                 |                                                 |                                                 |
| N                           | 126                                             | 55                                              | 7                                               | 62                                              |
| Confirmed median DoR by ICR |                                                 |                                                 |                                                 |                                                 |
| NumberwithconfirmedCRorPR   | 50                                              | 6                                               | 1                                               | 7                                               |
| Median DoR months           | 12.5                                            | 4.1                                             | 3.9                                             | 3.9                                             |
| 95% CIb                     | 5.6, NE                                         | 3.0, 4.9                                        | NE, NE                                          | 3.0, 4.9                                        |

<div style=\"page-break-after: always\"></div>

## Ancillary analyses

Figure 2: Forest Plot Comparing Confirmed Objective Response Rate Based on Independent Central Review Between Treatment Arms in Subgroups in Primary Cohort of Study J202 (Intent-to-Treat Analysis Set)

CI = confidence interval; DCO = data cut-off DS-8201a = trastuzumab deruxtecan, (T-DXd); ECOG PS = Eastem Cooperative Oncology Group perfonmance status; GEJ = gastroesophageal junction; HER2 = human epidermal growth factor receptor 2; IHC = immunohistochemistry; ISH = in situ hybridization; ORR = objective response rate; Phys. = physician; SCE = Summary of Clinical Efficacy

<!-- image -->

DCO = 08 Nov 2019

Source: Module 5.3.5.3 SCE J202 Figure 14.2.6.18 1.

## 2.4.3. Discussion on clinical efficacy

The sought new therapeutic indication of Enhertu for advanced HER2+ GC/GEJC  in the 2L+ setting (after a prior trastuzumab-based regimen) is based on efficacy data from pivotal study DESTINY-Gastric02 (U205) and supportive data from study DESTINY-Gastric01 (J202).

<div style=\"page-break-after: always\"></div>

The pivotal study DESTINY-Gastric02 (U205) was a Phase 2, multicentre, single-arm, open-label study to evaluate the efficacy and safety of T-DXd (6.4 mg/kg as IV infusion Q3W) in subjects with unresectable or  metastatic  HER2-positive  gastric  or  GEJ  adenocarcinoma  who  had  progressed  during  or  after  a trastuzumab-containing regimen (2L setting). The study was conducted at 24 sites in the US and Europe.

Supportive data come from study DESTINY-Gastric01 (J202), a Phase 2, multicentre, open-label, 2:1 randomized study to evaluate efficacy and safety of T-DXd (6.4 mg/kg as IV infusion Q3W) in subjects with advanced HER2-positive gastric or GEJ adenocarcinoma, who had progressed on 2 or more prior regimens (3L setting) that had to include a fluoropyrimidine agent (fluorouracil, capecitabine, or S-1) and  a  platinum  agent  (oxaliplatin  or  cisplatin)  in  addition  to  prior  trastuzumab  or  a  trastuzumab biosimilar. This primary cohort was compared with a TPC chemotherapy arm (irinotecan or paclitaxel). The study was conducted in Asian patients at multiple sites in Japan and South Korea.

It is acknowledged that there is an unmet medical need for patients with advanced HER2+ GC, who have progressed on 1L chemotherapy combined with trastuzumab or a trastuzumab biosimilar. The applied indication concerns a HER-2 driven disease and the focus of assessment of the pivotal trial is ORR and DOR as indicators of disease activity.

## Design and conduct of clinical studies

The pivotal U205 study enrolled 79 subjects in EU/USA. The subjects were treated with T-DXd at the dose of 6.4 mg/kg after progressing on or after a trastuzumab-containing regimen (2L setting), which is the target population for the sought extension of indication. The primary efficacy endpoint was confirmed ORR by ICR and secondary endpoints were OS, PFS and DoR. All patients provided fresh tumour samples for central assessment of HER2 status (IHC 3+ or IHC 2+ and evidence of HER2 amplification by ISH) as determined according to American Society of Clinical Oncology - College of American Pathologists guidelines based on this new tumor biopsy obtained after progression on or after a first-line trastuzumabcontaining regimen. Since HER-2 status can change post-trastuzumab, this approach was endorsed. The inclusion/exclusion criteria for the U205 study clearly define a second line patient population with disease progression on or after treatment including trastuzumab and are still in a good condition, i.e. ECOG PS 0-1.  The  main  limitations  are  related  to  the  single-arm  and  open-label  design  of  the  study,  which hampers the assessment, particularly of the time-to-event endpoints.

In the supportive J202 (DESTINY-Gastric01) study, 188 subjects with progressive disease after two or more  lines  (3L+  setting)  were  randomized:  126  to  the  experimental  T-DXd  arm  and  62  to  the chemotherapy arm. The study was conducted in Japan and North Korea. The primary endpoint was unconfirmed ORR by ICR. OS, PFS and DoR were secondary endpoints. The baseline characteristics and demographics across both arms of treatment were overall well-balanced. The choice of irinotecan and paclitaxel as comparators in the control arm (TPC) are considered appropriate and in line with clinical practice in the EU.

## Efficacy data and additional analyses

In the pivotal study U205, the primary endpoint of confirmed ORR is 41.8% (DCO 08 Nov 2021). With a median duration of follow-up of 5.9 months (range: 0.7 to 15.4) median DOR was 8.1 months (range 5.9, not estimable). Median OS was 12.1 months (95% CI: 8.6, NE). Median PFS was 5.6 months (95% CI: 4.2, 8.3). These results shows that T-DXd offers promising activity in a patient population with a high unmet medical need harbouring a highly symptomatic disease. Response rates in the range seen in pivotal U205 trial might relate to reduction of symptoms and duration of response.  Overall, T-

<div style=\"page-break-after: always\"></div>

DXd would offer a targeted option for these patients. All patients enrolled in the study were high expressors of HER-2, as per rebiopsy before enrolment.

At DCO as of 03 Jun 2020, the supportive study J202 showed a confirmed ORR of 39.7% for the primary cohort compared to 11.3% for the TPC group. In the ITT, median DoR was 12.5  months (95% CI: 5.6, NE) in the  50 subjects who obtained a response. For the TPC group, median DoR was 3.9 months (95% CI: 3.0, 4.9). The secondary endpoint of median OS is 12.5 and 8.9 months for the TDXd and TPC arms respectively, with a HR=0.59 (95%CI: 0.39, 0.88), which implies a clinically relevant median improvement of survival of nearly 4 months.

It is well known that prognosis of Asian patients with gastric cancer is better than prognosis of nonAsian patients. This is thought to be related to different factors, including differences in disease biology, differences in treatment patterns, and differences in methods for screening/diagnosis. For example, in Europe approximately 50% of the patients have advanced disease at the time of diagnosis, while this is true for ~20% in Asian patients (likely due to national screening programmes for gastric cancer in Asia). Furthermore, there are differences in the initial tumour localisation between regions, as GEJ cancer is much more common in non-Asian patients compared with Asian patients.

As a consequence Asian patients receive more lines of therapy for advanced disease than patients in the EU. For example, in Japan almost all patients with metastatic gastric cancer receive second-line therapy, and more than half of patients receive three lines of therapy. In Europe, on the other hand, only half of the patient population is offered second-line treatment on progression after first-line therapy, and only a small proportion of the patients receive third-line therapy.

## Additional expert consultation

A SAG-O was held on 03-NOV-2022. Minutes from this meeting are presented.

## 1)  The  representativeness  of  the  3L  Japanese/Korean  GC/GEJC  population  for  the  2L European  population,  given  regional  differences  in  prognosis,  diagnostic  approach  and treatment strategy;

The  SAG  discussed  the  many  differences  between  populations,  especially  between  the  J202  Asian population and the target 2 nd  line European population in U205, such as early diagnostic approaches (screening), surgical procedures and systemic therapies.  However, opinions were split in terms of the impact of such differences on expected treatment effects:

- According to a majority view, it is unclear to what extent the differences are predictive of a different treatment effect. As such, the observed differences do not have an obvious effect on the possibility  to  generalise  or  extrapolate  results.  Extrapolation  between  3 rd   and  2 nd   line  of chemotherapy treatment, for a HER2-targeted agent did not seem problematic in the target indication. Additionally, the prognostic parameters and outcome in respect to ORR, DOR, PFS and OS of the patients in the J202 3L trial are similar to those of the U205 2L trial. Thus, extrapolation between regions in terms of treatment effects seem acceptable.
- According to a minority view, the impact of observed differences is uncertain and generalisation and  extrapolation  across  lines  of  treatment  are  difficult,  regardless  of  the  type  of  agent. According to this view, extrapolation of treatment effects cannot be justified.

The SAG agreed that the analyses presented based on external controls are difficult to interpret due to possible selection bias, as evidenced by the long event-free period in the treatment group. The SAG also

<div style=\"page-break-after: always\"></div>

recommended that it is important to assess prior treatments by treatment group to ensure relevance of the trial populations.

## 2) Whether the effect size as observed in the Japanese/Korean 3L patients (J202) and the anti-disease  activity  as  shown  in  the  European  patients  included  in  the  U205  study  are sufficiently  large  to  overcome  the  uncertainty  (if  any)  related  to  representativeness  as considered above. Please elaborate.

The SAG-O is aware that the patient numbers in both trials are low and that the U205 trial is a single arm trial with limitations in respect especially to the magnitude of OS in comparison with other therapies.

However, according to the majority of experts, looking at the totality of evidence especially the results observed in trial J202, including a clear effect on overall survival, the high overall response rate (ORR) observed in the single arm trial U205, the likelihood of an improvement in tumour related symptoms, an acceptable  toxicity  profile,  and  considering  the  limited  therapeutic  options  with  no  well  established treatment  in  this  targeted  population,  justify  that  overall  the  activity  and  efficacy  observed  are sufficiently convincing to justify conditional approval even if the confirmatory data from the phase III trial in second-line are still outstanding. According to this view, it is important that the confirmatory trial should provide clinically and statistically convincing results in terms of true clinical endpoints in the target population. Feasibility of such confirmatory trial following early approval should be clearly demonstrated and required.

According to a minority view, the differences among populations are too large to overcome uncertainties, particularly taking into account the likely problem with phase III trial feasibility in the target population following early approval. Even if the available exploratory results are promising, overall they do not justify early approval in the target population.

## Additional efficacy data needed in the context of a conditional MA

Overall, data on the T-DXd in the intended 2L+ setting for patients with HER2-positive GC/GECJ are not deemed comprehensive, but it is likely that the MAH will be able to provide comprehensive data through results from the ongoing study DS8201-A-U306 (phase III RCT of trastuzumab deruxtecan versus ramucirumab + paclitaxel in the 2L population including EU and USA patients). The Study U306 will provide interpretable results of time to event endpoints in the 2L setting in a patient population representative of the EU population.

As of 08 Nov 2022, 148 subjects have been enrolled and treated. Planned sample size is ~490 subjects. Study U306 enrollment is projected to be completed in Dec 2024 and the CSR ready in Q4 of 2025. The study is conducted in 22 countries from Europe, Latin America and Asia. This requirement constitutes a specific obligation (SOB) and is reflected in Annex II of the Opinion

## Assessment of paediatric data on clinical efficacy

Not applicable

## 2.4.4. Conclusions on the clinical efficacy

The single-arm pivotal study U205 in an European population with advanced GC/GEJC showed compelling results of T-DXd in terms of ORR and DoR in the 2L setting which is the sought indication.

<div style=\"page-break-after: always\"></div>

The main limitations of these data are related to the single-arm design of the study, which hampers the assessment, particularly of the time-to-event endpoints. The supportive randomised Phase II study J202 in an Asian population showed similar results but was conducted in a different line of treatment.

The following measures are considered necessary to address issues related to efficacy:

SOB: In order to confirm the efficacy and safety of Enhertu in the treatment of adult patients with advanced HER2 -positive gastric or gastroesophageal junction (GEJ) adenocarcinoma who have received a prior trastuzumab -based regimen, the MAH should submit the final results of study DS-8201-A-U306, a phase 3, multicentre, 2 -arm, randomised, open-label study of Enhertu in subjects with HER2 -positive metastatic and/or unresectable gastric or GEJ adenocarcinoma that has progressed on or after a trastuzumab-containing regimen.

## 2.5. Clinical safety

## 2.5.1.1. Introduction

The  safety  information  to  support  the  extension  of  indication  comes  from  3  studies.  The  proposed recommended dose is 6.4 mg/kg administered intravenously (IV) once every 3 weeks (Q3W).

- Study J202 (asian  (Japan+South Korea) population, 3L+, n=125, DCO 3.6.2020), phase II randomised
- Study U205 (western (US+EU) population, 2L, n=79, DCO 9.4.2021), phase II SAT
- Study  J101 (from  this  study  only  asian  GC  patients  treated  with  6.4mg/kg,  n=25,  DCO 1.8.2019), phase I

were pooled to form the HER2-positive GC Pool (N = 229) (Table 1.2).

The pooled safety population has been evaluated for patients who received at least one dose of Enhertu 6.4 mg/kg (n = 619), across multiple tumour types in clinical studies.

This dossier only presented safety data for the patients with GC receiving 6.4 mg/kg. Other patients with other cancer diseases in other trials have also received 6.4mg/kg, but their safety data was not presented in this dossier, and therefore not assessed in this procedure.

<div style=\"page-break-after: always\"></div>

Table 1.2: Summaryof GroupsIncluded inDataPresentations

| Group                                 | Description (Safety Population)*                                                                                                                                                                                     | Number of Subjects Treated   |
|---------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------------------------|
| Study J202 (HER2-positive GC)         | T-DXd 6.4 mg/kg (primary cohort) or TPC (irinotecan or paclitaxel)                                                                                                                                                   | 125 62                       |
| Study U205 (HER2-p0sitive GC)         | T-DXd 6.4 mg/kg                                                                                                                                                                                                      | 79                           |
| HER2-positive GC T-DXd 6.4 mg/kg Pool | Total Study J202 T-DXd 6.4 mg/kg (primary cohort) Study U205 T-DXd 6.4 mg/kg Study J101 T-DXd 6.4 mg/kg (Part 1 Cohort 5 and Part 2b)                                                                                | 229 125 79 25                |
| All Tumor Types T-DXd ≥5.4 mg/kg Pool | Total Study J202 T-DXd 6.4 mg/kg Q3W (primary and exploratory cohort) Study U205 T-DXd 6.4 mg/kg Study J101 T-DXd 5.4, 6.4, and 8.0 mg/kg Study U201 T-DXd 5.4,6.4, and 7.4 mg/kg Study U204 T-DXd 5.4 and 6.4 mg/kg | 962 169 79 280 253 181       |

Source:Module5.3.5.3SCSSAPVersion3.0

Table1.2SummaryofGroupsIncludedinSafetyDataPresentations

BC = breast cancer, HER2 = human epidermal growth factor receptor 2; T-DXd = trastuzumab deruxctecan; TPC = treatment of physician's choice Source:, Module 5.3.5.3 SCS SAP v1.0

| Evaluation                                                                                                                        | Drug/Dose           | Number of Subjects Treated                                                       |
|-----------------------------------------------------------------------------------------------------------------------------------|---------------------|----------------------------------------------------------------------------------|
| Data for Primary Analysis Subjects with HER2-1ow BC from Study U303                                                               | T-DXd 5.4 mg/kg TPC | T-DXd: 371 TPC:172                                                               |
| A11 BC T-DXd 5.4 mg/kg Poo1 Multi-study pool of subjects with HER2-positive or HER2-1ow BC who received T-DXd 5.4 mg/kg (N = 883) | T-DXd 5.4 mg/kg     | 883 Study U303: 371 Study U302: 257 Study U201: 184 Study J101: 71               |
| A11 Tumor Tvpes T-DXd >5.4 mg/kg Pool Multi-study pool of subjects with any tumor type who received T-DXd ≥5.4 mg/kg (N = 1590)   | T-DXd 5.4 mg/kg     | Study U303:371 Study U302: 257 Study U201: 184 Study J101: 91 Study U204: 41     |
| A11 Tumor Tvpes T-DXd >5.4 mg/kg Pool Multi-study pool of subjects with any tumor type who received T-DXd ≥5.4 mg/kg (N = 1590)   | T-DXd 6.4 mg/kg     | 619 Study J101: 183 Study J202: 169 Study U201: 48 Study U204:140 Study U205: 79 |
| A11 Tumor Tvpes T-DXd >5.4 mg/kg Pool Multi-study pool of subjects with any tumor type who received T-DXd ≥5.4 mg/kg (N = 1590)   | T-DXd 7.4 mg/kg     | Study U201: 21                                                                   |
| A11 Tumor Tvpes T-DXd >5.4 mg/kg Pool Multi-study pool of subjects with any tumor type who received T-DXd ≥5.4 mg/kg (N = 1590)   | T-DXd 8.0 mg/kg     | Study J101: 6                                                                    |

<div style=\"page-break-after: always\"></div>

Patients in study U205 had slightly worse characteristics compared to patients in the T-DXd arm of J202 regarding: tumor burden, proportion of subjects with ECOG PS 1, liver metastases, and ≥2 metastatic sites. Conversely, other baseline characteristics were worse for subjects in the T-DXd arm of J202 than for subjects in U205: age ≥65 years , normal renal function, normal hepatic function, prior systemic anticancer therapy (median 3 vs. 1).

Table 2: Gastric Cancer History in Studies J202 and U205 (Intent-to-Treat Analysis Set)

|                                                                                     | Study J202 Primary Cohort (DCO = 08 Nov 2019)   | Study J202 Primary Cohort (DCO = 08 Nov 2019)   | Study U205 (DCO = 09 Apr 2021)   |
|-------------------------------------------------------------------------------------|-------------------------------------------------|-------------------------------------------------|----------------------------------|
|                                                                                     | T-DXd (N = 126)                                 | TPC (N = 62)                                    | T-DXd (N = 79)                   |
| Type of cancer, n (%)                                                               |                                                 |                                                 |                                  |
| Gastric                                                                             | 109 (86.5)                                      | 55 (88.7)                                       | 27 (34.2)                        |
| GEJ                                                                                 | 17 (13.5)                                       | 7 (11.3)                                        | 52 (65.8)                        |
| HER2 expression (IHC) per central laboratory (archived and fresh samples) a , n (%) |                                                 |                                                 |                                  |
| 2+/ISH-positive                                                                     | 29 (23.0)                                       | 15 (24.2)                                       | 10 (12.7)                        |
| 3+                                                                                  | 96 (76.2)                                       | 47 (75.8)                                       | 68 (86.1)                        |
| IHC missing                                                                         | 1 (0.8)                                         | 0                                               | -                                |
| Not evaluable                                                                       | 0                                               | 0                                               | 1 (1.3)                          |
| Histological subtype, n (%)                                                         |                                                 |                                                 |                                  |
| Adenocarcinoma                                                                      | -                                               | -                                               | 78 (98.7)                        |
| Intestinal                                                                          | 89 (70.6)                                       | 38 (61.3)                                       | 19 (24.1)                        |
| Diffuse                                                                             | 29 (23.0)                                       | 18 (29.0)                                       | 1 (1.3)                          |
| Mixed                                                                               | -                                               | -                                               | 1 (1.3)                          |
| Unknown                                                                             | -                                               | -                                               | 57 (72.2)                        |
| Other                                                                               | 8 (6.3)                                         | 6 (9.7)                                         | 1 (1.3)                          |
| Time from initial diagnosis (months)                                                |                                                 |                                                 |                                  |
| Median                                                                              | 22.9                                            | 20.3                                            | 14.19                            |
| Min-Max                                                                             | 4.6-156.3                                       | 4.5-233.4                                       | 3.6-88.5                         |
| Tumor stage at study entry, n (%)                                                   |                                                 |                                                 |                                  |
| Stage IIB b                                                                         | 0                                               | 0                                               | 1 (1.3)                          |
| Stage IV                                                                            | 121 (96.0)                                      | 62 (100.0)                                      | 78 (98.7)                        |
| Other (ie, recurrence)                                                              | 5 (4.0)                                         | 0                                               | 0                                |
| Number of metastatic sites at baseline, n (%)                                       |                                                 |                                                 |                                  |
| <2                                                                                  | 24 (19.0)                                       | 10 (16.1)                                       | 5 (6.3)                          |
| ≥2                                                                                  | 102 (81.0)                                      | 52 (83.9)                                       | 74 (93.7)                        |
| Lung metastases at baseline, n (%)                                                  | 39 (31.0)                                       | 15 (24.2)                                       | 21 (26.6)                        |
| Liver metastases at baseline, n (%)                                                 | 68 (54.0)                                       | 34 (54.8)                                       | 50 (63.3)                        |
| Brain metastases at baseline, n (%)                                                 | 4 (3.7)                                         | 4 (6.5)                                         | 4 (5.1)                          |
| Peritoneal metastases at baseline, n (%)                                            | 21 (16.7)                                       | 11 (17.7)                                       | 8 (10.1)                         |
| Tumor burden (sum of diameters of target lesions based on ICR at baseline)          |                                                 |                                                 |                                  |
| n                                                                                   | 120                                             | 56                                              | 78                               |
| Median (cm)                                                                         | 4.8                                             | 5.3                                             | 6.3                              |

<div style=\"page-break-after: always\"></div>

|                                | Study J202 Primary Cohort (DCO = 08 Nov 2019)   | Study J202 Primary Cohort (DCO = 08 Nov 2019)   | Study U205 (DCO = 09 Apr 2021)   |
|--------------------------------|-------------------------------------------------|-------------------------------------------------|----------------------------------|
|                                | T-DXd (N = 126)                                 | TPC (N = 62)                                    | T-DXd (N = 79)                   |
| Min-Max                        | 1.2-20.4                                        | 1.0-22.8                                        | 1.0-30.6                         |
| Missing                        | 6 (4.8)                                         | 6 (9.7)                                         | 1 (1.3)                          |
| <5 cm, n (%)                   | 63 (50.0)                                       | 26 (41.9)                                       | 32 (40.5)                        |
| ≥5 to <10 cm                   | 34 (27.0)                                       | 22 (35.5)                                       | 26 (32.9)                        |
| ≥10 cm                         | 23 (18.3)                                       | 8 (12.9)                                        | 20 (25.3)                        |
| ECOG performance status, n (%) |                                                 |                                                 |                                  |
| 0                              | 62 (49.2)                                       | 30 (48.4)                                       | 29 (36.7)                        |
| 1                              | 63 (50.0)                                       | 32 (51.6)                                       | 50 (63.3)                        |
| Prior treatment type, n (%)    |                                                 |                                                 |                                  |
| Prior cancer surgery           | 60 (47.6)                                       | 23 (37.1)                                       | 21 (26.6)                        |
| Total gastrectomy (yes)        | 22 (17.5)                                       | 9 (14.5)                                        | 0                                |

DCO = data cut-off; ECG = electrocardiogram; ECOG = Eastern Cooperative Oncology Group; GEJ = gastroesophageal junction; HER2 = human epidermal growth factor receptor 2; ICR = independent central review; IHC = immunohistochemistry; ISH = in situ hybridization; Max = maximum; Min = minimum; QTcF = QT interval corrected for heart rate by Fridericia's formula; SAP = Statistical Analysis Plan; SCE = Summary of Clinical Efficacy; T-DXd = trastuzumab deruxtecan; TPC = treatment of physician's choice

- a   Subject No. 81182209, who was randomized to the T-DXd arm of J202, became ineligible before first dose, as the subject's ECG results at Cycle 1 Day 1 predose met exclusion criterion 2 (ie, QTcF prolongation to &gt;470 ms [females] or &gt;450 ms [males] based on average of the screening triplicate 12-lead ECG).  Because the HER2 status by central laboratory was derived as the last value before the date of first dose (as per baseline definition in the SAP) and the subject did not have a first dose date, his central laboratory HER2 status was entered as 'IHC missing' in demographic tables.  However, the subject had a central HER2 status of IHC 2+/ISH-positive before randomization date.
- b Subject No. 39032008 was described as Stage IV at initial diagnosis and stage IIB at study entry with metastasis (liver, lymph node).

Source: Module 5.3.5.3 SCE J202 Tables 14.1.2.1\\_1, 14.1.3.1\\_1, and 14.1.3.3, Module 5.3.5.2 DS8201-A-U205 CSR.

Amendment Tables 14.1.2.1, 14.1.3.1, 14.2.6.1, Listing 16.2.4.2, Module 5.3.5.2 U205 Ad Hoc Table 14 DCO 08 Nov 2021

Table 3 summarizes the number (%) of subjects with the most common (reported in ≥10% of subjects) ongoing PMHs, with both ongoing PMHs and TEAEs, and with TEAEs in the HER2-positive GC Pool.

Table 3: Most Common (Reported in ≥ 10% of Subjects) Ongoing Past Medical Histories and Treatment-emergent Adverse Events (Safety Analysis Set)

| MedDRA PT (PMH)                  | HER2-positive GC T-DXd 6.4 mg/kg Pool (N = 229)   | HER2-positive GC T-DXd 6.4 mg/kg Pool (N = 229)   | HER2-positive GC T-DXd 6.4 mg/kg Pool (N = 229)   |
|----------------------------------|---------------------------------------------------|---------------------------------------------------|---------------------------------------------------|
|                                  | Subjects with Ongoing PMH at Baseline a n (%)     | Subjects with Both TEAE and Ongoing PMH a n (%)   | Subjects with TEAEs a n (%)                       |
| Hypertension                     | 88 (38.4)                                         | 2 (2.3)                                           | 4 (1.7)                                           |
| Anaemia                          | 77 (33.6)                                         | 50 (64.9)                                         | 112 (48.9)                                        |
| Peripheral sensory neuropathy    | 63 (27.5)                                         | 0                                                 | 5 (2.2)                                           |
| Constipation                     | 53 (23.1)                                         | 7 (13.2)                                          | 59 (25.8)                                         |
| Insomnia                         | 34 (14.8)                                         | 1 (2.9)                                           | 18 (7.9)                                          |
| Cataract                         | 33 (14.4)                                         | 3 (9.1)                                           | 4 (1.7)                                           |
| Decreased appetite               | 29 (12.7)                                         | 17 (58.6)                                         | 124 (54.1)                                        |
| Gastrooesophageal reflux disease | 27 (11.8)                                         | 2 (7.4)                                           | 10 (4.4)                                          |

<div style=\"page-break-after: always\"></div>

| MedDRA PT (PMH)       | HER2-positive GC T-DXd 6.4 mg/kg Pool (N = 229)   | HER2-positive GC T-DXd 6.4 mg/kg Pool (N = 229)   | HER2-positive GC T-DXd 6.4 mg/kg Pool (N = 229)   |
|-----------------------|---------------------------------------------------|---------------------------------------------------|---------------------------------------------------|
|                       | Subjects with Ongoing PMH at Baseline a n (%)     | Subjects with Both TEAE and Ongoing PMH a n (%)   | Subjects with TEAEs a n (%)                       |
| Abdominal pain        | 26 (11.4)                                         | 8 (30.8)                                          | 27 (11.8)                                         |
| Fatigue               | 24 (10.5)                                         | 11 (45.8)                                         | 62 (27.1)                                         |
| Back pain             | 24 (10.5)                                         | 1 (4.2)                                           | 19 (8.3)                                          |
| Nausea                | 23 (10.0)                                         | 13 (56.5)                                         | 150 (65.5)                                        |
| Neuropathy peripheral | 23 (10.0)                                         | 0                                                 | 2 (0.9)                                           |

CRF = case report form; GC = gastric cancer/gastric or gastroesophageal junction adenocarcinoma; HER2 = human epidermal growth factor receptor 2; MedDRA = Medical Dictionary for Regulatory Activities; n = number of subject with event; N = total subjects; PMH = past medical history; PT = preferred term; SCS = Summary of Clinical Safety; T-DXd = trastuzumab deruxtecan;

TEAE = treatment-emergent adverse event

The HER2-positive GC 6.4 mg/kg Pool includes data from Studies DS8201-A-J101, DS8201-A-J202, and DS8201-A-U205.

Medical history information was taken from the Medical History CRF page, and 'Ongoing' was based on the CRF checkbox.

a   Percentage of subjects with ongoing PMH at Baseline was calculated with subjects in the safety analysis set as denominator.

b   Baseline PMH symptoms were reported as TEAEs if they worsened after the first T-DXd dose.  Percentage of subjects with both (drug-related) TEAE and ongoing PMH was calculated with subjects having that particular PMH PT as denominator.

c Percentage of subjects with TEAEs was calculated with subjects in the safety analysis set as denominator.

Source: Module 5.3.5.3 SCS Table 1.2.1.3; Appendix 1 Table 1

Table 1.7: Summary of Prior Systemic Anticancer Therapy (Safety Analysis Set)

| Parameter                | Study J202 HER2-positive GC (Primary Cohort)   | Study J202 HER2-positive GC (Primary Cohort)   | Study U205 HER2-positive GC T-DXd 6.4 mg/kg (N =79)   | HER2-positive GC T-DXd 6.4 mg/kg Pool (N =229)   |
|--------------------------|------------------------------------------------|------------------------------------------------|-------------------------------------------------------|--------------------------------------------------|
|                          | PXI-L 6.4 mg/kg (N = 125)                      | TPC (N =62)                                    | Study U205 HER2-positive GC T-DXd 6.4 mg/kg (N =79)   | HER2-positive GC T-DXd 6.4 mg/kg Pool (N =229)   |
| Number of Regimens       | Number of Regimens                             | Number of Regimens                             | Number of Regimens                                    | Number of Regimens                               |
| Mean (Std Dev)           | 2.9 (1.15)                                     | 2.6 (0.78)                                     | 1.0 (0.19)                                            | 2.4 (1.40)                                       |
| Median                   | 3.0                                            | 2.0                                            | 1.0                                                   | 2.0                                              |
| Range                    | 2,9                                            | 2,5                                            | 1,2                                                   | 1, 9                                             |
| Number of Regimens,n (%) | Number of Regimens,n (%)                       | Number of Regimens,n (%)                       | Number of Regimens,n (%)                              | Number of Regimens,n (%)                         |
| 1                        | 0                                              | 0                                              | 76 (96.2)                                             | 77 (33.6)                                        |

<div style=\"page-break-after: always\"></div>

| 2                                                                                                              | 58 (46.4)                                                                                                      | 34 (54.8)                                                                                                      | 3 (3.8) b                                                                                                      | 67 (29.3)                                                                                                      |
|----------------------------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------------------------|
| 3                                                                                                              | 37 (29.6)                                                                                                      | 21 (33.9)                                                                                                      | 0                                                                                                              | 40 (17.5)                                                                                                      |
| 4                                                                                                              | 21 (16.8)                                                                                                      | 5 (8.1)                                                                                                        | 0                                                                                                              | 27 (11.8)                                                                                                      |
| ≥5                                                                                                             | 9 (7.2)                                                                                                        | 2 (3.2)                                                                                                        | 0                                                                                                              | 18 (7.9)                                                                                                       |
| Regimen Intent, n (%) a                                                                                        |                                                                                                                |                                                                                                                |                                                                                                                |                                                                                                                |
| Neo-Adjuvant                                                                                                   | 5 (4.0)                                                                                                        | 1 (1.6)                                                                                                        | 8 (10.1)                                                                                                       | 17 (7.4)                                                                                                       |
| Adjuvant                                                                                                       | 26 (20.8)                                                                                                      | 10 (16.1)                                                                                                      | 3 (3.8)                                                                                                        | 38 (16.6)                                                                                                      |
| Locally Advanced                                                                                               | 0                                                                                                              | 0                                                                                                              | 7 (8.9)                                                                                                        | 7 (3.1)                                                                                                        |
| Metastatic                                                                                                     | 0                                                                                                              | 0                                                                                                              | 68 (86.1)                                                                                                      | 68 (29.7)                                                                                                      |
| Locally Advanced/Metastatic                                                                                    | 125 (100)                                                                                                      | 62 (100)                                                                                                       | 0                                                                                                              | 149 (65.1)                                                                                                     |
| Maintenance                                                                                                    | 0                                                                                                              | 0                                                                                                              | 10 (12.7)                                                                                                      | 10 (4.4)                                                                                                       |
| Preventive                                                                                                     | 0                                                                                                              | 0                                                                                                              | 0                                                                                                              | 0                                                                                                              |
| Other                                                                                                          | 2 (1.6)                                                                                                        | 0                                                                                                              | 3 (3.8)                                                                                                        | 6 (2.6)                                                                                                        |
| Any Prior Anticancer Therapy Reported in At Least 20% of subjects in HER2-positive GC 6.4 mg/kg Pool, n (%) cd | Any Prior Anticancer Therapy Reported in At Least 20% of subjects in HER2-positive GC 6.4 mg/kg Pool, n (%) cd | Any Prior Anticancer Therapy Reported in At Least 20% of subjects in HER2-positive GC 6.4 mg/kg Pool, n (%) cd | Any Prior Anticancer Therapy Reported in At Least 20% of subjects in HER2-positive GC 6.4 mg/kg Pool, n (%) cd | Any Prior Anticancer Therapy Reported in At Least 20% of subjects in HER2-positive GC 6.4 mg/kg Pool, n (%) cd |
| Trastuzumab                                                                                                    | 125 (100)                                                                                                      | 62 (100)                                                                                                       | 79 (100)                                                                                                       | 229 (100)                                                                                                      |
| Capecitabine                                                                                                   | 93 (74.4)                                                                                                      | 41 (66.1)                                                                                                      | 34 (43.0)                                                                                                      | 147 (64.2)                                                                                                     |
| Cisplatin                                                                                                      | 79 (63.2)                                                                                                      | 37 (59.7)                                                                                                      | 36 (45.6)                                                                                                      | 135 (59.0)                                                                                                     |
| Ramucirumab                                                                                                    | 94 (75.2)                                                                                                      | 41 (66.1)                                                                                                      | 0                                                                                                              | 111 (48.5)                                                                                                     |
| Oxaliplatin                                                                                                    | 61 (48.8)                                                                                                      | 27 (43.5)                                                                                                      | 38 (48.1)                                                                                                      | 109 (47.6)                                                                                                     |
| Paclitaxel                                                                                                     | 86 (68.8)                                                                                                      | 46 (74.2)                                                                                                      | 2 (2.5)                                                                                                        | 108 (47.2)                                                                                                     |
| Gimeracil W/Oteracil Potassium/Tegafur                                                                         | 61 (48.8)                                                                                                      | 29 (46.8)                                                                                                      | 0                                                                                                              | 61 (26.6)                                                                                                      |
| Fluorouracil                                                                                                   | 8 (6.4)                                                                                                        | 6 (9.7)                                                                                                        | 44 (55.7)                                                                                                      | 52 (22.7)                                                                                                      |

U205.

Percentages were calculated using the number of subjects in the Safety Analysis Set as the denominator. If a subiect received more than 1 regimen. that subiect was counted in each relevant category.

a Study J101/J202 collected locally advanced and metastatic regimen intent as a combined parameter, whereas Study U205 collected locally advanced and metastatic regimen separately.

If a subject received more than 1 therapy within the same regimen, that subject was counted for each relevant therapy.

b Among the 3 subjects receiving 2 regimens, received trastuzumab intended for neoadjuvant and a secondregimen intended for metastatic. and both received only 1 trastuzumabcontaining regimen.

- d Agents are sorted in descending frequency based on the HER2-positive GC T-DXd 6.4 mg/kg Pool.

Source: Module 5.3.5.3 SCS Table 1.1.4

<div style=\"page-break-after: always\"></div>

## 2.5.2. Patient exposure

Table 1.3: Summary of Exposure (Safety Analysis Set)

| Parameter                                       | StudyJ202 HER2-positiveGC (Primary Cohort)      | StudyJ202 HER2-positiveGC (Primary Cohort)      | StudyJ202 HER2-positiveGC (Primary Cohort)      | StudyJ202 HER2-positiveGC (Primary Cohort)      | Study U205                                      | HER2-positive GC T-DXd 6.4 mg/kg                |
|-------------------------------------------------|-------------------------------------------------|-------------------------------------------------|-------------------------------------------------|-------------------------------------------------|-------------------------------------------------|-------------------------------------------------|
| Parameter                                       | PXI-L 6.4 mg/kg (N =125)                        | Irinotecan (N=55)                               | Paclitaxel (N=7)                                | TPC (N=62)                                      | HER2-positive GC T-DXd 6.4 mg/kg (N=79)         | Pool (N =229)                                   |
| Treatment Duration(months)a                     | Treatment Duration(months)a                     | Treatment Duration(months)a                     | Treatment Duration(months)a                     | Treatment Duration(months)a                     | Treatment Duration(months)a                     | Treatment Duration(months)a                     |
| Mean (Std Dev)                                  | 6.71 (5.717)                                    | 2.97 (1.985)                                    | 4.83 (4.289)                                    | 3.18 (2.377)                                    | 5.06 (3.536)                                    | 6.03 (4.953)                                    |
| Median                                          | 4.60                                            | 2.76                                            | 4.60                                            | 2.76                                            | 4.34                                            | 4.60                                            |
| Range                                           | 0.7, 29.7                                       | 0.5, 11.3                                       | 0.9, 13.1                                       | 0.5, 13.1                                       | 0.7, 15.9                                       | 0.7,29.7                                        |
| Treatment Duration (months Categories) *, n (%) | Treatment Duration (months Categories) *, n (%) | Treatment Duration (months Categories) *, n (%) | Treatment Duration (months Categories) *, n (%) | Treatment Duration (months Categories) *, n (%) | Treatment Duration (months Categories) *, n (%) | Treatment Duration (months Categories) *, n (%) |
| 00                                              | 40 (32.0)                                       | 37 (67.3)                                       | 3 (42.9)                                        | 40 (64.5)                                       | 30 (38.0)                                       | 81 (35.4)                                       |
| >3 to ≤6                                        | 35 (28.0)                                       | 14 (25.5)                                       | 2 (28.6)                                        | 16 (25.8)                                       | 25 (31.6)                                       | 64 (27.9)                                       |
| >6 to ≤9                                        | 20 (16.0)                                       | 3 (5.5)                                         | 1 (14.3)                                        | 4 (6.5)                                         | 14 (17.7)                                       | 39 (17.0)                                       |
| >9 to ≤12                                       | 9 (7.2)                                         | 1 (1.8)                                         | 0                                               | 1 (1.6)                                         | 5 (6.3)                                         | 16 (7.0)                                        |
| >12 to ≤18                                      | 15 (12.0)                                       | 0                                               | 1 (14.3)                                        | 1 (1.6)                                         | 5 (6.3)                                         | 23 (10.0)                                       |
| >18 to ≤24                                      | 3 (2.4)                                         | 0                                               | 0                                               | 0                                               | 0                                               | 3 (1.3)                                         |
| >24                                             | 3 (2.4)                                         | 0                                               | 0                                               | 0                                               | 0                                               | 3 (1.3)                                         |
| Patient-years of exposure b                     | 69.9                                            | 13.6                                            | 2.8                                             | 16.5                                            | 33.3                                            | 115.1                                           |
| Cumulative Dose Level °                         | Cumulative Dose Level °                         | Cumulative Dose Level °                         | Cumulative Dose Level °                         | Cumulative Dose Level °                         | Cumulative Dose Level °                         | Cumulative Dose Level °                         |
| Mean (Std Dev)                                  | 53.45 (43.927)                                  | 807.64 (591.483)                                | 1120.00 (1110.015)                              |                                                 | 43.08 (29.779)                                  | 48.88 (38.606)                                  |
| Median                                          | 39.98                                           | 630.00                                          | 1060.00                                         |                                                 | 38.20                                           | 38.65                                           |
| Range                                           | 6.4, 236.6                                      | 150,3600                                        | 80,3280                                         |                                                 | 6.4,138.8                                       | 6.4,236.6                                       |
| Number of Cycles d                              | Number of Cycles d                              | Number of Cycles d                              | Number of Cycles d                              | Number of Cycles d                              | Number of Cycles d                              | Number of Cycles d                              |
| Mean (Std Dev)                                  | 9.0 (7.71)                                      |                                                 |                                                 |                                                 | 6.9 (4.79)                                      | 8.1 (6.65)                                      |
| Median                                          | 6.0                                             |                                                 |                                                 |                                                 | 6.0                                             | 6.0                                             |
| Range                                           | 1,41                                            |                                                 |                                                 |                                                 | 1,22                                            | 1,41                                            |
| Dose Intensity                                  | Dose Intensity                                  | Dose Intensity                                  | Dose Intensity                                  | Dose Intensity                                  | Dose Intensity                                  | Dose Intensity                                  |
| Mean (Std Dev)                                  | 5.74 (0.742)                                    | 126.86 (20.358)                                 | 188.44 (52.912)                                 |                                                 | 5.99 (0.583)                                    | 5.81 (0.724)                                    |
| Median                                          | 5.91                                            | 126.00                                          | 196.49                                          |                                                 | 6.19                                            | 6.00                                            |
| Range                                           | 3.7, 6.8                                        | 79.8, 161.5                                     | 80, 230.6                                       |                                                 | 3.9, 6.7                                        | 3.2, 6.8                                        |
| Relative Dose Intensity f (%)                   | Relative Dose Intensity f (%)                   | Relative Dose Intensity f (%)                   | Relative Dose Intensity f (%)                   | Relative Dose Intensity f (%)                   | Relative Dose Intensity f (%)                   | Relative Dose Intensity f (%)                   |
| Mean (Std Dev)                                  | 89.67 (11.596)                                  | 84.58 (13.572)                                  | 78.52 (22.047)                                  | 83.89 (14.650)                                  | 93.52 (9.109)                                   | 90.75 (11.311)                                  |
| Median                                          | 92.39                                           | 84.00                                           | 81.87                                           | 83.67                                           | 96.78                                           | 93.78                                           |
| Range                                           | 58.2,106.5                                      | 53.2,107.7                                      | 33.3, 96.1                                      | 33.3,107.7                                      | 60.3,104.1                                      | 50.4,106.5                                      |
| Relative Dose Intensity Categories f, n (%)     | Relative Dose Intensity Categories f, n (%)     | Relative Dose Intensity Categories f, n (%)     | Relative Dose Intensity Categories f, n (%)     | Relative Dose Intensity Categories f, n (%)     | Relative Dose Intensity Categories f, n (%)     | Relative Dose Intensity Categories f, n (%)     |
| ≥90%                                            | 67 (53.6)                                       | 22 (40.0)                                       | 3 (42.9)                                        | 25 (40.3)                                       | 56 (70.9)                                       | 136 (59.4)                                      |
| <90% to ≥80%                                    | 36 (28.8)                                       | 12 (21.8)                                       | 1 (14.3)                                        | 13 (21.0)                                       | 15 (19.0)                                       | 56 (24.5)                                       |
| <80% to ≥60%                                    | 21 (16.8)                                       | 19 (34.5)                                       | 2 (28.6)                                        | 21 (33.9)                                       | 8 (10.1)                                        | 35 (15.3)                                       |
| <60%                                            | 1 (0.8)                                         | 2 (3.6)                                         | 1 (14.3)                                        | 3 (4.8)                                         | 0                                               | 2 (0.9)                                         |

GC=gastric/gastroesophageal junction cancer;HER2 =human epidermal growthfactor receptor 2; N=total number of treated subjects; n=number of subjects; Std Dey=standard deviation;T-DXd=trastuzumab deruxtecan;TPC=treatment ofphysician's choice(includes subjects who received irinotecan[n=55]or paclitaxel [n = 7])

<div style=\"page-break-after: always\"></div>

Percentages were calculated using the number of subjects in theSafetyAnalysisSet as the denominator.

- aTreatment duration(months):
- 1 month = 365.25/12 = 30.44 days.

T-DXd=(date ofthelast dose-date ofthe firstdose+21)/30.44

Irinotecan=(date ofthelast dose-date ofthe first dose+14)/30.44

Paclitaxel =(date of last dose - date of first dose + 28[ifthe last dose is the first dose in a cycle], or + 21 [if the last dose is the second dose in a cycle], or + 14 [ifthe last dose is the third dose in a cycle])/ 30.44.

- b Total patient-years of exposure = sum of duration oftreatment (months) / 12.
- c Cumulative dose level = sum (the actual dose level received) (mg/kg for T-DXd and mg/m2 for irinotecan and paclitaxel).
- d Irinotecan monotherapy was administered as an intravenous infusion biweekly. The subjects were given this treatment followed by a rest period of at least 3weeks as necessary.Paclitaxel monotherapywas administered as an intravenous infusion weekly.The subjects were given this treatment for 3 consecutive weeks,followedbyarestperiodofatleast2weeksasnecessary.Therefore,there arenodataonnumber ofcyclesforirinotecan,paclitaxel,andTPC.
- Dose Intensity:

T-DXd(mg/kg/3weeks)=total amount of dosestaken/(days oftreatment/ 21)

Irinotecan(mg/m2/2weeks)=total amount of doses taken/(days of treatment/14)

- f Relative Dose Intensity (%):

Paclitaxel(mg/m2/4weeks)=total amount of doses taken/(days of treatment/28).

T-DXd=dose intensity/assigned doselevel (mg/kg/3 weeks)

Irinotecan=dose intensity/150(mg/m²/2weeks)

Paclitaxel =dose intensity/ 240 (mg/m²/ 4 weeks).

Source:Module5.3.5.3SCSTable1.1.3

The numbers missing in table 1.3 above are presented in table 2 below.

Table 2: NumberofDrug Doses-Study J202HER2-positive GC,Primary Cohort(Safety Analysis Set)

|                | Irinotecan (N = 55)   | PTX (N = 7)   | TPC (N = 62)   |
|----------------|-----------------------|---------------|----------------|
|                | 55                    | 7             | 62             |
| Mean (Std Dev) | 6.0 (4.22)            | 14.6 (13.88)  | 7.0 (6.50)     |
| Median         | 5.0                   | 14.0          | 5.0            |
| Range          | 1, 24                 | 1, 41         | 1, 41          |

CSR = clinical study report; DCO = data cut-off; GC = gastric cancer/gastric or gastroesophageal junction adenocarcinoma; HER2 = human epidermal growth factor receptor 2; N = total number of treated subjects: n = number of subjects; PTX = paclitaxel; Std Dev = standard deviation; TPC = treatment of physician's choice (includes subjects who received irinotecan [n = 55] or PTX [n = 7])

Source: Module 5.3.5.1 DS8201-A-J202 Abbreviated CSR Table 14.1.5.1 for 03 Jun 2020 DCO

The median treatment duration across all subgroups for the HER2-postive GC Pool ranged between 3.89 and 5.63 months, with elderly, male subjects, subjects with moderate renal impairment, and European population having a relatively longer median duration.

<div style=\"page-break-after: always\"></div>

Table 1.4: Summary of Subject Disposition (Safety Analysis Set)

| Parameter                                                  | Study J202 HER2- positive GC (Primary Cohort)   | Study J202 HER2- positive GC (Primary Cohort)   | Study U205 HER2- positive GC T-DXd 6.4 mg/kg   | HER2- Positive GC T-DXd 6.4 mg/kg Pool   |
|------------------------------------------------------------|-------------------------------------------------|-------------------------------------------------|------------------------------------------------|------------------------------------------|
|                                                            | PXI-L 6.4 mg/kg (N =125)                        | TPC (N =62)                                     | (N = 79)                                       | (N= 229)                                 |
| Subjects who were Ongoing Study Drug at DCO, n (%)         | 10 (8.0)                                        | 0                                               | 23 (29.1)                                      | 33 (14.4)                                |
| Subjects who Discontinued Study Drug for Any Reason, n (%) | 115 (92.0)                                      | 62 (100)                                        | 56 (70.9)                                      | 196 (85.6)                               |
| Progressive Disease a                                      | 82 (65.6)                                       | 50 (80.6)                                       | 39 (49.4)                                      | 140 (61.1)                               |
| Adverse Event                                              | 22 (17.6)                                       | 4 (6.5)                                         | 9 (11.4)                                       | 37 (16.2)                                |
| Clinical Progression b                                     | 6 (4.8)                                         | 5 (8.1)                                         | 2 (2.5)                                        | 8 (3.5)                                  |
| Death                                                      | 2 (1.6)                                         | 0                                               | 2 (2.5)                                        | 4 (1.7)                                  |
| Withdrawal by Subject                                      | 2 (1.6)                                         | 3 (4.8)                                         | 2 (2.5)                                        | 4 (1.7)                                  |
| Physician Decision                                         | 1 (0.8)                                         | 0                                               | 1 (1.3)                                        | 2 (0.9)                                  |
| Other *                                                    | 0                                               | 0                                               | 1 (1.3)                                        | 1 (0.4)                                  |

Evaluation Criteria in Solid Tumors Version 1.1; T-DXd =trastuzumab deruxtecan; TPC = treatment of physician's choice (includes subjects who received irinotecan [n=55] or paclitaxel [n =7])

HER2-p0sitive GC 6.4 mg/kg Pool includes data from studies: DS8201-A-J101, DS8201-A-J202,and DS8201-AU205.

Percentages were calculated using the number of subjects in the Safety Analysis Set as the denominator.

- Based on RECIST v1.1

b Per investigator assessment

Other reason was reported for a subject in Study U205 and was *drug hold too long. (see Module 5.3.5.2 DS8201-A-205 CSR U205Listing 16.2.7.3)

Source:Module 5.3.5.3SCS Table1.1.1

## 2.5.3. Adverse events

In the HER2-positive GC Pool, all subjects (100%) had at least 1 TEAE , 167/229 (72.9%) subjects had a worst TEAE of ≥Grade 3 , 92/229 (40.2%) subjects had an SAE , and 19/229 (8.3%) subjects had a TEAE associated with an outcome of death . For 2/229 (0.9%) subjects this TEAE was considered drugrelated; see Section 2.1.6.2 (Table 2.2).

<div style=\"page-break-after: always\"></div>

Table 2.2: Overview of Treatment-Emergent Adverse Events (Safety Analysis Set)

| Parameter                                                     | Number (%) of Subjects                       | Number (%) of Subjects                       | Number (%) of Subjects                     | Number (%) of Subjects                 |
|---------------------------------------------------------------|----------------------------------------------|----------------------------------------------|--------------------------------------------|----------------------------------------|
|                                                               | Study J202 HER2-positive GC (Primary Cohort) | Study J202 HER2-positive GC (Primary Cohort) | Study U205 HER2- positive 6.4 mg/kg (N=79) | HER2- positive GC T-DXd 6.4 mg/kg Pool |
|                                                               | PXI-L 6.4 mg/kg (N =125)                     | TPC (N = 62)                                 | GC T-DXd                                   | (N = 229)                              |
| Subjects with any TEAE                                        | 125 (100)                                    | 61 (98.4)                                    | 79 (100)                                   | 229 (100)                              |
| TEAEs with worst CTCAE ≥Grade 3 *                             | 107 (85.6)                                   | 35 (56.5)                                    | 40 (50.6)                                  | 167 (72.9)                             |
| Serious TEAEs                                                 | 56 (44.8)                                    | 16 (25.8)                                    | 29 (36.7)                                  | 92 (40.2)                              |
| TEAEs associated with study drug discontinuation              | 22 (17.6)                                    | 4 (6.5)                                      | 12 (15.2)                                  | 38 (16.6)                              |
| TEAEs associated with dose reduction                          | 40 (32.0)                                    | 21 (33.9)                                    | 19 (24.1)                                  | 68 (29.7)                              |
| TEAEs associated with study drug interruption                 | 79 (63.2)                                    | 23 (37.1)                                    | 17 (21.5)                                  | 109 (47.6)                             |
| TEAEs associated with an outcome of death b                   | 8 (6.4)                                      | 2 (3.2)                                      | 10 (12.7)                                  | 19 (8.3)                               |
| Subjects with any drug-related TEAE c                         | 122 (97.6)                                   | 56 (90.3)                                    | 74 (93.7)                                  | 221 (96.5)                             |
| Drug-related TEAEs with worst CTCAE ≥Grade 3 a                | 94 (75.2)                                    | 27 (43.5)                                    | 21 (26.6)                                  | 131 (57.2)                             |
| Drug-related serious TEAEs                                    | 30 (24.0)                                    | 5 (8.1)                                      | 8 (10.1)                                   | 41 (17.9)                              |
| Drug-related TEAEs associated with study drug discontinuation | 14 (11.2)                                    | 3 (4.8)                                      | 7 (8.9)                                    | 24 (10.5)                              |
| Drug-related TEAEs associated with dose reduction             | 38 (30.4)                                    | 21 (33.9)                                    | 15 (19.0)                                  | 62 (27.1)                              |
| Drug-related TEAEs associated with study drug interruption    | 65 (52.0)                                    | 19 (30.6)                                    | 7 (8.9)                                    | 83 (36.2)                              |
| Drug-related TEAEs associated with an outcome of death b      | 1 (0.8)                                      | 0                                            | 1 (1.3)                                    | 2 (0.9)                                |

HER2-positive GC 6.4 mg/kg Pool includes data from studies: DS8201-A-J101, DS8201-A-J202, and DS8201-AU205.

CTCAE = Common Terminology Criteria for Adverse Events; GC = gastric/gastroesophageal junction cancer; HER2 = human epidermal growth factor receptor 2; N = total number of treated subjects; T-DXd = trastuzumab deruxtecan; TEAE = treatment-emergent adverse event; TPC = treatment of physician's choice (includes subjects who received irinotecan [n = 55] or paclitaxel [n = 7])

Percentages were calculated using the number of subjects in the Safety Analysis Set as the denominator.

b For specific TEAEs associated with outcome of death, refer to Table 2.8.

a A subject was counted once at the maximum severity.

If relationship was missing, the TEAE was considered to be related to the drug.

Source: Module 5.3.5.3 SCS Table 1.2.1.1.1

<div style=\"page-break-after: always\"></div>

Table 2.3: Treatment-Emergent AdverseEvents Reported in at Least 10% of Subjects in the HER2-positive GC T-DXd 6.4 mg/kg Pool, by Preferred Term/Grouped Term (Safety Analysis Set)

| MedDRAPreferredTerm/ Grouped Term a   | Number (%) of Subjects                     | Number (%) of Subjects                     | Number (%) of Subjects                               | Number (%) of Subjects                          |
|---------------------------------------|--------------------------------------------|--------------------------------------------|------------------------------------------------------|-------------------------------------------------|
| MedDRAPreferredTerm/ Grouped Term a   | StudyJ202HER2-p0sitive GC (Primary Cohort) | StudyJ202HER2-p0sitive GC (Primary Cohort) | Study U205 HER2-positive GC T-DXd 6.4 mg/kg (N = 79) | HER2-positive GC T-DXd 6.4 mg/kg Pool (N = 229) |
| MedDRAPreferredTerm/ Grouped Term a   | T-DXd 6.4 mg/kg (N = 125)                  | TPC (N = 62)                               | Study U205 HER2-positive GC T-DXd 6.4 mg/kg (N = 79) | HER2-positive GC T-DXd 6.4 mg/kg Pool (N = 229) |
| Subjects with any TEAE                | 125 (100)                                  | 61 (98.4)                                  | 79 (100)                                             | 229 (100)                                       |
| Nausea                                | 79 (63.2)                                  | 29 (46.8)                                  | 52 (65.8)                                            | 150 (65.5)                                      |
| Decreased appetite                    | 76 (60.8)                                  | 28 (45.2)                                  | 26 (32.9)                                            | 124 (54.1)                                      |
| Fatigue a                             | 69 (55.2)                                  | 27 (43.5)                                  | 44 (55.7)                                            | 121 (52.8)                                      |
| Anaemia a                             | 72 (57.6)                                  | 19 (30.6)                                  | 27 (34.2)                                            | 113 (49.3)                                      |
| Neutropenia a                         | 81 (64.8)                                  | 22 (35.5)                                  | 20 (25.3)                                            | 113 (49.3)                                      |
| Thrombocytopenia a                    | 50 (40.0)                                  | 4 (6.5)                                    | 16 (20.3)                                            | 78 (34.1)                                       |
| Vomiting                              | 33 (26.4)                                  | 5 (8.1)                                    | 33 (41.8)                                            | 74 (32.3)                                       |
| Diarrhoea                             | 41 (32.8)                                  | 20 (32.3)                                  | 27 (34.2)                                            | 73 (31.9)                                       |
| Leukopenia a                          | 48 (38.4)                                  | 22 (35.5)                                  | 7 (8.9)                                              | 66 (28.8)                                       |
| Constipation                          | 31 (24.8)                                  | 15 (24.2)                                  | 21 (26.6)                                            | 59 (25.8)                                       |
| Alopecia                              | 28 (22.4)                                  | 9 (14.5)                                   | 19 (24.1)                                            | 51 (22.3)                                       |
| Pyrexia                               | 31 (24.8)                                  | 10 (16.1)                                  | 8 (10.1)                                             | 47 (20.5)                                       |
| Weight decreased                      | 19 (15.2)                                  | 5 (8.1)                                    | 27 (34.2)                                            | 46 (20.1)                                       |
| Lymphopenia a                         | 29 (23.2)                                  | 2 (3.2)                                    | 4 (5.1)                                              | 37 (16.2)                                       |
| Abdominal pain a                      | 19 (15.2)                                  | 9 (14.5)                                   | 16 (20.3)                                            | 35 (15.3)                                       |
| Hypoalbuminaemia                      | 18 (14.4)                                  | 8 (12.9)                                   | 6 (7.6)                                              | 28 (12.2)                                       |
| Hypokalaemia                          | 10 (8.0)                                   | 4 (6.5)                                    | 12 (15.2)                                            | 25 (10.9)                                       |
| Interstitial lung disease b           | 16 (12.8)                                  | 0                                          | 6 (7.6)                                              | 25 (10.9)                                       |
| Aspartateaminotransferase increased   | 12 (9.6)                                   | 3 (4.8)                                    | 9 (11.4)                                             | 24 (10.5)                                       |

ILD = interstitial lung disease; MedDRA = Medical Dictionary for Regulatory Activities, Version 23.0; N = total number of treated subjects; PT = preferred term; SMQ = Standardised MedDRA Query; T-DXd = trastuzumab deruxtecan; TEAE = treatment-emergent adverse event; TPC = treatment of physician's choice (includes subjects who received irinotecan [n = 55] or paclitaxel [n = 7])

HER2-positive GC 6.4 mg/kg Pool includes data from studies: DS8201-A-J101, DS8201-A-J202, and DS8201-AU205.

PT/grouped terms are presented in descending order of frequency in the HER2-positive GC T-DXd 6.4 mg/kg Pool.

If a subject had multiple occurrences of the same PT/grouped term, the subject was counted once for that PT/grouped term.

Percentages were calculated using the number of subjects in the Safety Analysis Set as the denominator.

b Interstitial lung disease includes events that were adjudicated as ILD and considered study drug related by adjudicationcommittee.

a The PTs that were included in each grouped term are listed in Table 2.1.

Source:Module 5.3.5.3SCS Tables 1.2.1.3,1.2.2.1,and1.2.4.1

<div style=\"page-break-after: always\"></div>

Table 2.4: Drug-Related Treatment-Emergent Adverse Events Reported in at Least 5%o of Subjects in the HER2-positive GC T-DXd 6.4 mg/kg Pool, by Preferred Term/Grouped Term (Safety Analysis Set)

| MedDRAPreferred Term/ Grouped Term \"   | Number (%) of Subjects                       | Number (%) of Subjects                       | Number (%) of Subjects                               | Number (%) of Subjects                         |
|----------------------------------------|----------------------------------------------|----------------------------------------------|------------------------------------------------------|------------------------------------------------|
| MedDRAPreferred Term/ Grouped Term \"   | Study J202 HER2-p0sitive GC (Primary Cohort) | Study J202 HER2-p0sitive GC (Primary Cohort) | Study U205 HER2-positive GC T-DXd 6.4 mg/kg (N = 79) | HER2-Positive GC T-DXd 6.4 mg/kg Pool (N= 229) |
| MedDRAPreferred Term/ Grouped Term \"   | T-DXd 6.4 mg/kg (N =125)                     | TPC (N =62)                                  | Study U205 HER2-positive GC T-DXd 6.4 mg/kg (N = 79) | HER2-Positive GC T-DXd 6.4 mg/kg Pool (N= 229) |
| Subjects with any drug-related TEAE    | 122 (97.6)                                   | 56 (90.3)                                    | 74 (93.7)                                            | 221 (96.5)                                     |
| Nausea                                 | 72 (57.6)                                    | 25 (40.3)                                    | 46 (58.2)                                            | 137 (59.8)                                     |
| Neutropenia *                          | 80 (64.0)                                    | 22 (35.5)                                    | 20 (25.3)                                            | 112 (48.9)                                     |
| Fatigue a                              | 66 (52.8)                                    | 24 (38.7)                                    | 37 (46.8)                                            | 111 (48.5)                                     |
| Decreased appetite                     | 66 (52.8)                                    | 25 (40.3)                                    | 18 (22.8)                                            | 106 (46.3)                                     |
| Anaemia *                              | 51 (40.8)                                    | 13 (21.0)                                    | 15 (19.0)                                            | 78 (34.1)                                      |
| Thrombocytopenia                       | 49 (39.2)                                    | 4 (6.5)                                      | 15 (19.0)                                            | 76 (33.2)                                      |
| Leukopenia *                           | 48 (38.4)                                    | 22 (35.5)                                    | 7 (8.9)                                              | 66 (28.8)                                      |
| Vomiting                               | 26 (20.8)                                    | 4 (6.5)                                      | 26 (32.9)                                            | 59 (25.8)                                      |
| Diarrhoea                              | 32 (25.6)                                    | 18 (29.0)                                    | 22 (27.8)                                            | 58 (25.3)                                      |
| Alopecia                               | 28 (22.4)                                    | 9 (14.5)                                     | 17 (21.5)                                            | 49 (21.4)                                      |
| Lymphopenia a                          | 29 (23.2)                                    | 1 (1.6)                                      | 4 (5.1)                                              | 37 (16.2)                                      |
| Constipation                           | 11 (8.8)                                     | 8 (12.9)                                     | 10 (12.7)                                            | 26 (11.4)                                      |
| Interstitial lung disease b            | 16 (12.8)                                    | 0                                            | 6 (7.6)                                              | 25 (10.9)                                      |
| Weight decreased                       | 16 (12.8)                                    | 4 (6.5)                                      | 8 (10.1)                                             | 24 (10.5)                                      |
| Pyrexia                                | 11 (8.8)                                     | 3 (4.8)                                      | 1 (1.3)                                              | 16 (7.0)                                       |
| Aspartate aminotransferase increased   | 6 (4.8)                                      | 0                                            | 5 (6.3)                                              | 14 (6.1)                                       |
| Dysgeusia                              | 8 (6.4)                                      | 4 (6.5)                                      | 3 (3.8)                                              | 14 (6.1)                                       |
| Stomatitis a                           | 10 (8.0)                                     | 3 (4.8)                                      | 1 (1.3)                                              | 14 (6.1)                                       |
| Hypoalbuminaemia                       | 5 (4.0)                                      | 1 (1.6)                                      | 3 (3.8)                                              | 12 (5.2)                                       |
| Hypokalaemia                           | 5 (4.0)                                      | 1 (1.6)                                      | 5 (6.3)                                              | 12 (5.2)                                       |

<div style=\"page-break-after: always\"></div>

Table 4: Treatment-emergent Adverse Events of at Least CTCAE Grade 3 Reported in at Least 2% of Subjects (in Any Column) by Preferred Term (Safety Analysis Set)

| MedDRA Preferred Term                | Number (%) of Subjects                       | Number (%) of Subjects                       | Number (%) of Subjects                                | Number (%) of Subjects                          |
|--------------------------------------|----------------------------------------------|----------------------------------------------|-------------------------------------------------------|-------------------------------------------------|
| MedDRA Preferred Term                | Study J202 HER2-positive GC (Primary Cohort) | Study J202 HER2-positive GC (Primary Cohort) | Study U205 HER2- positive GC T-DXd 6.4 mg/kg (N = 79) | HER2-positive GC T-DXd 6.4 mg/kg Pool (N = 229) |
| MedDRA Preferred Term                | T-DXd 6.4 mg/kg (N = 125)                    | TPC (N = 62)                                 | Study U205 HER2- positive GC T-DXd 6.4 mg/kg (N = 79) | HER2-positive GC T-DXd 6.4 mg/kg Pool (N = 229) |
| Subjects with any TEAE ≥Grade 3      | 107 (85.6)                                   | 35 (56.5)                                    | 42 (53.2)                                             | 169 (73.8)                                      |
| Neutrophil count decreased           | 62 (49.6)                                    | 14 (22.6)                                    | 6 (7.6)                                               | 77 (33.6)                                       |
| Anaemia                              | 48 (38.4)                                    | 14 (22.6)                                    | 11 (13.9)                                             | 68 (29.7)                                       |
| White blood cells count decreased    | 26 (20.8)                                    | 7 (11.3)                                     | 4 (5.1)                                               | 37 (16.2)                                       |
| Decreased appetite                   | 21 (16.8)                                    | 8 (12.9)                                     | 4 (5.1)                                               | 28 (12.2)                                       |
| Lymphocyte count decreased           | 15 (12.0)                                    | 1 (1.6)                                      | 2 (2.5)                                               | 21 (9.2)                                        |
| Platelet count decreased             | 14 (11.2)                                    | 2 (3.2)                                      | 2 (2.5)                                               | 21 (9.2)                                        |
| Nausea                               | 7 (5.6)                                      | 1 (1.6)                                      | 6 (7.6)                                               | 14 (6.1)                                        |
| Fatigue                              | 9 (7.2)                                      | 2 (3.2)                                      | 3 (3.8)                                               | 12 (5.2)                                        |
| Febrile neutropenia                  | 6 (4.8)                                      | 2 (3.2)                                      | 2 (2.5)                                               | 9 (3.9)                                         |
| Hypokalaemia                         | 5 (4.0)                                      | 4 (6.5)                                      | 1 (1.3)                                               | 9 (3.9)                                         |
| Pneumonia                            | 4 (3.2)                                      | 0                                            | 2 (2.5)                                               | 7 (3.1)                                         |
| Disease progression                  | 3 (2.4)                                      | 2 (3.2)                                      | 2 (2.5)                                               | 6 (2.6)                                         |
| Hyponatraemia                        | 3 (2.4)                                      | 3 (4.8)                                      | 0                                                     | 6 (2.6)                                         |
| Neutropenia                          | 2 (1.6)                                      | 1 (1.6)                                      | 4 (5.1)                                               | 6 (2.6)                                         |
| Ascites                              | 3 (2.4)                                      | 1 (1.6)                                      | 2 (2.5)                                               | 5 (2.2)                                         |
| Blood alkaline phosphatase increased | 4 (3.2)                                      | 0                                            | 1 (1.3)                                               | 5 (2.2)                                         |
| Aspartate aminotransferase increased | 3 (2.4)                                      | 0                                            | 1 (1.3)                                               | 4 (1.7)                                         |
| Diarrhoea                            | 3 (2.4)                                      | 1 (1.6)                                      | 1 (1.3)                                               | 4 (1.7)                                         |
| Hepatic function abnormal            | 4 (3.2)                                      | 1 (1.6)                                      | 0                                                     | 4 (1.7)                                         |
| Hypoalbuminaemia                     | 4 (3.2)                                      | 3 (4.8)                                      | 0                                                     | 4 (1.7)                                         |
| Jaundice cholestatic                 | 4 (3.2)                                      | 1 (1.6)                                      | 0                                                     | 4 (1.7)                                         |
| Tumour haemorrhage                   | 3 (2.4)                                      | 0                                            | 1 (1.3)                                               | 4 (1.7)                                         |
| Weight decreased                     | 1 (0.8)                                      | 1 (1.6)                                      | 3 (3.8)                                               | 4 (1.7)                                         |
| ILD a                                | 3 (2.4)                                      | 0                                            | 1 (1.3)                                               | 4 (1.7)                                         |

<div style=\"page-break-after: always\"></div>

| MedDRA Preferred Term          | Number (%) of Subjects                       | Number (%) of Subjects                       | Number (%) of Subjects                                | Number (%) of Subjects                          |
|--------------------------------|----------------------------------------------|----------------------------------------------|-------------------------------------------------------|-------------------------------------------------|
| MedDRA Preferred Term          | Study J202 HER2-positive GC (Primary Cohort) | Study J202 HER2-positive GC (Primary Cohort) | Study U205 HER2- positive GC T-DXd 6.4 mg/kg (N = 79) | HER2-positive GC T-DXd 6.4 mg/kg Pool (N = 229) |
| MedDRA Preferred Term          | T-DXd 6.4 mg/kg (N = 125)                    | TPC (N = 62)                                 | Study U205 HER2- positive GC T-DXd 6.4 mg/kg (N = 79) | HER2-positive GC T-DXd 6.4 mg/kg Pool (N = 229) |
| Abdominal pain                 | 1 (0.8)                                      | 2 (3.2)                                      | 2 (2.5)                                               | 3 (1.3)                                         |
| Acute kidney injury            | 1 (0.8)                                      | 0                                            | 2 (2.5)                                               | 3 (1.3)                                         |
| COVID-19                       | 0                                            | 0                                            | 3 (3.8)                                               | 3 (1.3)                                         |
| Dehydration                    | 3 (2.4)                                      | 1 (1.6)                                      | 0                                                     | 3 (1.3)                                         |
| Dysphagia                      | 0                                            | 0                                            | 3 (3.8)                                               | 3 (1.3)                                         |
| Embolism                       | 1 (0.8)                                      | 0                                            | 2 (2.5)                                               | 3 (1.3)                                         |
| Hypertension                   | 0                                            | 2 (3.2)                                      | 1 (1.3)                                               | 2 (0.9)                                         |
| Hypophosphataemia              | 0                                            | 1 (1.6)                                      | 2 (2.5)                                               | 2 (0.9)                                         |
| Malignant neoplasm progression | 0                                            | 0                                            | 2 (2.5)                                               | 2 (0.9)                                         |
| Pulmonary embolism             | 0                                            | 0                                            | 2 (2.5)                                               | 2 (0.9)                                         |
| Vomiting                       | 0                                            | 0                                            | 2 (2.5)                                               | 2 (0.9)                                         |

AC = adjudication committee; CTCAE = Common Terminology Criteria for Adverse Events;

COVID-19 = coronavirus disease 2019; GC = gastric cancer/gastric or gastroesophageal junction adenocarcinoma; HER2 = human epidermal growth factor receptor 2; ILD = interstitial lung disease; MedDRA = Medical Dictionary for Regulatory Activities, Version 24.0; PTX = paclitaxel; SCS = Summary of Clinical Safety;

T-DXd = trastuzumab deruxtecan; TEAE = treatment-emergent adverse event; TPC = treatment of physician's choice (includes subjects who received irinotecan [n = 55] or PTX [n = 7])

The HER2-positive GC T-DXd 6.4 mg/kg Pool includes data from Studies DS8201-A-J101, DS8201-A-J202, and DS8201-A-U205.

a All adjudicated ILD considered as drug-related events by the ILD AC.

Source: Module 5.3.5.3 SCS Tables 1.2.1.5 and 1.2.4.1

<div style=\"page-break-after: always\"></div>

## 2.5.3.1. Adverse events of special interest

Table 2.18: Selected Preferred Terms in Adverse Events of Special Interest

| Category                                      | SelectedPreferred TermsforReview                                                                                                                                                                                                                                                                                                                           |
|-----------------------------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| ILD/pneumonitis                               | Events of ILD/pneumonitis from PTs triggering adjudication, based on the MedDRA Version 23.0 for the narrow ILD SMQ, selected terms from the broad ILD SMQ, and PTs of respiratory failure and acute respiratory failure                                                                                                                                   |
| Left ventricular dysfunction (LV dysfunction) | Acute left ventricular failure Acute right ventricular failure Cardiac failure Cardiac failure acute Cardiac failure chronic Cardiac failure congestive Chronic left ventricular failure Chronic right ventricular failure Ejection fraction decreased Left ventricular dysfunction Left ventricular failure Right ventricular failure Ventricular failure |

ILD = interstitial lung disease; MedDRA = Medical Dictionary for Regulatory Activities; PT = preferred term; SMQ = Standardised MedDRA Query

## Interstitial Lung Disease (ILD)/Pneumonitis

After the first suspected fatal ILD case occurred, the Sponsor established an external ILD Adjudication Committee (AC).

The ILD AC adjudicated each potential ILD event with regard to whether it was ILD and whether it was related to T-DXd (regardless of the determination made by the investigator) and determined onset dates and adjudicated grades for events that the AC considered to be ILD. In June 2019, a global ILD awareness campaign was initiated to educate both investigators and subjects with the goal of reducing the risk of severe ILD (including fatal cases) by proactively detecting and intensively managing ILD at an early stage.

A total of 27/229 ( 11.8% ) subjects in HER2-positive GC Pool experienced events adjudicated as ILD, including 25/229 ( 10.9% ) subjects who experienced events adjudicated as being drug-related ILD .

Adjudicated drug-related ILD was associated with the outcome of death in 1/79 (1.3%) subject from Study U205 and in none of the subjects from the Study J202.

The median time to adjudicated onset date of the first drug-related adjudicated ILD event in the HER2-positive GC Pool was 85 days (range: 36 to 638).

<div style=\"page-break-after: always\"></div>

Table 2.19: Interstitial Lung Disease Events by Adjudicated Outcome and Adjudicated Grade (Safety Analysis Set)

| Adjudicated Outcome/ CTCAE Grade Reported by Adjudication Committee a   | Study J202HER2-p0sitive GC (Primary Cohort)   | Study J202HER2-p0sitive GC (Primary Cohort)   | Study U205 HER2- positive GC T-DXd 6.4 mg/kg   | HER2- positive GC T-DXd 6.4 mg/kg Pool (N = 229)   |
|-------------------------------------------------------------------------|-----------------------------------------------|-----------------------------------------------|------------------------------------------------|----------------------------------------------------|
| Adjudicated Outcome/ CTCAE Grade Reported by Adjudication Committee a   | T-DXd 6.4 mg/kg (N =125)                      | TPC (N =62)                                   | (N=79)                                         |                                                    |
| Subjects with any event of potential ILD, n (%)                         | 20 (16.0)                                     | 0                                             | 9 (11.4)                                       | 34 (14.8)                                          |
| Adjudicated as ILD                                                      | 16 (12.8)                                     | 0                                             | 7 (8.9)                                        | 27 (11.8)                                          |
| Grade 1                                                                 | 4 (3.2)                                       | 0                                             | 2 (2.5)                                        | 6 (2.6)                                            |
| Grade 2                                                                 | 9 (7.2)                                       | 0                                             | 4 (5.1)                                        | 16 (7.0)                                           |
| Grade 3                                                                 | 2 (1.6)                                       | 0                                             | 0                                              | 3 (1.3)                                            |
| Grade 4                                                                 | 1 (0.8)                                       | 0                                             | 0                                              | 1 (0.4)                                            |
| Grade 5                                                                 | 0                                             | 0                                             | 1 (1.3)                                        | 1 (0.4)                                            |
| Adjudicated as drug-related ILD                                         | 16 (12.8)                                     | 0                                             | 6 (7.6)                                        | 25 (10.9)                                          |
| Grade 1                                                                 | 4 (3.2)                                       | 0                                             | 2 (2.5)                                        | 6 (2.6)                                            |
| Grade 2                                                                 | 9 (7.2)                                       | 0                                             | 3 (3.8)                                        | 15 (6.6)                                           |
| Grade 3                                                                 | 2 (1.6)                                       | 0                                             | 0                                              | 2 (0.9)                                            |
| Grade 4                                                                 | 1 (0.8)                                       | 0                                             | 0                                              | 1 (0.4)                                            |
| Grade 5                                                                 | 0                                             | 0                                             | 1 (1.3)                                        | 1 (0.4)                                            |
| Adjudicated as not drug-related ILD                                     | 0                                             | 0                                             | 1 (1.3)                                        | 2 (0.9)                                            |
| Grade 1                                                                 | 0                                             | 0                                             | 0                                              | 0                                                  |
| Grade 2                                                                 | 0                                             | 0                                             | 1 (1.3)                                        | 1 (0.4)                                            |
| Grade 3                                                                 | 0                                             | 0                                             | 0                                              | 1 (0.4)                                            |
| Grade 4                                                                 | 0                                             | 0                                             | 0                                              | 0                                                  |
| Grade 5                                                                 | 0                                             | 0                                             | 0                                              | 0                                                  |

ILD = interstitial lung disease; T-DXd = trastuzumab deruxtecan; TPC = treatment of physician's choice (includes subjects who received irinotecan [n = 55] or paclitaxel [n = 7])

U205.

Percentages are calculated using the number of subjects in the Safety Analysis Set as the denominator.

Table includes all events that were submitted to the ILD AC.

If a subject had multiple ILD events, the CTCAE grade is shown for the event with the worst grade.

a The ILD AC assigned grades to those events that were determined to be ILD.

Source: Module 5.3.5.3 SCS Table 1.2.5.1

<div style=\"page-break-after: always\"></div>

Table 2.20: Overview of Adjudicated Drug-related Interstitial LungDiseaseEvents (Safety Analysis Set)

| Parameter                                               | Number (%) of Subjects                        | Number (%) of Subjects                        | Number (%) of Subjects                       | Number (%) of Subjects                 |
|---------------------------------------------------------|-----------------------------------------------|-----------------------------------------------|----------------------------------------------|----------------------------------------|
|                                                         | Study J202 HER2- positive GC (Primary Cohort) | Study J202 HER2- positive GC (Primary Cohort) | Study U205 HER2- positive GC T-DXd 6.4 mg/kg | HER2- positive GC T-DXd 6.4 mg/kg Pool |
|                                                         | T-DXd 6.4 mg/kg (N =125)                      | TPC (N =62)                                   | (N =79)                                      | (N=229)                                |
| Subjects with any event adjudicated as drug-related ILD | 16 (12.8)                                     | 0                                             | 6 (7.6)                                      | 25 (10.9)                              |
| ILD CTCAE ≥Grade 3 *                                    | 3 (2.4)                                       | 0                                             | 1 (1.3)                                      | 4 (1.7)                                |
| Serious ILD                                             | 7 (5.6)                                       | 0                                             | 2 (2.5)                                      | 9 (3.9)                                |
| ILD associated with discontinuation of study drug       | 8 (6.4)                                       | 0                                             | 5 (6.3)                                      | 15 (6.6)                               |
| ILD associated with dose reduction                      | 0                                             | 0                                             | 1 (1.3)                                      | 1 (0.4)                                |
| ILD associated with study drug interruption             | 6 (4.8)                                       | 0                                             | 0                                            | 8 (3.5)                                |
| ILD associated with outcome of death                    | 0                                             | 0                                             | 1 (1.3)                                      | 1 (0.4)                                |

GC = gastric/gastroesophageal junction cancer; HER2 =human epidermal growth factor receptor 2;

TPC = treatment of physician's choice (includes subjects who received irinotecan [n = 55] or paclitaxel [n = 7]).

ILD = interstitial lung disease; N = total number of treated subjects; T-DXd = trastuzumab deruxtecan;

HER2-positive GC 6.4 mg/kg Pool includes data from studies DS8201-A-J101, DS8201-A-J202, and DS8201-AU205.

Percentages were calculated using the number of subjects in the Safety Analysis Set as the denominator.

The ILD AC assigned grades to those events that were determined to be ILD. A subject was counted once at the maximum severity.

Adjudicated drug-related ILD associated with death is derived based on adjudicated CTCAE Grade 5 events.

Source:Module 5.3.5.3 SCS Tables 1.2.4.1,1.2.4.2,1.2.4.3,1.2.4.4,1.2.4.5,and 1.2.4.6

Among the 25/229 subjects in the HER2-positive GC Pool who experienced adjudicated drug-related ILD, 16/25 (64.0%) received steroids , 9/25 (36.0%) received antibiotics , and 8/25 (32.0%) received both steroids and antibiotics .

<div style=\"page-break-after: always\"></div>

Table 2.21: Outcome of Events Adjudicated as Drug-Related Interstitial Lung Disease (Safety Analysis Set)

| Outcome of Event                                              | StudyJ202HER2-positive GC (Primary Cohort)   | StudyJ202HER2-positive GC (Primary Cohort)   | Study U205 HER2- positive GC PX(I-L 6.4 mg/kg   | HER2- positive GC PXI-L 6.4 mg/kg Pool   |
|---------------------------------------------------------------|----------------------------------------------|----------------------------------------------|-------------------------------------------------|------------------------------------------|
|                                                               | PXI-L 6.4 mg/kg (N = 125)                    | TPC (N =62)                                  | (N=79)                                          | (N =229)                                 |
| Subjectswith any event adjudicated as drug-related ILD, n (%) | 16 (12.8)                                    | 0                                            | 6 (7.6)                                         | 25 (10.9)                                |
| Recovered/resolved                                            | 6 (37.5)                                     | 0                                            | 2 (33.3)                                        | 9 (36.0)                                 |
| Not recovered/not resolved                                    | 6 (37.5)                                     | 0                                            | 1 (16.7)                                        | 9 (36.0)                                 |
| Recovering/resolving                                          | 4 (25.0)                                     | 0                                            | 1 (16.7)                                        | 5 (20.0)                                 |
| Recovered/resolved with sequelae                              | 0                                            | 0                                            | 1 (16.7)                                        | 1 (4.0)                                  |
| Fatal                                                         | 0                                            | 0                                            | 1 (16.7)                                        | 1 (4.0)                                  |

ILD =interstitial lung disease; N= total number of treated subjects; n=number of patients; T-DXd = trastuzumab deruxtecan; TEAE = treatment-emergent adverse event; TPC = treatment of physician's choice (includes subjects who received irinotecan [n= 55] or paclitaxel [n = 7]).

HER2-positive GC 6.4 mg/kg Pool includes data from studies DS8201-A-J101, DS8201-A-J202, and DS8201-AU205.

Percentage for adjudicated drug-related ILD was calculated using the number of subjects in the Safety Analysis Set as the denominator.

Percentages were calculated using the number of subjects who had adjudicated drug-related ILD as the denominator.

Source:Module 5.3.5.3SCSTable1.2.5.4

## Left ventricular dysfunction

Among the 13 relevant PTs included in the case definition of LV dysfunction (Table 2.18), only 1 subject in the HER2-positive GC Pool, with grade 3 ejection fraction decrease, met the criteria for LV dysfunction. No subjects from Studies J202 and U205 had events of potential LV dysfunction reported.

Measurements of LVEF from laboratory data (every 2 cycles in Study J101 and every 4 cycles in Study J202 and Study U205) were graded as follows per CTCAE Version 4.03 (or Version 5.0), with each LVEF measurement being assigned a CTCAE grade:

- Grade 2: Resting LVEF 50% to 40%; 10% to 19% decrease from baseline
- Grade 3: Resting LVEF 39% to 20%; ≥20% decrease from baseline
- Grade 4: Resting LVEF &lt;20%.

.

It should be noted that instructions given to the study sites regarding dose modification due to AEs of LVEF decrease were different  from  the  CTCAE  grading  above,  as  they  were  based  on  the  following guidelines for anti-HER2 therapy

- LVEF of 40% to ≤45% with &lt;10% decrease from baseline required no dose modification.
- LVEF of 40% to ≤45% with ≥10% decrease from baseline and LVEF &lt;40% or &gt;20% decrease from baseline required study drug interruption with discontinuation of study drug if the value had not improved upon repeat measurement within 3 weeks.

<div style=\"page-break-after: always\"></div>

Table 2.22: Summary of LeftVentricularEjectionFractionDecreaseBased on Laboratory Data (Safety Analysis Set)

| Parameter                                                 | Study J202 HER2-positive GC (Primary Cohort) T-DXd 6.4 mg/kg (N = 125)   | Study U205 HER2- positive GC T-DXd 6.4 mg/kg (N = 79)     | HER2- Positive GC T-DXd 6.4 mg/kg Pool (N = 229)          |
|-----------------------------------------------------------|--------------------------------------------------------------------------|-----------------------------------------------------------|-----------------------------------------------------------|
| Subjects with Worst LVEF CTCAE Grade Post-Baseline, n (%) | Subjects with Worst LVEF CTCAE Grade Post-Baseline, n (%)                | Subjects with Worst LVEF CTCAE Grade Post-Baseline, n (%) | Subjects with Worst LVEF CTCAE Grade Post-Baseline, n (%) |
| Non-missing, n a                                          | 117                                                                      | 57                                                        | 199                                                       |
| Grade 2                                                   | 11 (9.4)                                                                 | 2 (3.5)                                                   | 14 (7.0)                                                  |
| Subjects with LVEF Measurement since Worst Grade          | 6                                                                        | 1                                                         | 8                                                         |
| Recovered from Worst Grade to ≥90% of Baseline, n (%) bc  | 3 (50.0)                                                                 | 1 (100)                                                   | 4 (50.0)                                                  |
| Grade 3                                                   | 0                                                                        | 0                                                         | 1 (0.5)                                                   |
| Subjects with LVEF Measurement since Worst Grade          | 0                                                                        | 0                                                         | 0                                                         |
| Recovered from Worst Grade to≥90%of Baseline, n (%) b,c   | 0                                                                        | 0                                                         | 0                                                         |
| Lowest LVEF measurement post-baseline                     | Lowest LVEF measurement post-baseline                                    | Lowest LVEF measurement post-baseline                     | Lowest LVEF measurement post-baseline                     |
| Non-missing, n a                                          | 117                                                                      | 57                                                        | 199                                                       |
| Median                                                    | 65.0                                                                     | 60.0                                                      | 63.0                                                      |
| Range                                                     | 45,78                                                                    | 41,82                                                     | 41,82                                                     |
| 40% - 49%                                                 | 1 (0.8)                                                                  | 1 (1.3)                                                   | 2 (0.9)                                                   |
| 20% - 39%                                                 | 0                                                                        | 0                                                         | 0                                                         |
| <20%                                                      | 0                                                                        | 0                                                         | 0                                                         |
| MaximumLVEFdecreasefrombaseline                           | MaximumLVEFdecreasefrombaseline                                          | MaximumLVEFdecreasefrombaseline                           | MaximumLVEFdecreasefrombaseline                           |
| Non-missing, n a                                          | 117                                                                      | 57                                                        | 199                                                       |
| Median                                                    | -1.0                                                                     | 0                                                         | -1.0                                                      |
| Range                                                     | -17, 14                                                                  | -17, 9                                                    | -27, 14                                                   |
| 10% - 19% decrease                                        | 11 (8.8)                                                                 | 1 (1.3)                                                   | 13 (5.7)                                                  |
| ≥20% decrease                                             | 0                                                                        | 0                                                         | 1 (0.4)                                                   |

CTCAE = Common Terminology Criteria for Adverse Events; GC = gastric/ gastroesophageal junction cancer; HER2 = human epidermal growth factor receptor 2; LVEF = left ventricular ejection fraction; EF = ejection fraction; N = total number of subjects; n = number of subjects; Std Dev = standard deviation; T-DXd =trastuzumab deruxtecan

HER2-positive GC 6.4 mg/kg Pool includes data from studies DS8201-A-J101, DS8201-A-J202, and DS8201-AU205.

Percentages were calculated using the non-missing n as the denominator.

LVEF was defined as follows: Grade 2 = resting EF of ≥40% to &lt;50%, or a 10% to &lt;20% decrease from baseline; Grade 3 = resting EF of ≥20 to &lt;40%, or a ≥20% decrease from baseline; and Grade 4 = resting EF &lt;20%.

- a Non-missing n was the number of subjects with both baseline and postbaseline data.
- b ≥90% baseline since worst grade was defined as the highest postbaseline LVEF after the measurement with worst grade that was ≥90% of the baseline LVEF value.
- Percentages were calculated using the number of subjects having worst postbaseline LVEF at the specific grade. Ifthere was no LVEF measurement after the worst grade of LVEF, the subject was not included in the denominator.

Source:Module 5.3.5.3 SCS Table 1.2.6.8.1

<div style=\"page-break-after: always\"></div>

## 2.5.4. Serious adverse event/deaths/other significant events

## 2.5.4.1. SAEs

Table 5: Treatment-emergent Serious Adverse Events by Preferred Term (Safety Analysis Set)

| MedDRA Preferred Term          | Number (%) of Subjects                       | Number (%) of Subjects                       | Number (%) of Subjects                               | Number (%) of Subjects                          |
|--------------------------------|----------------------------------------------|----------------------------------------------|------------------------------------------------------|-------------------------------------------------|
| MedDRA Preferred Term          | Study J202 HER2-positive GC (Primary Cohort) | Study J202 HER2-positive GC (Primary Cohort) | Study U205 HER2-positive GC T-DXd 6.4 mg/kg (N = 79) | HER2-positive GC T-DXd 6.4 mg/kg Pool (N = 229) |
| MedDRA Preferred Term          | T-DXd 6.4 mg/kg (N = 125)                    | TPC (N = 62)                                 | Study U205 HER2-positive GC T-DXd 6.4 mg/kg (N = 79) | HER2-positive GC T-DXd 6.4 mg/kg Pool (N = 229) |
| Subjects with any serious TEAE | 56 (44.8)                                    | 16 (25.8)                                    | 29 (36.7)                                            | 92 (40.2)                                       |
| Decreased appetite             | 13 (10.4)                                    | 1 (1.6)                                      | 0                                                    | 16 (7.0)                                        |
| ILD a                          | 7 (5.6)                                      | 0                                            | 2 (2.5)                                              | 9 (3.9)                                         |
| Pneumonia                      | 5 (4.0)                                      | 0                                            | 2 (2.5)                                              | 9 (3.9)                                         |
| Disease progression            | 3 (2.4)                                      | 2 (3.2)                                      | 2 (2.5)                                              | 6 (2.6)                                         |
| Cholangitis                    | 3 (2.4)                                      | 1 (1.6)                                      | 0                                                    | 5 (2.2)                                         |
| Nausea                         | 1 (0.8)                                      | 0                                            | 4 (5.1)                                              | 5 (2.2)                                         |
| Anaemia                        | 4 (3.2)                                      | 2 (3.2)                                      | 0                                                    | 4 (1.7)                                         |
| Dehydration                    | 4 (3.2)                                      | 0                                            | 0                                                    | 4 (1.7)                                         |
| Tumour haemorrhage             | 3 (2.4)                                      | 0                                            | 1 (1.3)                                              | 4 (1.7)                                         |
| Vomiting                       | 1 (0.8)                                      | 0                                            | 3 (3.8)                                              | 4 (1.7)                                         |
| Abdominal pain                 | 1 (0.8)                                      | 0                                            | 2 (2.5)                                              | 3 (1.3)                                         |
| Acute kidney injury            | 1 (0.8)                                      | 1 (1.6)                                      | 2 (2.5)                                              | 3 (1.3)                                         |
| Diarrhoea                      | 2 (1.6)                                      | 0                                            | 1 (1.3)                                              | 3 (1.3)                                         |
| Jaundice cholestatic           | 3 (2.4)                                      | 1 (1.6)                                      | 0                                                    | 3 (1.3)                                         |
| Pyrexia                        | 3 (2.4)                                      | 1 (1.6)                                      | 0                                                    | 3 (1.3)                                         |
| Bacteraemia                    | 1 (0.8)                                      | 0                                            | 0                                                    | 2 (0.9)                                         |
| COVID-19                       | 0                                            | 0                                            | 2 (2.5)                                              | 2 (0.9)                                         |
| Gastric stenosis               | 2 (1.6)                                      | 0                                            | 0                                                    | 2 (0.9)                                         |
| Hydronephrosis                 | 1 (0.8)                                      | 1 (1.6)                                      | 1 (1.3)                                              | 2 (0.9)                                         |
| Hypotension                    | 2 (1.6)                                      | 0                                            | 0                                                    | 2 (0.9)                                         |
| Malignant neoplasm progression | 0                                            | 0                                            | 2 (2.5)                                              | 2 (0.9)                                         |
| Neoplasm progression           | 2 (1.6)                                      | 1 (1.6)                                      | 0                                                    | 2 (0.9)                                         |
| Platelet count decreased       | 1 (0.8)                                      | 0                                            | 0                                                    | 2 (0.9)                                         |

<div style=\"page-break-after: always\"></div>

| MedDRA Preferred Term                  | Number (%) of Subjects                       | Number (%) of Subjects                       | Number (%) of Subjects                               | Number (%) of Subjects                          |
|----------------------------------------|----------------------------------------------|----------------------------------------------|------------------------------------------------------|-------------------------------------------------|
| MedDRA Preferred Term                  | Study J202 HER2-positive GC (Primary Cohort) | Study J202 HER2-positive GC (Primary Cohort) | Study U205 HER2-positive GC T-DXd 6.4 mg/kg (N = 79) | HER2-positive GC T-DXd 6.4 mg/kg Pool (N = 229) |
| MedDRA Preferred Term                  | T-DXd 6.4 mg/kg (N = 125)                    | TPC (N = 62)                                 | Study U205 HER2-positive GC T-DXd 6.4 mg/kg (N = 79) | HER2-positive GC T-DXd 6.4 mg/kg Pool (N = 229) |
| Sepsis                                 | 2 (1.6)                                      | 0                                            | 0                                                    | 2 (0.9)                                         |
| Abdominal distension                   | 1 (0.8)                                      | 0                                            | 0                                                    | 1 (0.4)                                         |
| Acute coronary syndrome                | 1 (0.8)                                      | 0                                            | 0                                                    | 1 (0.4)                                         |
| Anal stenosis                          | 1 (0.8)                                      | 0                                            | 0                                                    | 1 (0.4)                                         |
| Animal bite                            | 0                                            | 0                                            | 1 (1.3)                                              | 1 (0.4)                                         |
| Bacterial sepsis                       | 0                                            | 0                                            | 1 (1.3)                                              | 1 (0.4)                                         |
| Basal ganglia infarction               | 0                                            | 0                                            | 1 (1.3)                                              | 1 (0.4)                                         |
| Biliary obstruction                    | 1 (0.8)                                      | 0                                            | 0                                                    | 1 (0.4)                                         |
| Bile duct stenosis                     | 0                                            | 0                                            | 1 (1.3)                                              | 1 (0.4)                                         |
| Bile duct stone                        | 1 (0.8)                                      | 0                                            | 0                                                    | 1 (0.4)                                         |
| Biliary sepsis                         | 1 (0.8)                                      | 0                                            | 0                                                    | 1 (0.4)                                         |
| Biliary tract infection                | 1 (0.8)                                      | 0                                            | 0                                                    | 1 (0.4)                                         |
| COVID-19 pneumonia                     | 0                                            | 0                                            | 1 (1.3)                                              | 1 (0.4)                                         |
| Cerebrovascular accident               | 0                                            | 0                                            | 1 (1.3)                                              | 1 (0.4)                                         |
| Cholangitis acute                      | 1 (0.8)                                      | 0                                            | 0                                                    | 1 (0.4)                                         |
| Cholangitis infective                  | 1 (0.8)                                      | 0                                            | 0                                                    | 1 (0.4)                                         |
| Colitis                                | 0                                            | 0                                            | 1 (1.3)                                              | 1 (0.4)                                         |
| Condition aggravated                   | 1 (0.8)                                      | 0                                            | 0                                                    | 1 (0.4)                                         |
| Device occlusion                       | 0                                            | 0                                            | 1 (1.3)                                              | 1 (0.4)                                         |
| Device related infection               | 0                                            | 0                                            | 1 (1.3)                                              | 1 (0.4)                                         |
| Disseminated intravascular coagulation | 1 (0.8)                                      | 0                                            | 0                                                    | 1 (0.4)                                         |
| Dysphagia                              | 0                                            | 0                                            | 1 (1.3)                                              | 1 (0.4)                                         |
| Enteritis                              | 0                                            | 0                                            | 1 (1.3)                                              | 1 (0.4)                                         |
| Exposure to communicable disease       | 0                                            | 0                                            | 1 (1.3)                                              | 1 (0.4)                                         |
| Fatigue                                | 1 (0.8)                                      | 1 (1.6)                                      | 0                                                    | 1 (0.4)                                         |
| Febrile neutropenia                    | 1 (0.8)                                      | 1 (1.6)                                      | 0                                                    | 1 (0.4)                                         |
| Gastric haemorrhage                    | 1 (0.8)                                      | 0                                            | 0                                                    | 1 (0.4)                                         |

<div style=\"page-break-after: always\"></div>

| MedDRA Preferred Term                 | Number (%) of Subjects                       | Number (%) of Subjects                       | Number (%) of Subjects                               | Number (%) of Subjects                          |
|---------------------------------------|----------------------------------------------|----------------------------------------------|------------------------------------------------------|-------------------------------------------------|
| MedDRA Preferred Term                 | Study J202 HER2-positive GC (Primary Cohort) | Study J202 HER2-positive GC (Primary Cohort) | Study U205 HER2-positive GC T-DXd 6.4 mg/kg (N = 79) | HER2-positive GC T-DXd 6.4 mg/kg Pool (N = 229) |
| MedDRA Preferred Term                 | T-DXd 6.4 mg/kg (N = 125)                    | TPC (N = 62)                                 | Study U205 HER2-positive GC T-DXd 6.4 mg/kg (N = 79) | HER2-positive GC T-DXd 6.4 mg/kg Pool (N = 229) |
| Gastrointestinal obstruction          | 1 (0.8)                                      | 1 (1.6)                                      | 0                                                    | 1 (0.4)                                         |
| General physical health deterioration | 1 (0.8)                                      | 0                                            | 0                                                    | 1 (0.4)                                         |
| Generalised tonic- clonic seizure     | 0                                            | 0                                            | 1 (1.3)                                              | 1 (0.4)                                         |
| Haematemesis                          | 0                                            | 0                                            | 1 (1.3)                                              | 1 (0.4)                                         |
| Hemiplegia                            | 1 (0.8)                                      | 0                                            | 0                                                    | 1 (0.4)                                         |
| Hepatic function abnormal             | 1 (0.8)                                      | 1 (1.6)                                      | 0                                                    | 1 (0.4)                                         |
| Hepatotoxicity                        | 0                                            | 0                                            | 1 (1.3)                                              | 1 (0.4)                                         |
| Hyperpyrexia                          | 0                                            | 0                                            | 1 (1.3)                                              | 1 (0.4)                                         |
| Hypophagia                            | 1 (0.8)                                      | 0                                            | 0                                                    | 1 (0.4)                                         |
| Inguinal hernia                       | 1 (0.8)                                      | 0                                            | 0                                                    | 1 (0.4)                                         |
| Intestinal obstruction                | 0                                            | 0                                            | 1 (1.3)                                              | 1 (0.4)                                         |
| Large intestine perforation           | 1 (0.8)                                      | 0                                            | 0                                                    | 1 (0.4)                                         |
| Liver injury                          | 1 (0.8)                                      | 0                                            | 0                                                    | 1 (0.4)                                         |
| Lymphangiosis carcinomatosa           | 0                                            | 0                                            | 1 (1.3)                                              | 1 (0.4)                                         |
| Neck pain                             | 1 (0.8)                                      | 0                                            | 0                                                    | 1 (0.4)                                         |
| Oesophageal stenosis                  | 1 (0.8)                                      | 0                                            | 0                                                    | 1 (0.4)                                         |
| Pancreatitis                          | 1 (0.8)                                      | 0                                            | 0                                                    | 1 (0.4)                                         |
| Pericardial effusion                  | 1 (0.8)                                      | 0                                            | 0                                                    | 1 (0.4)                                         |
| Pericarditis malignant                | 1 (0.8)                                      | 0                                            | 0                                                    | 1 (0.4)                                         |
| Pneumonia aspiration                  | 1 (0.8)                                      | 1 (1.6)                                      | 0                                                    | 1 (0.4)                                         |
| Pneumonia bacterial                   | 1 (0.8)                                      | 0                                            | 0                                                    | 1 (0.4)                                         |
| Presyncope                            | 1 (0.8)                                      | 0                                            | 0                                                    | 1 (0.4)                                         |
| Pulmonary embolism                    | 0                                            | 0                                            | 1 (1.3)                                              | 1 (0.4)                                         |
| Pyloric stenosis                      | 1 (0.8)                                      | 0                                            | 0                                                    | 1 (0.4)                                         |
| Staphylococcal infection              | 0                                            | 0                                            | 1 (1.3)                                              | 1 (0.4)                                         |
| Stomatitis                            | 1 (0.8)                                      | 0                                            | 0                                                    | 1 (0.4)                                         |
| Stress cardiomyopathy                 | 1 (0.8)                                      | 0                                            | 0                                                    | 1 (0.4)                                         |

<div style=\"page-break-after: always\"></div>

| MedDRA Preferred Term              | Number (%) of Subjects                       | Number (%) of Subjects                       | Number (%) of Subjects                               | Number (%) of Subjects                          |
|------------------------------------|----------------------------------------------|----------------------------------------------|------------------------------------------------------|-------------------------------------------------|
| MedDRA Preferred Term              | Study J202 HER2-positive GC (Primary Cohort) | Study J202 HER2-positive GC (Primary Cohort) | Study U205 HER2-positive GC T-DXd 6.4 mg/kg (N = 79) | HER2-positive GC T-DXd 6.4 mg/kg Pool (N = 229) |
| MedDRA Preferred Term              | T-DXd 6.4 mg/kg (N = 125)                    | TPC (N = 62)                                 | Study U205 HER2-positive GC T-DXd 6.4 mg/kg (N = 79) | HER2-positive GC T-DXd 6.4 mg/kg Pool (N = 229) |
| Upper gastrointestinal haemorrhage | 1 (0.8)                                      | 0                                            | 0                                                    | 1 (0.4)                                         |
| Urinary tract infection            | 0                                            | 0                                            | 1 (1.3)                                              | 1 (0.4)                                         |
| Urinary tract obstruction          | 0                                            | 0                                            | 1 (1.3)                                              | 1 (0.4)                                         |
| Vascular device infection          | 1 (0.8)                                      | 0                                            | 0                                                    | 1 (0.4)                                         |
| Wound infection                    | 0                                            | 0                                            | 1 (1.3)                                              | 1 (0.4)                                         |
| Asthenia                           | 0                                            | 1 (1.6)                                      | 0                                                    | 0                                               |
| Blood creatinine increased         | 0                                            | 2 (3.2)                                      | 0                                                    | 0                                               |
| Cancer pain                        | 0                                            | 1 (1.6)                                      | 0                                                    | 0                                               |
| Cerebral infarction                | 0                                            | 1 (1.6)                                      | 0                                                    | 0                                               |
| Dizziness                          | 0                                            | 1 (1.6)                                      | 0                                                    | 0                                               |
| Infectious pleural effusion        | 0                                            | 1 (1.6)                                      | 0                                                    | 0                                               |
| Liver disorder                     | 0                                            | 1 (1.6)                                      | 0                                                    | 0                                               |
| Neutropenia                        | 0                                            | 1 (1.6)                                      | 0                                                    | 0                                               |
| Neutrophil count decreased         | 0                                            | 1 (1.6)                                      | 0                                                    | 0                                               |
| White blood cell count decreased   | 0                                            | 1 (1.6)                                      | 0                                                    | 0                                               |

AC = adjudication committee; COVID-19 = coronavirus disease 2019; GC = gastric cancer/gastric or gastroesophageal junction adenocarcinoma; HER2 = human epidermal growth factor receptor 2; ILD = interstitial lung disease; MedDRA = Medical Dictionary for Regulatory Activities, Version 24.0; PTX = paclitaxel;

SCS = Summary of Clinical Safety; T-DXd = trastuzumab deruxtecan; TEAE = treatment-emergent adverse event;

TPC = treatment of physician's choice (includes subjects who received irinotecan [n = 55] or PTX [n = 7])

The HER2-positive GC T-DXd 6.4 mg/kg Pool includes data from Studies DS8201-A-J101, DS8201-A-J202, and DS8201-A-U205.

a All serious adjudicated ILD considered as drug-related events by the ILD AC.

Source: Module 5.3.5.3 SCS Tables 1.2.1.8 and 1.2.4.2

<div style=\"page-break-after: always\"></div>

Table 6: Number of Subjects with One or Multiple Serious Adverse Events in the HER2positive GC T-DXd 6.4 mg/kg Pool (Safety Analysis Set)

|           | Study J202 HER2-positiveGC (Primary Cohort)   | Study J202 HER2-positiveGC (Primary Cohort)   | Study U205 HER2- positive GC T-DXd 6.4 mg/kg (N = 79)   | HER2-positive GC T-DXd 6.4 mg/kg Pool (N = 229)   |
|-----------|-----------------------------------------------|-----------------------------------------------|---------------------------------------------------------|---------------------------------------------------|
|           | T-DXd 6.4 mg/kg (N = 125) n (%)               | TPC (N = 62) n (%)                            | n (%)                                                   | n (%)                                             |
| Any TESAE | 56 (44.8)                                     | 16 (25.8)                                     | 29 (36.7)                                               | 92 (40.2)                                         |
| 1 event   | 29 (23.2)                                     | 9 (14.5)                                      | 17 (21.5)                                               | 49 (21.4)                                         |
| 2 events  | 10 (8.0)                                      | 4 (6.5)                                       | 6 (7.6)                                                 | 19 (8.3)                                          |
| 3 events  | 4 (3.2)                                       | 0                                             | 3 (3.8)                                                 | 8 (3.5)                                           |
| 4 events  | 7 (5.6)                                       | 2 (3.2)                                       | 0                                                       | 7 (3.1)                                           |
| ≥5 events | 6 (4.8)                                       | 1 (1.6)                                       | 3 (3.8)                                                 | 9 (3.9)                                           |

GC = gastric cancer/gastric or gastroesophageal junction adenocarcinoma; HER2 = human epidermal growth factor receptor 2; PT = preferred term; PTX = paclitaxel; SCS = Summary of Clinical Safety; T-DXd = trastuzumab deruxtecan; TESAE = treatment-emergent serious adverse event; TPC = treatment of physician's choice (includes subjects who received irinotecan [n = 55] or PTX [n = 7])

The HER2-positive GC 6.4 mg/kg Pool includes data from Studies DS8201-A-J101, DS8201-A-J202, and DS8201-A-U205.

Multiple occurrences of the same PT were counted as different events.

Source: Module 5.3.5.3 SCS Table 1.2.1.1.1; Appendix 1 Table 2

## Ethnic differences in toxicity profile

Ethnic differences in drug toxicity are becoming increasingly recognized and are well documented in the scientific literature. In particular, higher hematologic toxicity has been described for Asian vs. Western cancer subjects. Although factors underlying such differences have not been precisely identified, various intrinsic and extrinsic factors such as variation in PK, genetic, and lifestyle factors are considered to be responsible for ethnic specific drug safety profiles.

While hematologic events were the most common TEAEs and drug-related TEAEs in both studies, the following grouped terms were more frequent in the T-DXd arm of Study J202 than in Study U205 (Module 5.3.5.3 SCS Tables 1.2.2.1 and 1.2.2.2):

- Anaemia (PTs: anaemia, haemoglobin decreased, haematocrit decreased, red blood cell count decreased): 57.6% vs. 34.2%; considered as drug-related, 40.8% vs. 19.0%.
- Neutropenia (PTs: neutropenia, neutrophil count decreased): 64.8% vs. 25.3%; considered as drug-related, 64.0% vs. 25.3%.
- Thrombocytopenia (PTs: thrombocytopenia, platelet count decreased): 40.0% vs. 21.5%; considered as drug-related, 39.2% vs. 20.3%.
- Leukopenia (PTs: leukopenia, white blood cell count decreased): 38.4% vs. 10.1%; considered as drug-related, 38.4% vs. 10.1%.
- Lymphopenia (PTs: lymphopenia, lymphocyte count decreased): 23.2% vs. 5.1%; considered as drug-related, 23.2% vs. 5.1%.

The higher hematologic toxicity observed in the T-DXd arm of Study J202 (Asian population) vs. Study U205 (Western population) is consistent with what has been reported in T-DXd studies in BC, other clinical studies of drugs for subjects with advanced GC, and other observations from the literature. The

<div style=\"page-break-after: always\"></div>

exact factors responsible for the more pronounced hematologic toxicity observed in the Japanese and Asian population are not known.

## 2.5.4.2. Deaths

This section summarizes data on all reported deaths, including the following:

- On-study deaths, defined as any death that occurred from the date of the first dose up to 28 days (for Study J101) or up to 47 days (for Studies J202 and U205) after the last dose of study drug (as defined in the respective protocols)
- Deaths that occurred after the 28-day (for Study J101) or 47-day (for Studies J202 and U205) follow-up period

Table 2.7: Primary Cause of Any Deaths and On-Treatment Deaths (Safety Analysis Set)

| Primary Cause of Death   | Number (%) of Subjects                       | Number (%) of Subjects                       | Number (%) of Subjects                              | Number (%) of Subjects                        |
|--------------------------|----------------------------------------------|----------------------------------------------|-----------------------------------------------------|-----------------------------------------------|
| Primary Cause of Death   | Study J202 HER2-positive GC (Primary Cohort) | Study J202 HER2-positive GC (Primary Cohort) | Study U205 HER2-positive GC T-DXd 6.4 mg/kg (N =79) | HER2-Positive GC T-DXd 6.4 mg/kg Pool (N=229) |
| Primary Cause of Death   | PX(-L 6.4 mg/kg (N = 125)                    | TPC (N = 62)                                 | Study U205 HER2-positive GC T-DXd 6.4 mg/kg (N =79) | HER2-Positive GC T-DXd 6.4 mg/kg Pool (N=229) |
| Any Death                | 84 (67.2)                                    | 49 (79.0)                                    | 22 (27.8)                                           | 115 (50.2)                                    |
| Disease Progression      | 80 (64.0)                                    | 46 (74.2)                                    | 12 (15.2)                                           | 100 (43.7)                                    |
| Adverse Event            | 3 (2.4)                                      | 1 (1.6)                                      | 7 (8.9)                                             | 11 (4.8) a                                    |
| Other                    | 0                                            | 2 (3.2)                                      | 1 (1.3)                                             | 1 (0.4) b                                     |
| Unknown                  | 1 (0.8)                                      | 0                                            | 2 (2.5)                                             | 3 (1.3)                                       |
| On-treatment Death c     | 8 (6.4)                                      | 7 (11.3)                                     | 9 (11.4)                                            | 18 (7.9)                                      |
| Disease Progression      | 5 (4.0)                                      | 7 (11.3)                                     | 5 (6.3)                                             | 11 (4.8)                                      |
| Adverse Event            | 3 (2.4)                                      | 0                                            | 4 (5.1)                                             | 7 (3.1) d                                     |
| Other                    | 0                                            | 0                                            | 0                                                   | 0                                             |
| Unknown                  | 0                                            | 0                                            | 0                                                   | 0                                             |

<div style=\"page-break-after: always\"></div>

- GC = gastric/gastroesophageal junction cancer; HER2 = human epidermal growth factor receptor 2; N = total number of treated subjects; PT =preferred term;T-DXd=trastuzumab deruxtecan; TPC =treatment of physician's choice (includes subjects who receivedirinotecan[n=55] or paclitaxel [n=7])

HER2-positive GC 6.4 mg/kg Pool includes data from studies DS8201-A-J101,DS8201-A-J202,and DS8201-AU205.

Percentageswere calculated using the number of subjects in theSafetyAnalysisSet as the denominator.

- Adverse events with outcome of death were \"Disseminated intravascular coagulation\" for subject DS8201-A-J202-
- \"Large intestine perforation\" for subject DS8201-A-J202-82042213,\"Pneumonia\" for subject DS8201A-J202 \"Interstitial lung disease\"for subject DS8201-A-U205\"Cerebrovascular accident\" for subject DS8201-A-U205\"COVID-19\" for subject DS8201-A-U205 andDS8201-AU205\"Encephalopathy\"for subjectDS8201-A-U205\"Lymphangiosis carcinomatosa\" for subject DS8201-A-U205\"Intestinal obstruction\"forsubject DS8201-A-U205and
- \"Extradural haematoma\"and\"Traumatic intracranial haemorrhage\"for subject DS8201-A-J101
- b The investigator recorded a primary cause of death as \"Other: PT sustained traumatic brain injury during car accident 07 Oct 2020 which was determined to be the cause of death\"for subject DS8201-A-U205-
- c On-treatment death was defined as any death that occurred from the date of the first dose up to 28 days (for Study J101) or up to 47 days (for Study J202 and Study U205) after the last dose of study drug.
- d Adverse events with outcome of death were \"Disseminated intravascular coagulation\" for subject DS8201-A-J202-
- \"Large intestine perforation\" for subject DS8201-A-J202\"Pneumonia\"for subject DS8201A-J202\"Cerebrovascular accident\" for subject DS8201-A-U205\"Lymphangiosis carcinomatosa\"for subject DS8201-A-U205 \"Intestinal obstruction\" for subject DS8201-A-U205and\"COVID-19\"for subject DS8201-A-U205

Source:Module 5.3.5.3 SCS Table 1.2.7,Listing 1.1, and Listing 1.2

Table 2.8: Treatment-Emergent AdverseEvents Associated with Outcome of Death,by Preferred Term (Safety Analysis Set)

| MedDRAPreferredTerm                                    | Number (%) of Subjects                      | Number (%) of Subjects                      | Number (%) of Subjects                       | Number (%) of Subjects        |
|--------------------------------------------------------|---------------------------------------------|---------------------------------------------|----------------------------------------------|-------------------------------|
| MedDRAPreferredTerm                                    | Study J202HER2-positive GC (Primary Cohort) | Study J202HER2-positive GC (Primary Cohort) | Study U205 HER2- positive GC T-DXd 6.4 mg/kg | HER2- Positive 6.4 mg/kg Pool |
| MedDRAPreferredTerm                                    | T-DXd 6.4 mg/kg (N =125)                    | TPC (N =62)                                 | (N=79)                                       | GC T-DXd (N =229)             |
| Any Subject with TEAE Associated with Outcome of Death | 8 (6.4)                                     | 2 (3.2)                                     | 10 (12.7)                                    | 19 (8.3)                      |
| Disease progression                                    | 3 (2.4)                                     | 1 (1.6)                                     | 2 (2.5)                                      | 6 (2.6)                       |
| COVID-19                                               | 0                                           | 0                                           | 2 (2.5)                                      | 2 (0.9)                       |
| Malignant neoplasm progression                         | 0                                           | 0                                           | 2 (2.5)                                      | 2 (0.9)                       |
| Neoplasm progression                                   | 2 (1.6)                                     | 1 (1.6)                                     | 0                                            | 2 (0.9)                       |
| Cerebrovascular accident                               | 0                                           | 0                                           | 1 (1.3)                                      | 1 (0.4)                       |
| Disseminatedintravascular coagulation                  | 1 (0.8)                                     | 0                                           | 0                                            | 1 (0.4)                       |
| Interstitial lung disease                              | 0                                           | 0                                           | 1 (1.3)                                      | 1 (0.4)                       |
| Intestinal obstruction                                 | 0                                           | 0                                           | 1 (1.3)                                      | 1 (0.4)                       |
| Large intestine perforation                            | 1 (0.8)                                     | 0                                           | 0                                            | 1 (0.4)                       |
| Lymphangiosis carcinomatosa                            | 0                                           | 0                                           | 1 (1.3)                                      | 1 (0.4)                       |
| Pneumonia                                              | 1 (0.8)                                     | 0                                           | 0                                            | 1 (0.4)                       |

COVID-19=coronavirus disease 2019;GC=gastric/gastroesophagealjunction cancer;HER2=human epidermal growth factor receptor 2;MedDRA=Medical Dictionary forRegulatory Activities,Version 23.0;

N =total number of treated subjects; T-DXd =trastuzumab deruxtecan;

TEAE =treatment-emergent adverse event; TPC = treatment of physician's choice (includes subjects who received irinotecan[n=55] or paclitaxel[n=7]).

HER2-positive GC 6.4 mg/kg Pool includes data from studies DS8201-A-J101, DS8201-A-J202,and DS8201-AU205.

Preferred terms are presented in descending order offrequency in the HER2-positive GC T-DXd 6.4 mg/kg Pool. Percentages were calculated using the number of subjects in the Safety AnalysisSet as the denominator.

Source:Module 5.3.5.3SCSTable 1.2.1.16

<div style=\"page-break-after: always\"></div>

According to the SCS Table 2.8, a total of 10 subjects in Study J202 experienced a fatal TEAE: 8 subjects in the T-DXd arm and 2 subjects in the TPC arm.  In the tabular list of narratives in the J202 CSR, there were 18 subjects marked with a 'Y' in the death column.  Eight of these 18 subjects are not included in the SCS Table 2.8 for the following reasons:

- Three subjects were from the exploratory cohorts and therefore were not included in the Safety Analysis Set (ie, Subjects No. 81122213 and 81132203 from the exploratory cohort 1 and Subject No. 81092230 from the exploratory cohort 2).
- Five subjects in the TPC cohort died due to disease progression not reported as a TEAE (ie, Subjects No. 81112203, 81112218, 81112224, 81292206, and 81352204).

To conclude, there were a total of 19 subjects treated with T-DXd who experienced fatal TEAEs, as reported in the HER2-positive GC Pool column of the SCS Table 2.8:

- Eight subjects in Study J202 (all on-study deaths).
- Ten subjects in Study U205 (8 on-study deaths and 2 off-study deaths).
- One subject in Study J101 (on-study death).

## 2.5.4.3. Other significant events

## Time to onset of TEAEs and outcome (resolved/not resolved)

The time to onset of all the relevant TEAEs in Study J202, Study U205, and the HER2-positive GC Pool is  presented  in  Table  7.  The  relevant  TEAEs  include  the  selected  TEAEs,  ILD,  and  left  ventricular dysfunction.

## Table 7: Time to Onset of Relevant Treatment-emergent Adverse Events (Safety Analysis Set)

|                    | Time to First Onset (Days) b                | Time to First Onset (Days) b                | Time to First Onset (Days) b                | Time to First Onset (Days) b                | Time to First Onset (Days) b                | Time to First Onset (Days) b                | Time to First Onset (Days) b     | Time to First Onset (Days) b     |
|--------------------|---------------------------------------------|---------------------------------------------|---------------------------------------------|---------------------------------------------|---------------------------------------------|---------------------------------------------|----------------------------------|----------------------------------|
|                    | Study J202 HER2-positiveGC (Primary Cohort) | Study J202 HER2-positiveGC (Primary Cohort) | Study J202 HER2-positiveGC (Primary Cohort) | Study J202 HER2-positiveGC (Primary Cohort) | Study U205 HER2-positive GC T-DXd 6.4 mg/kg | Study U205 HER2-positive GC T-DXd 6.4 mg/kg | HER2-positive GC T-DXd 6.4 mg/kg | HER2-positive GC T-DXd 6.4 mg/kg |
|                    | T-DXd 6.4 mg/kg (N = 125)                   | T-DXd 6.4 mg/kg (N = 125)                   | TPC (N =                                    | TPC (N =                                    | (N = 79)                                    | (N = 79)                                    | Pool (N = 229)                   | Pool (N = 229)                   |
|                    | n                                           | Median (Range)                              | n                                           | Median (Range)                              | n                                           | Median (Range)                              | n                                | Median (Range)                   |
| Nausea             | 79                                          | 4.0 (1, 177)                                | 29                                          | 8.0 (1, 92)                                 | 52                                          | 4.0 (1, 173)                                | 150                              | 4.0 (1, 177)                     |
| Decreased appetite | 76                                          | 5.0 (1, 520)                                | 28                                          | 8.5 (1, 183)                                | 26                                          | 23.5 (1, 310)                               | 124                              | 6.0 (1, 520)                     |
| Fatigue a          | 69                                          | 8.0 (1, 294)                                | 27                                          | 11.0 (1, 141)                               | 44                                          | 4.0 (1, 175)                                | 121                              | 7.0 (1, 294)                     |
| Vomiting           | 33                                          | 6.0 (1, 291)                                | 5                                           | 19.0 (3, 44)                                | 33                                          | 7.0 (1, 153)                                | 74                               | 7.0 (1, 291)                     |
| Thrombocytopenia a | 50                                          | 8.0 (7, 298)                                | 4                                           | 13.5 (9, 16)                                | 17                                          | 8.0 (5, 232)                                | 79                               | 8.0 (5, 298)                     |
| Diarrhoea          | 41                                          | 9.0 (2, 395)                                | 20                                          | 9.0 (2, 94)                                 | 28                                          | 7.5 (2, 363)                                | 74                               | 9.0 (2, 395)                     |
| Lymphopenia a      | 29                                          | 14.0 (1, 269)                               | 2                                           | 72.0 (59, 85)                               | 4                                           | 8.0 (7, 8)                                  | 37                               | 9.0 (1, 269)                     |
| Leukopenia a       | 48                                          | 16.0 (7, 248)                               | 22                                          | 14.0 (7, 85)                                | 8                                           | 41.5 (15, 337)                              | 67                               | 16.0 (2, 337)                    |
| Neutropenia a      | 81                                          | 16.0 (6, 756)                               | 22                                          | 14.5 (7, 86)                                | 20                                          | 15.0 (8, 142)                               | 113                              | 16.0 (6, 756)                    |

<div style=\"page-break-after: always\"></div>

|                                     | Time to First Onset (Days) b                | Time to First Onset (Days) b                | Time to First Onset (Days) b                | Time to First Onset (Days) b                | Time to First Onset (Days) b                | Time to First Onset (Days) b                | Time to First Onset (Days) b     | Time to First Onset (Days) b     |
|-------------------------------------|---------------------------------------------|---------------------------------------------|---------------------------------------------|---------------------------------------------|---------------------------------------------|---------------------------------------------|----------------------------------|----------------------------------|
|                                     | Study J202 HER2-positiveGC (Primary Cohort) | Study J202 HER2-positiveGC (Primary Cohort) | Study J202 HER2-positiveGC (Primary Cohort) | Study J202 HER2-positiveGC (Primary Cohort) | Study U205 HER2-positive GC T-DXd 6.4 mg/kg | Study U205 HER2-positive GC T-DXd 6.4 mg/kg | HER2-positive GC T-DXd 6.4 mg/kg | HER2-positive GC T-DXd 6.4 mg/kg |
|                                     | T-DXd 6.4 mg/kg (N = 125)                   | T-DXd 6.4 mg/kg (N = 125)                   | TPC (N = 62)                                | TPC (N = 62)                                | (N = 79)                                    | (N = 79)                                    | Pool (N = 229)                   | Pool (N = 229)                   |
|                                     | n                                           | Median (Range)                              | n                                           | Median (Range)                              | n                                           | Median (Range)                              | n                                | Median (Range)                   |
| Anaemia a                           | 72                                          | 18.0 (2, 444)                               | 19                                          | 19.0 (8, 86)                                | 27                                          | 20.0 (1, 299)                               | 113                              | 22.0 (1, 444)                    |
| Headache a                          | 4                                           | 18.5 (4, 84)                                | 4                                           | 56.5 (6, 94)                                | 7                                           | 40.0 (22, 151)                              | 11                               | 26.0 (4, 151)                    |
| Ejection fraction decreased         | 0                                           | 0                                           | 0                                           | 0                                           | 0                                           | 0                                           | 1                                | 26.0 (26, 26)                    |
| Constipation                        | 31                                          | 42.0 (1, 777)                               | 15                                          | 10.0 (1, 397)                               | 21                                          | 24.0 (2, 287)                               | 59                               | 30.0 (1, 777)                    |
| Febrile neutropenia                 | 6                                           | 24.5 (13, 77)                               | 2                                           | 9.0 (9, 9)                                  | 2                                           | 25.5 (12, 39)                               | 9                                | 31.0 (12, 103)                   |
| Stomatitis a                        | 14                                          | 29.0 (2, 512)                               | 3                                           | 16.0 (7, 79)                                | 1                                           | 81.0 (81, 81)                               | 19                               | 33.0 (2, 512)                    |
| Rash a                              | 7                                           | 43.0 (4, 618)                               | 3                                           | 14.0 (5, 22)                                | 1                                           | 62.0 (62, 62)                               | 9                                | 47.0 (4, 618)                    |
| Upper respiratory tract infection a | 9                                           | 78.0 (21, 294)                              | 3                                           | 73.0 (34, 243)                              | 1                                           | 13.0 (13, 13)                               | 12                               | 69.0 (13, 294)                   |
| Abdominal pain a                    | 19                                          | 120.0 (1, 354)                              | 9                                           | 9.0 (1, 168)                                | 16                                          | 29.0 (3, 146)                               | 35                               | 85.0 (1, 354)                    |
| ILD c                               | 16                                          | 102.5 (36, 638)                             | 0                                           | 0                                           | 6                                           | 68.5 (42, 85)                               | 25                               | 85.0 (36, 638)                   |

AC = Adjudication Committee; GC = gastric cancer/gastric or gastroesophageal junction adenocarcinoma;

HER2 = human epidermal growth factor receptor 2; ILD = interstitial lung disease; n = number of subjects with the specific selected TEAE within the treatment arm or pool; N = total number of subjects treated; PT = preferred term; PTX = paclitaxel; SCS = Summary of Clinical Safety; T-DXd = trastuzumab deruxtecan; TEAE = treatment- emergent adverse event; TPC = treatment of physician's choice (includes subjects who received irinotecan [n = 55] or PTX [n = 7]).

The HER2-positive GC 6.4 mg/kg Pool includes data from Studies DS8201-A-J101, DS8201-A-J202, and DS8201-A-U205.

Results are presented in ascending order of time to onset within the HER2-positive GC T-DXd 6.4 mg/kg Pool.

a For the PTs that were included in each grouped term b Time to first onset (days) = date of onset of the subject's first post-dose selected TEAE - date of the first dose + 1. Time to first onset of adjudicated drug-related ILD (days) = onset date of first ILD adjudicated as drug-related first dose date + 1.

c ILD events include all adjudicated and considered as drug related events by the ILD AC.

Source: Module 5.3.5.3 SCS Tables 1.2.2.1, 1.2.5.4, and 1.2.6.7

The time to first worsening grade of LVEF decrease from Baseline based on laboratory data in the T-DXd arm of Study J202, Study U205, and the HER2-positive GC T-DXd 6.4 mg/kg Pool is summarized in Table 8.

<div style=\"page-break-after: always\"></div>

Table 8: Time to First Worsening Grade of LVEF Decrease from Baseline Based on Laboratory Data (Safety Analysis Set)

|        | Time to First Onset (Days)                                             | Time to First Onset (Days)                           | Time to First Onset (Days)                      |
|--------|------------------------------------------------------------------------|------------------------------------------------------|-------------------------------------------------|
|        | Study J202 HER2-positive GC (Primary Cohort) T-DXd 6.4 mg/kg (N = 125) | Study U205 HER2-positive GC T-DXd 6.4 mg/kg (N = 79) | HER2-positive GC T-DXd 6.4 mg/kg Pool (N = 229) |
| n      | 11                                                                     | 2                                                    | 15                                              |
| Median | 168.0                                                                  | 78.5                                                 | 166.0                                           |
| Range  | 82, 681                                                                | 78, 79                                               | 26, 681                                         |

CTCAE = Common Terminology Criteria for Adverse Events; GC = gastric cancer/gastric or gastroesophageal junction adenocarcinoma; HER2 = human epidermal growth factor receptor 2; LVEF = left ventricular ejection fraction; n = number of subjects with non-missing observation; N = total subjects; T-DXd = trastuzumab deruxtecan The HER2-positive GC 6.4 mg/kg Pool includes data from Studies DS8201-A-J101, DS8201-A-J202, and DS8201-A-U205.

Per CTCAE, Grade 2 LVEF decrease is defined by a resting ejection fraction of ≥ 40% to &lt;50%, or a 10% to &lt;20% drop from Baseline. Grade 3 LVEF decrease is defined by a resting ejection fraction of ≥ 20% to &lt;40% or a ≥ 20% drop from Baseline. Grade 4 LVEF decrease is defined by a resting ejection fraction &lt;20%.

Time to first worsening of LVEF = onset date of first worsening grade of laboratory LVEF decrease - date of the first dose + 1.

Source: Appendix 1 Table 3

The outcome of all relevant TEAEs (including the selected TEAEs, ILD, and left ventricular dysfunction) is presented in Table 9 (Study J202) and Table 10 (Study U205 and HER2-positive GC Pool).

Table 9: Outcome of Relevant Treatment-emergent Adverse Events in Study J202 (Safety Analysis Set)

|                    | Study J202 HER2-positiveGC (Primary Cohort)   | Study J202 HER2-positiveGC (Primary Cohort)   | Study J202 HER2-positiveGC (Primary Cohort)   | Study J202 HER2-positiveGC (Primary Cohort)   | Study J202 HER2-positiveGC (Primary Cohort)   | Study J202 HER2-positiveGC (Primary Cohort)   | Study J202 HER2-positiveGC (Primary Cohort)   | Study J202 HER2-positiveGC (Primary Cohort)   | Study J202 HER2-positiveGC (Primary Cohort)   | Study J202 HER2-positiveGC (Primary Cohort)   |
|--------------------|-----------------------------------------------|-----------------------------------------------|-----------------------------------------------|-----------------------------------------------|-----------------------------------------------|-----------------------------------------------|-----------------------------------------------|-----------------------------------------------|-----------------------------------------------|-----------------------------------------------|
|                    | T-DXd 6.4 mg/kg (N = 125)                     | T-DXd 6.4 mg/kg (N = 125)                     | T-DXd 6.4 mg/kg (N = 125)                     | T-DXd 6.4 mg/kg (N = 125)                     | T-DXd 6.4 mg/kg (N = 125)                     | TPC (N = 62)                                  | TPC (N = 62)                                  | TPC (N = 62)                                  | TPC (N = 62)                                  | TPC (N = 62)                                  |
|                    | n                                             | Number (%) of Subjects                        | Number (%) of Subjects                        | Number (%) of Subjects                        | Number (%) of Subjects                        | n                                             | Number (%) of Subjects                        | Number (%) of Subjects                        | Number (%) of Subjects                        | Number (%) of Subjects                        |
|                    |                                               | Resolve d                                     | Resolve d with Sequela e                      | Resolvi ng                                    | Not Resolve d                                 |                                               | Resolve d                                     | Resolve d with Sequela e                      | Resolvi ng                                    | Not Resolve d                                 |
| Neutropenia a      | 81                                            | 70 (86.4)                                     | 0                                             | 0                                             | 11 (13.6)                                     | 22                                            | 17 (77.3)                                     | 0                                             | 0                                             | 5 (22.7)                                      |
| Nausea             | 79                                            | 46 (58.2)                                     | 0                                             | 0                                             | 30 (38.0)                                     | 29                                            | 17 (58.6)                                     | 0                                             | 0                                             | 12 (41.4)                                     |
| Decreased appetite | 76                                            | 26 (34.2)                                     | 0                                             | 0                                             | 47 (61.8)                                     | 28                                            | 11 (39.3)                                     | 0                                             | 0                                             | 17 (60.7)                                     |
| Anaemia a          | 72                                            | 31 (43.1)                                     | 0                                             | 2 (2.8)                                       | 38 (52.8)                                     | 19                                            | 8 (42.1)                                      | 0                                             | 1 (5.3)                                       | 10 (52.6)                                     |
| Fatigue a          | 69                                            | 19 (27.5)                                     | 0                                             | 1 (1.4)                                       | 46 (66.7)                                     | 27                                            | 7 (25.9)                                      | 0                                             | 0                                             | 20 (74.1)                                     |
| Thrombocytopenia a | 50                                            | 30 (60.0)                                     | 0                                             | 0                                             | 18 (36.0)                                     | 4                                             | 2 (50.0)                                      | 0                                             | 0                                             | 2 (50.0)                                      |
| Leukopenia a       | 48                                            | 36 (75.0)                                     | 0                                             | 0                                             | 12 (25.0)                                     | 22                                            | 15 (68.2)                                     | 0                                             | 0                                             | 7 (31.8)                                      |
| Diarrhoea          | 41                                            | 34 (82.9)                                     | 0                                             | 0                                             | 7 (17.1)                                      | 20                                            | 15 (75.0)                                     | 0                                             | 0                                             | 5 (25.0)                                      |

<div style=\"page-break-after: always\"></div>

|                                     | Study J202 HER2-positiveGC (Primary Cohort)   | Study J202 HER2-positiveGC (Primary Cohort)   | Study J202 HER2-positiveGC (Primary Cohort)   | Study J202 HER2-positiveGC (Primary Cohort)   | Study J202 HER2-positiveGC (Primary Cohort)   | Study J202 HER2-positiveGC (Primary Cohort)   | Study J202 HER2-positiveGC (Primary Cohort)   | Study J202 HER2-positiveGC (Primary Cohort)   | Study J202 HER2-positiveGC (Primary Cohort)   | Study J202 HER2-positiveGC (Primary Cohort)   |
|-------------------------------------|-----------------------------------------------|-----------------------------------------------|-----------------------------------------------|-----------------------------------------------|-----------------------------------------------|-----------------------------------------------|-----------------------------------------------|-----------------------------------------------|-----------------------------------------------|-----------------------------------------------|
|                                     | T-DXd 6.4 mg/kg (N = 125)                     | T-DXd 6.4 mg/kg (N = 125)                     | T-DXd 6.4 mg/kg (N = 125)                     | T-DXd 6.4 mg/kg (N = 125)                     | T-DXd 6.4 mg/kg (N = 125)                     | TPC (N = 62)                                  | TPC (N = 62)                                  | TPC (N = 62)                                  | TPC (N = 62)                                  | TPC (N = 62)                                  |
|                                     | n                                             | Number (%) of Subjects                        | Number (%) of Subjects                        | Number (%) of Subjects                        | Number (%) of Subjects                        | n                                             | Number (%) of Subjects                        | Number (%) of Subjects                        | Number (%) of Subjects                        | Number (%) of Subjects                        |
|                                     |                                               | Resolve d                                     | Resolve d with Sequela e                      | Resolvi ng                                    | Not Resolve d                                 |                                               | Resolve d                                     | Resolve d with Sequela e                      | Resolvi ng                                    | Not Resolve d                                 |
| Vomiting                            | 33                                            | 27 (81.8)                                     | 0                                             | 0                                             | 6 (18.2)                                      | 5                                             | 3 (60.0)                                      | 0                                             | 0                                             | 2 (40.0)                                      |
| Constipation                        | 31                                            | 12 (38.7)                                     | 0                                             | 1 (3.2)                                       | 14 (45.2)                                     | 15                                            | 9 (60.0)                                      | 0                                             | 0                                             | 6 (40.0)                                      |
| Lymphopenia a                       | 29                                            | 18 (62.1)                                     | 0                                             | 0                                             | 10 (34.5)                                     | 2                                             | 1 (50.0)                                      | 0                                             | 0                                             | 1 (50.0)                                      |
| Abdominal pain a                    | 19                                            | 8 (42.1)                                      | 0                                             | 0                                             | 11 (57.9)                                     | 9                                             | 3 (33.3)                                      | 0                                             | 0                                             | 6 (66.7)                                      |
| ILD a                               | 16                                            | 6 (37.5)                                      | 0                                             | 4 (25.0)                                      | 6 (37.5)                                      | 0                                             | 0                                             | 0                                             | 0                                             | 0                                             |
| Stomatitis a                        | 14                                            | 6 (42.9)                                      | 0                                             | 0                                             | 7 (50.0)                                      | 3                                             | 3 (100)                                       | 0                                             | 0                                             | 0                                             |
| Upper respiratory tract infection a | 9                                             | 9 (100)                                       | 0                                             | 0                                             | 0                                             | 3                                             | 1 (33.3)                                      | 0                                             | 0                                             | 2 (66.7)                                      |
| Rash a                              | 7                                             | 6 (85.7)                                      | 0                                             | 1 (14.3)                                      | 0                                             | 3                                             | 1 (33.3)                                      | 0                                             | 0                                             | 2 (66.7)                                      |
| Febrile neutropenia                 | 6                                             | 6 (100)                                       | 0                                             | 0                                             | 0                                             | 2                                             | 2 (100)                                       | 0                                             | 0                                             | 0                                             |
| Headache a                          | 4                                             | 2 (50.0)                                      | 0                                             | 0                                             | 2 (50.0)                                      | 4                                             | 3 (75.0)                                      | 0                                             | 0                                             | 1 (25.0)                                      |

AC = Adjudication Committee; GC = gastric cancer/gastric or gastroesophageal junction adenocarcinoma;

HER2 = human epidermal growth factor receptor 2; ILD = interstitial lung disease; n = number of subjects with the specific selected TEAE within the treatment arm; N = number of subjects treated; PT = preferred term; PTX = paclitaxel; SCS = Summary of Clinical Safety; T-DXd = trastuzumab deruxtecan; TEAE = treatment-emergent adverse event; TPC = treatment of physician's choice (includes subjects who received irinotecan [n = 55] or PTX [n = 7])

Percentages were calculated using the number of subjects with the specific selected TEAE within the treatment arm a s the denominator. The denominator for outcome of the worst ILD event is the number of subjects with adjudicated drug-related ILD.

Some subjects have 'Missing/Unknown' outcomes for the specific selected TEAE (not included in the table).

TEAEs are presented in descending order of frequency in the T-DXd arm.

a For the PTs that were included in each grouped term b All adjudicated ILD considered as drug-related events by the ILD AC.

Source: Module 5.3.5.3 SCS Tables 1.2.2.1 and 1.2.5.4

<div style=\"page-break-after: always\"></div>

Table 10: Outcome of Relevant Treatment-emergent Adverse Events in Study U205 and the HER2-positive Gastric Cancer Pool (Safety Analysis Set)

|                                     | Study U205 HER2-positiveGC T-DXd 6.4 mg/kg (N = 79)   | Study U205 HER2-positiveGC T-DXd 6.4 mg/kg (N = 79)   | Study U205 HER2-positiveGC T-DXd 6.4 mg/kg (N = 79)   | Study U205 HER2-positiveGC T-DXd 6.4 mg/kg (N = 79)   | Study U205 HER2-positiveGC T-DXd 6.4 mg/kg (N = 79)   | HER2-positive GC T-DXd 6.4 mg/kgGC Pool (N = 229)   | HER2-positive GC T-DXd 6.4 mg/kgGC Pool (N = 229)   | HER2-positive GC T-DXd 6.4 mg/kgGC Pool (N = 229)   | HER2-positive GC T-DXd 6.4 mg/kgGC Pool (N = 229)   | HER2-positive GC T-DXd 6.4 mg/kgGC Pool (N = 229)   |
|-------------------------------------|-------------------------------------------------------|-------------------------------------------------------|-------------------------------------------------------|-------------------------------------------------------|-------------------------------------------------------|-----------------------------------------------------|-----------------------------------------------------|-----------------------------------------------------|-----------------------------------------------------|-----------------------------------------------------|
|                                     | n                                                     | Number (%) of Subjects                                | Number (%) of Subjects                                | Number (%) of Subjects                                | Number (%) of Subjects                                | n                                                   | Number (%) of Subjects                              | Number (%) of Subjects                              | Number (%) of Subjects                              | Number (%) of Subjects                              |
|                                     | n                                                     | Resolve d                                             | Resolve d with Sequela e                              | Resolvin g                                            | Not Resolve d                                         | n                                                   | Resolve d                                           | Resolve d with Sequela e                            | Resolvin g                                          | Not Resolve d                                       |
| Nausea                              | 5 2                                                   | 28 (53.8)                                             | 0                                                     | 6 (11.5)                                              | 16 (30.8)                                             | 15 0                                                | 83 (55.3)                                           | 0                                                   | 7 (4.7)                                             | 55 (36.7)                                           |
| Decreased appetite                  | 2 6                                                   | 10 (38.5)                                             | 0                                                     | 3 (11.5)                                              | 11 (42.3)                                             | 12 4                                                | 46 (37.1)                                           | 0                                                   | 5 (4.0)                                             | 68 (54.8)                                           |
| Fatigue a                           | 4 4                                                   | 20 (45.5)                                             | 2 (4.5)                                               | 5 (11.4)                                              | 16 (36.4)                                             | 12 1                                                | 44 (36.4)                                           | 2 (1.7)                                             | 6 (5.0)                                             | 65 (53.7)                                           |
| Anaemia a                           | 2 7                                                   | 15 (55.6)                                             | 2 (7.4)                                               | 2 (7.4)                                               | 6 (22.2)                                              | 11 3                                                | 53 (46.9)                                           | 2 (1.8)                                             | 4 (3.5)                                             | 51 (45.1)                                           |
| Neutropenia a                       | 2 0                                                   | 16 (80.0)                                             | 0                                                     | 0                                                     | 3 (15.0)                                              | 11 3                                                | 97 (85.8)                                           | 0                                                   | 1 (0.9)                                             | 14 (12.4)                                           |
| Thrombocytopenia a                  | 1 7                                                   | 10 (58.8)                                             | 0                                                     | 1 (5.9)                                               | 5 (29.4)                                              | 79                                                  | 50 (63.3)                                           | 0                                                   | 2 (2.5)                                             | 24 (30.4)                                           |
| Vomiting                            | 3 3                                                   | 23 (69.7)                                             | 0                                                     | 4 (12.1)                                              | 6 (18.2)                                              | 74                                                  | 58 (78.4)                                           | 0                                                   | 4 (5.4)                                             | 12 (16.2)                                           |
| Diarrhoea                           | 2 8                                                   | 23 (82.1)                                             | 0                                                     | 0                                                     | 5 (17.9)                                              | 74                                                  | 61 (82.4)                                           | 0                                                   | 0                                                   | 13 (17.6)                                           |
| Leukopenia a                        | 8                                                     | 6 (75.0)                                              | 0                                                     | 0                                                     | 2 (25.0)                                              | 67                                                  | 50 (74.6)                                           | 0                                                   | 0                                                   | 17 (25.4)                                           |
| Constipation                        | 2 1                                                   | 13 (61.9)                                             | 0                                                     | 1 (4.8)                                               | 5 (23.8)                                              | 59                                                  | 29 (49.2)                                           | 0                                                   | 2 (3.4)                                             | 22 (37.3)                                           |
| Lymphopenia a                       | 4                                                     | 4 (100)                                               | 0                                                     | 0                                                     | 0                                                     | 37                                                  | 23 (62.2)                                           | 0                                                   | 1 (2.7)                                             | 12 (32.4)                                           |
| Abdominal pain a                    | 1 6                                                   | 8 (50.0)                                              | 0                                                     | 1 (6.3)                                               | 7 (43.8)                                              | 35                                                  | 16 (45.7)                                           | 0                                                   | 1 (2.9)                                             | 18 (51.4)                                           |
| ILD b                               | 6                                                     | 2 (33.3)                                              | 1 (16.7)                                              | 1 (16.7)                                              | 1 (16.7)                                              | 25                                                  | 9 (36.0)                                            | 1 (4.0)                                             | 5 (20.0)                                            | 9 (36.0)                                            |
| Stomatitis a                        | 1                                                     | 1 (100)                                               | 0                                                     | 0                                                     | 0                                                     | 19                                                  | 8 (42.1)                                            | 0                                                   | 0                                                   | 10 (52.6)                                           |
| Upper respiratory tract infection a | 1                                                     | 1 (100)                                               | 0                                                     | 0                                                     | 0                                                     | 12                                                  | 12 (100)                                            | 0                                                   | 0                                                   | 0                                                   |
| Headache a                          | 7                                                     | 3 (42.9)                                              | 0                                                     | 1 (14.3)                                              | 2 (28.6)                                              | 11                                                  | 5 (45.5)                                            | 0                                                   | 1 (9.1)                                             | 4 (36.4)                                            |
| Febrile neutropenia                 | 2                                                     | 2 (100)                                               | 0                                                     | 0                                                     | 0                                                     | 9                                                   | 9 (100)                                             | 0                                                   | 0                                                   | 0                                                   |
| Rash a                              | 1                                                     | 1 (100)                                               | 0                                                     | 0                                                     | 0                                                     | 9                                                   | 8 (88.9)                                            | 0                                                   | 1 (11.1)                                            | 0                                                   |
| Ejection fraction decreased         | 0                                                     | 0                                                     | 0                                                     | 0                                                     | 0                                                     | 1                                                   | 0                                                   | 0                                                   | 0                                                   | 1 (100.0)                                           |

AC = Adjudication Committee; GC = gastric cancer/gastric or gastroesophageal junction adenocarcinoma;

HER2 = human epidermal growth factor receptor 2; ILD = interstitial lung disease. n = number of subjects with the specific selected TEAE within the treatment arm; N = number of subjects treated; PT = preferred term;

SCS = Summary of Clinical Safety; T-DXd = trastuzumab deruxtecan; TEAE = treatment-emergent adverse event

<div style=\"page-break-after: always\"></div>

The HER2-positive GC 6.4 mg/kg Pool includes data from Studies DS8201-A-J101, DS8201-A-J202, and DS8201A-U205.

Percentages were calculated using the number of subjects with the specific selected TEAE within the study or pool a s the denominator. The denominator for outcome of the worst ILD event is the number of subjects with adjudicated drug-related ILD.

TEAEs are presented in descending order of frequency in the HER2-positive GC T-DXd 6.4 mg/kg Pool. Some subjects have 'Missing/Unknown' outcomes for the specific selected TEAE (not included in the table). a For the PTs that were included in each grouped term

- b All adjudicated ILD considered as drug-related events by the ILD AC. Of note, there was 1 fatal event of ILD in Study U205. Source: Module 5.3.5.3 SCS Tables 1.2.2.1 and 1.2.5.4, and Listing 1.2

## 2.5.4.4. Adverse drug reactions

Figure 4.1: Methodology of ADRDeterminationforHER2-Positive GCPopulation

<!-- image -->

ADR = adverse drug reaction; AE = adverse event; BC = breast cancer; T-DXd = trastuzumab deruxtecan Comparator is defined as treatment of physician's choice

Based on the review of individual events:

- a If evidence suggests that the event is due to the underlying disease or has an alternative etiology, it may be determined as NOT an ADR
- b If there is a causal relationship between the event and study drug, it may be determined as an ADR

<div style=\"page-break-after: always\"></div>

Table 10.1: All Adverse Drug Reactions by MedDRA System Organ Class and Preferred term/Grouped Term in the HER2positive GC T-DXd 6.4 mg/kg Pool (Safety Analysis Set)

| MedDRASystemOrganClass                            | Number (%) of Subjects, by CTCAE Grade            | Number (%) of Subjects, by CTCAE Grade            | Number (%) of Subjects, by CTCAE Grade            | Number (%) of Subjects, by CTCAE Grade            | Number (%) of Subjects, by CTCAE Grade            | Number (%) of Subjects, by CTCAE Grade            | Number (%) of Subjects, by CTCAE Grade            | Number (%) of Subjects, by CTCAE Grade            |
|---------------------------------------------------|---------------------------------------------------|---------------------------------------------------|---------------------------------------------------|---------------------------------------------------|---------------------------------------------------|---------------------------------------------------|---------------------------------------------------|---------------------------------------------------|
| PreferredTerm/GroupedTerm                         | Study J202 HER2-positive GC (Primary Cohort)      | Study J202 HER2-positive GC (Primary Cohort)      | Study J202 HER2-positive GC (Primary Cohort)      | Study J202 HER2-positive GC (Primary Cohort)      | Study U205 HER2-positive GC T-DXd 6.4 mg/kg       | Study U205 HER2-positive GC T-DXd 6.4 mg/kg       | HER2-positive GC T-DXd 6.4 mg/kg Pool             | HER2-positive GC T-DXd 6.4 mg/kg Pool             |
|                                                   | T-DXd 6.4 mg/kg (N =125)                          | T-DXd 6.4 mg/kg (N =125)                          | TPC (N =62)                                       | TPC (N =62)                                       | (N =79)                                           | (N =79)                                           | (N =229)                                          | (N =229)                                          |
|                                                   | All Grades                                        | Grade 3or4                                        | All Grades                                        | Grade 3or4                                        | AlI Grades                                        | Grade 3or 4                                       | All Grades                                        | Grade 3or4                                        |
| Subjects with any ADR                             | 124 (99.2)                                        | 100 (80.0)                                        | 60 (96.8)                                         | 31 (50.0)                                         | 77 (97.5)                                         | 31 (39.2)                                         | 226 (98.7)                                        | 146 (63.8)                                        |
| Blood and lymphatic system disorders              | Blood and lymphatic system disorders              | Blood and lymphatic system disorders              | Blood and lymphatic system disorders              | Blood and lymphatic system disorders              | Blood and lymphatic system disorders              | Blood and lymphatic system disorders              | Blood and lymphatic system disorders              | Blood and lymphatic system disorders              |
| Anaemia a                                         | 72 (57.6)                                         | 48 (38.4)                                         | 19 (30.6)                                         | 14 (22.6)                                         | 27 (34.2)                                         | 11 (13.9)                                         | 113 (49.3)                                        | 68 (29.7)                                         |
| Neutropenia b                                     | 81 (64.8)                                         | 64 (51.2)                                         | 22 (35.5)                                         | 15 (24.2)                                         | 20 (25.3)                                         | 9 (11.4)                                          | 113 (49.3)                                        | 82 (35.8)                                         |
| Thrombocytopenia c                                | 50 (40.0)                                         | 14 (11.2)                                         | 4 (6.5)                                           | 2 (3.2)                                           | 16 (20.3)                                         | 3 (3.8)                                           | 78 (34.1)                                         | 22 (9.6)                                          |
| Leukopenia d                                      | 48 (38.4)                                         | 26 (20.8)                                         | 22 (35.5)                                         | 7 (11.3)                                          | 7 (8.9)                                           | 4 (5.1)                                           | 66 (28.8)                                         | 37 (16.2)                                         |
| Lymphopenia e                                     | 29 (23.2)                                         | 15 (12.0)                                         | 2 (3.2)                                           | 1 (1.6)                                           | 4 (5.1)                                           | 3 (3.8)                                           | 37 (16.2)                                         | 22 (9.6)                                          |
| Febrile neutropenia                               | 6 (4.8)                                           | 6 (4.8)                                           | 2 (3.2)                                           | 2 (3.2)                                           | 2 (2.5)                                           | 2 (2.5)                                           | 9 (3.9)                                           | 9 (3.9)                                           |
| Gastrointestinal disorders                        |                                                   |                                                   |                                                   |                                                   |                                                   |                                                   |                                                   |                                                   |
| Nausea                                            | 79 (63.2)                                         | 7 (5.6)                                           | 29 (46.8)                                         | 1 (1.6)                                           | 52 (65.8)                                         | 6 (7.6)                                           | 150 (65.5)                                        | 14 (6.1)                                          |
| Vomiting                                          | 33 (26.4)                                         | 0                                                 | 5 (8.1)                                           | 0                                                 | 33 (41.8)                                         | 2 (2.5)                                           | 74 (32.3)                                         | 2 (0.9)                                           |
| Diarrhoea                                         | 41 (32.8)                                         | 3 (2.4)                                           | 20 (32.3)                                         | 1 (1.6)                                           | 27 (34.2)                                         | 1 (1.3)                                           | 73 (31.9)                                         | 4 (1.7)                                           |
| Constipation                                      | 31 (24.8)                                         | 0                                                 | 15 (24.2)                                         | 0                                                 | 21 (26.6)                                         | 0                                                 | 59 (25.8)                                         | 0                                                 |
| Abdominal pain f                                  | 19 (15.2)                                         | 1 (0.8)                                           | 9 (14.5)                                          | 2 (3.2)                                           | 16 (20.3)                                         | 2 (2.5)                                           | 35 (15.3)                                         | 3 (1.3)                                           |
| Stomatitis g                                      | 14 (11.2)                                         | 2 (1.6)                                           | 3 (4.8)                                           | 0                                                 | 1 (1.3)                                           | 0                                                 | 19 (8.3)                                          | 2 (0.9)                                           |
| Generaldisorders and administrationsiteconditions | Generaldisorders and administrationsiteconditions | Generaldisorders and administrationsiteconditions | Generaldisorders and administrationsiteconditions | Generaldisorders and administrationsiteconditions | Generaldisorders and administrationsiteconditions | Generaldisorders and administrationsiteconditions | Generaldisorders and administrationsiteconditions | Generaldisorders and administrationsiteconditions |
| Fatigue h                                         | 69 (55.2)                                         | 11 (8.8)                                          | 27 (43.5)                                         | 3 (4.8)                                           | 44 (55.7)                                         | 4 (5.1)                                           | 121 (52.8)                                        | 15 (6.6)                                          |
| Pyrexia                                           | 31 (24.8)                                         | 0                                                 | 10 (16.1)                                         | 0                                                 | 8 (10.1)                                          | 0                                                 | 47 (20.5)                                         | 0                                                 |
| Oedema peripheral                                 | 14 (11.2)                                         | 0                                                 | 0                                                 | 0                                                 | 4 (5.1)                                           | 0                                                 | 19 (8.3)                                          | 0                                                 |
| Hepatobiliary disorders                           | Hepatobiliary disorders                           | Hepatobiliary disorders                           | Hepatobiliary disorders                           | Hepatobiliary disorders                           | Hepatobiliary disorders                           | Hepatobiliary disorders                           | Hepatobiliary disorders                           | Hepatobiliary disorders                           |
| Hepatic function abnormal                         | 11 (8.8)                                          | 4 (3.2)                                           | 1 (1.6)                                           | 1 (1.6)                                           | 0                                                 | 0                                                 | 14 (6.1)                                          | 4 (1.7)                                           |
| Infectionsandinfestations                         | Infectionsandinfestations                         | Infectionsandinfestations                         | Infectionsandinfestations                         | Infectionsandinfestations                         | Infectionsandinfestations                         | Infectionsandinfestations                         | Infectionsandinfestations                         | Infectionsandinfestations                         |
| Upper respiratory tract infection '               | 21 (16.8)                                         | 1 (0.8)                                           | 8 (12.9)                                          | 0                                                 | 1 (1.3)                                           | 0                                                 | 27 (11.8)                                         | 1 (0.4)                                           |
| Pneumonia                                         | 13 (10.4)                                         | 3 (2.4)                                           | 1 (1.6)                                           | 0                                                 | 2 (2.5)                                           | 2 (2.5)                                           | 20 (8.7)                                          | 6 (2.6)                                           |
| Injury, poisoning and procedural complications    | Injury, poisoning and procedural complications    | Injury, poisoning and procedural complications    | Injury, poisoning and procedural complications    | Injury, poisoning and procedural complications    | Injury, poisoning and procedural complications    | Injury, poisoning and procedural complications    | Injury, poisoning and procedural complications    | Injury, poisoning and procedural complications    |
| Infusion-related reaction j                       | 2 (1.6)                                           | 0                                                 | 0                                                 | 0                                                 | 0                                                 | 0                                                 | 2 (0.9)                                           | 0                                                 |
| Investigations                                    | Investigations                                    | Investigations                                    | Investigations                                    | Investigations                                    | Investigations                                    | Investigations                                    | Investigations                                    | Investigations                                    |
| Aspartate aminotransferase increased              | 12 (9.6)                                          | 3 (2.4)                                           | 3 (4.8)                                           | 0                                                 | 9 (11.4)                                          | 1 (1.3)                                           | 24 (10.5)                                         | 4 (1.7)                                           |
| Alanine aminotransferaseincreased                 | 9 (7.2)                                           | 2 (1.6)                                           | 3 (4.8)                                           | 0                                                 | 6 (7.6)                                           | 1 (1.3)                                           | 18 (7.9)                                          | 3 (1.3)                                           |
| Blood alkaline phosphatase increased              | 11 (8.8)                                          | 4 (3.2)                                           | 2 (3.2)                                           | 0                                                 | 6 (7.6)                                           | 1 (1.3)                                           | 18 (7.9)                                          | 5 (2.2)                                           |
| Blood bilirubinincreased                          | 10 (8.0)                                          | 1 (0.8)                                           | 0                                                 | 0                                                 | 4 (5.1)                                           | 1 (1.3)                                           | 15 (6.6)                                          | 3 (1.3)                                           |

<div style=\"page-break-after: always\"></div>

| MedDRASystemOrganClass                          | Number (%) of Subjects, by CTCAE Grade          | Number (%) of Subjects, by CTCAE Grade          | Number (%) of Subjects, by CTCAE Grade          | Number (%) of Subjects, by CTCAE Grade          | Number (%) of Subjects, by CTCAE Grade          | Number (%) of Subjects, by CTCAE Grade          | Number (%) of Subjects, by CTCAE Grade          | Number (%) of Subjects, by CTCAE Grade          |
|-------------------------------------------------|-------------------------------------------------|-------------------------------------------------|-------------------------------------------------|-------------------------------------------------|-------------------------------------------------|-------------------------------------------------|-------------------------------------------------|-------------------------------------------------|
| PreferredTerm/GroupedTerm                       | Study J202HER2-positive GC (Primary Cohort)     | Study J202HER2-positive GC (Primary Cohort)     | Study J202HER2-positive GC (Primary Cohort)     | Study J202HER2-positive GC (Primary Cohort)     | Study U205 HER2-positive GC                     | Study U205 HER2-positive GC                     | HER2-positive GC T-DXd 6.4 mg/kg Pool           | HER2-positive GC T-DXd 6.4 mg/kg Pool           |
|                                                 | T-DXd 6.4 mg/kg (N =125)                        | T-DXd 6.4 mg/kg (N =125)                        | TPC (N = 62)                                    | TPC (N = 62)                                    | T-DXd 6.4 mg/kg (N =79)                         | T-DXd 6.4 mg/kg (N =79)                         | (N = 229)                                       | (N = 229)                                       |
|                                                 | All Grades                                      | Grade 3or4                                      | AlI Grades                                      | Grade 3or4                                      | All Grades                                      | Grade 3or4                                      | AlI Grades                                      | Grade 3or4                                      |
| Metabolismandnutritiondisorders                 |                                                 |                                                 |                                                 |                                                 |                                                 |                                                 |                                                 |                                                 |
| Decreased appetite                              | 76 (60.8)                                       | 21 (16.8)                                       | 28 (45.2)                                       | 8 (12.9)                                        | 26 (32.9)                                       | 4 (5.1)                                         | 124 (54.1)                                      | 28 (12.2)                                       |
| Hypokalaemia                                    | 10 (8.0)                                        | 5 (4.0)                                         | 4 (6.5)                                         | 4 (6.5)                                         | 12 (15.2)                                       | 1 (1.3)                                         | 25 (10.9)                                       | 9 (3.9)                                         |
| Dehydration                                     | 8 (6.4)                                         | 3 (2.4)                                         | 2 (3.2)                                         | 1 (1.6)                                         | 2 (2.5)                                         | 0                                               | 10 (4.4)                                        | 3 (1.3)                                         |
| Respiratory, thoracic and mediastinal disorders | Respiratory, thoracic and mediastinal disorders | Respiratory, thoracic and mediastinal disorders | Respiratory, thoracic and mediastinal disorders | Respiratory, thoracic and mediastinal disorders | Respiratory, thoracic and mediastinal disorders | Respiratory, thoracic and mediastinal disorders | Respiratory, thoracic and mediastinal disorders | Respiratory, thoracic and mediastinal disorders |
| Interstitial lung disease k                     | 16 (12.8)                                       | 3 (2.4)                                         | 0                                               | 0                                               | 6 (7.6)                                         | 0                                               | 25 (10.9)                                       | 3 (1.3)                                         |
| Cough                                           | 6 (4.8)                                         | 0                                               | 2 (3.2)                                         | 0                                               | 6 (7.6)                                         | 1 (1.3)                                         | 13 (5.7)                                        | 1 (0.4)                                         |
| Epistaxis                                       | 4 (3.2)                                         | 0                                               | 0                                               | 0                                               | 6 (7.6)                                         | 0                                               | 13 (5.7)                                        | 0                                               |
| Dyspnoea                                        | 1 (0.8)                                         | 0                                               | 1 (1.6)                                         | 0                                               | 7 (8.9)                                         | 1 (1.3)                                         | 8 (3.5)                                         | 1 (0.4)                                         |
| Skin andsubcutaneous tissue disorders           | Skin andsubcutaneous tissue disorders           | Skin andsubcutaneous tissue disorders           | Skin andsubcutaneous tissue disorders           | Skin andsubcutaneous tissue disorders           | Skin andsubcutaneous tissue disorders           | Skin andsubcutaneous tissue disorders           | Skin andsubcutaneous tissue disorders           | Skin andsubcutaneous tissue disorders           |
| Alopecia                                        | 28 (22.4)                                       | 0                                               | 9 (14.5)                                        | 0                                               | 19 (24.1)                                       | 0                                               | 51 (22.3)                                       | 0                                               |
| Pruritus                                        | 10 (8.0)                                        | 0                                               | 2 (3.2)                                         | 0                                               | 2 (2.5)                                         | 0                                               | 13 (5.7)                                        | 0                                               |
| Rash 1                                          | 7 (5.6)                                         | 0                                               | 3 (4.8)                                         | 0                                               | 1 (1.3)                                         | 0                                               | 9 (3.9)                                         | 0                                               |

ADR = adverse drug reaction; CTCAE = Common Terminology Criteria for Adverse Events; GC = gastro/gastroesophageal junction cancer; HER2 = human epidermal growth factor receptor 2;ILD=interstitial lung disease;MedDRA =Medical Dictionaryfor RegulatoryActivities,version 23.0;N=number of treated subjects;PT=preferred term;T-Dxd=trastuzumabderuxtecan;TPC=treatment ofphysician's choice(includes subjects whoreceived irinotecan [n=55]orpaclitaxel[n=7])

HER2 positive GC 6.4 mg/kg Pool includes data from studies: DS8201-A-J101, DS8201-A-J202 and DS8201-A-U205.

Percentages were calculated using the number of subjects in the Safety Analysis Set as the denominator.

System Organ Class are sorted by alphabetic order. PT/Grouped terms are sorted by descending frequency in'All Grades' column of HER2-positive GC T-DXd 6.4 mg/kg Pool.

- aAnaemia (grouped term) includesPTs of Anaemia,Haemoglobin decreased,Haematocrit decreased, and Red blood cell count decreased.
- c Thrombocytopenia (grouped term) includes PTs of Thrombocytopenia and Platelet count decreased.
- b Neutropenia (grouped term) includes PTs of Neutropenia and Neutrophil count decreased.
- d Leukopenia (grouped term) includes PTs of Leukopenia and White blood cell count decreased.
- Abdominal pain (grouped term) includes PTs of Abdominal pain, Abdominal discomfort, Gastrointestinal pain, Abdominal pain lower, and Abdominal pain upper.
- e Lymphopenia (grouped term) includes PTs of Lymphopenia and Lymphocyte count decreased.
- Stomatitis (grouped term) includes PTs of Stomatitis, Aphthous ulcer, Mouth ulceration, Oral mucosa erosion, and Oral mucosal blistering.
- i Upper respiratory tract infection (grouped term) includes PTs Upper respiratory tract infection, Influenza, and Influenza-like illness. Grouped term Upper respiratory tract infection is updated from the original definition for CSR/SCS, with addition of PTs of nasopharyngitis, pharyngitis, sinusitis, rhinitis. The updated definition is used for summary of ADRs only.
- h Fatigue (grouped term) includes PTs of Fatigue, Asthenia, and Malaise.
- Cases of infusion-related reactions includeInfusion related reaction(n= 2).Cases ofinfusion-related reactions arebased on safety review of pre-specified PTs andadditionalPTof'infusionsiteextravasation'
- I Rash (grouped term) includes PTs of Rash, Rash pustular, and Rash maculo-papular.
- k Interstitial lung disease includes events that were adjudicated as ILD and considered study drug related by the adjudication committee.

<div style=\"page-break-after: always\"></div>

## 2.5.5. Laboratory findings

Table 2.24: Selected Laboratory Abnormalities (Safety Analysis Set)

| LaboratoryAbnormality                | Number (%)of Subjects,by CTCAE Grade              | Number (%)of Subjects,by CTCAE Grade              | Number (%)of Subjects,by CTCAE Grade              | Number (%)of Subjects,by CTCAE Grade              | Number (%)of Subjects,by CTCAE Grade        | Number (%)of Subjects,by CTCAE Grade        | Number (%)of Subjects,by CTCAE Grade   | Number (%)of Subjects,by CTCAE Grade   |
|--------------------------------------|---------------------------------------------------|---------------------------------------------------|---------------------------------------------------|---------------------------------------------------|---------------------------------------------|---------------------------------------------|----------------------------------------|----------------------------------------|
| LaboratoryAbnormality                | Study J202 with HER2-positive GC (Primary Cohort) | Study J202 with HER2-positive GC (Primary Cohort) | Study J202 with HER2-positive GC (Primary Cohort) | Study J202 with HER2-positive GC (Primary Cohort) | Study U205 HER2-positive GC T-DXd 6.4 mg/kg | Study U205 HER2-positive GC T-DXd 6.4 mg/kg | HER2-positive GC T-DXd 6.4 mg/kg Pool  | HER2-positive GC T-DXd 6.4 mg/kg Pool  |
| LaboratoryAbnormality                | T-DXd 6.4 mg/kg (N =125)                          | T-DXd 6.4 mg/kg (N =125)                          | TPC (N = 62)                                      | TPC (N = 62)                                      | (N = 79)                                    | (N = 79)                                    | (N = 229)                              | (N = 229)                              |
| LaboratoryAbnormality                | Any Grade                                         | Grades 3-4                                        | Any Grade                                         | Grades 3-4                                        | Any Grade                                   | Grades 3-4                                  | Any Grade                              | Grades 3-4                             |
| Hematology                           |                                                   |                                                   |                                                   |                                                   |                                             |                                             |                                        |                                        |
| Hemoglobin decreased                 | 96 (76.8)                                         | 50 (40.0)                                         | 33 (55.0)                                         | 14 (23.3)                                         | 39 (49.4)                                   | 7 (8.9)                                     | 152 (66.4)                             | 66 (28.8)                              |
| White blood cell count decreased     | 94 (75.2)                                         | 36 (28.8)                                         | 32 (53.3)                                         | 8 (13.3)                                          | 48 (60.8)                                   | 7 (8.9)                                     | 159 (69.4)                             | 50 (21.8)                              |
| Neutrophil count decreased           | 91 (72.8)                                         | 64 (51.2)                                         | 27 (45.0)                                         | 14 (23.3)                                         | 42 (53.2)                                   | 9 (11.4)                                    | 148 (64.6)                             | 82 (35.8)                              |
| Lymphocyte count decreased           | 92 (73.6)                                         | 37 (29.6)                                         | 32 (54.2)                                         | 7 (11.9)                                          | 42 (53.2)                                   | 12 (15.2)                                   | 156 (68.1)                             | 58 (25.3)                              |
| Platelet count decreased             | 88 (70.4)                                         | 15 (12.0)                                         | 7 (11.7)                                          | 3 (5.0)                                           | 35 (44.3)                                   | 1 (1.3)                                     | 141 (61.6)                             | 21 (9.2)                               |
| Chemistry                            |                                                   |                                                   |                                                   |                                                   |                                             |                                             |                                        |                                        |
| Aspartate aminotransferase increased | 72 (57.6)                                         | 11 (8.8)                                          | 20 (33.3)                                         | 6 (10.0)                                          | 25 (31.6)                                   | 2 (2.5)                                     | 111 (48.5)                             | 14 (6.1)                               |
| Blood alkaline phosphatase increased | 73 (58.4)                                         | 11 (8.8)                                          | 21 (35.6)                                         | 6 (10.2)                                          | 15 (19.2)                                   | 1 (1.3)                                     | 100 (43.9)                             | 12 (5.3)                               |
| Alanine aminotransferaseincreased    | 62 (49.6)                                         | 11 (8.8)                                          | 11 (18.3)                                         | 2 (3.3)                                           | 18 (22.8)                                   | 1 (1.3)                                     | 91 (39.7)                              | 12 (5.2)                               |
| Hypokalemia                          | 44 (35.2)                                         | 6 (4.8)                                           | 12 (20.0)                                         | 5 (8.3)                                           | 22 (27.8)                                   | 4 (5.1)                                     | 77 (33.6)                              | 13 (5.7)                               |
| Blood bilirubinincreased             | 32 (25.6)                                         | 10 (8.0)                                          | 4 (6.8)                                           | 2 (3.4)                                           | 11 (14.1)                                   | 0                                           | 46 (20.2)                              | 11 (4.8)                               |

HER2-positive GC 6.4 mg/kg Pool includes data from studies DS8201-A-J101, DS8201-A-J202, and DS8201-A-U205.

CTCAE = Common Terminology Criteria for Adverse Events; GC = gastric/gastroesophageal junction cancer; HER2 = human epidermal growth factor receptor 2; N = total number of treated subjects; T-DXd = trastuzumab deruxtecan; TPC = treatment of physician's choice (includes subjects who received irinotecan [n = 55] or paclitaxel [n = 7])

Percentages were calculated using the number of subjects with both baseline and post-treatment measurements as the denominator, based on CTCAE gradederived laboratory abnormalities of subjects whose post-baseline gradesworse than baseline grades.

Baseline value was defined as the last non-missing value prior to the first dose of study drug.

## 2.5.5.1. Hematology

Hematology parameters measured in the clinical studies included: platelets, hemoglobin, white blood cell count, absolute neutrophil count, and lymphocytes.

Blood  chemistry  parameters  included:  sodium,  magnesium,  potassium,  calcium,  AST  (aspartate aminotransferase) , ALT (alanine aminotransferase), serum creatinine, TBL (total bilirubin), albumin, and ALP (alkaline phosphatase).

## Anemia

Table 3.1: Summary of Shifts from Baseline to Worst Post-Baseline CTCAE Grade in Anemia (Hemoglobin Decreased) (Safety Analysis Set)

| Group                                         | Baseline CTCAE   | Number (%) of Subjects with Worst Post-Baseline CTCAE Grade   | Number (%) of Subjects with Worst Post-Baseline CTCAE Grade   | Number (%) of Subjects with Worst Post-Baseline CTCAE Grade   | Number (%) of Subjects with Worst Post-Baseline CTCAE Grade   |   Number (%) of Subjects with Worst Post-Baseline CTCAE Grade | Number (%) of Subjects with Worst Post-Baseline CTCAE Grade   |
|-----------------------------------------------|------------------|---------------------------------------------------------------|---------------------------------------------------------------|---------------------------------------------------------------|---------------------------------------------------------------|---------------------------------------------------------------|---------------------------------------------------------------|
|                                               | Grade            | Normal                                                        | 1                                                             | 2                                                             | 3                                                             |                                                             4 | Total                                                         |
| Study J202 with HER2-positive|Normal          |                  | 0                                                             | 4 (3.2)                                                       | 5 (4.0)                                                       | 3 (2.4)                                                       |                                                             0 | 12 (9.6)                                                      |
| GC (primary cohort) T-DXd 6.4 mg/kg (N = 125) | 1                | 0                                                             | 14 (11.2)                                                     | 37 (29.6)                                                     | 20 (16.0)                                                     |                                                             0 | 71 (56.8)                                                     |
|                                               | 2                | 0                                                             | 0                                                             | 14 (11.2) 27 (21.6)                                           |                                                               |                                                             0 | 41 (32.8)                                                     |

<div style=\"page-break-after: always\"></div>

<!-- image -->

|                                                                      |        | 0       | 0         | 0         | 1 (0.8)            |   0 | 1 (0.8)    |
|----------------------------------------------------------------------|--------|---------|-----------|-----------|--------------------|-----|------------|
|                                                                      | 4      | 0       | 0         | 0         | 0                  |   0 | 0          |
|                                                                      | Total  | 0       | 18 (14.4) | 56 (44.8) | 51 (40.8)          |   0 | 125 (100)  |
| Study J202 with HER2-positive|Nomal GC (primary cohort) TPC (N = 62) |        | 0       | 7 (11.7)  | 2 (3.3)   | 1 (1.7)            |   0 | 10 (16.7)  |
| Study J202 with HER2-positive|Nomal GC (primary cohort) TPC (N = 62) | 1      | 0       | 18 (30.0) | 10 (16.7) | 5 (8.3)            |   0 | 33 (55.0)  |
| Study J202 with HER2-positive|Nomal GC (primary cohort) TPC (N = 62) | 2      | 0       | 1 (1.7)   | 8 (13.3)  | 8 (13.3)           |   0 | 17 (28.3)  |
| Study J202 with HER2-positive|Nomal GC (primary cohort) TPC (N = 62) | 3      | 0       | 0         | 0         | 0                  |   0 | 0          |
| Study J202 with HER2-positive|Nomal GC (primary cohort) TPC (N = 62) | 4      | 0       | 0         | 0         | 0                  |   0 | 0          |
| Study J202 with HER2-positive|Nomal GC (primary cohort) TPC (N = 62) | Total  | 0       | 26 (43.3) | 20 (33.3) | 14 (23.3)          |   0 | 60 (100)   |
| Study U205 HER2-positive GC T-DXd 6.4 mg/kg (N = 79)                 | Nomal  | 5 (6.3) | 13 (16.5) | 2 (2.5)   | 0                  |   0 | 20 (25.3)  |
| Study U205 HER2-positive GC T-DXd 6.4 mg/kg (N = 79)                 | 1      | 0       | 26 (32.9) | 17 (21.5) | 4 (5.1)            |   0 | 47 (59.5)  |
| Study U205 HER2-positive GC T-DXd 6.4 mg/kg (N = 79)                 | 2      | 0       | 0         | 9 (11.4)  | 3 (3.8)            |   0 | 12 (15.2)  |
| Study U205 HER2-positive GC T-DXd 6.4 mg/kg (N = 79)                 |        | 0       | 0         | 0         | 0                  |   0 | 0          |
| Study U205 HER2-positive GC T-DXd 6.4 mg/kg (N = 79)                 | 4      | 0       | 0         | 0         | 0                  |   0 | 0          |
| Study U205 HER2-positive GC T-DXd 6.4 mg/kg (N = 79)                 | Total  | 5 (6.3) | 39 (49.4) | 28 (35.4) | 7 (8.9)            |   0 | 79 (100)   |
| HER2-positive GC T-DXd 6.4 mg/kg Pool (N = 229)                      | Normal | 6 (2.6) | 17 (7.4)  | 8 (3.5)   | 3 (1.3)            |   0 | 34 (14.8)  |
| HER2-positive GC T-DXd 6.4 mg/kg Pool (N = 229)                      | 1      | 0       | 42 (18.3) | 61 (26.6) | 29 (12.7)          |   0 | 132 (57.6) |
| HER2-positive GC T-DXd 6.4 mg/kg Pool (N = 229)                      | 2      | 0       | 0         | 28 (12.2) | 34 (14.8)          |   0 | 62 (27.1)  |
| HER2-positive GC T-DXd 6.4 mg/kg Pool (N = 229)                      | 3      | 0       | 0         | 0         | 1 (0.4)            |   0 | 1 (0.4)    |
| HER2-positive GC T-DXd 6.4 mg/kg Pool (N = 229)                      | 4      | 0       | 0         |           | 0                  |   0 | 0          |
| HER2-positive GC T-DXd 6.4 mg/kg Pool (N = 229)                      | Total  | 6 (2.6) | 59 (25.8) |           | 97 (42.4)67 (29.3) |   0 | 229 (100)  |

CTCAE = Common Terminology Criteria for Adverse Events; HER2 = human epidermal growth factor receptor 2; GC = gastric/gastroesophageal junction cancer; N = total number of treated subjects; T-DXd = trastuzumab paclitaxel [n = 7])]

HER2-positive GC 6.4 mg/kg Pool includes data from studies: DS8201-A-J101, DS8201-A-J202, and DS8201-A-U205.

pue sueseq t pey oum nag sisfouy fajes eu ui soefqnsjo naqunu au uo peseq aiam satauaiad dnoa ypa jog at least 1 post-baseline assessment.

Bolded values represent worsening from baseline.

Baseline value was defined as the last non-missing value prior to the first dose of study drug.

Source: Module 5.3.5.3 SCS Table 1.3.1.1

## Platelet count

Study J202 subject no. 81172203 and study U205 subject no. 39022002 experienced an event of major bleeding (tumour haemorrhage) within 14 days of the onset of ≥Grade 3 thrombocytopenia . Of note, 52/229 (22.7%) subjects in the HER2-positive GC Pool received a transfusion within

28 days after the onset of a TEAE of anemia or thrombocytopenia.

<div style=\"page-break-after: always\"></div>

Table 3.2: Summary of Shifts from Baseline toWorst Post-Baseline CTCAE Grade in Platelet Count (Decrease) (Safety Analysis Set)

| Group                                                                       | Baseline CTCAE   | Number (%) of Subjects with Worst Post-Baseline CTCAE Grade   | Number (%) of Subjects with Worst Post-Baseline CTCAE Grade   | Number (%) of Subjects with Worst Post-Baseline CTCAE Grade   | Number (%) of Subjects with Worst Post-Baseline CTCAE Grade   | Number (%) of Subjects with Worst Post-Baseline CTCAE Grade   | Number (%) of Subjects with Worst Post-Baseline CTCAE Grade   |
|-----------------------------------------------------------------------------|------------------|---------------------------------------------------------------|---------------------------------------------------------------|---------------------------------------------------------------|---------------------------------------------------------------|---------------------------------------------------------------|---------------------------------------------------------------|
| Group                                                                       | Grade            | Normal                                                        | 1                                                             | 2                                                             | 3                                                             | 4                                                             | Total                                                         |
| Study J202 with HER2-positive GC (primary cohort) T-DXd 6.4 mg/kg (N = 125) | Normal           | 30 (24.0)                                                     | 54 (43.2)                                                     | 13 (10.4)                                                     | 7 (5.6)                                                       | 2 (1.6)                                                       | 106 (84.8)                                                    |
| Study J202 with HER2-positive GC (primary cohort) T-DXd 6.4 mg/kg (N = 125) |                  | 0                                                             | 7 (5.6)                                                       | 6 (4.8)                                                       | 5 (4.0)                                                       | 1 (0.8)                                                       | 19 (15.2)                                                     |
| Study J202 with HER2-positive GC (primary cohort) T-DXd 6.4 mg/kg (N = 125) | 2                | 0                                                             | 0                                                             | 0                                                             | 0                                                             | 0                                                             | 0                                                             |
| Study J202 with HER2-positive GC (primary cohort) T-DXd 6.4 mg/kg (N = 125) | 3                | 0                                                             | 0                                                             | 0                                                             | 0                                                             | 0                                                             | 0                                                             |
| Study J202 with HER2-positive GC (primary cohort) T-DXd 6.4 mg/kg (N = 125) | 4                | 0                                                             | 0                                                             | 0                                                             | 0                                                             | 0                                                             | 0                                                             |
| Study J202 with HER2-positive GC (primary cohort) T-DXd 6.4 mg/kg (N = 125) | Total            | 30 (24.0)                                                     | 61 (48.8)                                                     | 19 (15.2)                                                     | 12 (9.6)                                                      | 3 (2.4)                                                       | 125 (100)                                                     |
| Study J202 with HER2-positiveNormal GC (primary cohort) TPC (N = 62)        |                  | 47 (78.3)                                                     | 4 (6.7)                                                       | 0                                                             | 2 (3.3)                                                       | 1 (1.7)                                                       | 54 (90.0)                                                     |
| Study J202 with HER2-positiveNormal GC (primary cohort) TPC (N = 62)        | 1                | 1 (1.7)                                                       | 5 (8.3)                                                       | 0                                                             | 0                                                             | 0                                                             | 6 (10.0)                                                      |
| Study J202 with HER2-positiveNormal GC (primary cohort) TPC (N = 62)        | 2                | 0                                                             | 0                                                             | 0                                                             | 0                                                             | 0                                                             | 0                                                             |
| Study J202 with HER2-positiveNormal GC (primary cohort) TPC (N = 62)        | 3                | 0                                                             | 0                                                             | 0                                                             | 0                                                             | 0                                                             | 0                                                             |
| Study J202 with HER2-positiveNormal GC (primary cohort) TPC (N = 62)        | 4                | 0                                                             | 0                                                             | 0                                                             | 0                                                             | 0                                                             | 0                                                             |
| Study J202 with HER2-positiveNormal GC (primary cohort) TPC (N = 62)        | Total            | 48 (80.0)                                                     | 9 (15.0)                                                      | 0                                                             | 2 (3.3)                                                       | 1 (1.7)                                                       | 60 (100)                                                      |
| Study U205 HER2-positive GC T-DXd 6.4 mg/kg (N = 79)                        | Normal           | 38 (48.1)                                                     | 27 (34.2)                                                     | 4 (5.1)                                                       | 1 (1.3)                                                       | 0                                                             | 70 (88.6)                                                     |
| Study U205 HER2-positive GC T-DXd 6.4 mg/kg (N = 79)                        |                  | 1 (1.3)                                                       | 5 (6.3)                                                       | 3 (3.8)                                                       | 0                                                             | 0                                                             | 9 (11.4)                                                      |
| Study U205 HER2-positive GC T-DXd 6.4 mg/kg (N = 79)                        | 2                | 0                                                             | 0                                                             | 0                                                             | 0                                                             | 0                                                             | 0                                                             |
| Study U205 HER2-positive GC T-DXd 6.4 mg/kg (N = 79)                        | 3                | 0                                                             | 0                                                             | 0                                                             | 0                                                             | 0                                                             | 0                                                             |
| Study U205 HER2-positive GC T-DXd 6.4 mg/kg (N = 79)                        | 4                | 0                                                             | 0                                                             | 0                                                             | 0                                                             | 0                                                             | 0                                                             |
| Study U205 HER2-positive GC T-DXd 6.4 mg/kg (N = 79)                        | Total            | 39 (49.4)                                                     | 32 (40.5)                                                     | 7 (8.9)                                                       | 1 (1.3)                                                       | 0                                                             | 79 (100)                                                      |
| HER2-positive GC T-DXd 6.4 mg/kg Pool (N = 229)                             | Normal           | 75 (32.8)                                                     | 91 (39.7)                                                     | 19 (8.3)                                                      | 11 (4.8)                                                      | 4 (1.7)                                                       | 200 (87.3)                                                    |
| HER2-positive GC T-DXd 6.4 mg/kg Pool (N = 229)                             |                  | 1 (0.4)                                                       | 12 (5.2)                                                      | 10 (4.4)                                                      | 5 (2.2)                                                       | 1 (0.4)                                                       | 29 (12.7)                                                     |
| HER2-positive GC T-DXd 6.4 mg/kg Pool (N = 229)                             | 2                | 0                                                             | 0                                                             | 0                                                             | 0                                                             | 0                                                             | 0                                                             |
| HER2-positive GC T-DXd 6.4 mg/kg Pool (N = 229)                             | 3                | 0                                                             | 0                                                             | 0                                                             | 0                                                             | 0                                                             | 0                                                             |
| HER2-positive GC T-DXd 6.4 mg/kg Pool (N = 229)                             | 4                | 0                                                             | 0                                                             | 0                                                             | 0                                                             | 0                                                             | 0                                                             |
| HER2-positive GC T-DXd 6.4 mg/kg Pool (N = 229)                             | Total            | 76 (33.2)103 (45.0)29 (12.7)                                  | 76 (33.2)103 (45.0)29 (12.7)                                  | 76 (33.2)103 (45.0)29 (12.7)                                  | 16 (7.0)                                                      | 5 (2.2)                                                       | 229 (100)                                                     |

CTCAE = Common Terminology Criteria for Adverse Events; HER2 = human epidermal growth factor receptor 2; GC = gastric/gastroesophageal junction cancer; N = total number of treated subjects; T-DXd = trastuzumab paclitaxel [n = 7])

HER2-positive GC 6.4 mg/kg Pool includes data from studies: DS8201-A-J101, DS8201-AJ202, and DS8201-A-U205.

Percentages were based on the number of subjects in the Safety Analysis Set who had a baseline and at least 1 post-b aseline assessment.

Bolded values represent worsening from baseline.

Baseline value was defined as the last non-missing value prior to the first dose of study drug.

Source:Module5.3.5.3SCSTable1.3.1.1

<div style=\"page-break-after: always\"></div>

Table 11: Number and Percentage of Subjects with Events of Bleeding and Thrombocytopenia (Grouped Term) (Safety Analysis Set)

| MedDRA PT                                                                                  | Study J202 HER2-positive GC (Primary Cohort)                                               | Study J202 HER2-positive GC (Primary Cohort)                                               | Study J202 HER2-positive GC (Primary Cohort)                                               | Study J202 HER2-positive GC (Primary Cohort)                                               | Study U205 HER2-positive GC T-DXd 6.4 mg/kg (N = 79)                                       | Study U205 HER2-positive GC T-DXd 6.4 mg/kg (N = 79)                                       | HER2-positive GC T-DXd 6.4 mg/kg Pool (N = 229)                                            | HER2-positive GC T-DXd 6.4 mg/kg Pool (N = 229)                                            |
|--------------------------------------------------------------------------------------------|--------------------------------------------------------------------------------------------|--------------------------------------------------------------------------------------------|--------------------------------------------------------------------------------------------|--------------------------------------------------------------------------------------------|--------------------------------------------------------------------------------------------|--------------------------------------------------------------------------------------------|--------------------------------------------------------------------------------------------|--------------------------------------------------------------------------------------------|
| MedDRA PT                                                                                  | T-DXd 6.4 mg/kg (N = 125) n (%)                                                            | T-DXd 6.4 mg/kg (N = 125) n (%)                                                            | TPC (N = 62) n (%)                                                                         | TPC (N = 62) n (%)                                                                         | n (%)                                                                                      | n (%)                                                                                      | n (%)                                                                                      | n (%)                                                                                      |
| MedDRA PT                                                                                  | Any Grade                                                                                  | Grade ≥3                                                                                   | Any Grade                                                                                  | Grade ≥3                                                                                   | Any Grade                                                                                  | Grade ≥3                                                                                   | Any Grade                                                                                  | Grade ≥3                                                                                   |
| Subjects with any bleeding event with any event of thrombocytopenia (grouped term)         | 12 (9.6)                                                                                   | 3 (2.4)                                                                                    | 0                                                                                          | 0                                                                                          | 3 (3.8)                                                                                    | 1 (1.3)                                                                                    | 17 (7.4)                                                                                   | 4 (1.7)                                                                                    |
| Epistaxis                                                                                  | 3 (2.4)                                                                                    | 0                                                                                          | 0                                                                                          | 0                                                                                          | 2 (2.5)                                                                                    | 0                                                                                          | 7 (3.1)                                                                                    | 0                                                                                          |
| Disseminated intravascular coagulation                                                     | 2 (1.6)                                                                                    | 2 (1.6)                                                                                    | 0                                                                                          | 0                                                                                          | 0                                                                                          | 0                                                                                          | 2 (0.9)                                                                                    | 2 (0.9)                                                                                    |
| Upper gastrointestinal haemorrhage                                                         | 2 (1.6)                                                                                    | 0                                                                                          | 0                                                                                          | 0                                                                                          | 0                                                                                          | 0                                                                                          | 2 (0.9)                                                                                    | 0                                                                                          |
| Gastric haemorrhage                                                                        | 1 (0.8)                                                                                    | 0                                                                                          | 0                                                                                          | 0                                                                                          | 0                                                                                          | 0                                                                                          | 1 (0.4)                                                                                    | 0                                                                                          |
| Haematemesis                                                                               | 0                                                                                          | 0                                                                                          | 0                                                                                          | 0                                                                                          | 1 (1.3)                                                                                    | 1 (1.3)                                                                                    | 1 (0.4)                                                                                    | 1 (0.4)                                                                                    |
| Haematuria                                                                                 | 1 (0.8)                                                                                    | 0                                                                                          | 0                                                                                          | 0                                                                                          | 0                                                                                          | 0                                                                                          | 1 (0.4)                                                                                    | 0                                                                                          |
| Haemorrhage subcutaneous                                                                   | 1 (0.8)                                                                                    | 0                                                                                          | 0                                                                                          | 0                                                                                          | 0                                                                                          | 0                                                                                          | 1 (0.4)                                                                                    | 0                                                                                          |
| Haemorrhoidal haemorrhage                                                                  | 1 (0.8)                                                                                    | 0                                                                                          | 0                                                                                          | 0                                                                                          | 0                                                                                          | 0                                                                                          | 1 (0.4)                                                                                    | 0                                                                                          |
| Melaena                                                                                    | 1 (0.8)                                                                                    | 0                                                                                          | 0                                                                                          | 0                                                                                          | 0                                                                                          | 0                                                                                          | 1 (0.4)                                                                                    | 0                                                                                          |
| Retinal haemorrhage                                                                        | 1 (0.8)                                                                                    | 0                                                                                          | 0                                                                                          | 0                                                                                          | 0                                                                                          | 0                                                                                          | 1 (0.4)                                                                                    | 0                                                                                          |
| Tumour haemorrhage                                                                         | 1 (0.8)                                                                                    | 1 (0.8)                                                                                    | 0                                                                                          | 0                                                                                          | 0                                                                                          | 0                                                                                          | 1 (0.4)                                                                                    | 1 (0.4)                                                                                    |
| Outcome of event of bleeding in subjects with any event of thrombocytopenia (grouped term) | Outcome of event of bleeding in subjects with any event of thrombocytopenia (grouped term) | Outcome of event of bleeding in subjects with any event of thrombocytopenia (grouped term) | Outcome of event of bleeding in subjects with any event of thrombocytopenia (grouped term) | Outcome of event of bleeding in subjects with any event of thrombocytopenia (grouped term) | Outcome of event of bleeding in subjects with any event of thrombocytopenia (grouped term) | Outcome of event of bleeding in subjects with any event of thrombocytopenia (grouped term) | Outcome of event of bleeding in subjects with any event of thrombocytopenia (grouped term) | Outcome of event of bleeding in subjects with any event of thrombocytopenia (grouped term) |
| Fatal                                                                                      | 1 (0.8)                                                                                    | 1 (0.8)                                                                                    | 0                                                                                          | 0                                                                                          | 0                                                                                          | 0                                                                                          | 1 (0.4)                                                                                    | 1 (0.4)                                                                                    |
| Not Recovered/Not Resolved                                                                 | 6 (4.8)                                                                                    | 2 (1.6)                                                                                    | 0                                                                                          | 0                                                                                          | 1 (1.3)                                                                                    | 0                                                                                          | 9 (3.9)                                                                                    | 2 (0.9)                                                                                    |
| Recovering/Resolving                                                                       | 0                                                                                          | 0                                                                                          | 0                                                                                          | 0                                                                                          | 0                                                                                          | 0                                                                                          | 0                                                                                          | 0                                                                                          |
| Recovered/Resolved with Sequelae                                                           | 0                                                                                          | 0                                                                                          | 0                                                                                          | 0                                                                                          | 0                                                                                          | 0                                                                                          | 0                                                                                          | 0                                                                                          |
| Recovered/Resolved                                                                         | 5 (4.0)                                                                                    | 0                                                                                          | 0                                                                                          | 0                                                                                          | 2 (2.5)                                                                                    | 1 (1.3)                                                                                    | 7 (3.1)                                                                                    | 1 (0.4)                                                                                    |

In the HER2-positive GC Pool, there were a total of 52 (22.7%) patients who received a transfusion within 28 days after the onset of a TEAE of anaemia or thrombocytopenia (Module 5.3.5.3 SCS Table 1.2.3.2).  The reasons for the transfusion were as follows (Module 5.3.5.3 SCS Listing 1.8):

<div style=\"page-break-after: always\"></div>

- Anaemia, n = 42.
- Anaemia and platelet count decreased, n = 7.
- Platelet count decreased, n = 3.

## Neutrophil count decrease

Two subjects in Study J202 experienced a ≥Grade 3 event of sepsis within 14 days of the onset of neutropenia (grouped term) or febrile neutropenia.

A total of 35/229 (15.3%) subjects in the HER2-positive GC Pool were treated with G-CSF within 28 days after onset of neutropenia or febrile neutropenia, with similar proportion of subjects between the T-DXd and the TPC arm of Study J202.

Table 3.3: Summary of Shifts from Baseline to Worst Post-Baseline CTCAE Grade in Neutrophil Count Decreased (Safety Analysis Set)

| Group                                                                        | Baseline CTCAE   | Number (%) of Subjects with Worst Post-Baseline CTCAE Grade   | Number (%) of Subjects with Worst Post-Baseline CTCAE Grade   | Number (%) of Subjects with Worst Post-Baseline CTCAE Grade   | Number (%) of Subjects with Worst Post-Baseline CTCAE Grade   | Number (%) of Subjects with Worst Post-Baseline CTCAE Grade   | Number (%) of Subjects with Worst Post-Baseline CTCAE Grade   |
|------------------------------------------------------------------------------|------------------|---------------------------------------------------------------|---------------------------------------------------------------|---------------------------------------------------------------|---------------------------------------------------------------|---------------------------------------------------------------|---------------------------------------------------------------|
|                                                                              | Grade            | Normal                                                        | 1                                                             | 2                                                             | 3                                                             | 4                                                             | Total                                                         |
| Study J202 with HER2- positive GC (primary cohort) T-DXd 6.4 mg/kg (N = 125) | Normal           | 33 (26.4)                                                     | 6 (4.8)                                                       | 21 (16.8)                                                     | 48 (38.4)                                                     | 15 (12.0)                                                     | 123 (98.4)                                                    |
| Study J202 with HER2- positive GC (primary cohort) T-DXd 6.4 mg/kg (N = 125) |                  | 0                                                             | 0                                                             | 0                                                             | 1 (0.8)                                                       | 0                                                             | 1 (0.8)                                                       |
| Study J202 with HER2- positive GC (primary cohort) T-DXd 6.4 mg/kg (N = 125) | 2                | 0                                                             | 0                                                             | 1 (0.8)                                                       | 0                                                             | 0                                                             | 1 (0.8)                                                       |
| Study J202 with HER2- positive GC (primary cohort) T-DXd 6.4 mg/kg (N = 125) | 3                | 0                                                             | 0                                                             | 0                                                             | 0                                                             | 0                                                             | 0                                                             |
| Study J202 with HER2- positive GC (primary cohort) T-DXd 6.4 mg/kg (N = 125) | 4                | 0                                                             | 0                                                             | 0                                                             | 0                                                             | 0                                                             | 0                                                             |
| Study J202 with HER2- positive GC (primary cohort) T-DXd 6.4 mg/kg (N = 125) | Total            | 33 (26.4)                                                     | 6 (4.8)                                                       | 22 (17.6)                                                     | 49 (39.2)                                                     | 15 (12.0)                                                     | 125 (100)                                                     |
| StudyJ202withHER2- positive GC (primary cohort) TPC (N = 62)                 | Normal           | 33 (55.0)                                                     | 3 (5.0)                                                       | 10 (16.7)                                                     | 8 (13.3)                                                      | 5 (8.3)                                                       | 59 (98.3)                                                     |
| StudyJ202withHER2- positive GC (primary cohort) TPC (N = 62)                 | 1                | 0                                                             | 0                                                             | 0                                                             | 1 (1.7)                                                       | 0                                                             | 1 (1.7)                                                       |
| StudyJ202withHER2- positive GC (primary cohort) TPC (N = 62)                 | 2                | 0                                                             | 0                                                             | 0                                                             | 0                                                             | 0                                                             | 0                                                             |
| StudyJ202withHER2- positive GC (primary cohort) TPC (N = 62)                 | 3                | 0                                                             | 0                                                             | 0                                                             | 0                                                             | 0                                                             | 0                                                             |
| StudyJ202withHER2- positive GC (primary cohort) TPC (N = 62)                 | 4                | 0                                                             | 0                                                             | 0                                                             | 0                                                             | 0                                                             | 0                                                             |
|                                                                              | Total            | 33 (55.0)                                                     | 3 (5.0)                                                       | 10 (16.7)                                                     | 9 (15.0)                                                      | 5 (8.3)                                                       | 60 (100)                                                      |
| Study U205HER2-positive                                                      | Normal           | 37 (46.8)                                                     | 12 (15.2)                                                     | 21 (26.6)                                                     | 5 (6.3)                                                       | 4 (5.1)                                                       | 79 (100)                                                      |
| GC T-DXd 6.4 mg/kg (N = 79)                                                  | 1                | 0                                                             | 0                                                             | 0                                                             | 0                                                             | 0                                                             | 0                                                             |
| GC T-DXd 6.4 mg/kg (N = 79)                                                  | 2                | 0                                                             | 0                                                             | 0                                                             | 0                                                             | 0                                                             | 0                                                             |
| GC T-DXd 6.4 mg/kg (N = 79)                                                  | 3                | 0                                                             | 0                                                             | 0                                                             | 0                                                             | 0                                                             | 0                                                             |

<div style=\"page-break-after: always\"></div>

|                                                 | 4        | 0           | 0          | 0           | 0                 | 0          | 0                  |
|-------------------------------------------------|----------|-------------|------------|-------------|-------------------|------------|--------------------|
|                                                 | Total    | 37 (46.8)   | 12 (15.2)  | 21 (26.6)   | 5 (6.3)           | 4 (5.1)    | 79 (100)           |
| HER2-positive GC T-DXd 6.4 mg/kg Pool (N = 229) | Normal 1 | 80 (34.9) 0 | 18 (7.9) 0 | 48 (21.0) 0 | 59 (25.8) 2 (0.9) | 21 (9.2) 0 | 226 (98.7) 2 (0.9) |
|                                                 | 2        | 0           | 0          | 1 (0.4)     | 0                 | 0          | 1 (0.4)            |
|                                                 | 3        | 0           | 0          | 0           | 0                 | 0          | 0                  |
|                                                 | 4        | 0           | 0          | 0           | 0                 | 0          | 0                  |
|                                                 | Total    | 80 (34.9)   | 18 (7.9)   | 49 (21.4)   | 61 (26.6)         | 21 (9.2)   | 229 (100)          |

CTCAE = Common Terminology Criteria for Adverse Events; HER2 = human epidermal growth factor receptor 2; GC = gastric/gastroesophageal junction cancer; N = total number of treated subjects; T-DXd = trastuzumab deruxtecan; TPC = treatment of physician's choice (includes subjects who received irinotecan [n = 55] or paclitaxel [n = 7])

HER2-positive GC 6.4 mg/kg Pool includes data from studies: DS8201-A-J101, DS8201-A-J202, and DS8201-A-U205.

For each group, percentages were based on the number of subjects in the Safety Analysis Set who had a baseline and at least 1 post-baseline assessment.

Baseline value was defined as the last non-missing value prior to the first dose of study drug.

Bolded values represent worsening from baseline.

Source:Module5.3.5.3SCSTable1.3.1.1

The  MAH  has  reviewed  all  subjects  who  received  G-CSF  during  T-DXd  treatment  and  identified 38 (16.6%) subjects in the HER2-positive Pool who received G-CSF as either prophylaxis or treatment. Subjects who received G-CSF as treatment are presented in Appendix 2 Listing 3. Two of the 38 subjects received  G-CSF  as  primary  prophylaxis  for  neutropenia  (Subject No. 81132201  in  Study  J202  and Subject  No.  10072002  in  Study  U205).    In  addition,  2 subjects  in  Study  U205  received  G-CSF  as secondary prophylaxis for neutropenia (Subject Nos. 44012005 and 39022004). Given the limited use of G-CSF as prophylaxis, the MAH considers that the overall incidence of these events is a true reflection of the toxicity profile in neutropenia and febrile neutropenia. Based on these observations, the MAH considers that neutropenia and febrile neutropenia can be managed by following the guidance on dose modification provided in the SmPC and through standard clinical practice.

<div style=\"page-break-after: always\"></div>

## Lymphocyte count decrease

Table 3.4: Summary of Shifts from Baseline to Worst Post-Baseline CTCAE Grade in Lymphocyte Count Decreased (Safety Analysis Set)

<!-- image -->

| Group                                                                      | Baseline CTCAE   | Number (%o) of Subjects with Worst Post-Baseline CTCAE Grade   | Number (%o) of Subjects with Worst Post-Baseline CTCAE Grade   | Number (%o) of Subjects with Worst Post-Baseline CTCAE Grade   | Number (%o) of Subjects with Worst Post-Baseline CTCAE Grade   | Number (%o) of Subjects with Worst Post-Baseline CTCAE Grade   | Number (%o) of Subjects with Worst Post-Baseline CTCAE Grade   |
|----------------------------------------------------------------------------|------------------|----------------------------------------------------------------|----------------------------------------------------------------|----------------------------------------------------------------|----------------------------------------------------------------|----------------------------------------------------------------|----------------------------------------------------------------|
|                                                                            | Grade            | Normal                                                         | 1                                                              | 2                                                              | 3                                                              | 4                                                              |                                                                |
| Study J202 with HER2-positive GC (primary cohort) T-DXd 6.4 mg/kg (N= 125) | Normal           | 15 (12.0)                                                      | 13 (10.4)20 (16.0)                                             |                                                                | 9 (7.2)                                                        | 1 (0.8)                                                        | 58 (46.4)                                                      |
| Study J202 with HER2-positive GC (primary cohort) T-DXd 6.4 mg/kg (N= 125) |                  | 1 (0.8)                                                        | 12 (9.6)                                                       | 22 (17.6)                                                      | 13 (10.4)                                                      | 0                                                              | 48 (38.4)                                                      |
| Study J202 with HER2-positive GC (primary cohort) T-DXd 6.4 mg/kg (N= 125) | 2                | 0                                                              | 0                                                              | 3 (2.4)                                                        | 8 (6.4)                                                        | 4 (3.2)                                                        | 15 (12.0)                                                      |
| Study J202 with HER2-positive GC (primary cohort) T-DXd 6.4 mg/kg (N= 125) | 3                | 0                                                              | 0                                                              | 0                                                              | 2 (1.6)                                                        | 2 (1.0)                                                        | 4 (3.2)                                                        |
| Study J202 with HER2-positive GC (primary cohort) T-DXd 6.4 mg/kg (N= 125) | 4                | 0                                                              | 0                                                              | 0                                                              | 0                                                              | 0                                                              | 0                                                              |
| Study J202 with HER2-positive GC (primary cohort) T-DXd 6.4 mg/kg (N= 125) | Total            | 16 (12.8)                                                      | 25 (20.0)                                                      | 45 (36.0)                                                      | 32 (25.6)                                                      | 7 (5.6)                                                        | 125 (100)                                                      |
| Study J202 with HER2-positive GC (primary cohort) TPC (N=62)               | Normal           | 11 (18.6)                                                      | 10 (16.9)                                                      | 4 (6.8)                                                        | 1 (1.7)                                                        | 0                                                              | 26 (44.1)                                                      |
| Study J202 with HER2-positive GC (primary cohort) TPC (N=62)               | 1                | 1 (1.7)                                                        | 10 (16.9)                                                      | 11 (18.6)                                                      | 3 (5.1)                                                        | 1 (1.7)                                                        | 26 (44.1)                                                      |
| Study J202 with HER2-positive GC (primary cohort) TPC (N=62)               | 2                | 0                                                              | 2 (3.4)                                                        | 1 (1.7)                                                        | 1 (1.7)                                                        | 1 (1.7)                                                        | 5 (8.5)                                                        |
| Study J202 with HER2-positive GC (primary cohort) TPC (N=62)               | 3                | 0                                                              | 0                                                              | 1 (1.7)                                                        | 1 (1.7)                                                        | 0                                                              | 2 (3.4)                                                        |
| Study J202 with HER2-positive GC (primary cohort) TPC (N=62)               | 4                | 0                                                              | 0                                                              | 0                                                              | 0                                                              | 0                                                              | 0                                                              |
| Study J202 with HER2-positive GC (primary cohort) TPC (N=62)               | Total            | 12 (20.3)                                                      | 22 (37.3)                                                      | 17 (28.8)                                                      | 6 (10.2)                                                       | 2 (3.4)                                                        | 59 (100)                                                       |
| Study U205 HER2-positive GC T-DXd 6.4 mg/kg (N = 79)                       | Normal           | 27 (34.2)                                                      | 13 (16.5)                                                      | 7 (8.9)                                                        | 5 (6.3)                                                        | 0                                                              | 52 (65.8)                                                      |
| Study U205 HER2-positive GC T-DXd 6.4 mg/kg (N = 79)                       | 1                | 0                                                              | 2 (2.5)                                                        | 10 (12.7)                                                      | 1 (1.3)                                                        | 0                                                              | 13 (16.5)                                                      |
| Study U205 HER2-positive GC T-DXd 6.4 mg/kg (N = 79)                       | 2                | 0                                                              | 0                                                              | 7 (8.9)                                                        | 6 (7.6)                                                        | 0                                                              | 13 (16.5)                                                      |
| Study U205 HER2-positive GC T-DXd 6.4 mg/kg (N = 79)                       | m                | 0                                                              | 0                                                              | 0                                                              | 1 (1.3)                                                        | 0                                                              | 1 (1.3)                                                        |
| Study U205 HER2-positive GC T-DXd 6.4 mg/kg (N = 79)                       | 4                | 0                                                              | 0                                                              | 0                                                              | 0                                                              | 0                                                              | 0                                                              |
| Study U205 HER2-positive GC T-DXd 6.4 mg/kg (N = 79)                       | Total            | 27 (34.2)                                                      | 15 (19.0)                                                      | 24 (30.4)                                                      | 13 (16.5)                                                      | 0                                                              | 79 (100)                                                       |
| HER2-positive GC T-DXd 6.4 mg/kg Pool (N = 229)                            | Normal           |                                                                | 45 (19.7)31 (13.5)33 (14.4)                                    |                                                                | 18 (7.9)                                                       | 2 (0.9)                                                        | 129 (56.3)                                                     |
| HER2-positive GC T-DXd 6.4 mg/kg Pool (N = 229)                            |                  | 1 (0.4)                                                        | 14 (6.1)                                                       | 34 (14.8)                                                      | 15 (6.6)                                                       | 1 (0.4)                                                        | 65 (28.4)                                                      |
| HER2-positive GC T-DXd 6.4 mg/kg Pool (N = 229)                            | 2                | 0                                                              | 0                                                              | 10 (4.4)                                                       | 16 (7.0)                                                       | 4 (1.7)                                                        | 30 (13.1)                                                      |
| HER2-positive GC T-DXd 6.4 mg/kg Pool (N = 229)                            | 3                | 0                                                              | 0                                                              | 0                                                              | 3 (1.3)                                                        | 2 (0.9)                                                        | 5 (2.2)                                                        |
| HER2-positive GC T-DXd 6.4 mg/kg Pool (N = 229)                            | 4                | 0                                                              | 0                                                              | 0                                                              | 0                                                              | 0                                                              | 0                                                              |
| HER2-positive GC T-DXd 6.4 mg/kg Pool (N = 229)                            | Total            |                                                                |                                                                | 46 (20.1)45 (19.7)77 (33.6)                                    | 52 (22.7)                                                      | 9 (3.9)                                                        | 229 (100)                                                      |

CTCAE = Common Terminology Criteria for Adverse Events; HER2 =human epidermal growth factor receptor 2;

GC = gastric/gastroesophageal junction cancer; N = total number of treated subjects; T-DXd = trastuzumab paclitaxel [n = 7])

HER2-positive GC 6.4 mg/kg Pool includes data from studies: DS8201-A-J101, DS8201-A-J202, and DS8201-A-U205.

For each group, percentages were based on the number of subjects in the Safety Analysis Set who had a baseline and at least 1 post-baseline assessment.

Baseline value was defined as the last non-missing value prior to the first dose of study drug.

Bolded values represent worsening from baseline.

Source: Module 5.3.5.3 SCS Table 1.3.1.1

<div style=\"page-break-after: always\"></div>

## 2.5.5.2. Blood chemistry

## Renal function - serum creatinine increase

Table 3.5: Summary of ShiftsfromBaseline toWorstPost-Baseline CTCAEGrade in Serum Creatinine Increased (Safety Analysis Set)

| Group                                                                        | Baseline CTCAE   | Number (%o) of Subjects with Worst Post-Baseline CTCAE Grade   | Number (%o) of Subjects with Worst Post-Baseline CTCAE Grade   | Number (%o) of Subjects with Worst Post-Baseline CTCAE Grade   | Number (%o) of Subjects with Worst Post-Baseline CTCAE Grade   | Number (%o) of Subjects with Worst Post-Baseline CTCAE Grade   | Number (%o) of Subjects with Worst Post-Baseline CTCAE Grade   |
|------------------------------------------------------------------------------|------------------|----------------------------------------------------------------|----------------------------------------------------------------|----------------------------------------------------------------|----------------------------------------------------------------|----------------------------------------------------------------|----------------------------------------------------------------|
|                                                                              | Grade            | Normal                                                         | 1                                                              | 2                                                              | 3                                                              | 4                                                              | Total                                                          |
| Study J202 with HER2- positive GC (primary cohort) T-DXd 6.4 mg/kg (N = 125) | Normal           | 3 (2.4)                                                        | 98 (78.4)                                                      | 8 (6.4)                                                        | 1 (0.8)                                                        | 0                                                              | 110 (88.0)                                                     |
| Study J202 with HER2- positive GC (primary cohort) T-DXd 6.4 mg/kg (N = 125) |                  | 2 (1.6)                                                        | 8 (6.4)                                                        | 4 (3.2)                                                        | 0                                                              | 0                                                              | 14 (11.2)                                                      |
| Study J202 with HER2- positive GC (primary cohort) T-DXd 6.4 mg/kg (N = 125) | 2                | 0                                                              | 0                                                              | 1 (0.8)                                                        | 0                                                              | 0                                                              | 1 (0.8)                                                        |
| Study J202 with HER2- positive GC (primary cohort) T-DXd 6.4 mg/kg (N = 125) | 3                | 0                                                              | 0                                                              | 0                                                              | 0                                                              | 0                                                              | 0                                                              |
| Study J202 with HER2- positive GC (primary cohort) T-DXd 6.4 mg/kg (N = 125) | 4                | 0                                                              | 0                                                              | 0                                                              | 0                                                              | 0                                                              | 0                                                              |
| Study J202 with HER2- positive GC (primary cohort) T-DXd 6.4 mg/kg (N = 125) | Total            | 5 (4.0)                                                        | 106 (84.8)                                                     | 13 (10.4)                                                      | 1 (0.8)                                                        | 0                                                              | 125 (100)                                                      |
| Study J202 with HER2- positive GC (primary cohort) TPC (N = 62)              | Normal           | 8 (13.6)                                                       | 37 (62.7)                                                      | 0                                                              | 1 (1.7)                                                        | 1 (1.7)                                                        | 47 (79.7)                                                      |
| Study J202 with HER2- positive GC (primary cohort) TPC (N = 62)              |                  | 2 (3.4)                                                        | 7 (11.9)                                                       | 2 (3.4)                                                        | 0                                                              | 0                                                              | 11 (18.6)                                                      |
| Study J202 with HER2- positive GC (primary cohort) TPC (N = 62)              | [2               | 0                                                              | 0                                                              | 1 (1.7)                                                        | 0                                                              | 0                                                              | 1 (1.7)                                                        |
| Study J202 with HER2- positive GC (primary cohort) TPC (N = 62)              | 3                | 0                                                              | 0                                                              | 0                                                              | 0                                                              | 0                                                              | 0                                                              |
| Study J202 with HER2- positive GC (primary cohort) TPC (N = 62)              | 4                | 0                                                              | 0                                                              | 0                                                              | 0                                                              | 0                                                              | 0                                                              |
| Study J202 with HER2- positive GC (primary cohort) TPC (N = 62)              | Total            | 10 (16.9)                                                      | 44 (74.6)                                                      | 3 (5.1)                                                        | 1 (1.7)                                                        | 1 (1.7)                                                        | 59 (100)                                                       |
| StudyU205HER2-positive GC T-DXd 6.4 mg/kg (N = 79)                           | Normal           | 62 (78.5)                                                      | 7 (8.9)                                                        | 0                                                              | 1 (1.3)                                                        | 0                                                              | 70 (88.6)                                                      |
| StudyU205HER2-positive GC T-DXd 6.4 mg/kg (N = 79)                           |                  | 0                                                              | 9 (11.4)                                                       | 0                                                              | 0                                                              | 0                                                              | 9 (11.4)                                                       |
| StudyU205HER2-positive GC T-DXd 6.4 mg/kg (N = 79)                           | 2                | 0                                                              | 0                                                              | 0                                                              | 0                                                              | 0                                                              | 0                                                              |
| StudyU205HER2-positive GC T-DXd 6.4 mg/kg (N = 79)                           | 3                | 0                                                              | 0                                                              | 0                                                              | 0                                                              | 0                                                              | 0                                                              |
| StudyU205HER2-positive GC T-DXd 6.4 mg/kg (N = 79)                           | 4                | 0                                                              | 0                                                              | 0                                                              | 0                                                              | 0                                                              | 0                                                              |
| StudyU205HER2-positive GC T-DXd 6.4 mg/kg (N = 79)                           | Total            | 62 (78.5)                                                      | 16 (20.3)                                                      | 0                                                              | 1 (1.3)                                                        | 0                                                              | 79 (100)                                                       |
| HER2-positive GC T-DXd 6.4 mg/kg Pool (N = 229)                              | Normal           | 65 (28.4)                                                      | 122 (53.3)                                                     | 12 (5.2)                                                       | 2 (0.9)                                                        | 0                                                              | 201 (87.8)                                                     |
| HER2-positive GC T-DXd 6.4 mg/kg Pool (N = 229)                              | 一                | 2 (0.9)                                                        | 20 (8.7)                                                       | 5 (2.2)                                                        | 0                                                              | 0                                                              | 27 (11.8)                                                      |
| HER2-positive GC T-DXd 6.4 mg/kg Pool (N = 229)                              | 2                | 0                                                              | 0                                                              | 1 (0.4)                                                        | 0                                                              | 0                                                              | 1 (0.4)                                                        |
| HER2-positive GC T-DXd 6.4 mg/kg Pool (N = 229)                              | 3                | 0                                                              | 0                                                              | 0                                                              | 0                                                              | 0                                                              | 0                                                              |
| HER2-positive GC T-DXd 6.4 mg/kg Pool (N = 229)                              | 4                | 0                                                              | 0                                                              | 0                                                              | 0                                                              | 0                                                              | 0                                                              |
| HER2-positive GC T-DXd 6.4 mg/kg Pool (N = 229)                              | Total            | 67 (29.3)                                                      | 142 (62.0)                                                     | 18 (7.9)                                                       | 2 (0.9)                                                        | 0                                                              | 229 (100)                                                      |

HER2-positive GC 6.4 mg/kg Pool includes data from studies: DS8201-A-J101, DS8201-A-J202, and DS8201-AU205.

For each group, percentages were based on the number of subjects in the Safety Analysis Set who had a baseline and at least I post-baseline assessment.

Bolded values represent worsening from baseline.

Baseline value was defined as the last non-missing value prior to the first dose of study drug.

Source:Module5.3.5.3SCSTable1.3.1.2

## Renal function - creatinine clearance

Creatinine clearance is defined using the Cockcroft-Gault equation.

<div style=\"page-break-after: always\"></div>

Table 3.6: Renal Function Abnormalities (Safety Analysis Set)

| Creatinine Clearance (mL/min) a   | Number(%o)of Subjects     | Number(%o)of Subjects   | Number(%o)of Subjects                               | Number(%o)of Subjects                           |
|-----------------------------------|---------------------------|-------------------------|-----------------------------------------------------|-------------------------------------------------|
| Creatinine Clearance (mL/min) a   | StudyJ202HER2-positive    | StudyJ202HER2-positive  | Study U205 HER2-positive GC T-DXd 6.4 mg/kg (N =79) | HER2-positive GC T-DXd 6.4 mg/kg Pool (N = 229) |
| Creatinine Clearance (mL/min) a   | GC (Primary Cohort)       | GC (Primary Cohort)     | Study U205 HER2-positive GC T-DXd 6.4 mg/kg (N =79) | HER2-positive GC T-DXd 6.4 mg/kg Pool (N = 229) |
| Creatinine Clearance (mL/min) a   | T-DXd 6.4 mg/kg (N = 125) | TPC (N =62)             | Study U205 HER2-positive GC T-DXd 6.4 mg/kg (N =79) | HER2-positive GC T-DXd 6.4 mg/kg Pool (N = 229) |
| Non-missing n b                   | 125                       | 59                      | 63                                                  | 212                                             |
| Minimumpost-baseline              | Minimumpost-baseline      | Minimumpost-baseline    | Minimumpost-baseline                                | Minimumpost-baseline                            |
| <30                               | 6 (4.8)                   | 4 (6.8)                 | 0                                                   | 7 (3.3)                                         |
| 30 -<60                           | 54 (43.2)                 | 24 (40.7)               | 10 (15.9)                                           | 81 (38.2)                                       |
| 60 -<90                           | 51 (40.8)                 | 25 (42.4)               | 26 (41.3)                                           | 83 (39.2)                                       |
| ≥90                               | 14 (11.2)                 | 6 (10.2)                | 27 (42.9)                                           | 41 (19.3)                                       |

Percentages were calculated using the non-missing n as the denominator.

b Non-missing n is the number of subjects with both baseline and post-baseline data.

a Creatinine clearance computed by the calculation by each site.

Source:Module5.3.5.3SCSTable1.3.1.4

<div style=\"page-break-after: always\"></div>

## Renal function - potassium decrease

Table 3.7: Summary of Shifts from Baseline to Worst Post-Baseline CTCAE Grade in Potassium Decreased (Hypokalemia) (Safety Analysis Set)

<!-- image -->

| Group                                                                       | Baseline CTCAE   | Number (%) of Subjects with Worst Post-Baseline CTCAE Grade   | Number (%) of Subjects with Worst Post-Baseline CTCAE Grade   | Number (%) of Subjects with Worst Post-Baseline CTCAE Grade   | Number (%) of Subjects with Worst Post-Baseline CTCAE Grade   | Number (%) of Subjects with Worst Post-Baseline CTCAE Grade   | Number (%) of Subjects with Worst Post-Baseline CTCAE Grade   |
|-----------------------------------------------------------------------------|------------------|---------------------------------------------------------------|---------------------------------------------------------------|---------------------------------------------------------------|---------------------------------------------------------------|---------------------------------------------------------------|---------------------------------------------------------------|
|                                                                             | Grade            | Normal                                                        | 1                                                             | 2                                                             | 3                                                             | 4                                                             | Total                                                         |
| Study J202 with HER2- positive GC (primary cohort) T-DXd 6.4 mg/kg (N= 125) | Normal           | 80 (64.0)                                                     | 0                                                             | 38 (30.4)                                                     | 6 (4.8)                                                       | 0                                                             | 124 (99.2)                                                    |
| Study J202 with HER2- positive GC (primary cohort) T-DXd 6.4 mg/kg (N= 125) |                  | 0                                                             | 0                                                             | 0                                                             | 0                                                             | 0                                                             | 0                                                             |
| Study J202 with HER2- positive GC (primary cohort) T-DXd 6.4 mg/kg (N= 125) | 2                | 0                                                             | 0                                                             | 1 (0.8)                                                       | 0                                                             | 0                                                             | 1 (0.8)                                                       |
| Study J202 with HER2- positive GC (primary cohort) T-DXd 6.4 mg/kg (N= 125) |                  | 0                                                             | 0                                                             | 0                                                             | 0                                                             | 0                                                             | 0                                                             |
| Study J202 with HER2- positive GC (primary cohort) T-DXd 6.4 mg/kg (N= 125) | 4                | 0                                                             | 0                                                             | 0                                                             | 0                                                             | 0                                                             | 0                                                             |
| Study J202 with HER2- positive GC (primary cohort) T-DXd 6.4 mg/kg (N= 125) | Total            | 80 (64.0)                                                     | 0                                                             | 39 (31.2)                                                     | 6 (4.8)                                                       |                                                               | 125 (100)                                                     |
| Study J202 with HER2- positive GC (primary cohort) TPC (N = 62)             | Normal           | 47 (78.3)                                                     | 0                                                             | 7 (11.7)                                                      | 3 (5.0)                                                       | 1 (1.7)                                                       | 58 (96.7)                                                     |
| Study J202 with HER2- positive GC (primary cohort) TPC (N = 62)             |                  | 0                                                             | 0                                                             | 0                                                             | 0                                                             | 0                                                             | 0                                                             |
| Study J202 with HER2- positive GC (primary cohort) TPC (N = 62)             | 2                | 0                                                             | 0                                                             | 1 (1.7)                                                       | 1 (1.7)                                                       | 0                                                             | 2 (3.3)                                                       |
| Study J202 with HER2- positive GC (primary cohort) TPC (N = 62)             | 3                | 0                                                             | 0                                                             | 0                                                             | 0                                                             | 0                                                             | 0                                                             |
| Study J202 with HER2- positive GC (primary cohort) TPC (N = 62)             | 4                | 0                                                             | 0                                                             | 0                                                             | 0                                                             | 0                                                             | 0                                                             |
| Study J202 with HER2- positive GC (primary cohort) TPC (N = 62)             | Total            | 47 (78.3)                                                     | 0                                                             | 8 (13.3)                                                      | 4 (6.7)                                                       | 1 (1.7)                                                       | 60 (100)                                                      |
| Study U205HER2-positive GC T-DXd 6.4 mg/kg (N= 79)                          | Normal           | 53 (67.1)                                                     | 18 (22.8)                                                     | 0                                                             | 3 (3.8)                                                       | 1 (1.3)                                                       | 75 (94.9)                                                     |
| Study U205HER2-positive GC T-DXd 6.4 mg/kg (N= 79)                          |                  | 1 (1.3)                                                       | 3 (3.8)                                                       | 0                                                             | 0                                                             | 0                                                             | 4 (5.1)                                                       |
| Study U205HER2-positive GC T-DXd 6.4 mg/kg (N= 79)                          | 2                | 0                                                             | 0                                                             | 0                                                             | 0                                                             | 0                                                             | 0                                                             |
| Study U205HER2-positive GC T-DXd 6.4 mg/kg (N= 79)                          |                  | 0                                                             | 0                                                             | 0                                                             | 0                                                             | 0                                                             | 0                                                             |
| Study U205HER2-positive GC T-DXd 6.4 mg/kg (N= 79)                          | 4                | 0                                                             | 0                                                             | 0                                                             | 0                                                             | 0                                                             | 0                                                             |
| Study U205HER2-positive GC T-DXd 6.4 mg/kg (N= 79)                          | Total            | 54 (68.4)                                                     | 21 (26.6)                                                     | 0                                                             | 3 (3.8)                                                       | 1 (1.3)                                                       | 79 (100)                                                      |
| HER2-positive GC T-DXd 6.4 mg/kg Pool (N = 229)                             | Normal           | 147 (64.2)                                                    | 18 (7.9)                                                      | 46 (20.1)                                                     | 11 (4.8)                                                      | 2 (0.9)                                                       | 224 (97.8)                                                    |
| HER2-positive GC T-DXd 6.4 mg/kg Pool (N = 229)                             |                  | 1 (0.4)                                                       | 3 (1.3)                                                       | 0                                                             | 0                                                             | 0                                                             | 4 (1.7)                                                       |
| HER2-positive GC T-DXd 6.4 mg/kg Pool (N = 229)                             | 2                | 0                                                             | 0                                                             | 1 (0.4)                                                       | 0                                                             | 0                                                             | 1 (0.4)                                                       |
| HER2-positive GC T-DXd 6.4 mg/kg Pool (N = 229)                             | 3                | 0                                                             | 0                                                             | 0                                                             | 0                                                             | 0                                                             | 0                                                             |
| HER2-positive GC T-DXd 6.4 mg/kg Pool (N = 229)                             | 4                | 0                                                             | 0                                                             | 0                                                             | 0                                                             | 0                                                             | 0                                                             |
| HER2-positive GC T-DXd 6.4 mg/kg Pool (N = 229)                             | Total            | 148 (64.6)                                                    | 21 (9.2)                                                      | 47 (20.5)                                                     | 11 (4.8)                                                      | 2 (0.9)                                                       | 229 (100)                                                     |

at least 1 post-baseline assessment.

Bolded values represent worsening from baseline.

Baseline value was defined as the last non-missing value prior to the first dose of study drug.

Source: Module 5.3.5.3 SCS Table 1.3.1.2

## Liver function test (LFT)

At enrollment , a total of 57/229 (24.9%) subjects in the HER2-positive GC Pool had mild and 1/229 (0.4%) had moderate hepatic impairment.

A total of 130/229 (56.8%) subjects in the HER2-positive GC Pool had liver metastases.

In  the  HER2-positive  GC  Pool,  8/229  ( 5.3% )  subjects  had  post-baseline  LFT  values  that  met  the biochemical criteria for potential Hy's Law (ALT or AST ≥3 × ULN and TBL ≥2 × ULN), of which 6/125

<div style=\"page-break-after: always\"></div>

(4.8%) subjects were in the Study J202 T-DXd arm and none in Study U205 (Table 3.8). Additionally, 3/59 ( 5.1% ) in the J202 TPC arm met the biochemical criteria of potential Hy's Law.

In all 11 subjects, the events of potential Hy's Law were determined not to be causally associated with study drug due to alternative etiologies at the time of occurrence of the events, the most common of which were biliary duct/drainage issues (5 events) and progressive disease (3 events)

Table 3.8: Hepatic Function Abnormalities (Safety Analysis Set)

| Hepatic Function Laboratory Parameter   | Number (%) of Subjects                       | Number (%) of Subjects                       | Number (%) of Subjects                              | Number (%) of Subjects                          |
|-----------------------------------------|----------------------------------------------|----------------------------------------------|-----------------------------------------------------|-------------------------------------------------|
| Hepatic Function Laboratory Parameter   | Study J202 HER2-positive GC (Primary Cohort) | Study J202 HER2-positive GC (Primary Cohort) | Study U205 HER2-positive GC T-DXd 6.4 mg/kg (N =79) | HER2- positiveGC T-DXd 6.4 mg/kg Pool (N = 229) |
| Hepatic Function Laboratory Parameter   | T-DXd 6.4 mg/kg (N =125)                     | TPC (N = 62)                                 | Study U205 HER2-positive GC T-DXd 6.4 mg/kg (N =79) | HER2- positiveGC T-DXd 6.4 mg/kg Pool (N = 229) |
| Alanine aminotransferase (ALT)          | Alanine aminotransferase (ALT)               | Alanine aminotransferase (ALT)               | Alanine aminotransferase (ALT)                      | Alanine aminotransferase (ALT)                  |
| Non-missing na                          | 125                                          | 60                                           | 79                                                  | 229                                             |
| Baseline ≥ULN                           | 15 (12.0)                                    | 8 (13.3)                                     | 7 (8.9)                                             | 25 (10.9)                                       |
| Maximum post-baseline value             | Maximum post-baseline value                  | Maximum post-baseline value                  | Maximum post-baseline value                         | Maximum post-baseline value                     |
| ≥3 × ULN                                | 15 (12.0)                                    | 7 (11.7)                                     | 3 (3.8)                                             | 19 (8.3)                                        |
| ≥5 x ULN                                | 11 (8.8)                                     | 2 (3.3)                                      | 1 (1.3)                                             | 12 (5.2)                                        |
| ≥8 x ULN                                | 3 (2.4)                                      | 1 (1.7)                                      | 1 (1.3)                                             | 4 (1.7)                                         |
| ≥10 x ULN                               | 3 (2.4)                                      | 1 (1.7)                                      | 1 (1.3)                                             | 4 (1.7)                                         |
| ≥20 x ULN                               | 2 (1.6)                                      | 0                                            | 0                                                   | 2 (0.9)                                         |
| Aspartate aminotransferase (AST)        | Aspartate aminotransferase (AST)             | Aspartate aminotransferase (AST)             | Aspartate aminotransferase (AST)                    | Aspartate aminotransferase (AST)                |
| Non-missing na                          | 125                                          | 60                                           | 79                                                  | 229                                             |
| Baseline ≥ULN                           | 36 (28.8)                                    | 14 (23.3)                                    | 14 (17.7)                                           | 58 (25.3)                                       |
| Maximum post-baseline value             | Maximum post-baseline value                  | Maximum post-baseline value                  | Maximum post-baseline value                         | Maximum post-baseline value                     |
| ≥3 x ULN                                | 23 (18.4)                                    | 10 (16.7)                                    | 7 (8.9)                                             | 35 (15.3)                                       |
| ≥5 x ULN                                | 11 (8.8)                                     | 6 (10.0)                                     | 3 (3.8)                                             | 15 (6.6)                                        |
| ≥8 x ULN                                | 6 (4.8)                                      | 2 (3.3)                                      | 0                                                   | 6 (2.6)                                         |
| ≥10 x ULN                               | 5 (4.0)                                      | 1 (1.7)                                      | 0                                                   | 5 (2.2)                                         |
| ≥20 x ULN                               | 0                                            | 1 (1.7)                                      | 0                                                   | 0                                               |
| ALT or AST                              | ALT or AST                                   | ALT or AST                                   | ALT or AST                                          | ALT or AST                                      |
| Non-missing na                          | 125                                          | 60                                           | 79                                                  | 229                                             |
| Baseline ≥ULN                           | 37 (29.6)                                    | 14 (23.3)                                    | 16 (20.3)                                           | 62 (27.1)                                       |

<div style=\"page-break-after: always\"></div>

| HepatieFunction Laboratory Parameter                                 | Number (%) of Subjects                                               | Number (%) of Subjects                                               | Number (%) of Subjects                                               | Number (%) of Subjects                                               |
|----------------------------------------------------------------------|----------------------------------------------------------------------|----------------------------------------------------------------------|----------------------------------------------------------------------|----------------------------------------------------------------------|
| HepatieFunction Laboratory Parameter                                 | Study J202 HER2-p0sitive GC (Primary Cohort)                         | Study J202 HER2-p0sitive GC (Primary Cohort)                         | Study U205 HER2-positive GC T-DXd 6.4 mg/kg (N = 79)                 | HER2- positiveGC T-DXd 6.4 mg/kg Pool (N = 229)                      |
| HepatieFunction Laboratory Parameter                                 | T-DXd 6.4 mg/kg (N = 125)                                            | TPC (N= 62)                                                          | Study U205 HER2-positive GC T-DXd 6.4 mg/kg (N = 79)                 | HER2- positiveGC T-DXd 6.4 mg/kg Pool (N = 229)                      |
| Maximum post-baseline value                                          | Maximum post-baseline value                                          | Maximum post-baseline value                                          | Maximum post-baseline value                                          | Maximum post-baseline value                                          |
| 23 × ULN                                                             | 27 (21.6)                                                            | 10 (16.7)                                                            | 9 (11.4)                                                             | 41 (17.9)                                                            |
| 25 × ULN                                                             | 13 (10.4)                                                            | 6 (10.0)                                                             | 3 (3.8)                                                              | 17 (7.4)                                                             |
| 28 × ULN                                                             | 6 (4.8)                                                              | 2 (3.3)                                                              | 1 (1.3)                                                              | 7 (3.1)                                                              |
| 210 ×ULN                                                             | 5 (4.0)                                                              | 1 (1.7)                                                              | 1 (1.3)                                                              | 6 (2.6)                                                              |
| 220 × ULN                                                            | 2 (1.6)                                                              | 1 (1.7)                                                              | 0                                                                    | 2 (0.9)                                                              |
| Total bilirubin (TBL)                                                | Total bilirubin (TBL)                                                | Total bilirubin (TBL)                                                | Total bilirubin (TBL)                                                | Total bilirubin (TBL)                                                |
| Non-missing na                                                       | 125                                                                  | 59                                                                   | 78                                                                   | 228                                                                  |
| BaselineULN                                                          | 5 (4.0)                                                              | 1 (1.7)                                                              | 1 (1.3)                                                              | 6 (2.6)                                                              |
| Maximum post-baseline value                                          | Maximum post-baseline value                                          | Maximum post-baseline value                                          | Maximum post-baseline value                                          | Maximum post-baseline value                                          |
| 21.5 ×ULN                                                            | 16 (12.8)                                                            | 4 (6.8)                                                              | 5 (6.4)                                                              | 23 (10.1)                                                            |
| 22 × ULN                                                             | 13 (10.4)                                                            | 3 (5.1)                                                              | 1 (1.3)                                                              | 16 (7.0)                                                             |
| 23 × ULN                                                             | 10 (8.0)                                                             | 2 (3.4)                                                              | 0                                                                    | 12 (5.3)                                                             |
| Alkaline phosphatase (ALP)                                           | Alkaline phosphatase (ALP)                                           | Alkaline phosphatase (ALP)                                           | Alkaline phosphatase (ALP)                                           | Alkaline phosphatase (ALP)                                           |
| Non-missing na                                                       | 125                                                                  | 59                                                                   | 78                                                                   | 228                                                                  |
| Baseline ULN                                                         | 47 (37.6)                                                            | 18 (30.5)                                                            | 28 (35.9)                                                            | 82 (36.0)                                                            |
| Maximum post-baseline value                                          | Maximum post-baseline value                                          | Maximum post-baseline value                                          | Maximum post-baseline value                                          | Maximum post-baseline value                                          |
| 21.5 × ULN                                                           | 68 (54.4)                                                            | 21 (35.6)                                                            | 24 (30.8)                                                            | 104 (45.6)                                                           |
| 22 × ULN                                                             | 44 (35.2)                                                            | 14 (23.7)                                                            | 16 (20.5)                                                            | 69 (30.3)                                                            |
| Concurrent TBL elevation with ALT or AST elevationb                  | Concurrent TBL elevation with ALT or AST elevationb                  | Concurrent TBL elevation with ALT or AST elevationb                  | Concurrent TBL elevation with ALT or AST elevationb                  | Concurrent TBL elevation with ALT or AST elevationb                  |
| Non-missing n                                                        | 125                                                                  | 59                                                                   | 0                                                                    | 150                                                                  |
| ALTorAST23xULN and TBL 22 × ULN                                      | 6 (4.8)                                                              | 3 (5.1)                                                              | 0                                                                    | 8 (5.3)                                                              |
| Concurrent TBL elevation with ALT or AST elevation and ALP <2 × ULNb | Concurrent TBL elevation with ALT or AST elevation and ALP <2 × ULNb | Concurrent TBL elevation with ALT or AST elevation and ALP <2 × ULNb | Concurrent TBL elevation with ALT or AST elevation and ALP <2 × ULNb | Concurrent TBL elevation with ALT or AST elevation and ALP <2 × ULNb |
| Non-missing n *                                                      | 125                                                                  | 59                                                                   | 0                                                                    | 150                                                                  |
| ALTorAST23xULN and TBL22 × ULN and ALP<2×ULN                         | 3 (2.4)                                                              | 2 (3.4)                                                              | 0                                                                    | 3 (2.0)                                                              |

ALT=alanine aminotransferase;ALP=alkaline phosphatase;AST=aspartale aminotransferase;

GC = gastric/gastroesophageal junction cancer; HER2 = human epidermal growth factor receptor 2;

N = total number of treated subjects; T-DXd = trastuzumab deruxtecan; TBL = total bilirubin; TPC = treatment of nomal.

U205.

Percentages were calculated using the non-missing n as the denominator.

Each subject was counted for only the worst case observed post-baseline.

a Non-missing n is the number of subjects with both baseline and post-baseline data.

Source:Module5.3.5.3SCSTable1.3.1.3

b \"Concurrent* means these abnormalities occurred within a 28-day window.

<div style=\"page-break-after: always\"></div>

None of the 11 cases of potential Hy's Law were considered to be drug-related by the investigators. In all  instances,  at  the  time  of  meeting  potential  Hy's  Law  biochemical  criteria,  ALP  was  &gt;2  × ULN suggesting an obstructive etiology caused the elevated LFT results. The alternative etiology for meeting biochemical  Hy's  Law  criteria  included  the  following:  liver  metastases,  biliary  dilatation  requiring stenting,  stent  revision,  or  biliary  drainage,  bile  stone,  cholangitis,  biliary  sepsis,  and  disease progression.

## 2.5.5.3. Other observations related to safety

## Vital signs

<!-- formula-not-decoded -->

|                                                  | Number (&) of Subiects in Study J202 HER2 positive GC   | Number (&) of Subiects in Study J202 HER2 positive GC   | Number (&) of Subiects in Study J202 HER2 positive GC   | Number (&)of Subiects in Pool   | Number (&)of Subiects in Pool   |
|--------------------------------------------------|---------------------------------------------------------|---------------------------------------------------------|---------------------------------------------------------|---------------------------------|---------------------------------|
|                                                  | (primary cohort)                                        | (primary cohort)                                        | U205 HER2 positive GC                                   | HER2 positive GC                | All Tumor Types T-DXd           |
| Vital Sign Parameter                             | T-DXd                                                   | TPC                                                     |                                                         |                                 |                                 |
|                                                  | 6.4 mg/kg                                               |                                                         | 6.4 mg/kg                                               | 6.4 mg/kg Pool                  | 5.4 mg/kg Pool                  |
| Criteria                                         | (N=125)                                                 | (N=62)                                                  | (N=79)                                                  | (N=229)                         | (N=962)                         |
| Systolic Blood Pressure (mmHg)                   |                                                         |                                                         |                                                         |                                 |                                 |
| Non-missing n [1]                                | 125                                                     | 60                                                      | 79                                                      | 229                             | 962                             |
| >=180 mmHg and increase >= 20 mmHg from baseline | 0                                                       | 0                                                       | 0                                                       | 0                               | 8 (0.8)                         |
| <= 90 mmHg and decrease >= 20 mmHg from baseline | 9 (7.2)                                                 | 5 (8.3)                                                 | 3 (3.8)                                                 | 14 (6.1)                        | 104 (10.8)                      |
| Diastolic Blood Pressure (mmHg)                  |                                                         |                                                         |                                                         |                                 |                                 |
| Non-missing n [1]                                | 125                                                     | 60                                                      | 79                                                      | 229                             | 962                             |
| >=105 mmHg and increase >= 15 mmHg from baseline | 1 (0.8)                                                 | 2 (3.3)                                                 | 1 (1.3)                                                 | 3 (1.3)                         | 9 (0.9)                         |
| <=50 mmHg anddecrease>=15 mmHg frombaseline      | 17 (13.6)                                               | 2 (3.3)                                                 | 5 (6.3)                                                 | 25 (10.9)                       | 107 (11.1)                      |
| Heart Rate (beats/min)                           |                                                         |                                                         |                                                         |                                 |                                 |
| Non-missing n [1]                                | 125                                                     | 59                                                      | 79                                                      | 229                             | 962                             |
| >= 120 bpm and increase from baseline>= 15       | 8 (6.4)                                                 | 5 (8.5)                                                 | 1 (1.3)                                                 | 10 (4.4)                        | 43 (4.5)                        |
| <= 50 bpm and decrease from baseline>=15         | 11 (8.8)                                                | 0                                                       | 3 (3.8)                                                 | 16 (7.0)                        | 34 (3.5)                        |
| Temperature (C)                                  |                                                         |                                                         |                                                         |                                 |                                 |
| Non-missing n [1]                                | 125                                                     | 61                                                      | 79                                                      | 229                             | 960                             |
| >39                                              | 7 (5.6)                                                 | 1 (1.6)                                                 | 0                                                       | 8 (3.5)                         | 12 (1.3)                        |
| <36                                              | 50 (40.0)                                               | 10 (16.4)                                               | 28 (35.4)                                               | 88 (38.4)                       | 345 (35.9)                      |
| Sp02 (%)                                         |                                                         |                                                         |                                                         |                                 |                                 |
| Non-missing n [1]                                | 124                                                     | 59                                                      | 78                                                      | 227                             | 947                             |
| <90%                                             | (0.8)                                                   | 0                                                       | 0                                                       | (0.9)                           | 25 (2.6)                        |

HER2 positive GC 6.4 mg/kg Pool inclucle data from studies: DS8201-A-J101, DS8201-A-J202 and DS8201-A-U205. A11 Tumor Types T-DXd &gt;= 5.4 mg/kg Pooled Data: DS8201-A-J101, DS8201-A-J202, DS8201-A-U201, DS8201-A-U204, DS8201-A-U205. [1]Non-missing n is the number of subjects with both baseline and post-baseline data.Percentages are calculated using the non-missing n as denominator.

## ECG

<div style=\"page-break-after: always\"></div>

Table 4.1: Summary of QTeF Intervals (Safety Analysis Set)

| QTeFInterval                             | Number (%) of Subjects                      | Number (%) of Subjects                      | Number (%) of Subjects                       | Number (%) of Subjects                 |
|------------------------------------------|---------------------------------------------|---------------------------------------------|----------------------------------------------|----------------------------------------|
|                                          | Study J202HER2-positive GC (Primary Cohort) | Study J202HER2-positive GC (Primary Cohort) | Study U205 HER2- positive GC T-DXd 6.4 mg/kg | HER2- positive GC T-DXd 6.4 mg/kg Pool |
|                                          | T-DXd 6.4 mg/kg (N =125)                    | TPC (N = 62)                                | (N =79)                                      | (N = 229)                              |
| Non-missing n a                          | 124                                         | 59                                          | 74                                           | 223                                    |
| New >470 ms (female) or >450 ms (male) b | 20 (16.1)                                   | 5 (8.5)                                     | 8 (10.8)                                     | 35 (15.7)                              |
| New >480 ms b                            | 5 (4.0)                                     | 2 (3.4)                                     | 4 (5.4)                                      | 11 (4.9)                               |
| New >500 ms b                            | 2 (1.6)                                     | 2 (3.4)                                     | 1 (1.4)                                      | 4 (1.8)                                |
| >30 ms increase from baseline *          | 13 (10.5)                                   | 5 (8.5)                                     | 16 (21.6)                                    | 32 (14.3)                              |
| >60 ms increase from baseline            | 4 (3.2)                                     | 2 (3.4)                                     | 3 (4.1)                                      | 9 (4.0)                                |

HER2 positive GC 6.4 mg/kg Pool includes data from studies: DS8201-A-J101, DS8201-A-J202 and DS8201-AU205.

Percentages were calculated using the non-missing n as the denominator.

- Non-missing n is the number of subjects with both baseline and post-baseline data.

The baseline value was defined as the last non-missing value before first dose of study drug. If multiple ECG measurements were taken at baseline, the average of all baseline values was used as baseline.

- b A new ECG abnormality was defined as an abnormal ECG finding post-baseline that was not present at baseline.

## 2.5.6. Safety in special populations

## 2.5.6.1. Intrinsic factors

TEAEs were evaluated for the following intrinsic factors: age (&lt;65, ≥65 years and &lt;75, and ≥75 years), race (White, Asian, and Other), sex (male, female), ECOG PS (0, 1), renal function at baseline (normal function,  mild  impairment,  and  moderate  impairment),  and hepatic  function at  baseline  (normal function, mild impairment).

## Age

One notable difference for the category TEAEs with an outcome of death was reported, with a higher proportion of subjects in the age group of &lt;65 years.

In the HER2-positive GC Pool, events in the following categories were reported in a higher proportion of subjects ≥75 years of age (n = 24) than in subjects &lt;75 years of age (n = 205):

- ≥Grade 3 TEAEs (20/24 [83.3%] vs.147/205 [71.7%])
- TEAEs associated with study drug interruption (14/24 [58.3%] vs. 95/205 [46.3%])
- TEAEs associated with dose reduction (10/24 [41.7%] vs. 58/205 [28.3%])
- SAEs (12/24 [50.0%] vs. 80/205 [39.0%])

A similar pattern was seen in the TPC arm.

<div style=\"page-break-after: always\"></div>

Table 5.1: Overall Summary of Treatment-Emergent Adverse Events by Age Group (Safety Analysis Set)

| Parameter                                                 | Age Group<65years Number (%) of Subjects    | Age Group<65years Number (%) of Subjects    | Age Group<65years Number (%) of Subjects             | Age Group<65years Number (%) of Subjects        | AgeGroup≥65years Number (%) of Subjects      | AgeGroup≥65years Number (%) of Subjects      | AgeGroup≥65years Number (%) of Subjects              | AgeGroup≥65years Number (%) of Subjects         |
|-----------------------------------------------------------|---------------------------------------------|---------------------------------------------|------------------------------------------------------|-------------------------------------------------|----------------------------------------------|----------------------------------------------|------------------------------------------------------|-------------------------------------------------|
|                                                           | StudyJ202HER2- positive GC (Primary Cohort) | StudyJ202HER2- positive GC (Primary Cohort) | Study U205 HER2- positive GC T-DXd 6.4 mg/kg (N =46) | HER2- positive GC T-DXd 6.4 mg/kg Pool (N =109) | Study J202HER2- positive GC (Primary Cohort) | Study J202HER2- positive GC (Primary Cohort) | Study U205 HER2- positive GC T-DXd 6.4 mg/kg (N =33) | HER2- positive GC T-DXd 6.4 mg/kg Pool (N =120) |
|                                                           | T-DXd 6.4 mg/kg (N =55)                     | TPC (N =27)                                 | Study U205 HER2- positive GC T-DXd 6.4 mg/kg (N =46) | HER2- positive GC T-DXd 6.4 mg/kg Pool (N =109) | T-DXd 6.4 mg/kg (N = 70)                     | TPC (N =35)                                  | Study U205 HER2- positive GC T-DXd 6.4 mg/kg (N =33) | HER2- positive GC T-DXd 6.4 mg/kg Pool (N =120) |
| Duration of treatment(months)                             |                                             |                                             |                                                      |                                                 |                                              |                                              |                                                      |                                                 |
| Median                                                    | 5.22                                        | 2.76                                        | 4.24                                                 | 4.37                                            | 4.48                                         | 2.76                                         | 5.16                                                 | 4.60                                            |
| Range                                                     | 0.7,25.4                                    | 0.5, 7.1                                    | 0.7, 15.4                                            | 0.7,25.4                                        | 0.7, 29.7                                    | 0.5, 13.1                                    | 0.7, 15.9                                            | 0.7,29.7                                        |
| Subjects with any TEAE, n (%)                             | 55 (100)                                    | 27 (100)                                    | 46 (100)                                             | 109 (100)                                       | 70 (100)                                     | 34 (97.1)                                    | 33 (100)                                             | 120 (100)                                       |
| TEAEswithworstCTCAE>Grade3a                               | 52 (94.5)                                   | 16 (59.3)                                   | 27 (58.7)                                            | 85 (78.0)                                       | 55 (78.6)                                    | 19 (54.3)                                    | 13 (39.4)                                            | 82 (68.3)                                       |
| SeriousTEAEs                                              | 24 (43.6)                                   | 7 (25.9)                                    | 18 (39.1)                                            | 43 (39.4)                                       | 32 (45.7)                                    | 9 (25.7)                                     | 11 (33.3)                                            | 49 (40.8)                                       |
| TEAEs associated with study drug discontinuation          | 7 (12.7)                                    | 0                                           | 7 (15.2)                                             | 14 (12.8)                                       | 15 (21.4)                                    | 4 (11.4)                                     | 5 (15.2)                                             | 24 (20.0)                                       |
| TEAEs associated with dose reduction                      | 17 (30.9)                                   | 10 (37.0)                                   | 14 (30.4)                                            | 33 (30.3)                                       | 23 (32.9)                                    | 11 (31.4)                                    | 5 (15.2)                                             | 35 (29.2)                                       |
| TEAEs associated with study drug interruption             | 33 (60.0)                                   | 10 (37.0)                                   | 10 (21.7)                                            | 47 (43.1)                                       | 46 (65.7)                                    | 13 (37.1)                                    | 7 (21.2)                                             | 62 (51.7)                                       |
| TEAEs associatedwith anoutcome of deathb                  | 4 (7.3)                                     | 0                                           | 9 (19.6)                                             | 13 (11.9)                                       | 4 (5.7)                                      | 2 (5.7)                                      | 1 (3.0)                                              | 6 (5.0)                                         |
| Subjects with any drug-related TEAE, n 5(%)               | 54 (98.2)                                   | 25 (92.6)                                   | 43 (93.5)                                            | 105 (96.3)                                      | 68 (97.1)                                    | 31 (88.6)                                    | 31 (93.9)                                            | 116 (96.7)                                      |
| Drug-related TEAEs with worst CTCAE ≥Grade 3a             | 44 (80.0)                                   | 13 (48.1)                                   | 14 (30.4)                                            | 62 (56.9)                                       | 50 (71.4)                                    | 14 (40.0)                                    | 7 (21.2)                                             | 69 (57.5)                                       |
| Drug-relatedseriousTEAEs                                  | 10 (18.2)                                   | 3 (11.1)                                    | 4 (8.7)                                              | 15 (13.8)                                       | 20 (28.6)                                    | 2 (5.7)                                      | 4 (12.1)                                             | 26 (21.7)                                       |
| Drug-relatedTEAEsassociatedwithstudy drug discontinuation | 5 (9.1)                                     | 0                                           | 3 (6.5)                                              | 8 (7.3)                                         | 9 (12.9)                                     | 3 (8.6)                                      | 4 (12.1)                                             | 16 (13.3)                                       |
| Drug-related TEAEs associated with dose reduction         | 17 (30.9)                                   | 10 (37.0)                                   | 10 (21.7)                                            | 29 (26.6)                                       | 21 (30.0)                                    | 11 (31.4)                                    | 5 (15.2)                                             | 33 (27.5)                                       |
| Drug-related TEAEs associatedwithstudy drug interruption  | 26 (47.3)                                   | 8 (29.6)                                    | 6 (13.0)                                             | 36 (33.0)                                       | 39 (55.7)                                    | 11 (31.4)                                    | 1 (3.0)                                              | 47 (39.2)                                       |
| Drug-relatedTEAEsassociatedwith an outcome of deathb      | 0                                           | 0                                           | 1 (2.2)                                              | 1 (0.9)                                         | 1 (1.4)                                      | 0                                            | 0                                                    | 1 (0.8)                                         |

HER2-positive GC 6.4 mg/kg Pool includes data from studies: DS8201-A-J101, DS8201-A-J202, and DS8201-A-U205.

Percentages were calculated using the number of subjects in the Safety Analysis Set as the denominator.

b For specific TEAEs associated with outcome of death, refer to Table 2.8.

a A subject was counted once at the maximum severity.

c Ifrelationship was missing, the TEAE was considered to be related to the drug. Source:Module5.3.5.3SCS Tables1.4.2 and1.4.3

<div style=\"page-break-after: always\"></div>

Table 12: Treatment-emergent Serious Adverse Events, Treatment-emergent Adverse Events Associated with Dose Reduction, Treatment-emergent Adverse Events Associated with an Outcome of Death (All and Drug-related Events) by Age (Safety Analysis Set)

|                                                        | Age Group <65 years Number (%) of Subjects   | Age Group <65 years Number (%) of Subjects   | Age Group <65 years Number (%) of Subjects   | Age Group <65 years Number (%) of Subjects       | Age Group ≥65 years Number (%) of Subjects   | Age Group ≥65 years Number (%) of Subjects   | Age Group ≥65 years Number (%) of Subjects   | Age Group ≥65 years Number (%) of Subjects       |
|--------------------------------------------------------|----------------------------------------------|----------------------------------------------|----------------------------------------------|--------------------------------------------------|----------------------------------------------|----------------------------------------------|----------------------------------------------|--------------------------------------------------|
|                                                        | Study J202 HER2-positive GC (Primary Cohort) | Study J202 HER2-positive GC (Primary Cohort) | Study U205 HER2- positive GC T-DXd 6.4 mg/kg | HER2- positive GC T-DXd 6.4 mg/kg Pool (N = 109) | Study J202 HER2-positive GC (Primary Cohort) | Study J202 HER2-positive GC (Primary Cohort) | Study U205 HER2- positive GC T-DXd 6.4 mg/kg | HER2- positive GC T-DXd 6.4 mg/kg Pool (N = 120) |
|                                                        | T-DXd 6.4 mg/kg (N = 55)                     | TPC (N = 27)                                 | (N = 46)                                     |                                                  | T-DXd 6.4 mg/kg (N = 70)                     | TPC (N = 35)                                 | (N = 33)                                     |                                                  |
| Treatment-emergent SAEs                                | 24 (43.6)                                    | 7 (25.9)                                     | 18 (39.1)                                    | 43 (39.4)                                        | 32 (45.7)                                    | 9 (25.7)                                     | 11 (33.3)                                    | 49 (40.8)                                        |
| Drug-related treatment- emergent SAEs a                | 10 (18.2)                                    | 3 (11.1)                                     | 4 (8.7)                                      | 15 (13.8)                                        | 20 (28.6)                                    | 2 (5.7)                                      | 4 (12.1)                                     | 26 (21.7)                                        |
| TEAEs associated with dose reduction                   | 17 (30.9)                                    | 10 (37.0)                                    | 12 (26.1)                                    | 31 (28.4)                                        | 23 (32.9)                                    | 11 (31.4)                                    | 5 (15.2)                                     | 35 (29.2)                                        |
| Drug-related TEAEs associated with dose reduction      | 17 (30.9)                                    | 10 (37.0)                                    | 9 (19.6)                                     | 28 (25.7)                                        | 21 (30.0)                                    | 11 (31.4)                                    | 5 (15.2)                                     | 33 (27.5)                                        |
| TEAEs associated with an outcome of death              | 4 (7.3)                                      | 0                                            | 9 (19.6)                                     | 13 (11.9)                                        | 4 (5.7)                                      | 2 (5.7)                                      | 1 (3.0)                                      | 6 (5.0)                                          |
| Drug-related TEAEs associated with an outcome of death | 0                                            | 0                                            | 1 (2.2)                                      | 1 (0.9)                                          | 1 (1.4)                                      | 0                                            | 0                                            | 1 (0.8)                                          |

GC = gastric cancer/gastric or gastroesophageal junction adenocarcinoma; HER2 = human epidermal growth factor receptor 2; N = total number of treated subjects; PTX = paclitaxel; SAE = serious adverse event; SCS = Summary of Clinical Safety; T-DXd = trastuzumab deruxtecan; TEAE = treatment-emergent adverse event; TPC = treatment of physician's choice (includes subjects who received irinotecan [n = 55] or PTX [n = 7])

The HER2-positive GC T-DXd 6.4 mg/kg Pool includes data from Studies DS8201-A-J101, DS8201-AJ202, and DS8201-A-U205.

Percentages were calculated using the number of subjects in the Safety Analysis Set as the denominator.

a If relationship was missing, the AE was also considered to be drug-related

Source: Module 5.3.5.3 SCS Table 1.4.3

## Sex

Within the HER2-positive GC Pool, notable differences in the frequency of events in the following categories were observed when comparing male subjects (n = 172) and female subjects

(n = 57) subjects:

a higher proportion of male subjects compared to female subjects experienced:

- Drug-related TEAEs associated with study drug discontinuation (21/172 [12.2%]

vs. 3/57 [5.3%])

a higher proportion of female subjects compared to male subjects experienced:

- SAEs (28/57 [49.1%] vs. 64/172 [37.2%])

<div style=\"page-break-after: always\"></div>

(Safety Analysis Set)

Gender: Female

Table 1.4.3 Subgroup Analysis of Overall Summary of Treatment-Emergent Adverse Events (Safety Analysis Set)

|                                                         | Number ()of Subjects in Study          | Number ()of Subjects in Study          | Number ()of Subjects in Study   | Number (%）of     |
|---------------------------------------------------------|----------------------------------------|----------------------------------------|---------------------------------|------------------|
|                                                         | J202 HER2 positive GC (primary cohort) | J202 HER2 positive GC (primary cohort) | U205 HER2                       |                  |
|                                                         | T-DXd                                  | TPC                                    | positive GC                     | HER2 positive GC |
|                                                         | 6.4 mg/kg                              |                                        | 6.4 mg/kg                       | 6.4 mg/kg Pool   |
|                                                         | (N = 30)                               | (N = 15)                               | (N = 22)                        | (N = 57)         |
| Treatment-Emergent Adverse Events (TEAE)                | 30 (100)                               | 15 (100)                               | 22 (100)                        | 57 (100)         |
| TEAE with CTCAE Grade >= 3                              | 26 (86.7)                              | 6 (40.0)                               | 12 (54.5)                       | 42 2(73.7)       |
| TEAE associated with an outcome of death                | 3 (10.0)                               | 0                                      | 1 (4.5)                         | 4 (7.0)          |
| TEAE associated with study drug discontinuation         | 6 (20.0)                               | 1 (6.7)                                | 2 (9.1)                         | 10 (17.5)        |
| TEAE associated with study drug interruption            | 16 5(53.3)                             | 6 (40.0)                               | 5 (22.7)                        | 23 3 (40.4)      |
| TEAE associated with dose reduction                     | 11 (36.7)                              | 5 (33.3)                               | (22.7)                          | 18 (31.6)        |
| Drug-Related TEAE (Related TEAE)                        | 29 (96.7)                              | 13 3(86.7)                             | 22 (100)                        | 56 (98.2)        |
| Related TEAE with CTCAE Grade >= 3                      | 23 (76.7)                              | 4 (26.7)                               | 8 (36.4)                        | 35 (61.4)        |
| Related TEAE associated with an outcome of death        | 0                                      | 0                                      | 0                               | 0                |
| Related TEAE associated with study drug discontinuation | 1 (3.3)                                | 1 (6.7)                                | 0                               | 3 (5.3)          |
| Related TEAE associatedwith study drug interruption     | 13 (43.3)                              | 4 (26.7)                               | 3 (13.6)                        | 18 3(31.6)       |
| Related TEAE associated with dose reduction             | 10 (33.3)                              | 5 (33.3)                               | 3 (13.6)                        | 15 (26.3)        |
| Treatment-Emergent Serious Adverse Events (SAE)         | 17 (56.7)                              | 2 (13.3)                               | 9(40.9)                         | 28 (49.1)        |
| SAE with CTCAE Grade >=3                                | 15 (50.0)                              | 2 (13.3)                               | (31.8)                          | 24 (42.1)        |
| SAE associated with an outcome of death                 | 3 (10.0)                               | 0                                      | 1 (4.5)                         | 4 (7.0)          |
| SAE associated with study drug discontinuation          | (16.7)                                 | 0                                      | 1 (4.5)                         | 7 (12.3)         |
| SAE associated with study drug interruption             | 3 (10.0)                               | (13.3)                                 | (4.5)                           | 5 (8.8)          |
| SAE associated with dose reduction                      | 6 (20.0)                               | 0                                      | 0                               | 6 (10.5)         |
| Drug-Related SAE (Related SAE)                          | 11 (36.7)                              | 0                                      | 2 (9.1)                         | 14 (24.6)        |
| Related SAE with CTCAE Grade >= 3                       | 8 (26.7)                               | 0                                      | 1 (4.5)                         | 10 (17.5)        |
| Related SAE associated with an outcome of death         | 0                                      | 0                                      | 0                               | 0                |
| Related SAE associated with study drug discontinuation  | 0                                      | 0                                      | 0                               | 1 (1.8)          |
| Related SAE associated with study drug interruption     | 2 (6.7)                                | 0                                      | 0                               | 2 (3.5)          |
| Related SAE associated with dose reduction              | 5 (16.7)                               | 0                                      | 0                               | 5 (8.8)          |

Gender: Male

|                                                         | Number (%）of Subjects in Study         | Number (%）of Subjects in Study         | Number (%）of Subjects in Study   | Number (%）of   |
|---------------------------------------------------------|----------------------------------------|----------------------------------------|----------------------------------|----------------|
|                                                         | J202 HER2 positive GC (primary cohort) | J202 HER2 positive GC (primary cohort) | U205 HER2 positive GC            | positive GC    |
|                                                         | T-DXd 6.4 mg/kg                        | TPC                                    |                                  | HER2           |
|                                                         |                                        |                                        | 6.4 mg/kg                        | 6.4 mg/kg Pool |
|                                                         | (N = 95)                               | (N = 47)                               | (N = 57)                         | (N = 172)      |
| Treatment-Emergent Adverse Events (TEAE)                | 95 (100)                               | 46 (97.9)                              | 57 (100)                         | 172 2 (100)    |
| TEAE with CTCAE Grade >= 3                              | 81 (85.3)                              | 29 (61.7)                              | 28 (49.1)                        | 125 (72.7)     |
| TEAE associated with an outcome of death                | 5 (5.3)                                | 2 (4.3)                                | (15.8)                           | 15 (8.7)       |
| TEAE associated with study drug discontinuation         | 16 (16.8)                              | 3 (6.4)                                | 10 (17.5)                        | 28 (16.3)      |
| TEAE associated with study drug interruption            | 63 (66.3)                              | 17 (36.2)                              | 12 (21.1)                        | 86 (50.0)      |
| TEAE associated with dose reduction                     | 29 (30.5)                              | 16 (34.0)                              | 14 (24.6)                        | 50 (29.1)      |
| Drug-Related TEAE (Related TEAE)                        | 93 (97.9)                              | 43 (91.5)                              | 52 (91.2)                        | 165 (95.9)     |
| Related TEAE with CTCAE Grade >= 3                      | 71 (74.7)                              | 23 (48.9)                              | 13 (22.8)                        | 96 (55.8)      |
| Related TEAE associated with an outcome of death        | 1 (1.1)                                | 0                                      | 1 (1.8)                          | 2 (1.2)        |
| Related TEAE associated with study drug discontinuation | 13 (13.7)                              | 2 (4.3)                                | (12.3)                           | 21 (12.2)      |
| Related TEAE associated with study drug interruption    | 52 (54.7)                              | 15 (31.9)                              | 4 (7.0)                          | 65 (37.8)      |
| Related TEAE associated with dose reduction             | 28 (29.5)                              | 16 (34.0)                              | 12 (21.1)                        | 47 (27.3)      |
| Treatment-Emergent Serious Adverse Events (SAE)         | 39 (41.1)                              | 14 (29.8)                              | 20 (35.1)                        | 64 (37.2)      |
| SAE with CTCAE Grade >= 3                               | 32 (33.7)                              | 13 (27.7)                              | 17 (29.8)                        | 53 (30.8)      |
| SAE associated withan outcomeof death                   | 5 (5.3)                                | (4.3)                                  | 9 (15.8)                         | 15 (8.7)       |
| SAE associated with study drug discontinuation          | 6 (6.3)                                | 1 (2.1)                                | 1 (12.3)                         | 15 (8.7)       |
| SAE associated with study drug interruption             | 16 (16.8)                              | (4.3)                                  | 6 (10.5)                         | 25 (14.5)      |
| SAE associated with dose reduction                      | 0                                      | (2.1)                                  | 2 (3.5)                          | 2 (1.2)        |
| Drug-Related SAE (Related SAE)                          | 19 (20.0)                              | 5 (10.6)                               | 6 (10.5)                         | 27 (15.7)      |
| Related SAE with CTCAE Grade >=3                        | 10 (10.5)                              | 4 (8.5)                                | 5 (8.8)                          | 17 (9.9)       |
| Related SAE associated with an outcome of death         | 1 (1.1)                                | 0                                      | 1 (1.8)                          | 2 (1.2)        |
| Related SAE associated with study drug discontinuation  | 4 (4.2)                                | 0                                      | 4 (7.0)                          | 9 (5.2)        |
| Related SAE associated with study drug interruption     | 5 (5.3)                                | 2 (4.3)                                | 1 (1.8)                          | 7 (4.1)        |
| Related SAE associated with dose reduction              | 0                                      | 1 (2.1)                                | 0                                | 0              |

<div style=\"page-break-after: always\"></div>

Table 13: Treatment-emergent Serious Adverse Events Considered as Drug-related, of Grade ≥ 3 (All Events), Associated with Dose Reduction (All and Drug-related Events), and Associated with an Outcome of Death (All and Drug-related Events) by Sex (Safety Analysis Set)

|                                                                           | Male Number (%) of Subjects                  | Male Number (%) of Subjects                  | Male Number (%) of Subjects                            | Male Number (%) of Subjects                       | Male Number (%) of Subjects          | Female Number (%) of Subjects                | Female Number (%) of Subjects                | Female Number (%) of Subjects                          | Female Number (%) of Subjects                    | Female Number (%) of Subjects        |
|---------------------------------------------------------------------------|----------------------------------------------|----------------------------------------------|--------------------------------------------------------|---------------------------------------------------|--------------------------------------|----------------------------------------------|----------------------------------------------|--------------------------------------------------------|--------------------------------------------------|--------------------------------------|
|                                                                           | Study J202 HER2-positive GC (Primary Cohort) | Study J202 HER2-positive GC (Primary Cohort) | Study U205 HER2- positive GC T-DXd 6.4 mg/k g (N = 57) | HER2- positive GC T-DXd 6.4 mg/k g Pool (N = 172) | ATT T-DXd ≥5.4 mg/k g Pool (N = 331) | Study J202 HER2-positive GC (Primary Cohort) | Study J202 HER2-positive GC (Primary Cohort) | Study U205 HER2- positive GC T-DXd 6.4 mg/k g (N = 22) | HER2- positive GC T-DXd 6.4 mg/k g Pool (N = 57) | ATT T-DXd ≥5.4 mg/k g Pool (N = 631) |
|                                                                           | T-DXd 6.4 mg/k g (N = 95)                    | TPC (N = 47)                                 | Study U205 HER2- positive GC T-DXd 6.4 mg/k g (N = 57) | HER2- positive GC T-DXd 6.4 mg/k g Pool (N = 172) | ATT T-DXd ≥5.4 mg/k g Pool (N = 331) | T-DXd 6.4 mg/k g (N = 30)                    | TPC (N = 15)                                 | Study U205 HER2- positive GC T-DXd 6.4 mg/k g (N = 22) | HER2- positive GC T-DXd 6.4 mg/k g Pool (N = 57) | ATT T-DXd ≥5.4 mg/k g Pool (N = 631) |
| Drug-related treatment-emerge nt SAEs a                                   | 19 (20.0)                                    | 5 (10.6 )                                    | 6 (10.5)                                               | 27 (15.7)                                         | 50 (15.1)                            | 11 (36.7)                                    | 0                                            | 2 (9.1)                                                | 14 (24.6)                                        | 104 (16.5)                           |
| Treatment-emerge nt SAEs of Grade ≥3 b                                    | 32 (33.7)                                    | 13 (27.7 )                                   | 17 (29.8)                                              | 53 (30.8)                                         | 105 (31.7)                           | 15 (50.0)                                    | 2 (13.3 )                                    | 7 (31.8)                                               | 24 (42.1)                                        | 175 (27.7)                           |
| Treatment- emergent SAEs associated with dose reduction                   | 0                                            | 1 (2.1)                                      | 2 (3.5)                                                | 2 (1.2)                                           | 7 (2.1)                              | 6 (20.0)                                     | 0                                            | 0                                                      | 6 (10.5)                                         | 21 (3.3)                             |
| Drug-related treatment-emerge nt SAEs associated with dose reduction      | 0                                            | 1 (2.1)                                      | 0                                                      | 0                                                 | 4 (1.2)                              | 5 (16.7)                                     | 0                                            | 0                                                      | 5 (8.8)                                          | 17 (2.7)                             |
| Treatment- emergent SAEs associated with an outcome of death              | 5 (5.3)                                      | 2 (4.3)                                      | 9 (15.8)                                               | 15 (8.7)                                          | 33 (10.0)                            | 3 (10.0)                                     | 0                                            | 1 (4.5)                                                | 4 (7.0)                                          | 43 (6.8)                             |
| Drug-related treatment-emerge nt SAEs associated with an outcome of death | 1 (1.1)                                      | 0                                            | 1 (1.8)                                                | 2 (1.2)                                           | 4 (1.2)                              | 0                                            | 0                                            | 0                                                      | 0                                                | 12 (1.9)                             |

ATT = all tumor types; GC = gastric cancer/gastric or gastroesophageal junction adenocarcinoma;

HER2 = human epidermal growth factor receptor 2; N = total number of treated subjects; n = number of subjects; PTX = paclitaxel; SAE = serious adverse event; SCS = Summary of Clinical Safety; T-DXd = trastuzumab deruxtecan; TPC = treatment of physician's

choice (includes subjects who received irinotecan [n = 55] or PTX [n = 7])

The HER2-positive GC T-DXd 6.4 mg/kg Pool includes data from Studies DS8201-A-J101, DS8201-AJ202, and DS8201-A-U205.

Percentages were calculated using the number of subjects in the Safety Analysis Set as the denominator.

a If relationship was missing, the AE was also considered to be drug-related.

b A subject was counted once at the maximum severity.

Source: Module 5.3.5.3 SCS Table 1.4.3

<div style=\"page-break-after: always\"></div>

## ECOG performance status

Table 5.2: Overall Summary of Treatment-Emergent Adverse Events by ECOG Performance Status (Safety Analysis Set)

| Parameter                                        | Baseline ECOG PS=0 Number (%) of Subjects   | Baseline ECOG PS=0 Number (%) of Subjects   | Baseline ECOG PS=0 Number (%) of Subjects   | Baseline ECOG PS=0 Number (%) of Subjects       | Baseline ECOG PS=1 Number (%) of Subjects    | Baseline ECOG PS=1 Number (%) of Subjects    | Baseline ECOG PS=1 Number (%) of Subjects            | Baseline ECOG PS=1 Number (%) of Subjects        |
|--------------------------------------------------|---------------------------------------------|---------------------------------------------|---------------------------------------------|-------------------------------------------------|----------------------------------------------|----------------------------------------------|------------------------------------------------------|--------------------------------------------------|
|                                                  | StudyJ202HER2- positive GC (Primary Cohort) | StudyJ202HER2- positive GC (Primary Cohort) | Study U205 HER2- positive GC T-DXd          | HER2- positive GC T-DXd 6.4 mg/kg Pool (N =110) | Study J202HER2- positive GC (Primary Cohort) | Study J202HER2- positive GC (Primary Cohort) | Study U205 HER2- positive GC T-DXd 6.4 mg/kg (N =50) | HER2- positive GC T-DXd 6.4 mg/kg Pool (N = 119) |
|                                                  | T-DXd 6.4 mg/kg (N =62)                     | TPC (N =30)                                 | 6.4 mg/kg (N =29)                           |                                                 | T-DXd 6.4 mg/kg (N= 63)                      | TPC (N =32)                                  | Study U205 HER2- positive GC T-DXd 6.4 mg/kg (N =50) | HER2- positive GC T-DXd 6.4 mg/kg Pool (N = 119) |
| Duration of treatment (months)                   |                                             |                                             |                                             |                                                 |                                              |                                              |                                                      |                                                  |
| Median                                           | 5.96                                        | 2.74                                        | 4.34                                        | 5.63                                            | 4.27                                         | 2.81                                         | 4.25                                                 | 4.27                                             |
| Range                                            | 1.4, 29.7                                   | 0.5, 13.1                                   | 1.4, 12.6                                   | 1.4, 29.7                                       | 0.7, 16.8                                    | 0.5,11.3                                     | 0.7, 15.9                                            | 0.7, 16.8                                        |
| Subjects with any TEAE, n (%)                    | 62 (100)                                    | 30 (100)                                    | 29 (100)                                    | 110 (100)                                       | 63 (100)                                     | 31 (96.9)                                    | 50 (100)                                             | 119 (100)                                        |
| TEAEswithworstCTCAE≥Grade3a                      | 50 (80.6)                                   | 15 (50.0)                                   | 8 (27.6)                                    | 74 (67.3)                                       | 57 (90.5)                                    | 20 (62.5)                                    | 32 (64.0)                                            | 93 (78.2)                                        |
| Serious TEAEs                                    | 20 (32.3)                                   | 4 (13.3)                                    | 4 (13.8)                                    | 30 (27.3)                                       | 36 (57.1)                                    | 12 (37.5)                                    | 25 (50.0)                                            | 62 (52.1)                                        |
| TEAEs associated with study drug discontinuation | 9 (14.5)                                    | 2 (6.7)                                     | 3 (10.3)                                    | 15 (13.6)                                       | 13 (20.6)                                    | 2 (6.3)                                      | 9 (18.0)                                             | 23 (19.3)                                        |
| TEAEsassociatedwithdosereduction                 | 20 (32.3)                                   | 11 (36.7)                                   | 3 (10.3)                                    | 30 (27.3)                                       | 20 (31.7)                                    | 10 (31.3)                                    | 16 (32.0)                                            | 38 (31.9)                                        |
| TEAEs associated with study drug interruption    | 45 (72.6)                                   | 11 (36.7)                                   | 5 (17.2)                                    | 60 (54.5)                                       | 34 (54.0)                                    | 12 (37.5)                                    | 12 (24.0)                                            | 49 (41.2)                                        |
| TEAEs associated with an outcome of death b      | 3 (4.8)                                     | 1 (3.3)                                     | 2 (6.9)                                     | 6 (5.5)                                         | 5 (7.9)                                      | 1 (3.1)                                      | 8 (16.0)                                             | 13 (10.9)                                        |
| Subjects with any drug-related TEAE, n (%)c      | 62 (100)                                    | 28 (93.3)                                   | 28 (96.6)                                   | 109 (99.1)                                      | 60 (95.2)                                    | 28 (87.5)                                    | 46 (92.0)                                            | 112 (94.1)                                       |
| Drug-related TEAEs with worst CTCAE ≥Grade 3a    | 45 (72.6)                                   | 12 (40.0)                                   | 3 (10.3)                                    | 60 (54.5)                                       | 49 (77.8)                                    | 15 (46.9)                                    | 18 (36.0)                                            | 71 (59.7)                                        |

| Drug-related seriousTEAEs                                     | 9 (14.5)   | 0         | 0        | 11 (10.0)   | 21 (33.3)   | 5 (15.6)   | 8 (16.0)   | 30 (25.2)   |
|---------------------------------------------------------------|------------|-----------|----------|-------------|-------------|------------|------------|-------------|
| Drug-related TEAEs associated with study drug discontinuation | 6 (9.7)    | 2 (6.7)   | 2 (6.9)  | 10 (9.1)    | 8 (12.7)    | 1 (3.1)    | 5 (10.0)   | 14 (11.8)   |
| Drug-related TEAEs associated with dose reduction             | 20 (32.3)  | 11 (36.7) | 3 (10.3) | 30 (27.3)   | 18 (28.6)   | 10 (31.3)  | 12 (24.0)  | 32 (26.9)   |
| Drug-related TEAEs associatedwith study drug interruption     | 38 (61.3)  | 10 (33.3) | 2 (6.9)  | 49 (44.5)   | 27 (42.9)   | 9 (28.1)   | 5 (10.0)   | 34 (28.6)   |
| Drug-relatedTEAEsassociatedwithan outcome of deathb           | 0          | 0         | 0        | 0           | 1 (1.6)     | 0          | 1 (2.0)    | 2 (1.7)     |

HER2-positive GC 6.4 mg/kg Poolincludes data from studies:DS8201-A-J101, DS8201-A-J202,and DS8201-A-U205.

PercentageswerecalculatedusingthenumberofsubjectsintheSafetyAnalysisSetasthedenominator.

b For specific TEAEs associated with outcome of death, refer to Table 2.8.

a A subject was counted once at the maximum severity.

c If relationship was missing, the TEAE was considered to be related to the drug. Source:Module5.3.5.3 SCS Tables1.4.2 and1.4.3

## Renal function at baseline

Subjects were categorized into groups of baseline renal function, calculated using the Cockcroft-Gault equation of serum creatinine clearance:

- Normal function: CrCl ≥90 mL/min
- Mild impairment: CrCl ≥60 and &lt;90 mL/min
- Moderate impairment: CrCl ≥30 and &lt;60 mL/min
- Severe impairment: CrCl ≥15 and &lt;30 mL/min
- End stage renal disease: CrCl &lt;15 mL/min not on dialysis or requiring dialysis

<div style=\"page-break-after: always\"></div>

Studies  J202,  U205,  and  J101 excluded subjects  with  severe  renal  impairment  or  end-stage  renal disease.

A relatively higher incidence of adjudicated drug-related ILD was seen in subjects with moderate renal impairment (14.3%) when compared to subjects with mild renal impairment (9.8%) and subjects with normal renal function (11.8%) in the HER2-positive GC Pool. Subjects with moderate renal impairment also presented with a higher incidence of ≥Grade 3 adjudicated drug -related ILD when compared to subjects with mild renal impairment and normal renal function (3.6% vs. 1.1% vs. 1.5%, respectively).

Table 5.3: Overall Summary of Treatment-Emergent Adverse Events by Baseline Renal Function (Safety Analysis Set)

| Parameter                                                     | Normal Renal Function                        | Normal Renal Function                        | Normal Renal Function                        | MildRenal Impairment                                                                   | MildRenal Impairment                         | MildRenal Impairment                         | MildRenal Impairment                         | ModerateRenalImpairment                                               | ModerateRenalImpairment                      | ModerateRenalImpairment                      | ModerateRenalImpairment                  | ModerateRenalImpairment                                     |
|---------------------------------------------------------------|----------------------------------------------|----------------------------------------------|----------------------------------------------|----------------------------------------------------------------------------------------|----------------------------------------------|----------------------------------------------|----------------------------------------------|-----------------------------------------------------------------------|----------------------------------------------|----------------------------------------------|------------------------------------------|-------------------------------------------------------------|
| Parameter                                                     | Study J202 HER2-positive GC (Primary Cohort) | Study J202 HER2-positive GC (Primary Cohort) | Study U205 HER2- positive GC T-DXd 6.4 mg/kg | HER2- positive GC T-DXd 6.4 mg/kg GC Pool (N =68)                                      | Study J202 HER2-positive GC (Primary Cohort) | Study J202 HER2-positive GC (Primary Cohort) | Study U205 HER2- positive GC T-DXd 6.4 mg/kg | HER2- positive GC T-DXd 6.4 mg/kg GC Pool (N =91)                     | Study J202 HER2-positive GC (Primary Cohort) | Study J202 HER2-positive GC (Primary Cohort) | Study U205 HER2- positive GC T-DXd (N=8) | HER2- positive GC T-DXd 6.4mg/kg GC Pool 6.4 mg/kg (N = 56) |
| Parameter                                                     | T-DXd 6.4 mg/kg(N = 13) (N=33)               | TPC                                          | (N = 32)                                     | HER2- positive GC T-DXd 6.4 mg/kg GC Pool (N =68)                                      | T-DXd 6.4 mg/kg(N = 28) (N =53)              | TPC                                          | (N =25)                                      | HER2- positive GC T-DXd 6.4 mg/kg GC Pool (N =91)                     | T-DXd 6.4 mg/kg(N = 20) (N = 39)             | TPC                                          | Study U205 HER2- positive GC T-DXd (N=8) | HER2- positive GC T-DXd 6.4mg/kg GC Pool 6.4 mg/kg (N = 56) |
| Durationof treatment(months)                                  | Durationof treatment(months)                 | Durationof treatment(months)                 | Durationof treatment(months)                 | Durationof treatment(months)                                                           | Durationof treatment(months)                 | Durationof treatment(months)                 | Durationof treatment(months)                 | Durationof treatment(months)                                          | Durationof treatment(months)                 | Durationof treatment(months)                 | Durationof treatment(months)             | Durationof treatment(months)                                |
| Median                                                        | 5.52                                         | 2.73                                         | 3.43                                         | 4.14                                                                                   | 4.37                                         | 2.30                                         | 4.37                                         | 4.37                                                                  | 4.60                                         | 2.99                                         | 5.91                                     | 5.29                                                        |
| Range                                                         | 1.4, 29.7                                    | 0.9, 4.6                                     | 0.7, 15.4                                    | 0.7,29.7                                                                               | 0.7,25.5                                     | 0.5, 13.1                                    | 0.7,15.2                                     | 0.7,25.5                                                              | 0.7, 18.6                                    | 0.5, 6.7                                     | 1.3, 15.9                                | 0.7, 18.6                                                   |
| Subjects with any TEAE, n (%)                                 | 33 (100)                                     | 13 (100)                                     | 32 (100)                                     | 68 (100)                                                                               | 53 (100)                                     | 28 (100)                                     | 25 (100)                                     | 91 (100)                                                              | 39 (100)                                     | 19 (95.0)                                    | 8 (100)                                  | 56 (100)                                                    |
| TEAEs with worst CTCAE ≥Grade 3a                              | 31 (93.9)                                    | 6 (46.2)                                     | 16 (50.0)                                    | 50 (73.5)                                                                              | 44 (83.0)19 (67.9)                           |                                              | 8 (32.0)                                     | 62 (68.1)                                                             | 32 (82.1)                                    | 9 (45.0)                                     | 6 (75.0)                                 | 45 (80.4)                                                   |
| Serious TEAEs                                                 | 11 (33.3)                                    | 2 (15.4)                                     | 12 (37.5)                                    | 24 (35.3)                                                                              | 25 (47.2)                                    | 10 (35.7)                                    | 6 (24.0)                                     | 34 (37.4)                                                             | 20 (51.3)                                    | 3 (15.0)                                     | 5 (62.5)                                 | 28 (50.0)                                                   |
| TEAEs associated with study drug discontinuation              | 3 (9.1)                                      | 1 (7.7)                                      | 6 (18.8)                                     | 9 (13.2)                                                                               | 10 (18.9)                                    | 1 (3.6)                                      | 2 (8.0)                                      | 14 (15.4)                                                             | 9 (23.1)                                     | 2 (10.0)                                     | 1 (12.5)                                 | 12 (21.4)                                                   |
| TEAEs associated with dose reduction                          | 12 (36.4)5 (38.5)                            |                                              |                                              |                                                                                        |                                              |                                              |                                              | 9 (28.1)22 (32.4)15 (28.3)10 (35.7)3 (12.0)23 (25.3)13 (33.3)6 (30.0) |                                              |                                              | 2 (25.0)                                 | 18 (32.1)                                                   |
| TEAEsassociated with study drug interruption                  | 17 (51.5)6 (46.2)                            |                                              | 7 (21.9)                                     |                                                                                        | 26 (38.2)36 (67.9)8 (28.6)                   |                                              | 4 (16.0)                                     |                                                                       | 47 (51.6)26 (66.7)8 (40.0)                   |                                              | 3 (37.5)                                 | 33 (58.9)                                                   |
| TEAEs associated with an outcome of deathb                    | 3 (9.1)                                      | 0                                            |                                              | 7 (21.9) 10 (14.7)3 (5.7)                                                              |                                              | 1 (3.6)                                      | 1 (4.0)                                      | 4 (4.4)                                                               | 2 (5.1)                                      | 1 (5.0)                                      | 1 (12.5)                                 | 4 (7.1)                                                     |
| Subjects with any drug- related TEAE,n(%)c                    |                                              |                                              |                                              | 33 (100)12(92.3)29(90.6)65 (95.6)52 (98.1)24 (85.7)23 (92.0)88 (96.7)37(94.9)19 (95.0) |                                              |                                              |                                              |                                                                       |                                              |                                              | 8 (100)                                  | 54 (96.4)                                                   |
| Drug-related TEAEs with worst CTCAE ≥Grade 3a                 | 27 (81.8)6 (46.2)8                           |                                              |                                              |                                                                                        |                                              |                                              |                                              |                                                                       |                                              |                                              | 3 (37.5)                                 | 37 (66.1)                                                   |
| Drug-related serious TEAEs                                    | 6 (18.2)                                     | 0                                            | 4 (12.5)                                     | 10 (14.7)                                                                              | 14 (26.4)4 (14.3)                            |                                              | 1 (4.0)                                      | 16 (17.6)10 (25.6)                                                    |                                              | 1 (5.0)                                      | 2 (25.0)                                 | 14 (25.0)                                                   |
| Drug-related TEAEs associated with study drug discontinuation | 1 (3.0)                                      | 1 (7.7)                                      | 5 (15.6)                                     | 6 (8.8)                                                                                | 7 (13.2)                                     | 0                                            | 2 (8.0)                                      | 10 (11.0)                                                             | 6 (15.4)                                     | 2 (10.0)                                     | 0                                        | 8 (14.3)                                                    |
| Drug-related TEAEs associated with dose reduction             | 12 (36.4)5 (38.5)                            |                                              | 7 (21.9)                                     |                                                                                        |                                              | 20 (29.4)14 (26.4)10 (35.7)3 (12.0)          |                                              | 22 (24.2)12 (30.8)6 (30.0)                                            |                                              |                                              | 1 (12.5)                                 | 16 (28.6)                                                   |
| Drug-related TEAEs associatedwithstudy drug interruption      | 14 (42.4)4 (30.8)                            |                                              | 3 (9.4)                                      |                                                                                        | 18 (26.5)29 (54.7)8 (28.6)                   |                                              | 1 (4.0)                                      |                                                                       | 37 (40.7)22 (56.4)7 (35.0)                   |                                              | 1 (12.5)                                 | 26 (46.4)                                                   |

<div style=\"page-break-after: always\"></div>

| Drug-relatedTEAEs associatedwithan outcomeofdeathb   | 0   | 0   | 1 (3.1)   | 1 (1.5)   | 1 (1.9)   | 0   | 0   | 1 (1.1)   | 0   | 0   | 0   | 0   |
|------------------------------------------------------|-----|-----|-----------|-----------|-----------|-----|-----|-----------|-----|-----|-----|-----|

HER2-positiveGC6.4mg/kgPoolincludesdatafromstudies:DS8201-A-J101,DS8201-A-J202,andDS8201-A-U205.

PercentageswerecalculatedusingthenumberofsubjectsintheSafetyAnalysisSetasthedenominator.

a A subject was counted once at the maximum severity.

bForspecificTEAEs associatedwithoutcomeof death,refertoTable2.8.

Ifrelationshipwas missing,theTEAEwas considered toberelated to the drug. Source:Module5.3.5.3SCSTables1.4.2and1.4.3

Table 14: Treatmentemergent Adverse Events of Grade ≥3, Drug -related Treatment-emergent Adverse Events, and Treatment-emergent Serious Adverse Events (All and Drug-related) by Baseline Renal Function (Safety Analysis Set)

|                                        | Normal Renal Function Number (%) of Subjects   | Normal Renal Function Number (%) of Subjects   | Normal Renal Function Number (%) of Subjects           | Normal Renal Function Number (%) of Subjects        | Mild Renal Impairment                         | Mild Renal Impairment                         | Mild Renal Impairment                                  | Mild Renal Impairment                               | Moderate Renal Impairment Number (%) of Subjects   | Moderate Renal Impairment Number (%) of Subjects   | Moderate Renal Impairment Number (%) of Subjects      | Moderate Renal Impairment Number (%) of Subjects    |
|----------------------------------------|------------------------------------------------|------------------------------------------------|--------------------------------------------------------|-----------------------------------------------------|-----------------------------------------------|-----------------------------------------------|--------------------------------------------------------|-----------------------------------------------------|----------------------------------------------------|----------------------------------------------------|-------------------------------------------------------|-----------------------------------------------------|
|                                        | Study J202 HER2- positive GC (Primary Cohort)  | Study J202 HER2- positive GC (Primary Cohort)  | Study U205 HER2- positive GC T-DXd 6.4 mg/k g (N = 32) | HER2- positive GC T-DXd 6.4 mg/k g GC Pool (N = 68) | Study J202 HER2- positive GC (Primary Cohort) | Study J202 HER2- positive GC (Primary Cohort) | Study U205 HER2- positive GC T-DXd 6.4 mg/k g (N = 25) | HER2- positive GC T-DXd 6.4 mg/k g GC Pool (N = 91) | Study J202 HER2- positive GC (Primary Cohort)      | Study J202 HER2- positive GC (Primary Cohort)      | Study U205 HER2- positive GC T-DXd 6.4 mg/k g (N = 8) | HER2- positive GC T-DXd 6.4 mg/k g GC Pool (N = 56) |
|                                        | T-DXd 6.4 mg/k g (N = 33)                      | TPC (N = 13)                                   | Study U205 HER2- positive GC T-DXd 6.4 mg/k g (N = 32) | HER2- positive GC T-DXd 6.4 mg/k g GC Pool (N = 68) | T-DXd 6.4 mg/k g (N = 53)                     | TPC (N = 28)                                  | Study U205 HER2- positive GC T-DXd 6.4 mg/k g (N = 25) | HER2- positive GC T-DXd 6.4 mg/k g GC Pool (N = 91) | T-DXd 6.4 mg/k g (N = 39)                          | TPC (N = 20)                                       | Study U205 HER2- positive GC T-DXd 6.4 mg/k g (N = 8) | HER2- positive GC T-DXd 6.4 mg/k g GC Pool (N = 56) |
| TEAEs with CTCAE ≥Grade 3 a            | 31 (93.9)                                      | 6 (46.2 )                                      | 16 (50.0)                                              | 50 (73.5)                                           | 44 (83.0)                                     | 19 (67.9 )                                    | 10 (40.0)                                              | 64 (70.3)                                           | 32 (82.1)                                          | 9 (45.0 )                                          | 6 (75.0)                                              | 45 (80.4)                                           |
| Drug-relate d TEAEs                    | 33 (100)                                       | 12 (92.3 )                                     | 30 (93.8)                                              | 66 (97.1)                                           | 52 (98.1)                                     | 24 (85.7 )                                    | 23 (92.0)                                              | 88 (96.7)                                           | 37 (94.9)                                          | 19 (95.0 )                                         | 8 (100)                                               | 54 (96.4)                                           |
| Treatment- emergent SAEs               | 11 (33.3)                                      | 2 (15.4 )                                      | 12 (37.5)                                              | 24 (35.3)                                           | 25 (47.2)                                     | 10 (35.7 )                                    | 6 (24.0)                                               | 34 (37.4)                                           | 20 (51.3)                                          | 3 (15.0 )                                          | 5 (62.5)                                              | 28 (50.0)                                           |
| Drug- related treatment- emergent SAEs | 6 (18.2)                                       | 0                                              | 4 (12.5)                                               | 10 (14.7)                                           | 14 (26.4)                                     | 4 (14.3 )                                     | 1 (4.0)                                                | 16 (17.6)                                           | 10 (25.6)                                          | 1 (5.0)                                            | 2 (25.0)                                              | 14 (25.0)                                           |

CTCAE = Common Terminology Criteria for Adverse Events; GC = gastric cancer/gastric or gastroesophageal junction adenocarcinoma; HER2 = human epidermal growth factor receptor 2; N = total number of treated subjects;

PTX = paclitaxel; SCS = Summary of Clinical Safety; T-DXd = trastuzumab deruxtecan; TEAE = treatmentemergent adverse event; TPC = treatment of physician's choice

(includes subjects who received irinotecan [n = 55] or PTX [n = 7])

The HER2-positive GC T-DXd 6.4 mg/kg Pool includes data from Studies DS8201-A-J101, DS8201-AJ202, and DS8201-A-U205.

Percentages were calculated using the number of subjects in the Safety Analysis Set as the denominator.

a A subject was counted once at the maximum severity.

Source: Module 5.3.5.3 SCS Table 1.4.3

## Hepatic function at baseline

Subjects were categorized into groups based on baseline hepatic function per the NCI criteria:

<div style=\"page-break-after: always\"></div>

- Normal function : TBL ≤ULN and AST ≤ULN except for subjects with Gilbert syndrome and TBL ≤3.0 × ULN and AST ≤ULN for subjects with Gilbert syndrome
- Mild  impairment :  TBL  &gt;ULN, ≤1.5 × ULN and any AST except for subjects with Gilbert syndrome; TBL &gt;ULN, ≤3.0 × ULN and AST &gt;ULN for subjects with Gilbert syndrome; and TBL ≤ULN and AST &gt;ULN regardless of Gilbert syndrome
- Moderate impairment: TBL &gt;1.5 × ULN, ≤3.0 × ULN and any AST exc ept for subjects with Gilbert syndrome
- Severe impairment: TBL &gt;3.0 × ULN and any AST regardless of Gilbert syndrome

No subject entered the study with severe hepatic impairment . One subject entered with moderate hepatic impairment at screening.

Table 5.4: Overall Summary of Treatment-Emergent AdverseEventsbyBaselineHepaticFunction(SafetyAnalysisSet)

| Parameter                                                  | NormalHepaticFunction                       | NormalHepaticFunction                       | NormalHepaticFunction                        | NormalHepaticFunction                           | MildHepaticImpairment                         | MildHepaticImpairment                         | MildHepaticImpairment                                | MildHepaticImpairment                           |
|------------------------------------------------------------|---------------------------------------------|---------------------------------------------|----------------------------------------------|-------------------------------------------------|-----------------------------------------------|-----------------------------------------------|------------------------------------------------------|-------------------------------------------------|
| Parameter                                                  | StudyJ202HER2- positive GC (Primary Cohort) | StudyJ202HER2- positive GC (Primary Cohort) | Study U205 HER2- positive GC T-DXd 6.4 mg/kg | HER2- positive GC T-DXd 6.4 mg/kg Pool (N =170) | Study J202 HER2- positive GC (Primary Cohort) | Study J202 HER2- positive GC (Primary Cohort) | StudyU205 HER2- positive GC T-DXd 6.4 mg/kg (N = 13) | HER2- positive GC T-DXd 6.4 mg/kg Pool (N = 57) |
| Parameter                                                  | T-DXd 6.4 mg/kg (N = 88)                    | TPC (N = 47)                                | (N =65)                                      | HER2- positive GC T-DXd 6.4 mg/kg Pool (N =170) | T-DXd 6.4 mg/kg (N =36)                       | TPC (N =15)                                   | StudyU205 HER2- positive GC T-DXd 6.4 mg/kg (N = 13) | HER2- positive GC T-DXd 6.4 mg/kg Pool (N = 57) |
| Duration of treatment (months)                             |                                             |                                             |                                              |                                                 |                                               |                                               |                                                      |                                                 |
| Median                                                     | 5.52                                        | 2.76                                        | 4.37                                         | 4.71                                            | 2.91                                          | 2.73                                          | 4.14                                                 | 4.04                                            |
| Range                                                      | 0.7,25.5                                    | 0.5, 13.1                                   | 0.7, 15.9                                    | 0.7, 25.5                                       | 0.7, 29.7                                     | 0.5, 11.3                                     | 0.7, 11.0                                            | 0.7, 29.7                                       |
| Subjects with any TEAE, n (%)                              | 88 (100)                                    | 46 (97.9)                                   | 65 (100)                                     | 170 (100)                                       | 36 (100)                                      | 15 (100)                                      | 13 (100)                                             | 57 (100)                                        |
| TEAEs with worst CTCAE≥Grade 3a                            | 75 (85.2)                                   | 26 (55.3)                                   | 30 (46.2)                                    | 117 (68.8)                                      | 31 (86.1)                                     | 9 (60.0)                                      | 9 (69.2)                                             | 48 (84.2)                                       |
| Serious TEAEs                                              | 39 (44.3)                                   | 12 (25.5)                                   | 21 (32.3)                                    | 66 (38.8)                                       | 17 (47.2)                                     | 4 (26.7)                                      | 7 (53.8)                                             | 25 (43.9)                                       |
| TEAEs associated with study drug discontinuation           | 16 (18.2)                                   | 3 (6.4)                                     | 8 (12.3)                                     | 27 (15.9)                                       | 6 (16.7)                                      | 1 (6.7)                                       | 4 (30.8)                                             | 11 (19.3)                                       |
| TEAEs associatedwith dosereduction                         | 30 (34.1)                                   | 18 (38.3)                                   | 14 (21.5)                                    | 50 (29.4)                                       | 10 (27.8)                                     | 3 (20.0)                                      | 5 (38.5)                                             | 18 (31.6)                                       |
| TEAEs associated with study drug interruption              | 59 (67.0)                                   | 15 (31.9)                                   | 14 (21.5)                                    | 80 (47.1)                                       | 19 (52.8)                                     | 8 (53.3)                                      | 3 (23.1)                                             | 28 (49.1)                                       |
| TEAEs associatedwith an outcome of deathb                  | 5 (5.7)                                     | 1 (2.1)                                     | 4 (6.2)                                      | 10 (5.9)                                        | 3 (8.3)                                       | 1 (6.7)                                       | 6 (46.2)                                             | 9 (15.8)                                        |
| Subjects with any drug-related TEAE, n (%)*                | 87 (98.9)                                   | 43 (91.5)                                   | 61 (93.8)                                    | 165 (97.1)                                      | 34 (94.4)                                     | 13 (86.7)                                     | 12 (92.3)                                            | 54 (94.7)                                       |
| Drug-related TEAEs with worst CTCAE ≥Grade 3a              | 65 (73.9)                                   | 20 (42.6)                                   | 14 (21.5)                                    | 88 (51.8)                                       | 28 (77.8)                                     | 7 (46.7)                                      | 6 (46.2)                                             | 41 (71.9)                                       |
| Drug-related seriousTEAEs                                  | 20 (22.7)                                   | 4 (8.5)                                     | 5 (7.7)                                      | 27 (15.9)                                       | 10 (27.8)                                     | 1 (6.7)                                       | 2 (15.4)                                             | 13 (22.8)                                       |
| Drug-relatedTEAEs associatedwithstudy drug discontinuation | 13 (14.8)                                   | 2 (4.3)                                     | 5 (7.7)                                      | 20 (11.8)                                       | 1 (2.8)                                       | 1 (6.7)                                       | 2 (15.4)                                             | 4 (7.0)                                         |
| Drug-relatedTEAEs associatedwithdose reduction             | 28 (31.8)                                   | 18 (38.3)                                   | 11 (16.9)                                    | 45 (26.5)                                       | 10 (27.8)                                     | 3 (20.0)                                      | 4 (30.8)                                             | 17 (29.8)                                       |
| Drug-related TEAEs associated with study drug interruption | 50 (56.8)                                   | 11 (23.4)                                   | 5 (7.7)                                      | 61 (35.9)                                       | 14 (38.9)                                     | 8 (53.3)                                      | 2 (15.4)                                             | 21 (36.8)                                       |
| Drug-relatedTEAEsassociatedwithan outcome of deathb        | 1 (1.1)                                     | 0                                           | 0                                            | 1 (0.6)                                         | 0                                             | 0                                             | 1 (7.7)                                              | 1 (1.8)                                         |

Percentageswere calculated using the number of subjects in theSafetyAnalysisSet as the denominator.

b For specific TEAEs associated with outcome of death, refer to Table 2.8.

a A subject was counted once at the maximum severity.

c If relationship was missing, the TEAE was considered to be related to the drug.

Source:Module5.3.5.3SCSTables1.4.2and1.4.3

<div style=\"page-break-after: always\"></div>

## 2.5.6.2. Extrinsic factors

TEAEs were evaluated for geographic region (Asia, North America, and Europe) and country (Japan and countries other than Japan).

## Geographic region

Table 5.5: Overall Summary of Treatment-Emergent Adverse Events by Region (Asia, North America, and Europe) (SafetyAnalysisSet)

| Parameter                                                      | Asia                                         | Asia                                         | Asia                                       | Asia                                                         | North America                                  | North America                                  | North America                      | North America                                                | Europe                                         | Europe                                         | Europe                                                        | Europe                                    |
|----------------------------------------------------------------|----------------------------------------------|----------------------------------------------|--------------------------------------------|--------------------------------------------------------------|------------------------------------------------|------------------------------------------------|------------------------------------|--------------------------------------------------------------|------------------------------------------------|------------------------------------------------|---------------------------------------------------------------|-------------------------------------------|
| Parameter                                                      | Study J202 HER2-positive GC (Primary Cohort) | Study J202 HER2-positive GC (Primary Cohort) | Study U205 d HER2- positive GC T-DXd (N=0) | HER2- positive GC T-DXd 6.4 mg/kg GC Pool 6.4 mg/kg(N = 150) | Study J202 e HER2-positive GC (Primary Cohort) | Study J202 e HER2-positive GC (Primary Cohort) | Study U205 HER2- positive GC T-DXd | HER2- positive GC T-DXd 6.4 mg/kg GC Pool 6.4 mg/kg (N = 34) | Study J202 e HER2-positive GC (Primary Cohort) | Study J202 e HER2-positive GC (Primary Cohort) | Study U205 HER2- positive GC T-DXd 6.4 mg/kg (N = 45) (N =45) | HER2- positive GC T-DXd 6.4 mg/kg GC Pool |
| Parameter                                                      | T-DXd 6.4 mg/kg(N= 62) (N =125)              | TPC                                          | Study U205 d HER2- positive GC T-DXd (N=0) | HER2- positive GC T-DXd 6.4 mg/kg GC Pool 6.4 mg/kg(N = 150) | T-DXd 6.4 mg/kg (N =0) (N=0)                   | TPC                                            | (N =34)                            | HER2- positive GC T-DXd 6.4 mg/kg GC Pool 6.4 mg/kg (N = 34) | T-DXd 6.4 mg/kg (N=0) (N=0)                    | TPC                                            | Study U205 HER2- positive GC T-DXd 6.4 mg/kg (N = 45) (N =45) | HER2- positive GC T-DXd 6.4 mg/kg GC Pool |
| Durationoftreatment(months)                                    | Durationoftreatment(months)                  | Durationoftreatment(months)                  | Durationoftreatment(months)                | Durationoftreatment(months)                                  | Durationoftreatment(months)                    | Durationoftreatment(months)                    | Durationoftreatment(months)        | Durationoftreatment(months)                                  | Durationoftreatment(months)                    | Durationoftreatment(months)                    | Durationoftreatment(months)                                   | Durationoftreatment(months)               |
| Median                                                         | 4.60                                         | 2.76                                         | N/A                                        | 4.60                                                         | N/A                                            | N/A                                            | 3.89                               | 3.89                                                         | N/A                                            | N/A                                            | 5.16                                                          | 5.16                                      |
| Range                                                          | 0.7,29.70.5,13.1                             |                                              | N/A                                        | 0.7,29.7                                                     | N/A                                            | N/A                                            | 0.7, 15.9                          | 0.7, 15.9                                                    | N/A                                            | N/A                                            | 0.7, 12.9                                                     | 0.7,12.9                                  |
| Subjects with any TEAE, n (%)                                  | 125 (100)61 (98.4)                           |                                              | N/A                                        | 150 (100)                                                    | N/A                                            | N/A                                            | 34 (100)                           | 34 (100)                                                     | N/A                                            | N/A                                            | 45 (100)                                                      | 45 (100)                                  |
| TEAEs with worst CTCAE ≥Grade 3a                               | 107 (85.6)35 (56.5)                          |                                              | N/A                                        | 127 (84.7)                                                   | N/A                                            | N/A                                            | 17 (50.0)                          | 17 (50.0)                                                    | N/A                                            | N/A                                            | 23 (51.1)                                                     | 23 (51.1)                                 |
| Serious TEAEs                                                  | 56 (44.8)                                    | 16 (25.8)                                    | N/A                                        | 63 (42.0)                                                    | N/A                                            | N/A                                            | 13 (38.2)                          | 13 (38.2)                                                    | N/A                                            | N/A                                            | 16 (35.6)                                                     | 16 (35.6)                                 |
| TEAEs associated with study drug discontinuation               | 22 (17.6)                                    | 4 (6.5)                                      | N/A                                        | 26 (17.3)                                                    | N/A                                            | N/A                                            | 7 (20.6)                           | 7 (20.6)                                                     | N/A                                            | N/A                                            | 5 (11.1)                                                      | 5 (11.1)                                  |
| TEAEs associated with dose reduction                           | 40 (32.0) 21 (33.9)                          |                                              | N/A                                        | 49 (32.7)                                                    | N/A                                            | N/A                                            | 9 (26.5)                           | 9 (26.5)                                                     | N/A                                            | N/A                                            | 10 (22.2)                                                     | 10 (22.2)                                 |
| TEAEs associated with study drug interruption                  | 79 (63.2) 23 (37.1)                          |                                              | N/A                                        | 92 (61.3)                                                    | N/A                                            | N/A                                            | 6 (17.6)                           | 6 (17.6)                                                     | N/A                                            | N/A                                            | 11 (24.4)                                                     | 11 (24.4)                                 |
| TEAEs associated with an outcome of deathb                     | 8 (6.4)                                      | 2 (3.2)                                      | N/A                                        | 9 (6.0)                                                      | N/A                                            | N/A                                            | 5 (14.7)                           | 5 (14.7)                                                     | N/A                                            | N/A                                            | 5 (11.1)                                                      | 5 (11.1)                                  |
| Subjects with any drug-122 (97.6)56 (90.3) related TEAE,n (%)c |                                              |                                              | N/A                                        | 147 (98.0)                                                   | N/A                                            | N/A                                            |                                    | 31 (91.2)31 (91.2)                                           | N/A                                            | N/A                                            |                                                               | 43 (95.6)43 (95.6)                        |
| Drug-related TEAEs with worst CTCAE ≥Grade 3a                  | 94 (75.2)27 (43.5)                           |                                              | N/A                                        | 110 (73.3)                                                   | N/A                                            | N/A                                            | 6 (17.6)                           | 6 (17.6)                                                     | N/A                                            | N/A                                            | 15 (33.3)                                                     | 15 (33.3)                                 |
| Drug-related serious TEAEs                                     | 30 (24.0)5 (8.1)                             |                                              | N/A                                        | 33 (22.0)                                                    | N/A                                            | N/A                                            | 2 (5.9)                            | 2 (5.9)                                                      | N/A                                            | N/A                                            | 6 (13.3)                                                      | 6 (13.3)                                  |
| Drug-related TEAEs associatedwithstudy drug discontinuation    | 14 (11.2)                                    | 3 (4.8)                                      | N/A                                        | 17 (11.3)                                                    | N/A                                            | N/A                                            | 3 (8.8)                            | 3 (8.8)                                                      | N/A                                            | N/A                                            | 4 (8.9)                                                       | 4 (8.9)                                   |
| Drug-related TEAEs associatedwith dose reduction               | 38 (30.4)21 (33.9)                           |                                              | N/A                                        | 47 (31.3)                                                    | N/A                                            | N/A                                            | 7 (20.6)                           | 7 (20.6)                                                     | N/A                                            | N/A                                            | 8 (17.8)                                                      | 8 (17.8)                                  |
| Drug-related TEAEs associated with study drug interruption     | 65 (52.0)19 (30.6)                           |                                              | N/A                                        | 76 (50.7)                                                    | N/A                                            | N/A                                            | 2 (5.9)                            | 2 (5.9)                                                      | N/A                                            | N/A                                            | 5 (11.1)                                                      | 5 (11.1)                                  |

<div style=\"page-break-after: always\"></div>

| Drug-relatedTEAEs associatedwithan outcomeofdeathb   | 1 (0.8)   | 0   | N/A   | 1 (0.7)   | N/A   | N/A   | 1 (2.9)   | 1 (2.9)   | N/A   | N/A   | 0   | 0   |
|------------------------------------------------------|-----------|-----|-------|-----------|-------|-------|-----------|-----------|-------|-------|-----|-----|

PercentageswerecalculatedusingthenumberofsubjectsintheSafetyAnalysisSetasthedenominator.

aAsubjectwascountedonceatthemaximumseverity.

c If relationship was missing, the TEAE was considered to be related to the drug.

bFor specific TEAEs associated with outcome of death, refer to Table 2.8.

d Study U205 is not conducted in Asia, therefore no applicable data.

StudyJ202isnotconductedinNorthAmericaandEurope,thereforenoapplicabledata.

Source:Module5.3.5.3SCSTables1.4.2and1.4.3

## Country

Within  the  HER2-positive  GC  Pool,  notable  differences  in  the  frequency  of  events  in  the  following categories were observed when comparing subjects from Japan (n = 124) with subjects from countries other than Japan (n = 105) (Table 5.5):

- ≥Grade 3 TEAEs (ove rall and drug-related) and TEAEs associated with study drug interruption (overall and drug-related) were reported in a higher proportion of subjects from Japan than nonJapan.
- TEAEs associated with an outcome of death were reported in a proportion at least twice as high in subjects from non-Japan countries (12/105 [11.4%]) than from Japan (7/124 [5.6%]).

Table 5.6: Overall Summary of Treatment-Emergent Adverse Events by Country (Japan, Non-Japan) (Safety Analysis Set)

| Parameter                                        | Japan                                        | Japan                                        | Japan                                                | Japan                                            | Non-Japan                                    | Non-Japan                                    | Non-Japan                                    | Non-Japan                         |
|--------------------------------------------------|----------------------------------------------|----------------------------------------------|------------------------------------------------------|--------------------------------------------------|----------------------------------------------|----------------------------------------------|----------------------------------------------|-----------------------------------|
|                                                  | Study J202HER2- positive GC (Primary Cohort) | Study J202HER2- positive GC (Primary Cohort) | Study U205d HER2- positive GC T-DXd 6.4 mg/kg (N =0) | HER2- positive GC T-DXd 6.4 mg/kg Pool (N = 124) | Study J202HER2- positive GC (Primary Cohort) | Study J202HER2- positive GC (Primary Cohort) | Study U205 HER2- positive GC T-DXd 6.4 mg/kg | HER2- positive GC T-DXd 6.4 mg/kg |
|                                                  | T-DXd 6.4 mg/kg (N=99)                       | TPC (N = 50)                                 |                                                      |                                                  | T-DXd 6.4 mg/kg (N =26)                      | TPC (N =12)                                  | (N =79)                                      | Pool (N =105)                     |
| Duration of treatment (months)                   |                                              |                                              |                                                      |                                                  |                                              |                                              |                                              |                                   |
| Median                                           | 4.99                                         | 2.76                                         | N/A                                                  | 4.80                                             | 4.48                                         | 2.10                                         | 4.34                                         | 4.37                              |
| Range                                            | 0.7, 29.7                                    | 0.5, 13.1                                    | N/A                                                  | 0.7, 29.7                                        | 0.7, 16.8                                    | 0.5, 7.1                                     | 0.7, 15.9                                    | 0.7, 16.8                         |
| Subjects with any TEAE, n (%)                    | 99 (100)                                     | 50 (100)                                     | N/A                                                  | 124 (100)                                        | 26 (100)                                     | 11 (91.7)                                    | 79 (100)                                     | 105 (100)                         |
| TEAEs with worst CTCAE ≥Grade 3a                 | 84 (84.8)                                    | 29 (58.0)                                    | N/A                                                  | 104 (83.9)                                       | 23 (88.5)                                    | 6 (50.0)                                     | 40 (50.6)                                    | 63 (60.0)                         |
| Serious TEAEs                                    | 42 (42.4)                                    | 12 (24.0)                                    | N/A                                                  | 49 (39.5)                                        | 14 (53.8)                                    | 4 (33.3)                                     | 29 (36.7)                                    | 43 (41.0)                         |
| TEAEs associated with study drug discontinuation | 16 (16.2)                                    | 3 (6.0)                                      | N/A                                                  | 20 (16.1)                                        | 6 (23.1)                                     | 1 (8.3)                                      | 12 (15.2)                                    | 18 (17.1)                         |
| TEAEsassociatedwithdosereduction                 | 31 (31.3)                                    | 17 (34.0)                                    | N/A                                                  | 40 (32.3)                                        | 9 (34.6)                                     | 4 (33.3)                                     | 19 (24.1)                                    | 28 (26.7)                         |
| TEAEs associated with study drug interruption    | 68 (68.7)                                    | 19 (38.0)                                    | N/A                                                  | 81 (65.3)                                        | 11 (42.3)                                    | 4 (33.3)                                     | 17 (21.5)                                    | 28 (26.7)                         |
| TEAEs associated with an outcome of deathb       | 6 (6.1)                                      | 1 (2.0)                                      | N/A                                                  | 7 (5.6)                                          | 2 (7.7)                                      | 1 (8.3)                                      | 10 (12.7)                                    | 12 (11.4)                         |
| Subjects with any drug-related TEAE, n (%)c      | 98 (99.0)                                    | 46 (92.0)                                    | N/A                                                  | 123 (99.2)                                       | 24 (92.3)                                    | 10 (83.3)                                    | 74 (93.7)                                    | 98 (93.3)                         |
| Drug-related TEAEs withworst CTCAE ≥Grade 3a     | 77 (77.8)                                    | 21 (42.0)                                    | N/A                                                  | 93 (75.0)                                        | 17 (65.4)                                    | 6 (50.0)                                     | 21 (26.6)                                    | 38 (36.2)                         |
| Drug-related serious TEAEs                       | 24 (24.2)                                    | 2 (4.0)                                      | N/A                                                  | 27 (21.8)                                        | 6 (23.1)                                     | 3 (25.0)                                     | 8 (10.1)                                     | 14 (13.3)                         |

<div style=\"page-break-after: always\"></div>

| Drug-relatedTEAEsassociatedwithstudy drugdiscontinuation   | 10 (10.1)   | 2 (4.0)   | N/A   | 13 (10.5)   | 4 (15.4)   | 1 (8.3)   | 7 (8.9)   | 11 (10.5)   |
|------------------------------------------------------------|-------------|-----------|-------|-------------|------------|-----------|-----------|-------------|
| Drug-relatedTEAEsassociatedwithdose reduction              | 30 (30.3)   | 17 (34.0) | N/A   | 39 (31.5)   | 8 (30.8)   | 4 (33.3)  | 15 (19.0) | 23 (21.9)   |
| Drug-relatedTEAEsassociatedwithstudy drug interruption     | 57 (57.6)   | 16 (32.0) | N/A   | 68 (54.8)   | 8 (30.8)   | 3 (25.0)  | 7 (8.9)   | 15 (14.3)   |
| Drug-relatedTEAEsassociatedwithan outcomeof deathb         | 0           | 0         | N/A   | 0           | 1 (3.8)    | 0         | 1 (1.3)   | 2 (1.9)     |

HER2-positiveGC 6.4 mg/kg Poolincludes data from studies:DS8201-A-J101,DS8201-A-J202,and DS8201-A-U205.

aA subject was counted once at the maximum severity.

cIfrelationship was missing, the TEAE was considered toberelated to the drug.

bFor specificTEAEs associated with outcome of death,refer toTable 2.8.

d Study U205 is not conducted in Japan, therefore no applicable data.

Source:Module5.3.5.3SCSTables1.4.2,and1.4.3

The higher frequency of TEAEs associated with an outcome of death in Study U205 vs. the T-DXd arm of Study J202 (ie, 10 [12.7%] vs. 8 [6.4%]) was mostly attributable to a greater proportion of deaths due to COVID-19 (2 [2.5%] vs. 0) and TEAEs related to disease progression (5 [6.3%] vs. 6 [4.8%]). Importantly, there were no differences between the 2 studies in terms of drug-related TEAEs associated with an outcome of death; indeed, such events were reported only in 1 subject in each study (ILD in Study U205 and pneumonia in the T-DXd arm of Study J202).

The higher frequency of hematologic toxicity in Asian vs. Western subjects, and more particularly in Japanese vs. non-Japanese subjects, is not surprising as it has been already observed in studies in HER2-positive  BC  conducted  by  the  Applicant,  as  well  as  in  published  reports  of  clinical  studies investigating  drugs  for  the  treatment  of  subjects  with  HER2-positive  metastatic  GC,  and  other observations from the literature.

## 2.5.7. Safety related to drug-drug interactions and other interactions

## 2.5.7.1. Drug-drug interactions

Although  no  drug-drug  interaction  (DDI)  studies  have  been  performed  in  subjects  with  GC,  no interactions  with  strong  cytochrome  P450  (CYP)3A  and  organic  anion  transporting  polypeptide  1B inhibitors were observed in a dedicated DDI study with ritonavir and itraconazole in subjects with HER2expressing advanced solid malignant tumors. No new information on drug interactions is available since the time of Study DS8201-A-A104 (DCO of 26 Sep 2018).

## 2.5.7.2. Other interactions

## Infusion-related reactions

T-DXd was not associated with severe infusion-related reactions (IRR).

In the T-DXd arm of Study J202 , 12/125 (9.6%) subjects were antidrug-antibodies (ADA) positive at baseline. No subjects were ADA-positive at both baseline and post-baseline. A total of 9/123 (7.3%) subjects were identified as having treatment-emergent ADAs.

In Study U205 , a similar proportion of subjects who had a baseline assessment were ADA positive at baseline (5/76 (6.6%)). No subjects were ADA-positive at both baseline and post-baseline. A total of

<div style=\"page-break-after: always\"></div>

2/73  (2.7%)  subjects  were  identified  as  having  treatment-emergent  ADAs  (defined  as  having  ADApositive samples post-baseline and a negative or missing baseline result).

After comprehensive review of each potential IRR event in the HER2-positive GC Pool, 2 subjects in the T-DXd arm of Study J202 were considered to have experienced IRR events. Both subjects were ADAnegative at baseline and post-baseline.

## 2.5.8. Discontinuation due to adverse events

In the HER2-positive GC Pool, 38/229 (16.6%) subjects experienced any TEAE associated with study drug discontinuation , with the most commonly reported TEAE being ILD (15/229 [6.6%]).

Table 2.10: Treatment-Emergent Adverse Events Associated with Study Drug Discontinuation Reported in Any Subject, by Preferred Term/Grouped Term (Safety Analysis Set)

| MedDRAPreferred Term/ Grouped Term                                | Number (%) of Subjects                     | Number (%) of Subjects                     | Number (%) of Subjects                               | Number (%) of Subjects                          |
|-------------------------------------------------------------------|--------------------------------------------|--------------------------------------------|------------------------------------------------------|-------------------------------------------------|
| MedDRAPreferred Term/ Grouped Term                                | StudyJ202HER2-p0sitive GC (Primary Cohort) | StudyJ202HER2-p0sitive GC (Primary Cohort) | Study U205 HER2-positive GC T-DXd 6.4 mg/kg (N = 79) | HER2-positive GC T-DXd 6.4 mg/kg Pool (N = 229) |
| MedDRAPreferred Term/ Grouped Term                                | PXI-L 6.4 mg/kg (N =125)                   | TPC (N = 62)                               | Study U205 HER2-positive GC T-DXd 6.4 mg/kg (N = 79) | HER2-positive GC T-DXd 6.4 mg/kg Pool (N = 229) |
| Subjects with Any TEAE Associated with Study Drug Discontinuation | 22 (17.6)                                  | 4 (6.5)                                    | 12 (15.2)                                            | 38 (16.6)                                       |
| Interstitial lung disease b                                       | 8 (6.4)                                    | 0                                          | 5 (6.3)                                              | 15 (6.6)                                        |
| Pneumonia                                                         | 2 (1.6)                                    | 0                                          | 0                                                    | 3 (1.3)                                         |
| Anaemia *                                                         | 2 (1.6)                                    | 0                                          | 0                                                    | 2 (0.9)                                         |
| Fatigue a                                                         | 2 (1.6)                                    | 1 (1.6)                                    | 0                                                    | 2 (0.9)                                         |
| COVID-19                                                          | 0                                          | 0                                          | 1 (1.3)                                              | 1 (0.4)                                         |
| COVID-19 pneumonia                                                | 0                                          | 0                                          | 1 (1.3)                                              | 1 (0.4)                                         |
| Cerebrovascular accident                                          | 0                                          | 0                                          | 1 (1.3)                                              | 1 (0.4)                                         |
| Cholangitis                                                       | 1 (0.8)                                    | 0                                          | 0                                                    | 1 (0.4)                                         |
| Colitis                                                           | 0                                          | 0                                          | 1 (1.3)                                              | 1 (0.4)                                         |
| Decreased appetite                                                | 0                                          | 0                                          | 0                                                    | 1 (0.4)                                         |
| Gastrointestinal obstruction                                      | 1 (0.8)                                    | 0                                          | 0                                                    | 1 (0.4)                                         |
| Hemiplegia                                                        | 1 (0.8)                                    | 0                                          | 0                                                    | 1 (0.4)                                         |
| Hepatic function abnormal                                         | 1 (0.8)                                    | 0                                          | 0                                                    | 1 (0.4)                                         |
| Hepatotoxicity                                                    | 0                                          | 0                                          | 1 (1.3)                                              | 1 (0.4)                                         |
| Hyponatraemia                                                     | 1 (0.8)                                    | 0                                          | 0                                                    | 1 (0.4)                                         |
| Large intestine perforation                                       | 1 (0.8)                                    | 0                                          | 0                                                    | 1 (0.4)                                         |
| Nausea                                                            | 0                                          | 0                                          | 1 (1.3)                                              | 1 (0.4)                                         |
| Pneumonia bacterial                                               | 1 (0.8)                                    | 0                                          | 0                                                    | 1 (0.4)                                         |
| Sepsis                                                            | 1 (0.8)                                    | 0                                          | 0                                                    | 1 (0.4)                                         |
| Thrombocytopenia a                                                | 0                                          | 0                                          | 0                                                    | 1 (0.4)                                         |
| Weight decreased                                                  | 0                                          | 0                                          | 1 (1.3)                                              | 1 (0.4)                                         |
| Cerebral infarction                                               | 0                                          | 1 (1.6)                                    | 0                                                    | 0                                               |
| Neutropenia a                                                     | 0                                          | 2 (3.2)                                    | 0                                                    | 0                                               |

<div style=\"page-break-after: always\"></div>

- COVID-19 = coronavirus disease 2019; GC = gastric/gastroesophageal junction cancer; HER2 =human epidermal growth factor receptor 2; ILD = interstitial lung disease; MedDRA =Medical Dictionary for Regulatory Activities, Version 23.0; N = total number of treated subjects; PT =preferred term; SMQ = Standardised MedDRA Query;

T-DXd=trastuzumab deruxtecan; TEAE =treatment-emergent adverse event;TPC=treatment of physician's choice (includes subjects who received irinotecan [n = 55] or paclitaxel [n= 7]).

HER2-p0sitive GC 6.4 mg/kg Pool includes data from studies DS8201-A-J101, DS8201-A-J202, and DS8201-AU205.

PT/grouped terms are presented in descending order of frequency in the HER2-positive GC T-DXd 6.4 mg/kg Pool. Percentages were calculated using the number of subjects in the Safety Analysis Set as the denominator.

a The PTs that were included in each grouped term are listed in Table 2.1.

Interstitial lung disease includes events that were adjudicated as ILD and considered study drug related by adjudication committee.

Source:Module 5.3.5.3 SCS Tables1.2.1.10,1.2.2.4,and 1.2.4.3

A similar proportion of subjects in the Study J202 T-DXd arm (40/125 [32.0%]) and the TPC arm (21/62 [33.9%]) experienced TEAEs associated with dose reduction except for leukopenia (grouped term), of which the incidence was at least twice as high in the TPC arm than in the T-DXd arm (3/62 [4.8%] vs. 2/125 [1.6%], respectively) (Table 2.11).

Table 2.11: Treatment-Emergent Adverse Events Associated with Dose Reduction Reported in at Least 1% of Subjects in the HER2-positive GC T-DXd 6.4 mg/kg Pool, by Preferred Term/Grouped Term (Safety Analysis Set)

| MedDRAPreferred Term/ Grouped Term                    | Number (%) of Subjects                       | Number (%) of Subjects                       | Number (%) of Subjects                               | Number (%) of Subjects                           |
|-------------------------------------------------------|----------------------------------------------|----------------------------------------------|------------------------------------------------------|--------------------------------------------------|
| MedDRAPreferred Term/ Grouped Term                    | Study .J202HER2-positive GC (Primary Cohort) | Study .J202HER2-positive GC (Primary Cohort) | Study U205 HER2- positive GC T-DXd 6.4 mg/kg (N =79) | HER2- positive GC T-DXd 6.4 mg/kg Pool (N = 229) |
| MedDRAPreferred Term/ Grouped Term                    | T-DXd 6.4 mg/kg (N =125)                     | TPC (N= 62)                                  | Study U205 HER2- positive GC T-DXd 6.4 mg/kg (N =79) | HER2- positive GC T-DXd 6.4 mg/kg Pool (N = 229) |
| Subjects with Any TEAE Associated with Dose Reduction | 40 (32.0)                                    | 21 (33.9)                                    | 19 (24.1)                                            | 68 (29.7)                                        |
| Neutropenia a                                         | 16 (12.8)                                    | 7 (11.3)                                     | 4 (5.1)                                              | 21 (9.2)                                         |
| Decreased appetite                                    | 12 (9.6)                                     | 3 (4.8)                                      | 2 (2.5)                                              | 19 (8.3)                                         |
| Nausea                                                | 7 (5.6)                                      | 5 (8.1)                                      | 7 (8.9)                                              | 15 (6.6)                                         |
| Fatigue a                                             | 10 (8.0)                                     | 4 (6.5)                                      | 3 (3.8)                                              | 13 (5.7)                                         |
| Febrile neutropenia                                   | 3 (2.4)                                      | 1 (1.6)                                      | 2 (2.5)                                              | 5 (2.2)                                          |
| Thrombocytopeniaa                                     | 1 (0.8)                                      | 0                                            | 0                                                    | 4 (1.7)                                          |

<div style=\"page-break-after: always\"></div>

| MedDRAPreferred Term/ Grouped Term *   | Number (%) of Subjects                       | Number (%) of Subjects                       | Number (%) of Subjects                               | Number (%) of Subjects                          |
|----------------------------------------|----------------------------------------------|----------------------------------------------|------------------------------------------------------|-------------------------------------------------|
| MedDRAPreferred Term/ Grouped Term *   | Study J202 HER2-positive GC (Primary Cohort) | Study J202 HER2-positive GC (Primary Cohort) | Study U205 HER2- positive GC T-DXd 6.4 mg/kg (N= 79) | HER2- positive GC T-DXd 6.4 mg/kg Pool (N =229) |
| MedDRAPreferred Term/ Grouped Term *   | PXI-L 6.4 mg/kg (N =125)                     | TPC (N =62)                                  | Study U205 HER2- positive GC T-DXd 6.4 mg/kg (N= 79) | HER2- positive GC T-DXd 6.4 mg/kg Pool (N =229) |
| Weight decreased                       | 0                                            | 2 (3.2)                                      | 4 (5.1)                                              | 4 (1.7)                                         |
| Diarrhoea                              | 1 (0.8)                                      | 1 (1.6)                                      | 1 (1.3)                                              | 3 (1.3)                                         |
| Leukopenia a                           | 2 (1.6)                                      | 3 (4.8)                                      | 0                                                    | 3 (1.3)                                         |

MedDRA =Medical Dictionary for Regulatory Activities,Version 23.0; N = total number of treated subjects;

GC = gastric/gastroesophageal junction cancer; HER2= human epidermal growth factor receptor 2;

PT =preferred term; T-DXd =trastuzumab deruxtecan; TEAE = treatment-emergent adverse event;

TPC = treatment of physician's choice (includes subjects who received irinotecan [n = 55] or paclitaxel [n = 7]). HER2-positive GC 6.4 mg/kg Pool includes data from studies DS8201-A-J101, DS8201-A-J202, and DS8201-AU205.

PT/grouped terms are presented in descending order of frequency in the HER2-positive GC T-DXd 6.4 mg/kg Pool. Percentages were calculated using the number of subjects in the Safety Analysis Set as the denominator.

a The PTs that were included in each grouped term are listed in Table 2.1.

Source: Module 5.3.5.3 SCS Tables 1.2.1.14 and 1.2.2.5

A total of 109/229 (47.6%) subjects in the HER2-positive GC Pool experienced TEAEs associated with study drug  interruption ,  with  a  notably  higher  incidence  in  the  Study  J202  T-DXd  arm  (79/125 [63.2%]) than in Study U205 (17/79 [21.5%]) (Table 2.12).

Table 2.12: Treatment-Emergent Adverse Events Associated with Study Drug Interruption Reported in at Least 1% of Subjects in the HER2-positive GC T-DXd 6.4 mg/kg Pool, by Preferred Term/Grouped Term (Safety Analysis Set)

| MedDRAPreferred Term/                                     | Number (%) of Subjects                      | Number (%) of Subjects                      | Number (%) of Subjects                                | Number (%) of Subjects                 |
|-----------------------------------------------------------|---------------------------------------------|---------------------------------------------|-------------------------------------------------------|----------------------------------------|
| Grouped Term                                              | Study J202HER2-p0sitive GC (Primary Cohort) | Study J202HER2-p0sitive GC (Primary Cohort) | Study U205 HER2- positive GC T-DXd 6.4 mg/kg (N = 79) | HER2- positive GC T-DXd 6.4 mg/kg Pool |
|                                                           | PXI-L 6.4 mg/kg (N =125)                    | TPC (N = 62)                                |                                                       | (N=229)                                |
| Subjectswith AnyTEAE Associated withStudyDrugInterruption | 79 (63.2)                                   | 23 (37.1)                                   | 17 (21.5)                                             | 109 (47.6)                             |

<div style=\"page-break-after: always\"></div>

| MedDRAPreferredTerm/ Grouped Term a   | Number (%) of Subjects                     | Number (%) of Subjects                     | Number (%) of Subjects                       | Number (%) of Subjects        |
|---------------------------------------|--------------------------------------------|--------------------------------------------|----------------------------------------------|-------------------------------|
| MedDRAPreferredTerm/ Grouped Term a   | StudyJ202HER2-positive GC (Primary Cohort) | StudyJ202HER2-positive GC (Primary Cohort) | Study U205 HER2- positive GC T-DXd 6.4 mg/kg | HER2- positive 6.4 mg/kg Pool |
| MedDRAPreferredTerm/ Grouped Term a   | T-DXd 6.4 mg/kg (N =125)                   | TPC (N = 62)                               | (N=79)                                       | GC T-DXd (N = 229)            |
| Neutropenia a                         | 35 (28.0)                                  | 7 (11.3)                                   | 1 (1.3)                                      | 41 (17.9)                     |
| Anaemia a                             | 15 (12.0)                                  | 2 (3.2)                                    | 3 (3.8)                                      | 19 (8.3)                      |
| Decreased appetite                    | 11 (8.8)                                   | 2 (3.2)                                    | 0                                            | 16 (7.0)                      |
| Leukopenia a                          | 11 (8.8)                                   | 8 (12.9)                                   | 1 (1.3)                                      | 12 (5.2)                      |
| Fatigue a                             | 9 (7.2)                                    | 4 (6.5)                                    | 1 (1.3)                                      | 10 (4.4)                      |
| Interstitial lung disease b           | 6 (4.8)                                    | 0                                          | 0                                            | 8 (3.5)                       |
| Pneumonia                             | 6 (4.8)                                    | 0                                          | 0                                            | 8 (3.5)                       |
| Thrombocytopenia a                    | 5 (4.0)                                    | 0                                          | 0                                            | 6 (2.6)                       |
| Lymphopenia a                         | 4 (3.2)                                    | 0                                          | 0                                            | 4 (1.7)                       |
| Upper respiratory tract infection a   | 4 (3.2)                                    | 0                                          | 0                                            | 4 (1.7)                       |
| Cholangitis                           | 1 (0.8)                                    | 0                                          | 0                                            | 3 (1.3)                       |
| Diarrhoea                             | 3 (2.4)                                    | 1 (1.6)                                    | 0                                            | 3 (1.3)                       |
| Hypokalaemia                          | 3 (2.4)                                    | 0                                          | 0                                            | 3 (1.3)                       |
| Vomiting                              | 0                                          | 0                                          | 3 (3.8)                                      | 3 (1.3)                       |

ILD = interstitial lung disease; MedDRA = Medical Dictionary for Regulatory Activities, Version 23.0; N = total number of treated subjects; PT =preferred term; SMQ =Standardised MedDRA Query; T-DXd= trastuzumab deruxtecan; TEAE = treatment-emergent adverse event; TPC = treatment of physician's choice (includes subjects who received irinotecan[n =55] or paclitaxel [n =7])

GC = gastric/gastroesophageal junction cancer; HER2 = human epidermal growth factor receptor 2;

HER2-positive GC 6.4 mg/kg Pool includes data from studies DS8201-A-J101, DS8201-A-J202,and DS8201-AU205.

PT/grouped terms are presented in descending order of frequency in the HER2-positive GC T-DXd 6.4 mg/kg Pool. Percentages were calculated using the number of subjects in the Safety Analysis Set as the denominator.

b Interstitial lung disease includes events that were adjudicated as ILD and considered study drug related by adjudication committee.

The PTs that were included in each grouped term are listed in Table 2.1.

Source: Module 5.3.5.3 SCS Tables 1.2.1.12, 1.2.2.6, and 1.2.4.5

## 2.5.9. Post marketing experience

Based on review of data from 20 Dec 2019 (first approval of T-DXd in the US) through 01 Aug 2021, no new safety findings have been identified from spontaneous reports during the post-marketing period. The reported events were generally consistent with the known safety profile of T-DXd.

## 2.5.10. Discussion on clinical safety

The safety population consisted of in total 229 adult patients ( the HER2+ 6.4 mg/kg GC Pool ): 125 (J202, 3L+, Asians) + 79 (U205, 2L, Westerns) + 25 (J101, phase I, Asian) with locally advanced or metastatic HER2-positive gastric or GEJ adenocarcinoma, who had received a prior anti-HER2-based regimen.  The  number,  demographics  and  baseline  characteristics  of  these  patients  are  considered relevant and the primary safety analysis is based on this pooled dataset. However, supplementary data from the confirmatory study DESTINY-Gastric04 (Specific Obligation) are awaited.

<div style=\"page-break-after: always\"></div>

Median duration of treatment was 4.6 months in the T-DXd arm of study J202 and 4.34 months in study U205, but somewhat shorter in the TPC arm (2.76 months). In J202 16.8% and in U205 6.3% received treatment more than 12 months, whereas only 2 patients (3.2%) in the TPC arm of J202 received treatment more than 9 months. Median number of cycles (6 - 6) and mean relative dose intensity (89.67% - 93.52%) were comparable between the T-DXd arm of J202 and U205 and the exposure to T-DXd is considered sufficient to assess the safety profile.

At the safety data DCOs all (100%) T-DXd 6.4 mg/kg exposed patients had experienced AEs . 72.9% had experienced ≥grade 3 AEs , 40.2% SAEs , 16.6% discontinuation of study-drug due to AEs and 8.3%  AEs  associated  with  the  outcome  of  death.  96.5%  of  all  T-DXd  6.4  mg/kg  exposed  patients experienced drug-related AEs, 57.2% drugrelated ≥grade 3 AEs, 17.9% drug -related  SAEs,  10.4% drug-related discontinuation and 0.9% drug-related AEs associated with the outcome of death. The majority of AEs and drug-related AEs in J202, U205 and in the HER2+ GC Pool were gastrointestinal or hematologic in nature. These are known adverse reactions to topoisomerase inhibitors and are in line with what is expected in this patient group in a 2L+ palliative setting from this ADC. The 10 most frequent AEs in the HER2+ 6.4 mg/kg GC pool were: nausea 65.5%, decreased appetite 54.1%, fatigue 52.8%, anemia  49.3%,  neutropenia  49.3%,  thrombocytopenia  34.1%,  vomiting  32.3%,  diarrhoea  31.9%, leukopenia  28.8%,  constipation  25.8%.  Within  the  2L  Western  population  (U205)  there  was,  in comparison to the 3L+ Asian (J202) population, observed lower frequencies of ≥grade 3 AEs (53.2% vs 85.6%), of SAEs (36.7% vs 44.8%) and  less dose-reductions (24.1% vs 32.0%) but a higher degree of AEs associated with the outcome of death (12.7% va 6.4%). Furthermore, the 2L Western population had lower levels of hematologic and higher levels of GI associated AEs compared to the 3L+ Asian population. The higher incidence of hematologic events in the Asian/Japanese population is consistent with the scientific literature in which ethnic differences in drug toxicity are well documented. It has been observed in clinical studies in HER2-positive BC patients conducted by the MAH as well as in published reports of clinical studies investigating other treatments for HER2-positive metastatic GC.

ILD, the most important AE of special interest , is a frequent and well-known adverse event (11.8%) with almost all cases considered drug-related; ADR (10.9%), by the adjudicated independent committee, and strongly associated with T-DXd, as no patients in the TPC arm experienced ILD. The incidence, grade and resolution of ILD appears comparable to what is known from the BC population. Mostly grade 1-3, a  few  grade  4  and  only  one  grade  5  ILDs  were  observed  leading  to  dose  discontinuation  (in  J202 predefined discontinuation if grade 2) in 6.6% of patients. The SmPC covers the ILD sufficiently in 4.2, 4.4, 4.8. LVEF decrease occurred with a low frequency (1.8%), was not fatal and mostly resolved.

In general, the frequency of SAEs is quite high in both J202 (44.8%), U205 (36.7%) and in the HER2+ 6.4 mg/kg GC pool (40.2%) and a notable number of patients experienced more than one SAE. The 3L+ Asian population has more decreased appetite (10.4% vs 0%), ILD (5.6% vs 2.5%), pneumonia (4% vs 2.5%),  cholangitis  (2.4%  vs  0%),  anemia3.2%  vs  0%),  dehydration  (3.2%  vs  0%),  tumour haemorrhage (2.4% vs 1.3%), jaundice cholestatic (2.4% vs 0%) and pyrexia (2.4% vs 0%). The 2L Western population had more nausea (5.1% vs 0.8%), vomiting (3.8% vs 0.8%), abdominal pain (2.5% vs 0.8%) and acute kidney injury (2.5% vs 0.8%). This pattern of differences in frequencies of SAEs is equivalent to the pattern seen from AEs, which was expected.

<div style=\"page-break-after: always\"></div>

In the HER2+ 6.4 mg/kg GC pool 8.3% experienced AEs associated with the outcome of death , hereof 2 (0.9%) considered drug-related. This is considered as a concerningly high frequency. The frequency was twice as high in the Western 2L compared to the Asian 3L+ (12.7% vs 6.4%) population, as was the on-treatment deaths (11.4% vs 6.4%). However, the main reason for deaths (6/10) in study U205 was disease progression or COVID-19 and as such not drug-related. Deaths due to AEs in the TPC arm of J202 was in comparison 3.2%.

The majority of ADRs were, as expected, gastrointestinal or hematologic in nature. The frequencies of all ADRs and grade 3 or 4 ADRs were in general high. The highest occurrence was seen in the T-DXd arm of J202A (all 99.2%, grade 3/4 80%), the lowest in U205 (all 97.5%, grade 3/4 39.2%). The TPC arm of J202 was in between (all 96.8%, grade 3/4 50%).

In the HER2+ 6.4 mg/kg GC pool, there were 113 (49.3%) subjects with neutropenia and 9 (3.9%) subjects with febrile neutropenia.

The Asian population (T-DXd arm of J202) had a ~2.5 times as high frequency (12 patients, 9.6%) of bleedings compared to the Western population (3 patients, 3.8%). This was anticipated considering the higher frequency of thrombocytopenia in the Asian population and is reflected in the SmPC.

All the patients fulfilling Hy's law had biochemical liver function tests suggesting an obstructive etiology. The etiologies  for  meeting  biochemical  Hy's  Law  criteria  included  liver  metastases,  biliary  dilatation requiring stenting, stent revision, or biliary drainage, bile stone, cholangitis, biliary sepsis and disease progression. Mild hepatic impairment at baseline, primarily in study U205, was associated with a higher occurrence of AEs and SAEs, including, drug related AEs and AEs associated with death, compared to patients with normal hepatic liver function at baseline. However, the sample size was small (n=14) and 5/6 deaths were unrelated to hepatic impairment or study drug. The data do not suggest that T-DXd has a different safety profile in subjects with mild hepatic impairment at baselineIn the T-DXd arm of study J202 17.6% experienced drug-discontinuation due to  AEs. In U205 this was 15.2% and in the HER2+ 6.4 mg/kg GC pool 16.6%. These discontinuation rates are rather high, but in the same range as what have been seen with 5.4 mg/kg.

In general, trastuzumab-deruxtecan has a different and more toxic safety profile than standard monochemotherapy,  as  is  also  seen  with  other  ADCs.  Although  substantial,  the  toxicity  of  T-DXd  was manageable.

## Additional expert consultations

Not relevant.

## 2.5.11. Conclusions on clinical safety

In the populations of study J202 and U205, the majority and most common AEs were gastrointestinal or hematologic. Hematologic AEs were reported more frequently in the T-DXd arm of J202 than in U205, representing the main difference in toxicity profile between the 2 study populations.

<div style=\"page-break-after: always\"></div>

Also,  with  regards  to  grade ≥ 3 AEs, the hematologic toxicity was far more pronounced in the Asian population compared to the Western and the primary reason for the notably higher degree of grade ≥ 3 AEs in the Asian (J202) population. These results are consistent with the scientific literature in which ethnic  differences  in  drug  toxicity  are  well  documented,  and  with  the  observations  from  the  clinical studies in HER2 positive BC patients conducted by the MAH, as well as published reports of clinical studies of other treatments for HER2-positive metastatic GC.

The incidence of SAEs was relatively high. The difference in occurence between the two studies was primarily due to higher frequency of decreased appetite and ILD in the Asian (J202) population. The discontinuation rate was relatively high but similar in the two studies and within the range of what is observed with targeted ADCs. AEs associated with an outcome of death were twice as high in U205 compared to the T-DXd arm of J202 but the majority of deaths were due to disease progression or COVID-19 and the difference is therefore acceptable. The frequency of ILD, an important identified risk factor associated with T-DXd treatment, was higher in the T-DXd arm of J202 than in U205. However, in both populations, the majority of drug-related ILD events were low grade, and the risk of and actions taken in case of ILD is sufficiently described in the SmPC.

In conclusion, the toxicity was manageable within both patient populations (T-DXd arm of J202 and U205) although with differences in the toxicity profile between the two groups. The differences were primarily due to expected higher hematologic toxicity in the Asian (mainly Japanese) population and due to the differences in baseline disease characteristics. Some differences were not obviously explainable. The toxicity profile of T-DXd 6.4 mg/kg is considered thoroughly described for both studies and was not worse or better for either group, but with somewhat different profiles. The median T-DXd treatment duration  and  median  relative  dose  intensity  were  consistent  in  the  T-DXd  arm  of  J202  and  U205, supporting that T-DXd was equally tolerated in the two study populations. Overall and across ethnicities and line of treatment, the toxicity profile of T-DXd is found to be challenging but considered manageable within the patient group encompassed by the sought and approved indication statement.

The  important  issues  stated  in  the  RMP  will  be  addressed  and  the  safety  profile  of  Enhertu  in  the treatment of adult patients with advanced HER2+ GC will be confirmed in the ongoing confirmatory study DESTINY-Gastric 04 (DS-8201-A-U306) of which results are required as a special obligation for the CMA of the current extension of indication.

## 2.5.12. PSUR cycle

The requirements for submission of periodic safety update reports for this medicinal product are set out in the list of Union reference dates (EURD list) provided for under Article 107c(7) of Directive 2001/83/EC and any subsequent updates published on the European medicines web-portal.

## 2.6. Risk management plan

The CHMP received the following PRAC Advice on the submitted Risk Management Plan:

The PRAC considered that the risk management plan version 3.0 is acceptable.

<div style=\"page-break-after: always\"></div>

## Safety concerns

| Summary of safety concerns   | Summary of safety concerns                                                      |
|------------------------------|---------------------------------------------------------------------------------|
| Important identified risks   | • Interstitial lung disease/Pneumonitis • Left ventricular dysfunction          |
| Important potential risks    | • Embryo-foetal toxicity • Product confusion-related medication errors          |
| Missing information          | • Use in patients with moderate or severe hepatic impairment • Long-term safety |

## Pharmacovigilance plan

| Study: Status                                                                                                                                                                                                                    | Summary of objectives                                                                                                                                                                                                            | Safety concerns addressed                                                                                                                                                                                                        | Milestones                                                                                                                                                                                                                       | Due dates                                                                                                                                                                                                                        |
|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Category 1 - Imposed mandatory additional pharmacovigilance activities which are conditions of the marketing authorization: None                                                                                                 | Category 1 - Imposed mandatory additional pharmacovigilance activities which are conditions of the marketing authorization: None                                                                                                 | Category 1 - Imposed mandatory additional pharmacovigilance activities which are conditions of the marketing authorization: None                                                                                                 | Category 1 - Imposed mandatory additional pharmacovigilance activities which are conditions of the marketing authorization: None                                                                                                 | Category 1 - Imposed mandatory additional pharmacovigilance activities which are conditions of the marketing authorization: None                                                                                                 |
| Category 2 - Imposed mandatory additional pharmacovigilance activities which are Specific Obligations in the context of a conditional marketing authorisation or a marketing authorisation under exceptional circumstances: None | Category 2 - Imposed mandatory additional pharmacovigilance activities which are Specific Obligations in the context of a conditional marketing authorisation or a marketing authorisation under exceptional circumstances: None | Category 2 - Imposed mandatory additional pharmacovigilance activities which are Specific Obligations in the context of a conditional marketing authorisation or a marketing authorisation under exceptional circumstances: None | Category 2 - Imposed mandatory additional pharmacovigilance activities which are Specific Obligations in the context of a conditional marketing authorisation or a marketing authorisation under exceptional circumstances: None | Category 2 - Imposed mandatory additional pharmacovigilance activities which are Specific Obligations in the context of a conditional marketing authorisation or a marketing authorisation under exceptional circumstances: None |
| Category 3 - Required additional pharmacovigilance activities                                                                                                                                                                    | Category 3 - Required additional pharmacovigilance activities                                                                                                                                                                    | Category 3 - Required additional pharmacovigilance activities                                                                                                                                                                    | Category 3 - Required additional pharmacovigilance activities                                                                                                                                                                    | Category 3 - Required additional pharmacovigilance activities                                                                                                                                                                    |
| Prescriber Survey preparations ongoing                                                                                                                                                                                           | EU survey of relevant healthcare professionals on understanding of key risk minimization measures pertaining to ILD/pneumonitis                                                                                                  | ILD                                                                                                                                                                                                                              | Final Report                                                                                                                                                                                                                     | Q2 2024                                                                                                                                                                                                                          |
| Phase 2 or 3 studies preparations ongoing                                                                                                                                                                                        | Collection of PK and safety data in at least 10 subjects with moderate hepatic impairment from ongoing Phase 2 or 3 clinical studies                                                                                             | Use in patients with moderate or severe hepatic impairment                                                                                                                                                                       | Final report (for 10 subjects)                                                                                                                                                                                                   | Q4 2023                                                                                                                                                                                                                          |

## Risk minimisation measures

<div style=\"page-break-after: always\"></div>

## Summary Table of Pharmacovigilance Activities and Risk Minimisation Activities by Safety Concern

| Safety concern                        | Risk minimisation measures                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              | Pharmacovigilance activities                                                                                                                                                    |
|---------------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Important Identified Risks            | Important Identified Risks                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              | Important Identified Risks                                                                                                                                                      |
| Interstitial Lung Disease/Pneumonitis | Routine risk minimisation measures: SmPC Section 4.2 SmPC Section 4.4 SmPC Section 4.8 Patient Information Leaflet Section 2 Patient Information Leaflet Section 4 Recommendations for ILD/pneumonitis monitoring and detecting early signs and symptoms of ILD/pneumonitis are included in SmPC Section 4.4. Dose modification guidance and recommendation for corticosteroid treatment for managing the risk of ILD/pneumonitis are included in SmPC Section 4.2. Additional risk minimisation activities: HCP Guide and Patient Card | Routine pharmacovigilance activities beyond adverse reactions reporting and signal detection: Targeted questionnaire Additional pharmacovigilance activities: Prescriber survey |
| Left ventricular dysfunction          | Routine risk minimisation measures: SmPC Section 4.2 SmPC Section 4.4 SmPC Section 4.8 Patient Information Leaflet Section 2 Recommendations for monitoring of left ventricular dysfunction are included in SmPC Section 4.4. Dose modification guidance for managing the risk of left ventricular dysfunction is included in SmPC Section 4.2. Additional risk minimisation activities: None                                                                                                                                           | Routine pharmacovigilance activities beyond adverse reactions reporting and signal detection: Targeted questionnaire Additional pharmacovigilance activities: None              |

<div style=\"page-break-after: always\"></div>

## Summary Table of Pharmacovigilance Activities and Risk Minimisation Activities by Safety Concern (Continued)

| Safety concern                                             | Risk minimisation measures                                                                                                                                                                                                                                                                          | Pharmacovigilance activities                                                                                                                                                                                                                                                                                           |
|------------------------------------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Important Potential Risks                                  | Important Potential Risks                                                                                                                                                                                                                                                                           | Important Potential Risks                                                                                                                                                                                                                                                                                              |
| Embryo-foetal toxicity                                     | Routine risk minimisation measures: SmPC Section 4.4 SmPC Section 4.6 Patient Information Leaflet Section 2 Recommendations for pregnancy monitoring and contraception usage are included in SmPC Section 4.4 and SmPC Section 4.6. Additional risk minimisation activities: None                   | Routine pharmacovigilance activities beyond adverse reactions reporting and signal detection: None Additional pharmacovigilance activities: None                                                                                                                                                                       |
| Product confusion-related medication error                 | Routine risk minimisation measures: SmPC Section 4.2 SmPC Section 4.4 SmPC Section 6.6 Pack and vials: specific livery for ENHERTU on the packaging and specific colours for vial cap and bottle to distinguish from other trastuzumab containing products Additional risk minimisation activities: | Routine pharmacovigilance activities beyond adverse reactions reporting and signal detection: None Additional pharmacovigilance activities: None                                                                                                                                                                       |
| Missing Information                                        | Missing Information                                                                                                                                                                                                                                                                                 | Missing Information                                                                                                                                                                                                                                                                                                    |
| Use in patients with moderate or severe hepatic impairment | Routine risk minimisation measures: SmPC Section 4.2 SmPC Section 4.4 SmPC Section 5.2 Additional risk minimisation activities: None                                                                                                                                                                | Routine pharmacovigilance activities beyond adverse reactions reporting and signal detection: Review of data from ongoing clinical studies Additional pharmacovigilance activities: Analysis of PK and safety data in at least 10 subjects with moderate hepatic impairment from ongoing Phase 2 or 3 clinical studies |

<div style=\"page-break-after: always\"></div>

## Summary Table of Pharmacovigilance Activities and Risk Minimisation Activities by Safety Concern (Continued)

| Safety concern      | Risk minimisation measures                                                             | Pharmacovigilance activities                                                                                                                     |
|---------------------|----------------------------------------------------------------------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------|
| Missing Information | Missing Information                                                                    | Missing Information                                                                                                                              |
| Long-term safety    | Routine risk minimisation measures: None Additional risk minimisation activities: None | Routine pharmacovigilance activities beyond adverse reactions reporting and signal detection: None Additional pharmacovigilance activities: None |

HCP = healthcare professional; ILD = interstitial lung disease; PK = pharmacokinetic; SmPC = Summary of Product Characteristics

## 2.7. Overall conclusion on the RMP

The changes to the RMP and the changes to the conditions and obligations of the MA are acceptable.

## 2.8. Changes to the Product Information

As a result of this variation, section(s) 4.1, 4.2, 4.3, 4.8, 5.1, 5.2, and 6.6 of the SmPC are being updated to reflect the new applied indication and corresponding changes to relevant sections. The Package Leaflet (PL) is updated accordingly.

Please refer to Attachment 1 which includes all agreed changes to the Product Information.

## 2.8.1. User consultation

A justification for not performing a full user consultation with target patient groups on the package leaflet has been submitted by the MAH and has been found acceptable for the following reasons:

A full user test of the PL was done during the review of the initial Marketing Authorisation Application (MAA) for Enhertu in 2020. Enhertu is prescribed by a physician and administered intravenously under the supervision of a healthcare professional at a hospital/clinical setting. The posology for the applied indication is new however the mode of administration and method of reconstitution is unchanged. The updated PIL will be kept in an identical format size, colours and layout/design.

## 3. Benefit-Risk Balance

## 3.1. Therapeutic Context

The MAH for Enhertu (trastuzumab deruxtecan) has submitted a type II variation for an extension of indication. The final approved indication is:

<div style=\"page-break-after: always\"></div>

Enhertu as monotherapy is indicated for the treatment of adult patients with advanced HER2 positive gastric or gastroesophageal junction (GEJ) adenocarcinoma who have received a prior trastuzumabbased regimen.

Patients treated with Enhertu for gastric or GEJ cancer should have documented HER2-positive tumour status, defined as a score of 3 + by IHC or a ratio of ≥ 2 by ISH or by FISH, assessed by a CE marked IVD medical device. If a CE marked IVD is not available, the HER2 status should be assessed by an alternate validated test.

The recommended dose of Enhertu is 6.4 mg/kg given as an intravenous infusion once every 3 weeks (21-day cycle) until disease progression or unacceptable toxicity.

## 3.1.1. Disease or condition

Usually stomach (gastric) cancer (GC) starts in the lining of the stomach, growing slowly over the course of  several  years  and  causing  few  if  any  symptoms.  Most  patients  (up  to  95  percent)  develop adenocarcinoma and are typically classified based on anatomic location (cardia/proximal, arising in the region adjoining the GEJ, or non-cardia/distal, arising in the lower portion of the stomach) and histologic type (diffuse, with undifferentiated tumour cells, or intestinal, with well-differentiated tumour cells).  11, 12  Overexpression or amplification of the HER2 gene or protein is reported in approximately 20% of patients with gastric adenocarcinoma, with higher rates of HER2 positivity seen in patients with intestinal histology than those with diffuse histology. Most patients present with inoperable advanced or metastatic disease requiring palliative treatment, although early detection is more common in Asia than in other regions. 5-year survival for advanced or metastatic gastric cancer is around 5-20%, with median overall survival being less than 1 year.

## 3.1.2. Available therapies and unmet medical need

Locally advanced or metastatic HER2-positive gastric adenocarcinoma remains an incurable disease. Once patients have progressed after a first-line regimen that includes anti-HER2 therapy, the disease outcomes are poor.  13 Ramucirumab (antiangiogenic monoclonal antibody) in combination with paclitaxel is  approved for second line GC/GEJC regardless of HER2 expression. Other treatment options in the second-line  or  subsequent  therapy  settings  include  docetaxel,  irinotecan  and  FOLFIRI  (folinic  acid, fluorouracil, and irinotecan). Currently, there is no approved targeted anti-HER2 therapy in the EU for the treatment of metastatic HER2-positive gastric adenocarcinoma in the second line or beyond settings, constituting a clear unmet need.

## 3.1.3. Main clinical studies

The pivotal study DESTINY-Gastric02 (U205) was a Phase 2, multicentre, single-arm, open-label study to evaluate the efficacy and safety of T-DXd (6.4 mg/kg as IV infusion Q3W) in 79 subjects with unresectable or metastatic HER2-positive gastric or GEJ adenocarcinoma who had progressed during or after a trastuzumab-containing regimen (2L+ setting). The study was conducted in a Western

11  National Comprehensive Cancer Network. NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®). Gastric cancer. Version 4.2021. 03 Aug 2021.

12  Rawla P, Barsouk A. Epidemiology of gastric cancer: global trends, risk factors and prevention. Gastroenterology Rev. 2019; 14(1):26-38.

13  Smyth EC, Verheij M, Allum W, et al. Gastric cancer: ESMO clinical practice guidelines for diagnosis, treatment, and follow-up. Ann Oncol. 2016; 27 (suppl\\_5):v38-v49.

<div style=\"page-break-after: always\"></div>

population at 24 sites in the US and Europe. The primary efficacy endpoint was confirmed ORR by ICR, while duration of response was a secondary endpoint.

The supportive study DESTINY-Gastric01 (J202) was a Phase 2, multicentre, open-label, 2:1 randomized study  to  evaluate  efficacy  and  safety  in  subjects  with  advanced  HER2-positive  gastric  or  GEJ adenocarcinoma who had progressed on 2 or more prior regimens including a fluoropyrimidine agent (fluorouracil, capecitabine, or S-1) and a platinum agent (oxaliplatin or cisplatin) in addition to prior trastuzumab or a trastuzumab biosimilar (3L+ setting). The study was conducted in Japan and South Korea. Of focus in this assessment is the Primary Cohort (N=188), in which subjects were randomized to receive either T-DXd monotherapy at the proposed dose (6.4 mg/kg Q3W, n=126) or treatment of physician's choice (irinotecan or paclitaxel, n=62). The primary efficacy endpoint was unconfirmed ORR by ICR and the secondary endpoints were OS, PFS, mDoR and ORR by ICR.

## 3.2. Favourable effects

## Pivotal U205 study in 2L US/European patients:

At initial DCO 09-APR-2021, confirmed ORR in this supportive SAT was 38.0% and mDoR was 8.1 months. At an updated DCO on 08-NOV-2021, confirmed ORR increased slightly to 41.8%. In this updated data, mDOR remained at 8.1 months.

## Supportive J202 study in 3L Asian patients:

At DCO 08-NOV-2019, pivotal study J202 met its primary endpoint of improved response rate in the experimental arm: unconfirmed ORR by ICR was 48.4% in the T-DXd arm vs. 12.9% in the control irinotecan or paclitaxel arm. Confirmed response in the T-DXd arm was 38.0%. At DCO 03-JUN-2020, updated confirmed ORR by ICR remained stable at 39.7%.

In  the  last  DCO,  median  DOR  was  12.5  months  in  the  T-DXd  arm  vs.  3.9  months  in  the  control chemotherapy arm. Time-to-event endpoints also showed an advantage of T-DXd: mOS 12.5 vs. 8.9 months and mPFS 5.6 vs 3.5 months.

## 3.3. Uncertainties and limitations about favourable effects

In the absence of a control arm in the U205 study any conclusion based on indirect comparison lacks validity, as it cannot be readily assumed that the study populations are sufficiently similar to use the external comparison in support for extrapolation between lines of treatment. Despite compelling data from this single-arm trial, comprehensive data on the product are not available and as it is likely that the applicant will be able to provide these data, the on-going study DS8201-A-U306 (phase III RCT of trastuzumab deruxtecan versus ramucirumab + paclitaxel in the 2L population including EU and USA patients) constitutes a SOB in Annex II of the Opinion.

Due to better prognosis, Asian patients are treated with more lines of therapy for advanced disease than patients in the West. Therefore, comparison of results across the 3L+ Asian and  the Western 2L+ setting is not straightforward because of intrinsic/extrinsic differences.

## 3.4. Unfavourable effects

At safety data DCOs (J202: 03-JUN-2020, U205: 09-APR-2021, J101: 01-AUG-2019) 73% of patients had experienced ≥grade 3 AEs , 40% SAEs, 17% discontinuation of study-drug due to AEs and 8% AEs associated with the outcome of death. The frequency of the same events in the physician's choice arm (mainly irinotecan, a few paclitaxel) of study J202 were all lower.

<div style=\"page-break-after: always\"></div>

The 10 most frequent AEs in the HER2+ 6.4 mg/kg GC pool were: nausea 66%, decreased appetite 54%, fatigue 53%, anaemia 49%, neutropenia 49%, thrombocytopenia 34%, vomiting 32%, diarrhoea 32%, leukopenia 29%, and constipation 26%.

Within the 2L Western population (U205) there were, in comparison to the 3L+ Asian (J202) population, lower frequencies of ≥grade 3 AEs (5 3% vs 86%) and SAEs (37% vs 45%). The same frequency of dose-discontinuations was seen between the two populations. The hematologic toxicity was far more pronounced in the Asian population compared to the Western one, and the primary reason for the notably higher degree of grade ≥3 AEs in the Asian (J202) population. This ethnic difference in toxicity is well known and described across Oncology trials. The frequency of SAEs was relatively high; 40%, in the HER2+ 6.4 mg/kg GC pool (45% in J202 and 37% in U205). The difference between the two studies was primarily  due  to  a  higher  frequency  of  decreased  appetite  and  ILD  in  the  Asian  (J202)  population. Nevertheless, it is acknowledged that hospitalisations in patients with GC/GEJC are quite frequent in view of clinical fragility and disease-associated factors.

The pattern of differences in frequencies of SAEs was equivalent to the pattern seen in AEs. In the TDXd arm of study J202, 17.6% experienced drug-discontinuation due to an AE. In U205 this was 15.2% and in the HER2+ 6.4 mg/kg GC pool 16.6%. These discontinuation rates are rather high. ILD as reason for discontinuation occurred equally frequent in the two T-DXd exposed study populations (6.4% vs 6.3%) and was the primary cause of drug-discontinuation in both studies. The majority of drug-related ILD events were low grade (grade 1 or 2 in 13/16 subjects in the T-DXd arm of J202 and 5/6 subjects in U205), although a few fatal cases were observed.

In the HER2+ 6.4 mg/kg GC pool, 19/229 patients (8.3%), hereof 2 (0.9%) considered drug-related, experienced  AEs  associated  with  the  outcome  of  death.  The  frequency  of  AEs  associated  with  the outcome of death was twice as high in the Western 2L population compared to the Asian 3L+ (12.7% vs 6.4%), as was the on-treatment deaths (11.4% vs 6.4%), However, 6/10 deaths in U205 were due to disease progression or COVID-19 and the difference therefore acceptable. AEs with outcome of death in the physician choice arm of J202 occurred in 3.2%.

In the small group of patients ≥75 years of age from the TXD-d pool (24/229) compared to patients &lt;75 years  of  age  (n=204) ,  there  was  a  higher  frequency  of  ≥grade  3  TEAEs  (83.3  vs  71.7%),  TEAEs associated with drug interruptions (58.3 vs 46.3%), dose reductions (41.7 vs 28.3%) and SAEs (50.0 vs 39%).

## 3.5. Uncertainties and limitations about unfavourable effects

The toxicity profiles of patients in study J202 T-DXd arm and study U205 are divergent with regard to the intrinsic factors age, sex, renal and hepatic function at baseline and with regards to the extrinsic factors concerning region and country. The frequencies of ≥grade 3 AEs, SAEs and AEs associated with death are also divergent, but to a large degree explainable. Differences in baseline disease characteristics and the well-established higher degree of hematologic toxicity in the Asian population, are some of the major reasons for the differences, but also the difference in study design, with one being a RCT (J202) and the other (U205) being a SAT, challenges the direct comparability of the safety profiles. Pooling data when the frequencies in quite a number of toxicity events are very far apart between the two populations is, to some degree, obscuring the data and the understandings that lead from them.

The safety evaluation in the HER2-positive GC pool is mainly based on data from the Asian population (n=150) with a smaller proportion of Western patients (n=79). Exposure-safety analyses indicated racecountry as a covariate for most safety parameters indicating that the safety profile in study J202 cannot

<div style=\"page-break-after: always\"></div>

easily be extrapolated to Western patients. In addition, the possibilities for extrapolation may be further impacted by the fact that the Asian patients included in study J202 were more heavily pre-treated than the European and US patients in studies U205, while having a better performance score.

The toxicity was manageable within both patient populations (T-DXd arm of J202 and U205) although with differences in the toxicity profile between the two groups. The differences were primarily due to expected  higher  hematologic  toxicity  in  the  Asian  (mainly  Japanese)  population  and  due  to  the differences in baseline disease characteristics. Some differences were not obviously explainable. The toxicity profile of T-DXd 6.4 mg/kg is considered thoroughly displayed for both studies and could not be described as worse or better for either group, but as with different profiles.

The described uncertainties regarding the safety profile of T-DXd in the treatment of patients with GC will be further clarified by the fulfillment of the RMP. Additionally, a confirmation of the safety profile will be provided with the outcome of the ongoing confirmatory trial DESTINY-Gastric 04 required as a specific obligation. This is needed to guarantee comprehensiveness of the safety (and efficacy) data and by that to ensure a fully established safety profile.

## 3.6. Effects Table

Table 1. Effects Table for ENHERTU (Trastuzumab deruxtecan) as monotherapy for the treatment of adult patients with locally advanced or metastatic HER2-positive gastric or gastroesophageal junction (GEJ) adenocarcinoma who have received a prior anti-HER2based regimen in the pivotal phase 2 study U205 and the supportive study J202 (compared to TPC)(data cut-off: 08 Nov 2021/03 June 2020)

| Effect                       | Short description                 | Unit                         | Treatment T-DXd N=79         | Control                      | Uncertainti es / Strength of evidence   | Reference s                  |
|------------------------------|-----------------------------------|------------------------------|------------------------------|------------------------------|-----------------------------------------|------------------------------|
| Favourable Effects           | Favourable Effects                | Favourable Effects           | Favourable Effects           | Favourable Effects           | Favourable Effects                      | Favourable Effects           |
| Primary endpoint for U205    | Primary endpoint for U205         | Primary endpoint for U205    | Primary endpoint for U205    | Primary endpoint for U205    | Primary endpoint for U205               | Primary endpoint for U205    |
| cORR by ICR                  | Confirmed overall response rate   | % 95% CI                     | 41.8 30.8, 53.4              | NA                           |                                         | DCO 08 Nov 2021              |
| Secondary endpoints for U205 | Secondary endpoints for U205      | Secondary endpoints for U205 | Secondary endpoints for U205 | Secondary endpoints for U205 | Secondary endpoints for U205            | Secondary endpoints for U205 |
| mDoR                         | Median duration of Response       | Months 95% CI                | 8.1 5.9,NE                   | NA                           |                                         | DCO 08 Nov 2021              |
| Effect                       | Short description                 | Unit                         | Treatment T-DXd N=126        | Control TPC N=62 total       | Uncertainti es / Strength of evidence   | Reference s                  |
| Primary endpoint for J202    | Primary endpoint for J202         | Primary endpoint for J202    | Primary endpoint for J202    | Primary endpoint for J202    | Primary endpoint for J202               | Primary endpoint for J202    |
| ORR by ICR                   | Overall Response Rate Unconfirmed | %                            | 48.4                         | 12.9                         |                                         | DCO 08 Nov 2019              |
| Secondary endpoints for J202 | Secondary endpoints for J202      | Secondary endpoints for J202 | Secondary endpoints for J202 | Secondary endpoints for J202 | Secondary endpoints for J202            | Secondary endpoints for J202 |
| mOS                          | Overall Survival                  | Months                       | 12.5                         | 8.9                          |                                         | DCO 03 Jun 2020              |
| mPFS                         | Progression Free                  | Months                       | 5.6                          | 3.5                          |                                         | DCO 03 Jun 2020              |

<div style=\"page-break-after: always\"></div>

| Effect     | Short description               | Unit   | Treatment T-DXd N=79   | Control   | Uncertainti es / Strength of evidence   | Reference s     |
|------------|---------------------------------|--------|------------------------|-----------|-----------------------------------------|-----------------|
|            | Survival                        |        |                        |           |                                         |                 |
| mDoR       | Duration of Response            | Months | 12.5                   | 3.9       |                                         | DCO 03 Jun 2020 |
| ORR by ICR | Overall Response Rate Confirmed | Months | 39.7                   | 11.3      | Exploratory secondary endpoint          | DCO 03 Jun 2020 |

## Unfavourable Effects (HER2+ GC 6.4 mg/kg pool, n=229)

|                                |      | HER2+ GC 6.4 mg/kg pool (n=229)   | TPC arm J202 (Asian, n=62)   | T-DXd arm J202 (Asian, n=125)   | U205 (Western, n=79)   |
|--------------------------------|------|-----------------------------------|------------------------------|---------------------------------|------------------------|
| Grade ≥3 AE                    | %(n) | 72.9% (167)                       | 56.5% (35)                   | 85.6% (107)                     | 53.2% (40)             |
| SAEs                           | %(n) | 40.2% (92)                        | 25.8% (16)                   | 44.8% (56)                      | 36.7% (29)             |
| AEs leading to discontinuation | %(n) | 16.6% (38)                        | 6.5% (4)                     | 17.6% (22)                      | 15.2% (12)             |
| AEs leading to death           | %(n) | 8.3% (19)                         | 3.2% (2)                     | 6.4% (8)                        | 12.7% (10)             |

Abbreviations: TPC=Treatment of Physicians Choice, T-DXd=Trastuzumab Deruxtecan, NA=Not available, NE=Not evaluable FAS=Full analysis set, ITT=Intention to treat analysis set

## 3.7. Benefit-risk assessment and discussion

## 3.7.1. Importance of favourable and unfavourable effects

Locally advanced or metastatic HER2-positive gastric and gastroesophageal junction adenocarcinoma remain an incurable disease. Once patients have progressed after a first-line regimen that includes an anti-HER2  therapy,  disease  outcomes  are  poor.  Currently,  there  is  no  approved  targeted  anti-HER2 therapy in the EU for the treatment of metastatic HER2-positive gastric adenocarcinoma in the secondline setting and beyond, which constitutes an unmet medical need.

Disease activity from T-DXd is evident from results in the pivotal trial and this preliminary promising efficacy is supported by the 3L+ Asian J202 trial, but it is not yet considered that comprehensive data for the intended 2L+ setting has been presented. To address this, the MAH has commited to providing results from the ongoing DESTINY-Gastric04 trial, currently imposed as a SOB in Annex II.

The  majority  of  AEs  and  ADRs  in  J202,  U205  and  in  the  HER2+  GC  Pool  were  gastrointestinal  or hematologic in nature. Hematologic AEs were reported more frequently in the T-DXd arm of J202 than in U205, representing the main difference in toxicity profile between the 2 study populations.There were notable differences in the toxicity profile between the two patient groups. These were primarily due to expected  higher  hematologic  toxicity  in  the  Asian  (mainly  Japanese)  population  and  due  to  the differences in baseline disease characteristics. The differences in baseline disease characteristics, ethnic differencies in toxicity profile and differences in study design challenges the comparability of the two

<div style=\"page-break-after: always\"></div>

study populations' safety profiles. Pooling data when the frequencies in quite a number of toxicity events are  very  far  apart  between  the  two  populations  is,  to  some  degree,  obscuring  the  data  and  the understandings led from them. Still, the toxicity profile of T-DXd 6.4 mg/kg is considered thoroughly displayed  for  both  studies  and  regarded  as  manageable  within  both  patient  populations.  However, comprehensive data are awaited with the ongoing confirmatory phase 3 study DESTINY-Gastric 04 (DS8201-A-U306).

However, the investigated patient group has metastatic gastric cancer, often symptomatic (and also leading to frequent hospitalisations) and many patients were heavily pre-treated. The targeted patient population  are  to  an  extent  fragile  and  if  left  untreated,  they  have  a  very  limited  remaining  life expectancy. Therefore, toxicity and treatment-related deaths can be considered acceptable in view of the potential efficacy benefits.

## 3.7.2. Balance of benefits and risks

The B/R of Enhertu for the intended 2L HER2+ GC/GEJC setting is positive in the context of a conditional approval.

## 3.7.3. Additional considerations on the benefit-risk balance

A SAG-O consultation concerning the remaining uncertainties of Enhertu for the proposed 2L HER2+ GC/GEJC was held on 03-NOV-2022. The SAG-O concluded that the activity and efficacy from T-DXd in the targeted population are sufficiently convincing to justify conditional approval even if the confirmatory data from the phase III trial in second-line are still outstanding. It was emphasised that the feasibility of the trial is the pillar for the considerations of the SAG-O.

## Conditional marketing authorisation

Enhertu was initially, and currently is, approved as a conditional marketing authorisation (CMA). As comprehensive data on the product for this extension of indication are also not available, a conditional marketing authorisation was requested for this extension of indication.

Importantly, this extension of indication falls within the scope of Article 14-a of Regulation (EC) No 726/2004 concerning conditional marketing authorisations, as it aims at the treatment of a seriously debilitating, life- threatening disease. Furthermore, the CHMP considers that the new indication for this product fulfils the requirements for a conditional marketing authorisation:

· The benefit-risk balance of T-DXd is positive, as the results from studies U205 (pivotal study) and J202 (supportive study) are of clinical relevance in the applied indication, with confirmed objective response rates (ORR) by blinded independent central review of 41.8% in Study U205 and 39.7% in Study J202, both studies showed clinically meaningful median duration of response (DoR) (8.1 and 12.5 months, respectively).

• It is likely that the applicant will be able to provide comprehensive data.

The DESTINY-Gastric04 study is a Phase 3, multicenter, 2-arm, randomized, open-label study of T-DXd 6.4 mg/kg in subjects with HER2-positive metastatic and/or unresectable gastric or GEJ adenocarcinoma who have progressed on or after a trastuzumab-containing regimen. The primary objective will assess OS and the secondary objectives will further assess efficacy, safety, PK, and immunogenicity of T-DXd compared with Ramucirumab + paclitaxel. As of 08 Nov 2022, 148 subjects have been enrolled and treated. Albeit recruitment might be impacted by approval in the EU, the MAH has substantiated the

<div style=\"page-break-after: always\"></div>

feasibility of this study and as of 08 Nov 2022, 148 subjects have been enrolled and treated. There is planned ~490 subjects to be enrolled. Study U306 enrollment is projected to be completed by Dec 2024 and the CSR ready in Q4 of 2025. The study is currently being conducted in the following 22 countries: Argentina, Belgium, Brazil, Chile, China, France, Germany, Hong Kong, Hungary, Ireland, Israel, Italy, Japan, South Korea, Poland, Portugal, Romania, Singapore, Spain, Taiwan, Turkey, and United Kingdom.

- T-DXd fulfils an unmet medical need as currently, for patients with locally advanced or metastatic HER2-positive GC, there is no approved HER2-targeted therapy after progression on chemotherapy with fluoropyrimidine + platinum agents plus trastuzumab (the standard of care in the first-line [1L] setting). The ORRs from currently approved treatments in 2L (PTX, docetaxel, irinotecan monotherapy, FOLFIRI [folinic acid, fluorouracil, and irinotecan] or ramucirumab + PTX or PTX-only) after a 1L regimen that includes an anti-HER2 therapy range from 3% to 28%. Median PFS ranges from approximately 1 month to 4 months and median OS ranges from approximately 4 months to 10 months in the 2L setting. While the limitations related to indirect comparisons between studies are acknowledged, T-DXd will act through a different mechanism of action, and is expected to bring a major therapeutic advantage to patients.
- The benefits to public health of the immediate availability outweigh the risks inherent in the fact that additional data are still required. Once the patient's GC has progressed on or after a 1L regimen that includes an anti-HER2 therapy, the disease outcomes are poor, with the 5-year survival rates ranging from 10% to approximately 30%. For those patients whose initial diagnosis is Stage IV disease, the prognosis is dismal in Asian and Western regions.

## 3.8. Conclusions

The overall B/R of trastuzumab-deruxtecan for the intended second line treatment of GC/GEJC is positive subject to the specific obligations and conditions imposed in order to obtain further clinical data to generate a comprehensive clinical data set. Consequently, the ongoing study DESTINYGastric04 (DS8201-A-U306) trial, a phase III RCT of trastuzumab deruxtecan versus ramucirumab + paclitaxel in the 2L population including EU and USA patients is imposed as a SOB in Annex II of the Opinion.

## 4. Recommendations

## Outcome

Based on the review of the submitted data, the CHMP considers the following variation acceptable and therefore recommends the variation to the terms of the Marketing Authorisation, concerning the following change:

| Variation accepted   | Variation accepted                                                                                                             | Type    | Annexes affected   |
|----------------------|--------------------------------------------------------------------------------------------------------------------------------|---------|--------------------|
| C.I.6.a              | C.I.6.a - Change(s) to therapeutic indication(s) - Addition of a new therapeutic indication or modification of an approved one | Type II | I, II and IIIB     |

Extension of indication to include monotherapy treatment of adult patients with advanced HER2positive gastric or gastroesophageal junction (GEJ) adenocarcinoma who have received a prior

<div style=\"page-break-after: always\"></div>

trastuzumab-based regimen for Enhertu based on final results from studies DS8201-A-U205 (DESTINY Gastric02) and DS8201 A J202 (DESTINY Gastric01); as a consequence, sections 4.1, 4.2, 4.4, 4.8, 5.1, and 5.2 of the SmPC are updated. The Annex II and the Package Leaflet are updated in accordance. In addition, changes regarding the dosing recommendation for corticosteroid treatment and the protection of the infusion bag from light have been introduced. Version 3.0 of the RMP has also been submitted.

The variation leads to amendments to the Summary of Product Characteristics and Package Leaflet and to the Risk Management Plan (RMP).

## Amendments to the marketing authorisation

In view of the data submitted with the variation, amendments to Annex(es) I, II and IIIB and to the Risk Management Plan are recommended.

## Conditions or restrictions with regard to the safe and effective use of the medicinal product

## Specific Obligation to complete post-authorisation measures for the conditional marketing authorisation

This being a conditional marketing authorisation and pursuant to Article 14(7) of Regulation (EC) No 726/2004, the MAH shall complete, within the stated timeframe, the following additional measure:

| Description                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        | Due date         |
|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------------|
| In order to confirm the efficacy and safety of Enhertu in the treatment of adult patients with advanced HER2 - positive gastric or gastroesophageal junction (GEJ) adenocarcinoma who have received a prior trastuzumab - based regimen, the MAH should submit the final results of study DS-8201-A-U306, a phase 3, multicentre, 2 - arm, randomised, open-label study of Enhertu in subjects with HER2 - positive metastatic and/or unresectable gastric or GEJ adenocarcinoma that has progressed on or after a trastuzumab-containing regimen. | 31 December 2025 |

## 5. EPAR changes

The EPAR will be updated following Commission Decision for this variation. In particular the EPAR module 8 \" steps after the authorisation \" will be updated as follows:

## Scope

Please refer to the Recommendations section above.

## Summary

Please refer to Scientific Discussion Enhertu II-0012